Clinical Practice Guideline: Executive Summary


A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

WRITING COMMITTEE MEMBERS
Paul K. Whelton, MB, MD, MSc, FAHA, Chair; Robert M. Carey, MD, FAHA, Vice Chair; Wilbert S. Aronow, MD, FACC, FAHA*; Donald E. Casey, Jr, MD, MPH, MBA, FAHA†; Karen J. Collins, MBA‡; Cheryl Dennison Himmelfarb, RN, ANP, PhD, FAHA§; Sondra M. DePalma, MHS, PA-C, CLS, AACC‖; Samuel Gidding, MD, FAHA¶; Kenneth A. Jamerson, MD#, Daniel W. Jones, MD, FAHA††; Eric J. MacLaughlin, PharmD**, Paul Muntner, PhD, FAHA‡‡; Bruce Ovbiagele, MD, MSc, MAS, MBA, FAHA††; Sidney C. Smith, Jr, MD, MACC, FAHA††; Crystal C. Spencer, JD†††; Randall S. Stafford, MD, PhD‡‡‡; Sandra J. Talier, MD, FAHA§§; Randall J. Thomas, MD, MS, FACC, FAHA¶¶; Kim A. Williams, Sr, MD, MACC, FAHA††; Jeff D. Williamson, MD, MHS¶¶¶; Jackson T. Wright, Jr, MD, PhD, FAHA##

ACC/AHA TASK FORCE MEMBERS
Glenn N. Levine, MD, FACC, FAHA, Chair; Patrick T. O’Gara, MD, FAHA, MACC, Chair-Elect; Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair; Sana M. Al-Khatib, MD, MHS, FACC, FAHA; Joshua A. Beckman, MD, MS, FAHA; Kim K. Birtcher, MS, PharmD, AACC; Biykem Bozkurt, MD, PhD, FACC, FAHA****; Ralph G. Brindis, MD, MPH, MACC*****; Joaquin E. Cigarroa, MD, FACC; Lesley H. Curtis, PhD, FAHA******; Anita Deswal, MD, MPH, FACC; Lee A. Fleisher, MD, FACC, FAHA; Federico Gentile, MD, FACC; Samuel Gidding, MD, FAHA****; Zachary D. Goldberger, MD, MS, FACC, FAHA; Mark A. Hlatky, MD, FACC, FAHA; John Ikonomidis, MD, PhD, FAHA; José A. Joglar, MD, FACC, FAHA; Laura Mauri, MD, MSc, FAHA; Susan J. Pressler, PhD, RN, FAHA****; Barbara Riegel, PhD, RN, FAHA; Duminda N. Wijeysundera, MD, PhD

*American Society for Preventive Cardiology Representative. †AHA/ACC Representative. ‡Lay Volunteer/Patient Representative. §Preventive Cardiovascular Nurses Association Representative. American Academy of Physician Assistants Representative. ¶Task Force Liaison. #Association of Black Cardiologists Representative. **American Pharmacists Association Representative. ††ACC/AHA Prevention Subcommittee Liaison. †††American College of Preventive Medicine Representative. §§American Society of Hypertension Representative. ¶¶Task Force on Performance Measures Liaison. ¶¶¶American Geriatrics Society Representative. ##National Medical Association Representative. ###Former Task Force member; current member during the writing effort.

This document was approved by the American College of Cardiology/American Heart Association Clinical Policy Oversight Committee and the American Heart Association Science Advisory and Coordinating Committee in September 2017 and by the American Heart Association Executive Committee in October 2017.

The Comprehensive RWI Data Supplement table is available with this article at HYPO:0000000000000066/-/DC1.

The online Data Supplement is available with this article at HYPO:0000000000000066/-/DC2.


This article has been copublished in the Journal of the American College of Cardiology.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the American Heart Association (professional.heart.org). A copy of the document is available at http://professional.heart.org/statements by using either “Search for Guidelines & Statements” or the “Browse by Topic” area. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://professional.heart.org/statements. Select the “Guidelines & Statements” drop-down menu, then click “Publication Development.”

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page.

Hypertension is available at HYPO:0000000000000066

1269
Table of Contents

1. Introduction .............................................. 1272
   1.1. Methodology and Evidence Review ...................... 1272
   1.2. Organization of the Writing Committee ................. 1273
   1.3. Document Review and Approval........................ 1274
   1.4. Scope of the Guideline ................................ 1274
   1.5. Abbreviations and Acronyms ............................ 1274
2. BP and CVD Risk ........................................... 1274
   2.1. Observational Relationship ............................. 1274
   2.2. BP Components ......................................... 1275
   2.3. Population Risk ......................................... 1276
   2.4. Coexistence of Hypertension and Related Chronic Conditions ........................................... 1276
3. Classification of BP ......................................... 1276
   3.1. Definition of High BP ................................... 1276
   3.2. Lifetime Risk of Hypertension .......................... 1277
   3.3. Prevalence of High BP ................................... 1277
4. Measurement of BP .......................................... 1277
   4.1. Accurate Measurement of BP in the Office .............. 1277
   4.2. Out-of-Office and Self-Monitoring of BP ............... 1278
   4.3. Masked and White Coat Hypertension .................... 1278
5. Causes of Hypertension ...................................... 1281
   5.1. Secondary Forms of Hypertension ....................... 1281
      5.1.1. Drugs and Other Substances .......................... 1283
         With Potential to Impair BP Control .................... 1283
      5.1.2. Primary Aldosteronism ................................ 1283
      5.1.3. Renal Artery Stenosis ............................... 1283
      5.1.4. Obstructive Sleep Apnea ............................. 1284
6. Nonpharmacological Interventions ........................... 1284
7. Patient Evaluation ......................................... 1286
8. Treatment of High BP ....................................... 1286
   8.1. Pharmacological Treatment ............................... 1286
      8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk ...................... 1286
      8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension ............ 1286
      8.1.3. Follow-Up After Initial BP Evaluation ............. 1287
      8.1.4. General Principles of Drug Therapy .................. 1288
      8.1.5. BP Goal for Patients With Hypertension .......... 1290
      8.1.6. Choice of Initial Medication ....................... 1290
   8.2. Follow-Up of BP During Antihypertensive Drug Therapy ........................................... 1290
      8.2.1. Follow-Up After Initiating Antihypertensive Drug Therapy ........................................... 1290
      8.2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP ................ 1291
9. Hypertension in Patients With Comorbidities .............. 1291
   9.1. Stable Ischemic Heart Disease .......................... 1291
   9.2. Heart Failure ........................................... 1292
      9.2.1. Heart Failure With Reduced Ejection Fraction ................ 1292
      9.2.2. Heart Failure With Preserved Ejection Fraction ......... 1292
   9.3. Chronic Kidney Disease .................................. 1292
   9.3.1. Hypertension After Renal Transplantation ............ 1292
   9.4. Cerebrovascular Disease ................................. 1293
      9.4.1. Acute Intracerebral Hemorrhage ....................... 1293
      9.4.2. Acute Ischemic Stroke ................................ 1293
      9.4.3. Secondary Stroke Prevention ........................ 1294
6. Peripheral Artery Disease ................................ 1295
6.1. Diabetes Mellitus ........................................ 1295
7. Metabolic Syndrome ........................................ 1296
8. Atrial Fibrillation ........................................... 1296
9. Valvular Heart Disease ..................................... 1296
10. Aortic Disease ............................................. 1296
11. Other Considerations ....................................... 1298
   11.1. Resistant Hypertension .................................. 1298
   11.2. Hypertensive Crises—Emergencies and Urgencies .................. 1298
   11.3. Cognitive Decline and Dementia ......................... 1301
   11.4. Patients Undergoing Surgical Procedures .............. 1301
12. Strategies to Improve Hypertension Treatment and Control ........................................... 1301
   12.1. Adherence Strategies for Treatment of Hypertension .................. 1301
      12.1.1. Antihypertensive Medication Adherence Strategies .................. 1301
      12.1.2. Strategies to Promote Lifestyle Modification .......... 1301
   12.2. Structured, Team-Based Care Interventions for Hypertension Control .................. 1301
   12.3. Health Information Technology—Based Strategies to Promote Hypertension Control .......... 1302
      12.3.1. EHR and Patient Registries .......................... 1302
      12.3.2. Telehealth Interventions to Improve Hypertension Control ........ 1302
   12.4. Improving Quality of Care for Patients With Hypertension ........................................... 1302
      12.4.1. Performance Measures ................................ 1302
      12.4.2. Quality Improvement Strategies ..................... 1302
      12.5. Financial Incentives .................................. 1302
13. The Plan of Care for Hypertension ......................... 1302
   13.1. Health Literacy .......................................... 1303
   13.2. Access to Health Insurance and Medication Assistance Plans .................. 1303
   13.3. Social and Community Services ......................... 1303
14. Summary of BP Thresholds and Goals for Pharmacological Therapy ........................................... 1304
   References ................................................. 1304
   Appendix 1. Author Relationships With Industry and Other Entities (Relevant) .................. 1317
   Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) .................. 1319

Preamble

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health. In 2013, the
National Heart, Lung, and Blood Institute (NHLBI) Advisory Council recommended that the NHLBI focus specifically on reviewing the highest-quality evidence and partner with other organizations to develop recommendations.\textsuperscript{P-5–P-2} Accordingly, the ACC and AHA collaborated with the NHLBI and stakeholder and professional organizations to complete and publish 4 guidelines (on assessment of cardiovascular risk, lifestyle modifications to reduce cardiovascular risk, management of blood cholesterol in adults, and management of overweight and obesity in adults) to make them available to the widest possible constituency. In 2014, the ACC and AHA, in partnership with several other professional societies, initiated a guideline on the prevention, detection, evaluation, and management of high blood pressure (BP) in adults. Under the management of the ACC/AHA Task Force, a Prevention Subcommittee was appointed to help guide development of the suite of guidelines on prevention of cardiovascular disease (CVD). These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a cornerstone for quality cardiovascular care. The ACC and AHA sponsor the development and publication of guidelines without commercial support, and members of each organization volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA.

\section*{Intended Use}

Practice guidelines provide recommendations applicable to patients with or at risk of developing CVD. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations can have a global impact. Although guidelines may be used to inform regulatory or payer decisions, they are intended to improve patients’ quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment.

\section*{Clinical Implementation}

Management in accordance with guideline recommendations is effective only when followed by both practitioners and patients. Adherence to recommendations can be enhanced by shared decision making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities.

\section*{Methodology and Modernization}

The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations, including the Institute of Medicine,\textsuperscript{P-5–P-4} and on the basis of internal reevaluation. Similarly, the presentation and delivery of guidelines are reevaluated and modified on the basis of evolving technologies and other factors to facilitate optimal dissemination of information to healthcare professionals at the point of care.

Toward this goal, this guideline continues the introduction of an evolved format of presenting guideline recommendations and associated text called the “modular knowledge chunk format.” Each modular “chunk” includes a table of related recommendations, a brief synopsis, recommendation-specific supportive text, and when appropriate, flow diagrams or additional tables. References are provided within the modular chunk itself to facilitate quick review. Additionally, this format will facilitate seamless updating of guidelines with focused updates as new evidence is published, as well as content tagging for rapid electronic retrieval of related recommendations on a topic of interest. This evolved approach format was instituted when this guideline was near completion; therefore, the present document represents a transitional format that best suits the text as written. Future guidelines will fully implement this format, including provisions for limiting the amount of text in a guideline.

Recognizing the importance of cost–value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology.\textsuperscript{5–5}

To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles. Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual\textsuperscript{P-6} and other methodology articles.\textsuperscript{P-7–P-10}

\section*{Selection of Writing Committee Members}

The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers.

\section*{Relationships With Industry and Other Entities}

The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence. The complete relationships with industry and other entities (RWI) policy can be found online. Appendix 1 of the present document lists writing committee members’ relevant RWI. For the purposes of full transparency, writing committee members’ comprehensive disclosure information is available online. Comprehensive disclosure information for the Task Force is available online.

\section*{Evidence Review and Evidence Review Committees}

In developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data.\textsuperscript{P-6–P-9} Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited.

An independent evidence review committee (ERC) is commissioned when there are 1 or more questions deemed
of utmost clinical importance that merit formal systematic review. The systematic review will determine which patients are most likely to benefit from a drug, device, or treatment strategy and to what degree. Criteria for commissioning an ERC and formal systematic review include: a) the absence of a current authoritative systematic review, b) the feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline, c) the relevance to a substantial number of patients, and d) the likelihood that the findings can be translated into actionable recommendations. ERC members may include methodologists, epidemiologists, healthcare providers, and biostatisticians. The recommendations developed by the writing committee on the basis of the systematic review are marked with “SR.”

Guideline-Directed Management and Therapy

The term guideline-directed management and therapy (GDMT) encompasses clinical evaluation, diagnostic testing, and pharmacological and procedural treatments. For these and all recommended drug treatment regimens, the reader should confirm the dosage by reviewing product insert material and evaluate the treatment regimen for contraindications and interactions. The recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States.

Class of Recommendation and Level of Evidence

The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1).

The reader is encouraged to consult the full-text guideline(5-13 for additional guidance and details about hypertension, since the executive summary contains mainly the recommendations.

Glenn N. Levine, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Practice Guidelines

1. Introduction

In 2013, the National Heart, Lung, and Blood Institute (NHLBI) Advisory Council recommended that the NHLBI focus specifically on reviewing the highest-quality evidence and partner with other organizations to develop recommendations. Accordingly, the ACC and AHA collaborated with the NHLBI and stakeholder and professional organizations to complete and publish 4 guidelines (on assessment of cardiovascular risk, lifestyle modifications to reduce cardiovascular risk, management of blood cholesterol in adults, and management of overweight and obesity in adults) to make them available to the widest possible constituency. In 2014, the ACC and AHA in partnership with several other professional societies initiated a guideline on the prevention, detection, evaluation and management of high blood pressure in adults. Under the management of the ACC/AHA Task Force, a Prevention Subcommittee was appointed to help guide development of the suite of guidelines on prevention of cardiovascular disease.

As early as the 1920s, and subsequently in the 1959 Build and Blood Pressure Study of almost 5 million adults insured between 1934 and 1954, a strong direct relationship was noted between level of BP and risk of clinical complications and death. In the 1960s, these findings were confirmed in a series of reports from the Framingham Heart Study. The 1967 and 1970 Veterans Administration Cooperative Study Group reports ushered in the era of effective treatment for high BP. The first comprehensive guideline for detection, evaluation, and management of high BP was published in 1977, under the sponsorship of the NHLBI. In subsequent years, a series of Joint National Committee (JNC) BP guidelines were published to assist the practice community and improve prevention, awareness, treatment, and control of high BP.

1.1. Methodology and Evidence Review

An extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted between February and August 2015. Key search words included but were not limited to the following: adherence; aerobic; alcohol intake; ambulatory care; antihypertensive: agents, drug, medication, therapy; beta adrenergic blockers; blood pressure: arterial, control, determination, devices, goal, high, improve, measurement, monitoring, ambulatory; calcium channel blockers; diet; diuretic agent; drug therapy; heart failure: diastolic, systolic; hypertension: white coat, masked, ambulatory, isolated ambulatory, isolated clinic, diagnosis, reverse white coat, prevention, therapy, treatment, control; intervention; lifestyle: measures, modification; office visits; patient outcome; performance measures; physical activity; potassium intake; protein intake; renin inhibitor; risk reduction: behavior, counseling; screening; sphygmomanometers; spironolactone; therapy; treatment: adherence, compliance, efficacy, outcome, protocol, regimen; weight. Additional relevant studies published through June 2016, during the guideline writing process, were also considered by the writing committee and added to the evidence tables when appropriate. The final evidence tables included in the Online Data Supplement summarize the evidence used by the writing committee to formulate recommendations.

As noted in the preamble, an independent ERC was commissioned to perform a formal systematic review of 4 critical clinical questions related to hypertension (Table 2), the results of which were considered by the writing committee for incorporation into this guideline. Concurrent with this process, writing committee members evaluated other published data relevant to the guideline. The findings of the ERC and the writing committee members were formally presented and discussed, and then guideline recommendations were developed. The systematic review report, “Systematic Review for the 2017 ACC/AHA/ABC/ACP/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults,” is published in conjunction with this guideline and its respective data supplements are available online. No writing
committee member reported a RWI. Drs. Whelton, Wright and Williamson had leadership roles in SPRINT (Systolic Blood Pressure Intervention Trial). Dr. Carey chaired committee discussions in which the SPRINT results were considered.

1.2. Organization of the Writing Committee
The writing committee consisted of clinicians, cardiologists, epidemiologists, internists, an endocrinologist, a geriatrician, a nephrologist, a neurologist, a nurse, a pharmacist, a physician assistant, and 2 lay/patient representatives. It included representatives from the ACC, AHA, American Academy of Physician Assistants (AAPA), Association of Black Cardiologists (ABC), American College of Preventive Medicine (ACPM), American Geriatrics Society (AGS), American Pharmacists Association (APhA), American Society of Hypertension (ASH), American Society for Preventive Cardiology (ASPC), National Medical Association (NMA), and Preventive Cardiovascular Nurses Association (PCNA).

Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)

<table>
<thead>
<tr>
<th>CLASS (STRENGTH) OF RECOMMENDATION</th>
<th>LEVEL (QUALITY) OF EVIDENCE‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLASS I (STRONG)</strong> Benefit &gt;&gt; Risk</td>
<td><strong>LEVEL A</strong></td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>– Is recommended</td>
<td></td>
</tr>
<tr>
<td>– Is indicated/useful/effective/beneficial</td>
<td></td>
</tr>
<tr>
<td>– Should be performed/administered/other</td>
<td></td>
</tr>
<tr>
<td>– Comparative-Effectiveness Phrases‡:</td>
<td></td>
</tr>
<tr>
<td>– Treatment/strategy A is recommended/indicated in preference to treatment B</td>
<td></td>
</tr>
<tr>
<td>– Treatment A should be chosen over treatment B</td>
<td></td>
</tr>
<tr>
<td><strong>CLASS IIa (MODERATE)</strong> Benefit &gt;&gt; Risk</td>
<td><strong>LEVEL B-R</strong> (Randomized)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>– Is reasonable</td>
<td></td>
</tr>
<tr>
<td>– Can be useful/effective/beneficial</td>
<td></td>
</tr>
<tr>
<td>– Comparative-Effectiveness Phrases‡:</td>
<td></td>
</tr>
<tr>
<td>– Treatment/strategy A is probably recommended/indicated in preference to treatment B</td>
<td></td>
</tr>
<tr>
<td>– It is reasonable to choose treatment A over treatment B</td>
<td></td>
</tr>
<tr>
<td><strong>CLASS IIb (WEAK)</strong> Benefit ≥ Risk</td>
<td><strong>LEVEL B-NR</strong> (Nonrandomized)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>– May/might be reasonable</td>
<td></td>
</tr>
<tr>
<td>– May/might be considered</td>
<td></td>
</tr>
<tr>
<td>– Usefulness/effectiveness is unknown/unclear/uncertain or not well established</td>
<td></td>
</tr>
<tr>
<td><strong>CLASS III: No Benefit (MODERATE)</strong> Benefit = Risk (Generally, LOE A or B use only)</td>
<td><strong>LEVEL C-LD</strong> (Limited Data)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>– Is not recommended</td>
<td></td>
</tr>
<tr>
<td>– Is not indicated/useful/effective/beneficial</td>
<td></td>
</tr>
<tr>
<td>– Should not be performed/administered/other</td>
<td></td>
</tr>
<tr>
<td><strong>CLASS III: Harm (STRONG)</strong> Risk &gt; Benefit</td>
<td><strong>LEVEL C-EO</strong> (Expert Opinion)</td>
</tr>
<tr>
<td>Suggested phrases for writing recommendations:</td>
<td></td>
</tr>
<tr>
<td>– Potentially harmful</td>
<td></td>
</tr>
<tr>
<td>– Causes harm</td>
<td></td>
</tr>
<tr>
<td>– Associated with excess morbidity/mortality</td>
<td></td>
</tr>
<tr>
<td>– Should not be performed/administered/other</td>
<td></td>
</tr>
</tbody>
</table>

COR and LOE are determined independently (any COR may be paired with any LOE). A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information). †For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. ‡The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee. COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers nominated by the ACC and AHA; 1 reviewer each from the AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC NMA, and PCNA; and 38 individual content reviewers. Reviewers’ RWI information was distributed to the writing committee and is published in this document (Appendix 2).
This document was approved for publication by the governing bodies of the ACC, AHA, AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC, NMA, and PCNA.

1.4. Scope of the Guideline
The present guideline is intended to be a resource for the clinical and public health practice communities. It is designed to be comprehensive but succinct and practical in providing guidance for prevention, detection, evaluation, and management of high BP. It is an update of the NHLBI publication, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure” (JNC 7).19 It incorporates new information from studies of office-based BP-related risk of CVD, ambulatory blood pressure monitoring (ABPM), home blood pressure monitoring (HBPM), telemedicine, and various other areas. This guideline does not address the use of BP-lowering medications for the purposes of prevention of recurrent CVD events in patients with stable ischemic heart disease (SIHD) or chronic heart failure (HF) in the absence of hypertension; these topics are the focus of other ACC/AHA guidelines.1-11,1-12 In developing the present guideline, the writing committee reviewed prior published guidelines, evidence reviews, and related statements. Table 3 contains a list of publications and statements deemed pertinent to this writing effort and is intended for use as a resource, thus obviating the need to repeat existing guideline recommendations.

2. BP and CVD Risk
2.1. Observational Relationship
Observational studies have demonstrated graded associations between higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) and increased CVD risk.1,2 In a meta-analysis of 61 prospective studies, the risk of CVD increased in a log-linear fashion from SBP levels <115 mm Hg to >180 mm Hg and from DBP levels <75 mm Hg to >105 mm Hg.2,1-2 In that analysis, 20 mm Hg higher SBP and 10 mm Hg higher DBP were each associated with a doubling in the risk of death from stroke, heart disease, or other vascular disease. In a separate observational study including >1 million adult patients ≥30 years of age,
higher SBP and DBP were associated with increased risk of CVD incidence and angina, myocardial infarction (MI), HF, stroke, peripheral artery disease (PAD), and abdominal aortic aneurysm, each evaluated separately.\textsuperscript{52,1-2} An increased risk of CVD associated with higher SBP and DBP has been reported across a broad age spectrum, from 30 years to >80 years of age. Although the relative risk of incident CVD associated with higher SBP and DBP is smaller at older ages,
the corresponding high BP–related increase in absolute risk is larger in older persons (265 years) given the higher absolute risk of CVD at an older age. S2.1-1

2.2. BP Components

Epidemiological studies have evaluated associations of SBP and DBP, as well as derived components of BP measurements (including pulse pressure, mean BP, and mid-BP), with CVD outcomes (Table 4). When considered separately, higher levels of both SBP and DBP have been associated with increased CVD risk. S2.2-1, S2.2-2 Higher SBP has consistently been associated with increased CVD risk after adjustment for, or within strata of, DBP. S2.2-3–S2.2-5 In contrast, after consideration of SBP through adjustment or stratification, DBP has not been consistently associated with CVD risk. S2.2-6,S2.2-7 Although pulse pressure and mid-BP have been associated with increased CVD risk independent of SBP and DBP in some studies, SBP (especially) and DBP are prioritized in the present document because of the robust evidence base for these measures in both observational studies and clinical trials and because of their ease of measurement in practice settings. S2.2-8–S2.2-11

2.3. Population Risk

In 2010, high BP was the leading cause of death and disability-adjusted life years worldwide. S2.3-1–S2.3-3 In the United States, hypertension (see Section 3.1 for definition) accounted for more CVD deaths than any other modifiable CVD risk factor and was second only to cigarette smoking as a preventable cause of death for any reason. S2.3-4 In a follow-up study of 23,272 US NHANES (National Health and Nutrition Examination Survey) participants, >50% of deaths from coronary heart disease (CHD) and stroke occurred among individuals with hypertension. S2.3-4 Because of the high prevalence of hypertension and its associated increased risk of CHD, stroke, and end-stage renal disease (ESRD), the population-attributable risk of these outcomes associated with hypertension is high. S2.3-4,S2.3-5 In the population-based ARIC (Atherosclerosis Risk in Communities) study, 25% of the cardiovascular events (CHD, coronary revascularization, stroke, or HF) were attributable to hypertension. In the Northern Manhattan study, the percentage of events attributable to hypertension was higher in women (32%) than in men (19%) and higher in blacks (36%) than in whites (21%). S2.3-6 In 2012, hypertension was the second leading assigned cause of ESRD, behind diabetes mellitus (DM), and accounted for 34% of incident ESRD cases in the US population. S2.3-7

2.4. Coexistence of Hypertension and Related Chronic Conditions

Table 4. BP Measurement Definitions

<table>
<thead>
<tr>
<th>BP Measurement</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>First Korotkoff sound*</td>
</tr>
<tr>
<td>DBP</td>
<td>Fifth Korotkoff sound*</td>
</tr>
<tr>
<td>Pulse pressure</td>
<td>SBP minus DBP</td>
</tr>
<tr>
<td>Mean arterial pressure</td>
<td>DBP plus one third pulse pressure†</td>
</tr>
<tr>
<td>Mid-BP</td>
<td>Sum of SBP and DBP, divided by 2</td>
</tr>
</tbody>
</table>

*See Section 4 for a description of Korotkoff sounds.† Calculation assumes normal heart rate.

BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.

Table 5. CVD Risk Factors Common in Patients With Hypertension

<table>
<thead>
<tr>
<th>Modifiable Risk Factors*</th>
<th>Relatively Fixed Risk Factors†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current cigarette smoking, secondhand smoking</td>
<td>CKD</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Family history</td>
</tr>
<tr>
<td>Dyslipidemia/hypercholesterolemia</td>
<td>Low socioeconomic/educational status</td>
</tr>
<tr>
<td>Overweight/obesity</td>
<td>Male sex</td>
</tr>
<tr>
<td>Physical inactivity/low fitness</td>
<td>Obstructive sleep apnea</td>
</tr>
<tr>
<td>Unhealthy diet</td>
<td>Psychosocial stress</td>
</tr>
</tbody>
</table>

*Factors that can be changed and, if changed, may reduce CVD risk.†Factors that are difficult to change (CKD, low socioeconomic/educational status, obstructive sleep apnea), cannot be changed (family history, increased age, male sex), or, if changed through the use of current intervention techniques, may not reduce CVD risk (psychosocial stress).

Table 6. Categories of BP in Adults*

<table>
<thead>
<tr>
<th>BP Category</th>
<th>SBP</th>
<th>DBP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt;120 mm Hg</td>
<td>&lt;80 mm Hg</td>
</tr>
<tr>
<td>Elevated</td>
<td>120–129 mm Hg</td>
<td>&lt;80 mm Hg</td>
</tr>
</tbody>
</table>

*Individuals with SBP and DBP in 2 categories should be designated to the higher BP category.

BP indicates blood pressure (based on an average of ≥2 careful readings obtained on ≥2 occasions, as detailed in Section 4); DBP, diastolic blood pressure; and SBP, systolic blood pressure.
3.2. Lifetime Risk of Hypertension
Observational studies have documented a relatively high incidence of hypertension over periods of 5 to 10 years of follow-up.3.2-1,3.2-2 Thus, there is a much higher long-term population burden of hypertension as BP progressively increases with age. Several studies have estimated the long-term cumulative incidence of developing hypertension.3.2-3,3.2-4 In an analysis of 1132 white male medical students (mean age: approximately 23 years at baseline) in the Johns Hopkins Precursors study, 0.3%, 6.5%, and 37% developed hypertension at age 25, 45, and 65 years, respectively.3.2-5 In MESA (Multi-Ethnic Study of Atherosclerosis), the percentage of the population developing hypertension over their lifetimes was higher for African Americans and Hispanics than for whites and Asians.3.2-3,3.2-4 For adults 45 years of age without hypertension, the 40-year risk of developing hypertension was 93% for African-American, 92% for Hispanic, 86% for white, and 84% for Chinese adults.3.2-3 In the Framingham Heart Study, approximately 92% for Hispanic, 86% for white, and 84% for Chinese adults.3.2-3 In the Framingham Heart Study, approximately 90% of adults free of hypertension at age 55 or 65 years developed hypertension during their lifetimes.3.2-4 All of these estimates were based on use of the 140/90–mm Hg cutpoint for recognition of hypertension and would have been higher had the 130/80–mm Hg cutpoint been used.

3.3. Prevalence of High BP

Table 7. Prevalence of Hypertension Based on 2 SBP/DBP Thresholds†

<table>
<thead>
<tr>
<th>Race-ethnicity§</th>
<th>Overall, crude</th>
<th>Overall, age-sex adjusted</th>
<th>Age group, y</th>
<th>SBP/DBP ≥130/80 mm Hg or Self-Reported Antihypertensive Medication†</th>
<th>SBP/DBP ≥140/90 mm Hg or Self-Reported Antihypertensive Medication‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Hispanic white</td>
<td>47%</td>
<td>41%</td>
<td>48%</td>
<td>30%</td>
<td>19%</td>
</tr>
<tr>
<td>Non-Hispanic black</td>
<td>59%</td>
<td>56%</td>
<td>50%</td>
<td>44%</td>
<td>42%</td>
</tr>
<tr>
<td>Non-Hispanic Asian</td>
<td>45%</td>
<td>36%</td>
<td>57%</td>
<td>77%</td>
<td>75%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>44%</td>
<td>42%</td>
<td>79%</td>
<td>79%</td>
<td>85%</td>
</tr>
</tbody>
</table>

The prevalence estimates have been rounded to the nearest full percentage. *130/80 and 140/90 mm Hg in 9623 participants (≥20 years of age) in NHANES 2011–2014. †BP cutpoints for definition of hypertension in the present guideline. ‡BP cutpoints for definition of hypertension in JNC 7. §Adjusted to the 2010 age-sex distribution of the US adult population. BP indicates blood pressure; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic blood pressure.

4. Measurement of BP

4.1. Accurate Measurement of BP in the Office

Recommendation for Accurate Measurement of BP in the Office

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>1. For diagnosis and management of high BP, proper methods are recommended for accurate measurement and documentation of BP (Table 8).</td>
</tr>
</tbody>
</table>

Table 8. Checklist for Accurate Measurement of BP

<table>
<thead>
<tr>
<th>Key Steps for Proper BP Measurements</th>
<th>Specific Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1: Properly prepare the patient</td>
<td>1. Have the patient relax, sitting in a chair (feet on floor, back supported) for &gt;5 min.</td>
</tr>
<tr>
<td>Step 2: Use proper technique for BP measurements</td>
<td>2. The patient should avoid caffeine, exercise, and smoking for at least 30 min before measurement.</td>
</tr>
<tr>
<td>Step 3: Take the proper measurements needed for diagnosis and treatment of elevated BP/hypertension</td>
<td>3. Ensure patient has emptied his/her bladder.</td>
</tr>
<tr>
<td></td>
<td>4. Neither the patient nor the observer should talk during the rest period or during the measurement.</td>
</tr>
<tr>
<td></td>
<td>5. Remove all clothing covering the location of cuff placement.</td>
</tr>
<tr>
<td></td>
<td>6. Measurements made while the patient is sitting or lying on an examining table do not fulfill these criteria.</td>
</tr>
</tbody>
</table>

1. Use a BP measurement device that has been validated, and ensure that the device is calibrated periodically.*
2. Support the patient’s arm (eg, resting on a desk).
3. Position the middle of the cuff on the patient’s upper arm at the level of the right atrium (the midpoint of the sternum).
4. Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger- or smaller-than-normal cuff size is used (Table 9).
5. Either the stethoscope diaphragm or bell may be used for auscultatory readings.3.4.1-2

Step 3: Take the proper measurements needed for diagnosis and treatment of elevated BP/hypertension

1. At the first visit, record BP in both arms. Use the arm that gives the higher reading for subsequent readings.
2. Separate repeated measurements by 1–2 min.
3. For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP. Inflate the cuff 20–30 mm Hg above this level for an auscultatory determination of the BP level.
4. For auscultatory readings, deflate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.

(Continued)
4.2. Out-of-Office and Self-Monitoring of BP

Recommendation for Out-of-Office and Self-Monitoring of BP

References that support the recommendation are summarized in Online Data Supplement 3 and Systematic Review Report.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>1. Out-of-office BP measurements are recommended to confirm the diagnosis of hypertension (Table 11) and for titration of BP-lowering medication, in conjunction with telehealth counseling or clinical interventions.</td>
</tr>
</tbody>
</table>

SR indicates systematic review.

Table 9. Selection Criteria for BP Cuff Size for Measurement of BP in Adults

<table>
<thead>
<tr>
<th>Arm Circumference</th>
<th>Usual Cuff Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>22–26 cm</td>
<td>Small adult</td>
</tr>
<tr>
<td>27–34 cm</td>
<td>Adult</td>
</tr>
<tr>
<td>35–44 cm</td>
<td>Large adult</td>
</tr>
<tr>
<td>45–52 cm</td>
<td>Adult thigh</td>
</tr>
</tbody>
</table>

Adapted with permission from Pickering et al. (American Heart Association, Inc.), and Weir et al. (American College of Physicians, Inc.).

BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.

4.3. Masked and White Coat Hypertension

Recommendations for Masked and White Coat Hypertension

References that support recommendations are summarized in Online Data Supplements 4, 5, and 6.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIA</td>
<td>B-NR</td>
<td>1. In adults with an untreated SBP greater than 130 mm Hg but less than 160 mm Hg or DBP greater than 80 mm Hg but less than 100 mm Hg, it is reasonable to screen for the presence of white coat hypertension by using either daytime ABPM or HBPM before diagnosis of hypertension.</td>
</tr>
</tbody>
</table>

IIA C-LD 2. In adults with white coat hypertension, periodic monitoring with either ABPM or HBPM is reasonable to detect transition to sustained hypertension.

Adapted with permission from Mancia et al., Pickering et al., and Weir et al. (Oxford University Press, American Heart Association, Inc., and American College of Physicians, Inc.).

BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.

Table 10. Procedures for Use of HBPM

Patient training should occur under medical supervision, including:

- Information about hypertension
- Selection of equipment
- Acknowledgment that individual BP readings may vary substantially
- Interpretation of results

See Table 11 for HBPM targets. BP indicates blood pressure; and HBPM, home blood pressure monitoring.
Whelton et al 2017 High Blood Pressure Clinical Practice Guideline: Executive Summary

Table 11. Corresponding Values of SBP/DBP for Clinic, HBPM, Daytime, Nighttime, and 24-Hour ABPM Measurements

<table>
<thead>
<tr>
<th>Clinic</th>
<th>HBPM</th>
<th>Daytime ABPM</th>
<th>Nighttime ABPM</th>
<th>24-Hour ABPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>120/80</td>
<td>120/80</td>
<td>120/80</td>
<td>100/65</td>
<td>115/75</td>
</tr>
<tr>
<td>130/80</td>
<td>130/80</td>
<td>130/80</td>
<td>110/65</td>
<td>125/75</td>
</tr>
<tr>
<td>140/90</td>
<td>135/85</td>
<td>135/85</td>
<td>120/70</td>
<td>130/80</td>
</tr>
<tr>
<td>160/100</td>
<td>145/90</td>
<td>145/90</td>
<td>140/85</td>
<td>145/90</td>
</tr>
</tbody>
</table>

ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; and SBP, systolic blood pressure.

Table 12. BP Patterns Based on Office and Out-of-Office Measurements

<table>
<thead>
<tr>
<th></th>
<th>Office/Clinic/Healthcare Setting</th>
<th>Home/Nonhealthcare/ABPM Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normotensive</td>
<td>No hypertension</td>
<td>No hypertension</td>
</tr>
<tr>
<td>Sustained hypertension</td>
<td>Hypertension</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Masked hypertension</td>
<td>No hypertension</td>
<td>Hypertension</td>
</tr>
<tr>
<td>White coat hypertension</td>
<td>Hypertension</td>
<td>No hypertension</td>
</tr>
</tbody>
</table>

ABPM indicates ambulatory blood pressure monitoring; and BP, blood pressure.

Figure 1. Detection of white coat hypertension or masked hypertension in patients not on drug therapy. Colors correspond to Class of Recommendation in Table 1. ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; and HBPM, home blood pressure monitoring.
Figure 2. Detection of white coat effect or masked uncontrolled hypertension in patients on drug therapy. Colors correspond to Class of Recommendation in Table 1. See Section 8 for treatment options. ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; CVD, cardiovascular disease; and HBPM, home blood pressure monitoring.
5. Causes of Hypertension

Conditions
- Drug-resistant/induced hypertension
- Abrupt onset of hypertension
- Onset of hypertension at <30 y
- Exacerbation of previously controlled hypertension
- Disproportionate TOD for degree of hypertension
- Accelerated/malignant hypertension
- Onset of diastolic hypertension in older adults (age >65 y)
- Unprovoked or excessive hypokalemia

Screen for secondary hypertension (Class I) (see Table 13)

Positive screening test

Refer to clinician with specific expertise (Class IIb)

No

Screening not indicated (No Benefit)

Referal not necessary (No Benefit)

Table 13. Causes of Secondary Hypertension With Clinical Indications and Diagnostic Screening Tests

<table>
<thead>
<tr>
<th>Common causes</th>
<th>Prevalence</th>
<th>Clinical Indications</th>
<th>Physical Examination</th>
<th>Screening Tests</th>
<th>Additional/Confirmatory Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal parenchymal disease(^{5,1,3,3,1-2})</td>
<td>1%–2%</td>
<td>Urinary tract infections; obstruction, hematuria; urinary frequency and nocturia; analgesic abuse; family history of polycystic kidney disease; elevated serum creatinine; abnormal urinalysis</td>
<td>Abdominal mass (polycystic kidney disease); skin pallor</td>
<td>Renal ultrasound</td>
<td>Tests to evaluate cause of renal disease</td>
</tr>
<tr>
<td>Renovascular disease(^{5,1,3,1-2})</td>
<td>5%–34%*</td>
<td>Resistant hypertension; hypertension of abrupt onset or worsening or increasingly difficult to control; flash pulmonary edema (atherosclerotic); early-onset hypertension, especially in women (fibromuscular hyperplasia)</td>
<td>Abdominal systolic-diastolic bruit; bruits over other arteries (carotid – atherosclerotic or fibromuscular dysplasia), femoral</td>
<td>Renal Duplex Doppler ultrasound; MRA; abdominal CT</td>
<td>Bilateral selective renal intra-arterial angiography</td>
</tr>
</tbody>
</table>

Figure 3. Screening for secondary hypertension. Colors correspond to Class of Recommendation in Table 1. TOD indicates target organ damage (eg, cerebrovascular disease, hypertensive retinopathy, left ventricular hypertrophy, left ventricular dysfunction, heart failure, coronary artery disease, chronic kidney disease, albuminuria, peripheral artery disease).
### Common causes (Continued)

<table>
<thead>
<tr>
<th>Common causes</th>
<th>Prevalence</th>
<th>Clinical Indications</th>
<th>Physical Examination</th>
<th>Screening Tests</th>
<th>Additional/Confirmatory Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary aldosteronism</strong>&lt;sup&gt;5.1-4,55.1-5&lt;/sup&gt;</td>
<td>8%–20%†</td>
<td>Resistant hypertension; hypertension with hypokalemia (spontaneous or diuretic induced); hypertension and muscle cramps or weakness; hypertension and incidentally discovered adrenal mass; hypertension and obstructive sleep apnea; hypertension and family history of early-onset hypertension or stroke</td>
<td>Arrhythmias (with hypokalemia); especially atrial fibrillation</td>
<td>Plasma aldosterone/renin ratio under standardized conditions (correction of hypokalemia and withdrawal of aldosterone antagonists for 4–6 wk)</td>
<td>Oral sodium loading test (with 24-h urine aldosterone) or IV saline infusion test with plasma aldosterone at 4 h of infusion Adrenal CT scan, adrenal vein sampling.</td>
</tr>
<tr>
<td><strong>Obstructive sleep apnea</strong>&lt;sup&gt;5.1-6‡&lt;/sup&gt;</td>
<td>25%–50%</td>
<td>Resistant hypertension; snoring; fitful sleep; breathing pauses during sleep; daytime sleepiness</td>
<td>Obesity, Mallampati class III–IV; loss of normal nocturnal BP fall</td>
<td>Berlin Questionnaire;&lt;sup&gt;5.1-7&lt;/sup&gt; Epworth Sleepiness Score;&lt;sup&gt;5.1-8&lt;/sup&gt; overnight oximetry</td>
<td>Polysomnography</td>
</tr>
<tr>
<td><strong>Drug or alcohol induced</strong>&lt;sup&gt;5.1-9§&lt;/sup&gt;</td>
<td>2%–4%</td>
<td>Sodium-containing antacids; caffeine; nicotine (smoking); alcohol; NSAIDs; oral contraceptives; cyclosporine or tacrolimus; sympathomimetics (decongestants, anorectics); cocaine, amphetamines and other illicit drugs; neuropsychiatric agents; erythropoiesis-stimulating agents; clonidine withdrawal; herbal agents (Ma Huang, ephedra)</td>
<td>Fine tremor, tachycardia, sweating (cocaine, ephedrine, MAO inhibitors); acute abdominal pain (cocaine)</td>
<td>Urinary drug screen (illicit drugs)</td>
<td>Response to withdrawal of suspected agent</td>
</tr>
</tbody>
</table>

### Uncommon causes

<table>
<thead>
<tr>
<th>Uncommon causes</th>
<th>Prevalence</th>
<th>Clinical Indications</th>
<th>Physical Examination</th>
<th>Screening Tests</th>
<th>Additional/Confirmatory Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pheochromocytoma/paraganglioma</strong>&lt;sup&gt;5.1-10&lt;/sup&gt;</td>
<td>0.1%–0.6%</td>
<td>Resistant hypertension; paroxysmal hypertension or crisis superimposed on sustained hypertension; “spells,” BP lability, headache, sweating, palpitations, pallor; positive family history of pheochromocytoma/paraganglioma; adrenal incidentaloma</td>
<td>Skin stigmata of neurofibromatosis (café-au-lait spots; neurofibromas); Orthostatic hypotension</td>
<td>24-h urinary fractionated metanephrines or plasma metanephrines under standard conditions (supine position with indwelling IV cannula)</td>
<td>CT or MRI scan of abdomen/pelvis</td>
</tr>
<tr>
<td><strong>Cushing’s syndrome</strong>&lt;sup&gt;5.1-11&lt;/sup&gt;</td>
<td>&lt;0.1%</td>
<td>Rapid weight gain, especially with central distribution; proximal muscle weakness; depression; hyperglycemia</td>
<td>Central obesity, “moon” face, dorsal and supraclavicular fat pads, wide (1-cm) violaceous striae, hirsutism</td>
<td>Overnight 1-mg dexamethasone suppression test</td>
<td>24-h urinary free cortisol excretion (preferably multiple); midnight salivary cortisol</td>
</tr>
<tr>
<td><strong>Hypothyroidism</strong>&lt;sup&gt;5.1-9&lt;/sup&gt;</td>
<td>&lt;1%</td>
<td>Dry skin; cold intolerance; constipation; hoarseness; weight gain</td>
<td>Delayed ankle reflex; periorbital puffiness; coarse skin; cold skin; slow movement; goiter</td>
<td>Thyroid-stimulating hormone; free thyroxine</td>
<td>None</td>
</tr>
<tr>
<td><strong>Hyperthyroidism</strong>&lt;sup&gt;5.1-9&lt;/sup&gt;</td>
<td>&lt;1%</td>
<td>Warm, moist skin; heat intolerance; nervousness; tremulousness; insomnia; weight loss; diarrhea; proximal muscle weakness</td>
<td>Lid lag; fine tremor of the outstretched hands; warm, moist skin</td>
<td>Thyroid-stimulating hormone; free thyroxine</td>
<td>Radioactive iodine uptake and scan</td>
</tr>
<tr>
<td><strong>Aortic coarctation (undiagnosed or repaired)</strong>&lt;sup&gt;5.1-12&lt;/sup&gt;</td>
<td>0.1%</td>
<td>Young patient with hypertension (&lt;30 y of age)</td>
<td>BP higher in upper extremities than in lower extremities; absent femoral pulses; continuous murmur over patient’s back, chest, or abdominal bruit; left thoracotomy scar (postoperative)</td>
<td>Echocardiogram</td>
<td>Thoracic and abdominal CT angiogram or MRA</td>
</tr>
</tbody>
</table>

(Continued)
5.1.1. Drugs and Other Substances With Potential to Impair BP Control

5.1.2. Primary Aldosteronism

Table 13. Continued

<table>
<thead>
<tr>
<th>Uncommon Causes (Continued)</th>
<th>Prevalence</th>
<th>Clinical Indications</th>
<th>Physical Examination</th>
<th>Screening Tests</th>
<th>Additional/Confirmatory Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary hyperparathyroidism</td>
<td>Rare</td>
<td>Hypercalcemia</td>
<td>Usually none</td>
<td>Serum calcium</td>
<td>Serum parathyroid hormone</td>
</tr>
<tr>
<td>Congenital adrenal hyperplasia</td>
<td>Rare</td>
<td>Hypertension and hypokalemia; virilization (11-beta-hydroxylase deficiency [11-beta-OH]; incomplete masculinization in males and primary amenorrhea in females (17-alpha-hydroxylase deficiency [17-alpha-OH])</td>
<td>Signs of virilization (11-beta-OH) or incomplete masculinization (17-alpha-OH)</td>
<td>Hypertension and hypokalemia with low or normal aldosterone and renin</td>
<td>11-beta-OH: elevated deoxycorticosterone (DOC), 11-deoxycortisol, and androgens17-alpha-OH; decreased androgens and estrogen; elevated deoxycorticosterone and corticosterone</td>
</tr>
<tr>
<td>Mineralocorticoid excess syndromes other than primary aldosteronism</td>
<td>Rare</td>
<td>Early-onset hypertension; resistant hypertension; hypokalemia or hyperkalemia</td>
<td>Arrhythmias (with hypokalemia)</td>
<td>Low aldosterone and renin</td>
<td>Urinary cortisol metabolites; genetic testing</td>
</tr>
<tr>
<td>Acromegaly</td>
<td>Rare</td>
<td>Acral features, enlarging shoe, glove, or hat size; headache, visual disturbances; diabetes mellitus</td>
<td>Acral features; large hands and feet; frontal bossing</td>
<td>Serum growth hormone ≥1 ng/mL during oral glucose load</td>
<td>Elevated age- and sex-matched IGF-1 level; MRI scan of the pituitary</td>
</tr>
</tbody>
</table>

*Depending on the clinical situation (hypertension alone, 5%; hypertension starting dialysis, 22%; hypertension and peripheral vascular disease, 28%; hypertension in the elderly with congestive heart failure, 34%). 18% in general population with hypertension; up to 20% in patients with resistant hypertension. †Although obstructive sleep apnea is listed as a cause of secondary hypertension, RCTs on the effects of continuous positive airway pressure on lowering BP in patients with hypertension have produced mixed results (see Section 5.4.4 for details). §For a list of frequently used drugs causing hypertension and accompanying evidence, see Table 14. BP indicates blood pressure; CT, computed tomography; DOC, 11-deoxycorticosterone; IGF-1, insulin-like growth factor-1; IV, intravenous; MAO, monamine oxidase; MRI, magnetic resonance imaging; MRA, magnetic resonance arteriography; NSAIDs, nonsteroidal anti-inflammatory drugs; OH, hydroxylase; and RCT, randomized clinical trial.

5.1.3. Renal Artery Stenosis

5.1.3.1. Recommendations for Renal Artery Stenosis

References that support recommendations are summarized in Online Data Supplements 7 and 24.

<table>
<thead>
<tr>
<th>Recommendations for Renal Artery Stenosis</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Medical therapy is recommended for adults with atherosclerotic renal artery stenosis.</td>
<td>I</td>
<td>A</td>
<td>1.</td>
</tr>
<tr>
<td>2. In adults with renal artery stenosis for whom medical management has failed (refractory hypertension, worsening renal function, and/or intractable HF) and those with nonatherosclerotic disease, including fibromuscular dysplasia, it may be reasonable to refer the patient for consideration of revascularization (percutaneous renal artery angioplasty and/or stent placement).</td>
<td>IIb</td>
<td>C-E0</td>
<td>2.</td>
</tr>
</tbody>
</table>
Table 14. Frequently Used Medications and Other Substances That May Cause Elevated BP*

<table>
<thead>
<tr>
<th>Agent</th>
<th>Possible Management Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>Limit alcohol to ≤1 drink daily for women and ≤2 drinks for men[^5.1.1-1]</td>
</tr>
<tr>
<td>Amphetamines (eg, amphetamine, methylphenidate, dextroamphetamine)</td>
<td>Discontinue or decrease dose[^5.1.1-2] and consider behavioral therapies for ADHD[^5.1.1-3]</td>
</tr>
<tr>
<td>Antidepressants (eg, MAOIs, SNRIs, TCAs)</td>
<td>Consider alternative agents (eg, SSRIs) depending on indication and avoid tyramine-containing foods with MAOIs</td>
</tr>
<tr>
<td>Atypical antipsychotics (eg, clozapine, olanzapine)</td>
<td>Discontinue or limit use when possible and consider behavior therapy where appropriate</td>
</tr>
<tr>
<td></td>
<td>Recommend lifestyle modification (see Section 6.2)</td>
</tr>
<tr>
<td></td>
<td>Avoid tyramine-containing foods if using MAOIs.</td>
</tr>
<tr>
<td>Caffeine</td>
<td>Generally limit caffeine intake to &lt;300 mg/d</td>
</tr>
<tr>
<td></td>
<td>Avoid use in patients with uncontrolled hypertension.</td>
</tr>
<tr>
<td></td>
<td>Coffee use in patients with hypertension is associated with acute increases in BP; long-term use is not associated with increased BP or CVD[^5.1.1-6]</td>
</tr>
<tr>
<td>Decongestants (eg, phenylephrine, pseudoephedrine)</td>
<td>Use for shortest duration possible, and avoid in severe or uncontrolled hypertension</td>
</tr>
<tr>
<td></td>
<td>Consider alternative therapies (eg, nasal saline, intransal corticosteroids, antihistamines) as appropriate</td>
</tr>
<tr>
<td>Herbal supplements (eg, Ma Huang [ephedra], St. John’s wort [with MAO inhibitors, yohimbine])</td>
<td>Avoid use</td>
</tr>
<tr>
<td>Immunosuppressants (eg, cyclosporine)</td>
<td>Consider converting to tacrolimus, which may be associated with fewer effects on BP[^5.1.1-7-5.1.1-8]</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>Use low-dose (eg, 20–30 mcg ethinyl estradiol) agents[^5.1.1-10] for a progestin-only form of contraception, or consider alternative forms of birth control where appropriate (eg, barrier, abstinence, IUD) Avoid use in women with uncontrolled hypertension[^5.1.1-10]</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Avoid systemic NSAIDs when possible</td>
</tr>
<tr>
<td>Recreational drugs (eg, “bath salts” [MDPV], cocaine, methamphetamine, etc.)</td>
<td>Consider alternative analgesics (eg, acetaminophen, tramadol, topical NSAIDs), depending on indication and risk</td>
</tr>
<tr>
<td>Systemic corticosteroids (eg, dexamethasone, fluoro cortisone, methylprednisolone, prednisone, prednisolone)</td>
<td>Avoid or limit use when possible Consider alternative modes of administration (eg, inhaled, topical) when feasible</td>
</tr>
<tr>
<td>Angiogenesis inhibitor (eg, bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenib)</td>
<td>Initiate or intensify antihypertensive therapy</td>
</tr>
<tr>
<td>*List is not all inclusive.</td>
<td>ADH indicates attention-deficit/hyperactivity disorder; BP, blood pressure; CVD, cardiovascular disease; IUD, intra-uterine device; MAOI, monoamine-oxidase inhibitors; MDPV, methylenedioxyxypovarone; NSAIDs, nonsteroidal anti-inflammatory drugs; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; and TCA, tricyclic antidepressant.</td>
</tr>
</tbody>
</table>

5.1.4. Obstructive Sleep Apnea

**Recommendation for Obstructive Sleep Apnea**

*References that support the recommendation are summarized in Online Data Supplement 8.*

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>1. In adults with hypertension and obstructive sleep apnea, the effectiveness of continuous positive airway pressure (CPAP) to reduce BP is not well established[^5.1.4-1-5.1.4-5]</td>
</tr>
</tbody>
</table>

6. Nonpharmacological Interventions

**Recommendations for Nonpharmacological Interventions**

*References that support recommendations are summarized in Online Data Supplements 9-21.*

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>1. Weight loss is recommended to reduce BP in adults with elevated BP or hypertension who are overweight or obese[^5.5-5.6-4]</td>
</tr>
<tr>
<td>I</td>
<td>A</td>
<td>2. A heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) diet, that facilitates achieving a desirable weight is recommended for adults with elevated BP or hypertension[^5.5-5.6-7]</td>
</tr>
<tr>
<td>I</td>
<td>A</td>
<td>3. Sodium reduction is recommended for adults with elevated BP or hypertension[^5.5-5.6-12]</td>
</tr>
</tbody>
</table>
4. Potassium supplementation, preferably in dietary modification, is recommended for adults with elevated BP or hypertension, unless contraindicated by the presence of CKD or use of drugs that reduce potassium excretion.\textsuperscript{S6-13–S6-17}

5. Increased physical activity with a structured exercise program is recommended for adults with elevated BP or hypertension.\textsuperscript{S6-3,S6-4,S6-12,S6-18–S6-22}

6. Adult men and women with elevated BP or hypertension who currently consume alcohol should be advised to drink no more than 2 and 1 standard drinks* per day, respectively.\textsuperscript{S6-23–S6-28}

\*In the United States, 1 “standard” drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol).\textsuperscript{S6-29}

---

### Table 15. Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension*

<table>
<thead>
<tr>
<th>Nonpharmacological Intervention</th>
<th>Dose</th>
<th>Approximate Impact on SBP</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weight loss</strong></td>
<td>Weight/body fat Best goal is ideal body weight, but aim for at least a 1-kg reduction in body weight for most adults who are overweight. Expect about 1 mm Hg for every 1-kg reduction in body weight.</td>
<td>Hypertension: −5 mm Hg Normotension: −2/3 mm Hg</td>
<td>S6-1</td>
</tr>
<tr>
<td><strong>Healthy diet</strong></td>
<td>DASH dietary pattern Consume a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with reduced content of saturated and total fat.</td>
<td>Hypertension: −11 mm Hg Normotension: −3 mm Hg</td>
<td>S6-6,S6-7</td>
</tr>
<tr>
<td><strong>Reduced intake of dietary sodium</strong></td>
<td>Dietary sodium Optimal goal is &lt;1500 mg/d, but aim for at least a 1000-mg/d reduction in most adults.</td>
<td>Hypertension: −5/6 mm Hg Normotension: −2/3 mm Hg</td>
<td>S6-9,S6-10</td>
</tr>
<tr>
<td><strong>Enhanced intake of dietary potassium</strong></td>
<td>Dietary potassium Aim for 3500–5000 mg/d, preferably by consumption of a diet rich in potassium.</td>
<td>Hypertension: −4/5 mm Hg Normotension: −2 mm Hg</td>
<td>S6-13</td>
</tr>
<tr>
<td><strong>Physical activity</strong></td>
<td>Aerobic 90–150 min/wk 65%–75% heart rate reserve</td>
<td>Hypertension: −5/8 mm Hg Normotension: −2/4 mm Hg</td>
<td>S6-18,S6-22</td>
</tr>
<tr>
<td><strong>Dynamic resistance</strong></td>
<td>90–150 min/wk 50%–80% 1 rep maximum 6 exercises, 3 sets/exercise, 10 repetitions/set</td>
<td>Hypertension: −4 mm Hg Normotension: −2 mm Hg</td>
<td>S6-18</td>
</tr>
<tr>
<td><strong>Isometric resistance</strong></td>
<td>4 × 2 min (hand grip), 1 min rest between exercises, 30%–40% maximum voluntary contraction, 3 sessions/wk 8–10 wk</td>
<td>Hypertension: −5 mm Hg Normotension: −4 mm Hg</td>
<td>S6-19,S6-30</td>
</tr>
<tr>
<td><strong>Moderation in alcohol intake</strong></td>
<td>Alcohol consumption In individuals who drink alcohol, reduce alcohol\dagger to: Men: ≤2 drinks daily Women: ≤1 drink daily</td>
<td>Hypertension: −4 mm Hg Normotension: −3 mm Hg</td>
<td>S6-22–S6-24</td>
</tr>
</tbody>
</table>

---

**Resources:** Your Guide to Lowering Your Blood Pressure With DASH—How Do I Make the DASH? Available at: https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to. Accessed September 15, 2017.\textsuperscript{S6-31}

**Top 10 Dash Diet Tips. Available at:** http://dashdiet.org/dash_diet_tips.asp. Accessed September 15, 2017.\textsuperscript{S6-32}

\*Type, dose, and expected impact on BP in adults with a normal BP and with hypertension.

\daggerIn the United States, one “standard” drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol).\textsuperscript{S6-29}

DASH indicates Dietary Approaches to Stop Hypertension; and SBP, systolic blood pressure.
7. Patient Evaluation

7.1. Laboratory Tests and Other Diagnostic Procedures

Table 16. Historical Features Favoring Hypertension Cause

<table>
<thead>
<tr>
<th>Primary Hypertension</th>
<th>Secondary Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gradual increase in BP, with slow rate of rise in BP</td>
<td>BP lability, episodic pallor and dizziness (pheochromocytoma)</td>
</tr>
<tr>
<td>Lifestyle factors that favor higher BP (eg, weight gain, high-sodium diet, decreased physical activity, job change entailing increased travel, excessive consumption of alcohol)</td>
<td>Snoring, hypersomnolence (obstructive sleep apnea)</td>
</tr>
<tr>
<td>Family history of hypertension</td>
<td>Muscle cramps, weakness (hypokalemia from primary aldosteronism or secondary aldosteronism due to renovascular disease)</td>
</tr>
<tr>
<td>Weight loss, palpitations, heat intolerance (hyperthyroidism)</td>
<td>Edema, fatigue, frequent urination (kidney disease or failure)</td>
</tr>
<tr>
<td>History of coarctation repair (residual hypertension associated with coarctation)</td>
<td>Central obesity, facial rounding, easy bruising (Cushing’s syndrome)</td>
</tr>
<tr>
<td>Medication or substance use (eg, alcohol, NSAIDS, cocaine, amphetamines)</td>
<td>Absence of family history of hypertension</td>
</tr>
</tbody>
</table>

BP indicates blood pressure; and NSAIDs, nonsteroidal anti-inflammatory drugs.

Table 17. Basic and Optional Laboratory Tests for Primary Hypertension

<table>
<thead>
<tr>
<th>Basic testing</th>
<th>Optional testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose*</td>
<td>Echocardiogram</td>
</tr>
<tr>
<td>Complete blood count</td>
<td>Uric acid</td>
</tr>
<tr>
<td>Lipid profile</td>
<td>Urinary albumin to creatinine ratio</td>
</tr>
<tr>
<td>Serum creatinine with eGFR*</td>
<td></td>
</tr>
<tr>
<td>Serum sodium, potassium, calcium*</td>
<td></td>
</tr>
<tr>
<td>Thyroid-stimulating hormone</td>
<td></td>
</tr>
<tr>
<td>Urinalysis</td>
<td></td>
</tr>
<tr>
<td>Electrocardiogram</td>
<td></td>
</tr>
</tbody>
</table>

*May be included in a comprehensive metabolic panel. eGFR indicates estimated glomerular filtration rate.

8. Treatment of High BP

8.1. Pharmacological Treatment

8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk

For any specific difference in BP, the relative risk of CVD is constant across groups that differ in absolute risk of atherosclerotic CVD, albeit with some evidence of lesser relative risk but greater excess risk in older than in younger adults. Thus, there are more potentially preventable CVD events attributable to elevated BP in individuals with higher than with lower risk of CVD and in older than in younger adults. The relative risk reduction for CVD prevention with use of BP-lowering medications is fairly constant for groups that differ in CVD risk across a wide range of estimated absolute risk and across groups defined by sex, age, body mass index, and the presence or absence of DM, AF, and CKD. As a consequence, the absolute CVD risk reduction attributable to BP lowering is greater at greater absolute levels of CVD risk. Put another way, for a given magnitude of BP reduction due to antihypertensive medications, fewer individuals at high CVD risk would need to be treated to prevent a CVD event (ie, lower number needed to treat) than those at low CVD risk.

8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension

References that support recommendations are summarized in Online Data Supplement 23.

Table 18. Recommendations for BP Treatment Threshold and Use of Risk Estimation* to Guide Drug Treatment of Hypertension

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>SBP: A</td>
<td>1. Use of BP-lowering medications is recommended for secondary prevention of recurrent CVD events in patients with clinical CVD and an average SBP of 130 mm Hg or higher or an average DBP of 80 mm Hg or higher, and for primary prevention in adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher and an average SBP 130 mm Hg or higher or an average DBP 80 mm Hg or higher.</td>
</tr>
<tr>
<td>C-LD</td>
<td>DBP: C-EQ</td>
<td>2. Use of BP-lowering medication is recommended for primary prevention of CVD in adults with no history of CVD and with an estimated 10-year ASCVD risk &lt;10% and an SBP of 140 mm Hg or higher or a DBP of 90 mm Hg or higher.</td>
</tr>
</tbody>
</table>

*ACC/AHA Pooled Cohort Equations (http://tools.acc.org/ASCVD-Risk-Estimator) to estimate 10-year risk of atherosclerotic CVD. ASCVD was defined as a first CHD death, non-fatal MI or fatal or non-fatal stroke.
8.1.3. Follow-Up After Initial BP Evaluation

References that support recommendations are summarized in Online Data Supplement 24.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>1. Adults with an elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than 10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months. S8.1.3-1,S8.1.3-2</td>
</tr>
<tr>
<td>I</td>
<td>B-R</td>
<td>2. Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be managed initially with a combination of nonpharmacological and antihypertensive drug therapy and have a repeat BP evaluation in 1 month. S8.1.3-1,S8.1.3-2</td>
</tr>
</tbody>
</table>

Recommendations for Follow-Up After Initial BP Evaluation (Continued)

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>3. Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within 1 month of the initial diagnosis, have a combination of nonpharmacological and antihypertensive drug therapy (with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month. S8.1.3-1,S8.1.3-2</td>
</tr>
<tr>
<td>I</td>
<td>B-R</td>
<td>4. For adults with a very high average BP (eg, SBP ≥180 mm Hg or DBP ≥110 mm Hg), evaluation followed by prompt antihypertensive drug treatment is recommended. S8.1.3-1,S8.1.3-2</td>
</tr>
<tr>
<td>IIa</td>
<td>C-EO</td>
<td>5. For adults with a normal BP, repeat evaluation every year is reasonable.</td>
</tr>
</tbody>
</table>
### 8.1.4. General Principles of Drug Therapy

#### Recommendation for General Principle of Drug Therapy

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>III: Harm</td>
<td>A</td>
<td>1. Simultaneous use of an ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and is not recommended to treat adults with hypertension.</td>
</tr>
</tbody>
</table>

References that support recommendations are summarized in Online Data Supplement 25.

#### Table 18. Oral Antihypertensive Drugs

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Usual Dose, Range (mg/d)*</th>
<th>Daily Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary agents</td>
<td>Thiazide or thiazide-type diuretics</td>
<td>Chlorthalidone 12.5–25</td>
<td>1</td>
<td>Chlorthalidone is preferred on the basis of prolonged half-life and proven trial reduction of CVD. Monitor for hyponatremia and hypokalemia, uric acid and calcium levels. Use with caution in patients with history of acute gout unless patient is on uric acid–lowering therapy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hydrochlorothiazide 25–50</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indapamide 1.25–2.5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metolazone 2.5–5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ACE inhibitors</td>
<td>Benazepril 10–40</td>
<td>1 or 2</td>
<td>Do not use in combination with ARBs or direct renin inhibitor. There is an increased risk of hyperkalemia, especially in patients with CKD or in those on K⁺ supplements or K⁺-sparking drugs. There is a risk of acute renal failure in patients with severe bilateral renal artery stenosis. Do not use if patient has history of angioedema with ACE inhibitors. Avoid in pregnancy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Captopril 12.5–150</td>
<td>2 or 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enalapril 5–40</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fosinopril 10–40</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lisinopril 10–40</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moexipril 7.5–30</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Perindopril 4–16</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quinapril 10–80</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ramipril 2.5–20</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trandolapril 1–4</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ARBs</td>
<td>Azilsartan 40–80</td>
<td>1</td>
<td>Do not use in combination with ACE inhibitors or direct renin inhibitor. There is an increased risk of hyperkalemia in CKD or in those on K⁺ supplements or K⁺-sparking drugs. There is a risk of acute renal failure in patients with severe bilateral renal artery stenosis. Do not use if patient has history of angioedema with ARBs. Patients with a history of angioedema with an ACE inhibitor can receive an ARB beginning 6 weeks after ACE inhibitor is discontinued. Avoid in pregnancy.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Candesartan 8–32</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eprosartan 600–800</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irbesartan 150–300</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Losartan 50–100</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Olmesartan 20–40</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Telmisartan 20–80</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Valsartan 80–320</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCB—dihydropyridines</td>
<td>Amlodipine 2.5–10</td>
<td>1</td>
<td>Avoid use in patients with HF/EF; amlodipine or felodipine may be used if required. They are associated with dose-related pedal edema, which is more common in women than men.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Felodipine 2.5–10</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Isradipine 5–10</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nicardipine SR 60–120</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nifedipine LA 30–90</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nisoldipine 17–34</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCB—nondihydropyridines</td>
<td>Diltiazem ER 120–360</td>
<td>1</td>
<td>Avoid routine use with beta blockers because of increased risk of bradycardia and heart block.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Verapamil IR 120–360</td>
<td>3</td>
<td>Do not use in patients with HF/EF. There are drug interactions with diltiazem and verapamil (CYP3A4 major substrate and moderate inhibitor).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Verapamil SR 120–360</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Verapamil-delayed onset ER 100–300</td>
<td>1 (in the evening)</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Secondary agents

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Usual Dose, Range (mg/d)</th>
<th>Daily Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diuretics—loop</td>
<td>Bumetanide</td>
<td>0.5–2</td>
<td>2</td>
<td>These are preferred diuretics in patients with symptomatic HF. They are preferred over thiazides in patients with moderate-to-severe CKD (e.g., GFR &lt;30 mL/min).</td>
</tr>
<tr>
<td></td>
<td>Furosemide</td>
<td>20–80</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Torsemide</td>
<td>5–10</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Diuretics—potassium sparing</td>
<td>Amiloride</td>
<td>5–10</td>
<td>1 or 2</td>
<td>These are monotherapy agents and minimally effective antihypertensive agents. Combination therapy of potassium-sparing diuretic with a thiazide can be considered in patients with hypokalemia on thiazide monotherapy. Avoid in patients with significant CKD (e.g., GFR &lt;45 mL/min).</td>
</tr>
<tr>
<td></td>
<td>Triamterene</td>
<td>50–100</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td>Diuretics—aldosterone antagonists</td>
<td>Eplerenone</td>
<td>50–100</td>
<td>1 or 2</td>
<td>These are preferred agents in primary aldosteronism and resistant hypertension. Spironolactone is associated with greater risk of gynecomasia and impotence as compared with eplerenone. This is common add-on therapy in resistant hypertension. Avoid use with K⁺ supplements, other K⁺-sparing diuretics, or significant renal dysfunction. Eplerenone often requires twice-daily dosing for adequate BP lowering.</td>
</tr>
<tr>
<td></td>
<td>Spironolactone</td>
<td>25–100</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Beta blockers—cardioselective</td>
<td>Atenolol</td>
<td>25–100</td>
<td>2</td>
<td>Beta blockers are not recommended as first-line agents unless the patient has IHD or HF. These are preferred in patients with bronchospastic airway disease requiring a beta blocker. Bisoprolol and metoprolol succinate are preferred in patients with HF/EF. Avoid abrupt cessation.</td>
</tr>
<tr>
<td></td>
<td>Betaxolol</td>
<td>5–20</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bisoprolol</td>
<td>2.5–10</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metoprolol tartrate</td>
<td>100–200</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metoprolol succinate</td>
<td>50–200</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Beta blockers—cardioselective and vasodilatory</td>
<td>Nebivolol</td>
<td>5–40</td>
<td>1</td>
<td>Nebivolol induces nitric oxide–induced vasodilation. Avoid abrupt cessation.</td>
</tr>
<tr>
<td>Beta blockers—noncardioselective</td>
<td>Nadolol</td>
<td>40–120</td>
<td>1</td>
<td>Avoid in patients with reactive airways disease. Avoid abrupt cessation.</td>
</tr>
<tr>
<td></td>
<td>Propranolol IR</td>
<td>80–160</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Propranolol LA</td>
<td>80–160</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Beta blockers— intrinsic sympathomimetic activity</td>
<td>Acebutolol</td>
<td>200–800</td>
<td>2</td>
<td>Generally avoid, especially in patients with IHD or HF. Avoid abrupt cessation.</td>
</tr>
<tr>
<td></td>
<td>Penbutolol</td>
<td>10–40</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pindolol</td>
<td>10–60</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Beta blockers—combined alpha- and beta-receptor</td>
<td>Carvedilol</td>
<td>12.5–50</td>
<td>2</td>
<td>Carvedilol is preferred in patients with HF/EF. Avoid abrupt cessation.</td>
</tr>
<tr>
<td></td>
<td>Carvedilol phosphate</td>
<td>20–80</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Labetalol</td>
<td>200–800</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Direct renin inhibitor</td>
<td>Aliskiren</td>
<td>150–300</td>
<td>1</td>
<td>Do not use in combination with ACE inhibitors or ARBs. Aliskiren is very long acting. There is an increased risk of hyperkalemia in CKD or in those on K⁺ supplements or K⁺-sparing drugs. Aliskiren may cause acute renal failure in patients with severe bilateral renal artery stenosis. Avoid in pregnancy.</td>
</tr>
<tr>
<td>Alpha-1 blockers</td>
<td>Doxazosin</td>
<td>1–16</td>
<td>1</td>
<td>These are associated with orthostatic hypotension, especially in older adults. They may be considered as second-line agent in patients with concomitant BPH.</td>
</tr>
<tr>
<td></td>
<td>Prazosin</td>
<td>2–20</td>
<td>2 or 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Terazosin</td>
<td>1–20</td>
<td>1 or 2</td>
<td></td>
</tr>
<tr>
<td>Central alpha₂ agonist and other centrally acting drugs</td>
<td>Clonidine oral</td>
<td>0.1–0.8</td>
<td>2</td>
<td>These are generally reserved as last-line because of significant CNS adverse effects, especially in older adults. Avoid abrupt discontinuation of clonidine, which may induce hypertensive crisis; clonidine must be tapered to avoid rebound hypertension.</td>
</tr>
<tr>
<td></td>
<td>Clonidine patch</td>
<td>0.1–0.3</td>
<td>1 weekly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Methylpapa</td>
<td>250–1000</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guanfacine</td>
<td>0.5–2</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
Table 18. Continued

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Usual Dose, Range (mg/d)</th>
<th>Daily Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct vasodilators</td>
<td>Hydralazine</td>
<td>100-200</td>
<td>2 or 3</td>
<td>These are associated with sodium and water retention and reflex tachycardia; use with a diuretic and beta blocker. Hydralazine is associated with drug-induced lupus-like syndrome at higher doses.</td>
</tr>
<tr>
<td></td>
<td>Minoxidil</td>
<td>5-100</td>
<td>1-3</td>
<td>Minoxidil is associated with hirsutism and requires a loop diuretic. Minoxidil can induce pericardial effusion.</td>
</tr>
</tbody>
</table>

*Dosages may vary from those listed in the FDA-approved labeling (available at https://dailymed.nlm.nih.gov/dailymed/). From Chobanian et al JNC 7. [8] 1.4.4

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; BPH, benign prostatic hyperplasia; CCB, calcium channel blocker; CKD, chronic kidney disease; CNS, central nervous system; CVD, cardiovascular disease; ER, extended release; GFR, glomerular filtration rate; HF, heart failure; HF/LF, heart failure with reduced ejection fraction; IHD, ischemic heart disease; IR, immediate release; LA, long-acting; and SR, sustained release.

8.1.5. BP Goal for Patients With Hypertension

Recommendations for BP Goal for Patients With Hypertension

References that support recommendations are summarized in Online Data Supplement 26 and Systematic Review Report

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>SBP: B-RSR</td>
<td>1. For adults with confirmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher (see Section 8.1.2), a BP target of less than 130/80 mm Hg is recommended.</td>
</tr>
<tr>
<td></td>
<td>DBP: C-EO</td>
<td></td>
</tr>
<tr>
<td>IIb</td>
<td>SBP: B-NR</td>
<td>2. For adults with confirmed hypertension, without additional markers of increased CVD risk, a BP target of less than 130/80 mm Hg may be reasonable.</td>
</tr>
<tr>
<td></td>
<td>DBP: C-EO</td>
<td></td>
</tr>
</tbody>
</table>

SR indicates systematic review.

8.1.6. Choice of Initial Medication

Recommendation for Choice of Initial Medication

References that support the recommendation are summarized in Online Data Supplement 27 and Systematic Review Report

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A-IR</td>
<td>1. For initiation of antihypertensive drug therapy, first-line agents include thiazide diuretics, CCBs, and ACE inhibitors or ARBs.</td>
</tr>
</tbody>
</table>

SR indicates systematic review.

8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy

Recommendations for Choice of Initial Monotherapy Versus Initial Combination Drug Therapy*

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-EO</td>
<td>1. Initiation of antihypertensive drug therapy with 2 first-line agents of different classes, either as separate agents or in a fixed-dose combination, is recommended in adults with stage 2 hypertension and an average BP more than 20/10 mm Hg above their BP target.</td>
</tr>
</tbody>
</table>

*Fixed-dose combination antihypertensive medications are listed in Online Data Supplement D.

8.2. Follow-Up of BP During Antihypertensive Drug Therapy

Appropriate follow-up and monitoring enable assessment of adherence (see Section 12.1) and response to therapy, help identify adverse responses to therapy and target organ damage, and allow assessment of progress toward treatment goals. High-quality RCTs have successfully and safely developed strategies for follow-up, monitoring, and reassessment from which recommendations can be made (Figure 4). [58.2-1,58.2-2]

A systematic approach to out-of-office BP assessment is an essential part of follow-up and monitoring of BP, to assess response to therapy; check for evidence of white coat hypertension, white coat effect, masked hypertension, or masked uncontrolled hypertension; and help achieve BP targets (see Sections 4 and 12).

8.2.1. Follow-Up After Initiating Antihypertensive Drug Therapy

Recommendation for Follow-Up After Initiating Antihypertensive Drug Therapy

References that support the recommendation are summarized in Online Data Supplement 28.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>1. Adults initiating a new or adjusted drug regimen for hypertension should have a follow-up evaluation of adherence and response to treatment at monthly intervals until control is achieved.</td>
</tr>
</tbody>
</table>

Downloaded from http://hyper.ahajournals.org/ by guest on May 12, 2018
8.2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP

Recommendation for Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP

References that support the recommendation are summarized in Online Data Supplement 29.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>1. Follow-up and monitoring after initiation of drug therapy for hypertension control should include systematic strategies to help improve BP, including use of HBPM, team-based care, and telehealth strategies.</td>
</tr>
</tbody>
</table>

9. Hypertension in Patients With Comorbidities

Certain comorbidities may affect clinical decision-making in hypertension. These include ischemic heart disease, HF with reduced ejection fraction (HFrEF), HFrEF, CKD (including renal transplantation), cerebrovascular disease, AF, PAD, DM, and metabolic syndrome. As noted in Section 8.1.2, this guideline generally recommends use of BP-lowering medications for secondary prevention of CVD in patients with clinical CVD (CHD, HF, and stroke) and an average BP ≥130/80 mm Hg and for primary prevention of CVD in adults with an estimated 10-year ASCVD risk of ≥10% and an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg. Although we recommend use of the ACC/AHA Pooled Cohort Equations (http://tools.acc.org/ASCVD-Risk-Estimator/) to estimate 10-year risk of ASCVD to establish the BP threshold for treatment, the vast majority of adults with a co-morbidity are likely to have a 10-year risk of ASCVD that exceeds 10%. In some instances, clinical trial confirmation of treatment in patients with comorbidities is limited to a target BP of 140/90 mm Hg. In addition, the selection of medications for use in treating high BP in patients with CVD is guided by their use for other compelling indications (eg, beta blockers after MI, ACE inhibitors for HFrEF), as discussed in specific guidelines for the clinical condition. The present guideline does not address the recommendations for treatment of hypertension occurring with acute coronary syndromes.

9.1. Stable Ischemic Heart Disease

Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD) (Continued)

References that support recommendations are summarized in Online Data Supplements 30-32.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>2. Adults with SIHD and hypertension (BP ≥130/80 mm Hg) should be treated with medications (eg, GDMT, beta blockers, ACE inhibitors, or ARBs) for compelling indications (eg, previous MI, stable angina) as first-line therapy, with the addition of other drugs (eg, dihydropyridine CCBs, thiazide diuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension.</td>
</tr>
<tr>
<td></td>
<td>C-EQ</td>
<td>3. In adults with SIHD and angina and persistent uncontrolled hypertension, the addition of dihydropyridine CCBs to GDMT beta blockers is recommended.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>4. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT beta blockers beyond 3 years as long-term therapy for hypertension.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-EQ</td>
<td>5. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without HFrEF) who had an MI more than 3 years ago and have angina.</td>
</tr>
</tbody>
</table>

Figure 5. Management of hypertension in patients with SIHD. Colors correspond to Class of Recommendation in Table 1. *GDMT beta blockers for BP control or relief of angina include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, and timolol. Avoid beta blockers with intrinsic sympathomimetic activity. The beta blocker atenolol should not be used because it is less effective than placebo in reducing cardiovascular events. †If needed for BP control. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; GDMT, guideline-directed management and therapy; and SIHD, stable ischemic heart disease.
9.2. Heart Failure

### Recommendation for Prevention of HF in Adults With Hypertension

References that support the recommendation are summarized in Online Data Supplement 33.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| I   | SBP: B-R  
     DBP: C-EO | 1. In adults at increased risk of HF, the optimal BP in those with hypertension should be less than 130/80 mm Hg. |

9.2.1. Heart Failure With Reduced Ejection Fraction

### Recommendations for Treatment of Hypertension in Patients With HF/EF

References that support recommendations are summarized in Online Data Supplement 34.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-EO</td>
<td>1. Adults with HF/EF and hypertension should be prescribed GDMT (2) titrated to attain a BP of less than 130/80 mm Hg.</td>
</tr>
</tbody>
</table>

9.2.2. Heart Failure With Preserved Ejection Fraction

### Recommendations for Treatment of Hypertension in Patients With HFpEF

References that support recommendations are summarized in Online Data Supplements 35 and 36.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-EO</td>
<td>1. In adults with HFpEF who present with symptoms of volume overload, diuretics should be prescribed to control hypertension.</td>
</tr>
<tr>
<td>I</td>
<td>C-LD</td>
<td>2. Adults with HFpEF and persistent hypertension after management of volume overload should be prescribed ACE inhibitors or ARBs and beta blockers titrated to attain SBP of less than 130 mm Hg.</td>
</tr>
</tbody>
</table>

9.3. Chronic Kidney Disease

### Recommendations for Treatment of Hypertension in Patients With CKD

References that support recommendations are summarized in Online Data Supplements 37 and 38 and Systematic Review Report.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| I   | SBP: B-R  
     DBP: C-EO | 1. Adults with hypertension and CKD should be treated to a BP goal of less than 130/80 mm Hg. |
| Ila | B-R | 2. In adults with hypertension and CKD (stage 3 or higher or stage 1 or 2 with albuminuria ≥300 mg/d or ≥300 mg/g albumin-to-creatinine ratio in the first morning void), treatment with an ACE inhibitor is reasonable to slow kidney disease progression. |

9.3.1. Hypertension After Renal Transplantation

### Recommendations for Treatment of Hypertension After Renal Transplantation

References that support recommendations are summarized in Online Data Supplements 39 and 40.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| Ila | SBP: B-NR  
     DBP: C-EO | 1. After kidney transplantation, it is reasonable to treat patients with hypertension to a BP goal of less than 130/80 mm Hg. |
2. After kidney transplantation, it is reasonable to treat patients with hypertension with a calcium antagonist on the basis of improved GFR and kidney survival.

9.4. Cerebrovascular Disease

9.4.1. Acute Intracerebral Hemorrhage

Recommendations for Management of Hypertension in Patients With Acute Intracerebral Hemorrhage (ICH)

References that support recommendations are summarized in Online Data Supplement 41.

**COR LOE Recommendations**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIA</td>
<td>B-R</td>
<td>2. After kidney transplantation, it is reasonable to treat patients with hypertension with a calcium antagonist on the basis of improved GFR and kidney survival.</td>
</tr>
</tbody>
</table>

9.4.2. Acute Ischemic Stroke

Recommendations for Management of Hypertension in Patients With Acute Ischemic Stroke

References that support recommendations are summarized in Online Data Supplement 42.

**COR LOE Recommendations**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>III: No Benefit</td>
<td>A</td>
<td>5. In patients with BP less than 220/120 mm Hg who did not receive intravenous thrombolysis or endovascular treatment and do not have a comorbid condition requiring acute antihypertensive treatment, initiating or reinitiating treatment of hypertension within the first 48 to 72 hours after an acute ischemic stroke is not effective to prevent death or dependency.</td>
</tr>
<tr>
<td>IIb</td>
<td>C-E0</td>
<td>4. In patients with BP of 220/120 mm Hg or higher who did not receive intravenous alteplase or endovascular treatment and have no comorbid conditions requiring acute antihypertensive treatment, the benefit of initiating or reinitiating treatment of hypertension within the first 48 to 72 hours is uncertain. It might be reasonable to lower BP by 15% during the first 24 hours after onset of stroke.</td>
</tr>
<tr>
<td>I</td>
<td>B-NR</td>
<td>2. In adults with an acute ischemic stroke, BP should be less than 185/110 mm Hg before administration of intravenous tissue plasminogen activator and should be maintained below 180/105 mm Hg for at least the first 24 hours after initiating drug therapy.</td>
</tr>
<tr>
<td>I</td>
<td>B-NR</td>
<td>1. Adults with acute ischemic stroke and elevated BP who are eligible for treatment with intravenous tissue plasminogen activator should have their BP slowly lowered to less than 185/110 mm Hg before thrombolytic therapy is initiated.</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
<td>3. Starting or restarting antihypertensive therapy during hospitalization in patients with BP greater than 140/90 mm Hg who are neurologically stable is safe and reasonable to improve long-term BP control, unless contraindicated.</td>
</tr>
<tr>
<td>IIa</td>
<td>C-E0</td>
<td>1. In adults with ICH who present with SBP greater than 220 mm Hg, it is reasonable to use continuous intravenous drug infusion (Table 19) and close BP monitoring to lower SBP.</td>
</tr>
<tr>
<td>III: Harm</td>
<td>A</td>
<td>2. Immediate lowering of SBP (Table 19) to less than 140 mm Hg in adults with spontaneous ICH who present within 6 hours of the acute event and have an SBP between 150 mm Hg and 220 mm Hg is not of benefit to reduce death or severe disability and can be potentially harmful.</td>
</tr>
</tbody>
</table>

Figure 7. Management of hypertension in patients with acute ICH. Colors correspond to Class of Recommendation in Table 1. BP indicates blood pressure; ICH, intracerebral hemorrhage; IV, intravenous; and SBP, systolic blood pressure.
9.4.3. Secondary Stroke Prevention

**Recommendations for Treatment of Hypertension for Secondary Stroke Prevention**

References that support recommendations are summarized in Online Data Supplements 43 and 44.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>1. Adults with previously treated hypertension who experience a stroke or transient ischemic attack (TIA) should be restarted on antihypertensive treatment after the first few days of the index event to reduce the risk of recurrent stroke and other vascular events. 59,4.3-1,59,4.3-3</td>
</tr>
<tr>
<td>I</td>
<td>A</td>
<td>2. For adults who experience a stroke or TIA, treatment with a thiazide diuretic, ACE inhibitor, or ARB, or combination treatment consisting of a thiazide diuretic plus ACE inhibitor, is useful. 59,4.3-1,59,4.3-3,59,4.3-5</td>
</tr>
</tbody>
</table>

**COR LOE Recommendations (Continued)**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>3. Adults not previously treated for hypertension who experience a stroke or TIA and have an established BP of 140/90 mm Hg or higher should be prescribed antihypertensive treatment a few days after the index event to reduce the risk of recurrent stroke and other vascular events. 59,4.3-1,59,4.3-3</td>
</tr>
<tr>
<td>I</td>
<td>B-NR</td>
<td>4. For adults who experience a stroke or TIA, selection of specific drugs should be individualized on the basis of patient comorbidities and agent pharmacological class. 59,4.3-6</td>
</tr>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>5. For adults who experience a stroke or TIA, a BP goal of less than 130/80 mm Hg may be reasonable. 59,4.3-6,59,4.3-7</td>
</tr>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>6. For adults with a lacunar stroke, a target SBP goal of less than 130 mm Hg may be reasonable. 59,4.3-8</td>
</tr>
</tbody>
</table>

**Figure 8.** Management of hypertension in patients with acute ischemic stroke. Colors correspond to Class of Recommendation in Table 1. BP indicates blood pressure; DBP, diastolic blood pressure; IV, intravenous; and SBP, systolic blood pressure.
In adults previously untreated for hypertension who experience an ischemic stroke or TIA and have a SBP less than 140 mm Hg and a DBP less than 90 mm Hg, the usefulness of initiating antihypertensive treatment is not well established.

**9.5. Peripheral Artery Disease**

**Recommendations for Treatment of Hypertension in Patients With PAD**

References that support the recommendation are summarized in Online Data Supplement 45.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>1. Adults with hypertension and PAD should be treated similarly to patients with hypertension without PAD.</td>
</tr>
</tbody>
</table>

**9.6. Diabetes Mellitus**

**Recommendations for Treatment of Hypertension in Patients With DM**

References that support recommendations are summarized in Online Data Supplements 46 and 47 and Systematic Review Report.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>1. In adults with DM and hypertension, antihypertensive drug treatment should be initiated at a BP of 130/80 mm Hg or higher with a treatment goal of less than 130/80 mm Hg.</td>
</tr>
<tr>
<td>I</td>
<td>C-EO</td>
<td>2. In adults with DM and hypertension, all first-line classes of antihypertensive agents (ie, diuretics, ACE inhibitors, ARBs, and CCBs) are useful and effective.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-NR</td>
<td>3. In adults with DM and hypertension, ACE inhibitors or ARBs may be considered in the presence of albuminuria.</td>
</tr>
</tbody>
</table>

SR indicates systematic review.
9.7. Metabolic Syndrome

Metabolic syndrome is a state of metabolic dysregulation characterized by visceral fat accumulation, insulin resistance, hyperinsulinemia, and hyperlipidemia, as well as predisposition to type 2 DM, hypertension, and atherosclerotic CVD. According to data from the NHANES III and NHANES 1999–2006, the prevalence of metabolic syndrome in the United States was 34.2% in 2006 and has likely increased substantially since that time. The metabolic syndrome is linked to several other disorders, including non-alcoholic steatohepatitis, polycystic ovary syndrome, certain cancers, CKD, Alzheimer’s disease, Cushing’s syndrome, lipodystrophy, and hyperalimentation.

Lifestyle modification, with an emphasis on improving insulin sensitivity by means of dietary modification, weight reduction, and exercise, is the foundation of treatment of the metabolic syndrome. The optimal antihypertensive drug therapy for patients with hypertension in the setting of the metabolic syndrome has not been clearly defined. Although caution exists with regard to the use of thiazide diuretics in this population because of their ability to increase insulin resistance, dyslipidemia, and hyperuricemia and to accelerate conversion to overt DM, no data are currently available demonstrating deterioration in cardiovascular or renal outcomes in patients treated with these agents. Indeed, as shown in follow-up of ALLHAT, chlorthalidone use was associated with only a small increase in fasting glucose levels (1.5–4.0 mg/dL), and this increase did not translate into increased CVD risk at a later date. In addition, in post hoc analysis of the nearly two thirds of participants in ALLHAT that met criteria for the metabolic syndrome, chlorthalidone was unsurpassed in reducing CVD and renal outcomes compared with lisinopril, amlodipine, or doxazosin. Similarly, high-dose ARB therapy reduces arterial stiffness in patients with hypertension with the metabolic syndrome, but no outcomes data are available from patients in which this form of treatment was used. Use of traditional beta blockers may lead to dyslipidemia or deterioration of glucose tolerance, and ability to lose weight. In several large clinical trials, the risk of developing DM as a result of traditional beta-blocker therapy was 15% to 29%. However, the newer vasodilating beta blockers (eg, labetalol, carvedilol, nebivolol) have shown neutral or favorable effects on metabolic profiles compared with the traditional beta blockers. Trials using vasodilator beta blockers have not been performed to demonstrate effects on CVD outcomes.

9.8. Atrial Fibrillation

9.9. Valvular Heart Disease

9.10. Aortic Disease

10. Special Patient Groups

10.1. Racial and Ethnic Differences in Treatment

10.2. Sex-Related Issues

The prevalence of hypertension is lower in women than in men until about the fifth decade but is higher later in life. Other than special recommendations for management of hypertension during pregnancy, there is no evidence that the BP threshold for initiating drug treatment, the treatment target, the choice of initial antihypertensive medication, or the combination of medications for lowering BP differs for women versus men.
10.2.1. Women

A potential limitation of RCTs, including SPRINT, is that they are not specifically powered to determine the value of intensive SBP reduction in subgroups, including women in the case of SPRINT. However, in prespecified analyses, there was no evidence of an interaction between sex and treatment effect. Furthermore, no significant differences in CVD outcomes were observed between men and women in a large meta-analysis that included 31 RCTs with about 100,000 men and 90,000 women with hypertension (1 Some have called for conduct of a SPRINT-like trial with sufficient power to assess the effects of intensive SBP reduction in women (Wenger, 2016 #9131). Some have called for a SPRINT-like trial with sufficient power to assess the effects of intensive SBP reduction in women. In meta-analyses, there was no convincing evidence that different antihypertensive drug classes exerted sex-related differences in BP lowering or provided distinct CVD protection. Calcium antagonists offered slightly greater benefits for stroke prevention than did ACE inhibitors for women than for men, whereas calcium antagonists reduced all-cause deaths compared with placebo in men but not in women. However, these sex-related differences might have been due to chance because of the large number of statistical comparisons that were performed. The Heart Attack Trial and Hypertension Care Computing Project reported that beta blockers were associated with reduced mortality in men but not in women, but this finding was likely due to the low event rates in women. Similarly, in the open-label Second Australian National BP study, a significant reduction in CVD events was demonstrated in men but not in women with ACE inhibitors versus diuretics.

Adverse effects of antihypertensive therapy were noted twice as often in women as in men in the TOMHS study. A higher incidence of ACE inhibitor–induced cough and of edema with calcium antagonists was observed in women than in men. Women were more likely to experience hypokalemia and hyponatremia and less likely to experience gout with diuretics. Hypertension in pregnancy has special requirements (see Section 10.2.2).

10.2.2. Pregnancy

10.3. Age-Related Issues

10.3.1. Older Persons
11. Other Considerations

11.1. Resistant Hypertension

**Cor LOE Recommendations**

<table>
<thead>
<tr>
<th>Recommendations for Hypertensive Crises and Emergencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>References that support recommendations are summarized in Online Data Supplement 55.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-NR</td>
<td>1. In adults with a hypertensive emergency, admission to an intensive care unit is recommended for continuous monitoring of BP and target organ damage and for parental administration of an appropriate agent (Tables 19 and 20).</td>
</tr>
</tbody>
</table>

**Figure 10.** Resistant hypertension: diagnosis, evaluation, and treatment. *See additional details in Section 6, Nonpharmacological Intervention.†See Section 5.4.1 and Table 14 for complete list of drugs that elevate BP.‡See Section 5.4 and Table 13 for secondary hypertension. BP indicates blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs; and SBP, systolic blood pressure. Adapted with permission from Calhoun et al.11.1-1 (American Heart Association, Inc.).

11.2. Hypertensive Crises—Emergencies and Urgencies

**Recommendations for Hypertensive Crises and Emergencies (Continued)**

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-E0</td>
<td>2. For adults with a compelling condition (ie, aortic dissection, severe preeclampsia or eclampsia, or pheochromocytoma crisis), SBP should be reduced to less than 140 mm Hg during the first hour and to less than 120 mm Hg in aortic dissection.</td>
</tr>
<tr>
<td>I</td>
<td>C-E0</td>
<td>3. For adults without a compelling condition, SBP should be reduced by no more than 25% within the first hour, then, if stable, to 160/100 mm Hg within the next 2 to 6 hours; and then cautiously to normal during the following 24 to 48 hours.</td>
</tr>
</tbody>
</table>
### Table 19. Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug(s)</th>
<th>Usual Dose Range</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCB—dihydropyridines</td>
<td>Nicardipine</td>
<td>Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to maximum 15 mg/h.</td>
<td>Contraindicated in advanced aortic stenosis; no dose adjustment needed for elderly.</td>
</tr>
<tr>
<td></td>
<td>Clevidipine</td>
<td>Initial 1–2 mg/h, doubling every 90 s until BP approaches target, then increasing by less than double every 5–10 min; maximum dose 32 mg/h; maximum duration 72 h.</td>
<td>Contraindicated in patients with soybean, soy product, egg, and egg product allergy and in patients with defective lipid metabolism (eg, pathological hyperlipidemia, lipoid nephrosis or acute pancreatitis). Use low-end dose range for elderly patients.</td>
</tr>
<tr>
<td>Vasodilators—Nitric-oxide dependent</td>
<td>Sodium nitroprusside</td>
<td>Initial 0.3–0.5 mcg/kg/min; increase in increments of 0.5 mcg/kg/min to achieve BP target; maximum dose 10 mcg/kg/min; duration of treatment as short as possible. For infusion rates ≥4–10 mcg/kg/min or duration &gt;30 min, thiosulfate can be coadministered to prevent cyanide toxicity.</td>
<td>Intra-arterial BP monitoring recommended to prevent “overshoot.” Lower dosing adjustment required for elderly. Tachyphylaxis common with extended use. Cyanide toxicity with prolonged use can result in irreversible neurological changes and cardiac arrest.</td>
</tr>
<tr>
<td></td>
<td>Nitroglycerin</td>
<td>Initial 5 mcg/min; increase in increments of 5 mcg/min every 3–5 min to a maximum of 20 mcg/min.</td>
<td>Use only in patients with acute coronary syndrome and/or acute pulmonary edema. Do not use in volume-depleted patients.</td>
</tr>
<tr>
<td>Vasodilators—direct</td>
<td>Hydralazine</td>
<td>Initial 10 mg via slow IV infusion (maximum initial dose 20 mg); repeat every 4–6 h as needed.</td>
<td>BP begins to decrease within 10–30 min, and the fall lasts 2–4 h. Unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in most patients.</td>
</tr>
</tbody>
</table>

Figure 11. Diagnosis and management of a hypertensive crisis. Colors correspond to Class of Recommendation in Table 1. *Use drug(s) specified in Table 19. †If other comorbidities are present, select a drug specified in Table 20. BP indicates blood pressure; DBP, diastolic blood pressure; ICU, intensive care unit; and SBP, systolic blood pressure.

(Continued)
### Table 20. Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies in Patients With Selected Comorbidities

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Preferred Drug(s)*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute aortic dissection</td>
<td>Esmolol, labetalol</td>
<td>Requires rapid lowering of SBP to ≤120 mm Hg. Beta blockade should precede vasodilator (eg, nicardipine or nitroprusside) administration, if needed for BP control or to prevent reflex tachycardia or inotropic effect; SBP ≤120 mm Hg should be achieved within 20 min.</td>
</tr>
<tr>
<td>Acute pulmonary edema</td>
<td>Clevidipine, nitroglycerin, nitroprusside</td>
<td>BP blocks contraindicated.</td>
</tr>
<tr>
<td>Acute coronary syndromes</td>
<td>Esmolol,† labetalol, nicardipine, nitroglycerin†</td>
<td>Nitrates given in the presence of PDE-5 inhibitors may induce profound hypotension. Contraindications to beta blockers include moderate-to-severe LV failure with pulmonary edema, bradycardia (&lt;60 bpm), hypotension (SBP &lt;100 mm Hg), poor peripheral perfusion, second- or third-degree heart block, and reactive airways disease.</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>Clevidipine, fenoldopam, nicardipine</td>
<td>N/A</td>
</tr>
<tr>
<td>Eclampsia or preeclampsia</td>
<td>Hydralazine, labetalol, nicardipine</td>
<td>Requires rapid BP lowering. ACE inhibitors, ARBs, renin inhibitors, and nitroprusside contraindicated.</td>
</tr>
<tr>
<td>Perioperative hypertension (BP ≥160/90 mm Hg or SBP elevation ≥20% of the preoperative value that persists for &gt;15 min)</td>
<td>Clevidipine, esmolol, nicardipine, nitroglycerin</td>
<td>Intraoperative hypertension is most frequently seen during anesthesia induction and airway manipulation.</td>
</tr>
<tr>
<td>Acute sympathetic discharge or catecholamine excess states (eg, pheochromocytoma, postcarotid endarterectomy status)</td>
<td>Clevidipine, nicardipine, phentolamine</td>
<td>Requires rapid lowering of BP.</td>
</tr>
<tr>
<td>Acute ICH</td>
<td>Section 9.4.1</td>
<td>Section 9.4.1</td>
</tr>
<tr>
<td>Acute ischemic stroke</td>
<td>Section 9.4.2</td>
<td>Section 9.4.2</td>
</tr>
</tbody>
</table>

*Agents are listed in alphabetical order, not in order of preference.
†Agent of choice for acute coronary syndromes.
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; ICH, intracerebral hemorrhage; LV, left ventricular; PDE-5, phosphodiesterase type-5; and SBP, systolic blood pressure.
11.3. Cognitive Decline and Dementia

**Recommendation for Prevention of Cognitive Decline and Dementia**

References that support the recommendation are summarized in Online Data Supplement 56.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>1. In adults with hypertension, BP lowering is reasonable to prevent cognitive decline and dementia. S11.3-1–S11.3-6</td>
</tr>
</tbody>
</table>

11.4. Patients Undergoing Surgical Procedures

**Recommendations for Treatment of Hypertension in Patients Undergoing Surgical Procedures**

References that support recommendations are summarized in Online Data Supplements 57 and 58.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preoperative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>B-NR</td>
<td>1. In patients with hypertension undergoing major surgery who have been on beta blockers chronically, beta blockers should be continued. S11.4-1–S11.4-7</td>
</tr>
<tr>
<td>IIa</td>
<td>C-EO</td>
<td>2. In patients with hypertension undergoing planned elective major surgery, it is reasonable to continue medical therapy for hypertension until surgery.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-NR</td>
<td>3. In patients with hypertension undergoing major surgery, discontinuation of ACE inhibitors or ARBs perioperatively may be considered. S11.4-8–S11.4-10</td>
</tr>
<tr>
<td>IIb</td>
<td>C-LD</td>
<td>4. In patients with planned elective major surgery and SBP of 180 mm Hg or higher or DBP of 110 mm Hg or higher, deferring surgery may be considered. S11.4-11,S11.4-12</td>
</tr>
</tbody>
</table>

III: Harm |

| III: Harm | B-NR | 5. For patients undergoing surgery, abrupt preoperative discontinuation of beta blockers or clonidine is potentially harmful. S11.4-13 |
| III: Harm | B-NR | 6. Beta blockers should not be started on the day of surgery in beta blocker–naive patients. S11.4-14 |

Intraoperative |

| I | C-EO | 7. Patients with intraoperative hypertension should be managed with intravenous medications (Table 19) until such time as oral medications can be resumed. |

12. Strategies to Improve Hypertension Treatment and Control

12.1. Adherence Strategies for Treatment of Hypertension

12.1.1. Antihypertensive Medication Adherence Strategies

**Recommendations for Antihypertensive Medication Adherence Strategies**

References that support recommendations are summarized in Online Data Supplements 59 and 60.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td>1. In adults with hypertension, dosing of antihypertensive medication once daily rather than multiple times daily is beneficial to improve adherence. S12.1.1-1–S12.1.1-3</td>
</tr>
</tbody>
</table>

IIa | B-NR | 2. Use of combination pills rather than free individual components can be useful to improve adherence to antihypertensive therapy. S12.1.1-4–S12.1.1-7 |

Available fixed-dose combination drug therapy is listed in Online Data Supplement D.

12.1.2. Strategies to Promote Lifestyle Modification

**Recommendation for Strategies to Promote Lifestyle Modification**

References that support the recommendation are summarized in Online Data Supplement 61.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C-EO</td>
<td>1. Effective behavioral and motivational strategies to achieve a healthy lifestyle (ie, tobacco cessation, weight loss, moderation in alcohol intake, increased physical activity, reduced sodium intake, and consumption of a healthy diet) are recommended for adults with hypertension. S12.1.2-1,S12.1.2-2</td>
</tr>
</tbody>
</table>

12.2. Structured, Team-Based Care Interventions for Hypertension Control

**Recommendation for Structured, Team-Based Care Interventions for Hypertension Control**

References that support the recommendation are summarized in Online Data Supplement 62.

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>1. A team-based care approach is recommended for adults with hypertension. S12.2-1–S12.2-7</td>
</tr>
</tbody>
</table>
12.3. Health Information Technology–Based Strategies to Promote Hypertension Control

12.3.1. EHR and Patient Registries

<table>
<thead>
<tr>
<th>Recommendations for EHR and Patient Registries</th>
<th>References that support recommendations are summarized in Online Data Supplement 63.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>I</td>
<td>B-NR</td>
</tr>
<tr>
<td>I</td>
<td>B-NR</td>
</tr>
</tbody>
</table>

12.3.2. Telehealth Interventions to Improve Hypertension Control

<table>
<thead>
<tr>
<th>Recommendation for Telehealth Interventions to Improve Hypertension Control</th>
<th>References that support the recommendation are summarized in Online Data Supplement 64.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>IIa</td>
<td>A</td>
</tr>
</tbody>
</table>

12.4. Improving Quality of Care for Patients With Hypertension

12.4.1. Performance Measures

<table>
<thead>
<tr>
<th>Recommendation for Performance Measures</th>
<th>References that support the recommendation are summarized in Online Data Supplement 65.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
</tr>
</tbody>
</table>

12.4.2. Quality Improvement Strategies

<table>
<thead>
<tr>
<th>Recommendation for Quality Improvement Strategies</th>
<th>References that support the recommendation are summarized in Online Data Supplement 66 and 67.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
</tr>
</tbody>
</table>

12.5. Financial Incentives

<table>
<thead>
<tr>
<th>Recommendations for Financial Incentives</th>
<th>References that support recommendations are summarized in Online Data Supplement 68.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>IIa</td>
<td>B-R</td>
</tr>
<tr>
<td>IIa</td>
<td>B-NR</td>
</tr>
</tbody>
</table>

13. The Plan of Care for Hypertension

<table>
<thead>
<tr>
<th>Recommendation for the Plan of Care for Hypertension</th>
<th>References that support the recommendation are summarized in Online Data Supplement 69.</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
<td>LOE</td>
</tr>
<tr>
<td>I</td>
<td>C-EO</td>
</tr>
</tbody>
</table>

Table 21. Clinician’s Sequential Flow Chart for the Management of Hypertension

| Measure office BP accurately               | Section 4 |
| Detect white coat hypertension or masked hypertension by using ABPM and HBPM | Section 4 |
| Evaluate for secondary hypertension       | Section 5 |
| Identify target organ damage              | Sections 5 and 7 |
| Introduce lifestyle interventions         | Section 6 |
| Identify and discuss treatment goals      | Sections 7 and 8 |
| Use ASCVD risk estimation to guide BP threshold for drug therapy | Section 8.1.2 |
| Align treatment options with comorbidities | Section 9 |
| Account for age, race, ethnicity, sex, and special circumstances in antihypertensive treatment | Sections 10 and 11 |
| Initiate antihypertensive pharmacological therapy | Section 8 |
| Insure appropriate follow-up              | Section 8 |
| Use team-based care                       | Section 12 |
| Connect patient to clinician via telehealth | Section 12 |
| Detect and reverse nonadherence           | Section 12 |
| Detect white coat effect or masked uncontrolled hypertension | Section 4 |
| Use health information technology for remote monitoring and self-monitoring of BP | Section 12 |

ABPM indicates ambulatory blood pressure monitoring; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; and HBPM, home blood pressure monitoring.
13.1. Health Literacy

Communicating alternative behaviors that support self-management of healthy BP in addition to medication adherence is important. This should be done both verbally and in writing. Today, mobile phones have a recording option. For patients with mobile phones, the phone can be used to inform patients and family members of medical instructions after the doctor's visit as an additional level of communication. Inclusion of a family member or friend that can help interpret and encourage self-management treatment goals is suggested when appropriate. Examples of needed communication for alternative behaviors include a specific regimen relating to physical activity; a specific sodium-reduced meal plan indicating selections for breakfast, lunch, and dinner; lifestyle recommendations relating to sleep, rest, and relaxation; and finally, suggestions and alternatives to environmental barriers, such as barriers that prevent healthy food shopping or limit reliable transportation to and from appointments with health providers and pharmacy visits.

13.2. Access to Health Insurance and Medication Assistance Plans

Health insurance and medication plan assistance for patients is especially important to improving access to and affordability of medical care and BP medications. Learning how the patient financially supports and budgets for his or her medical care and medications offers the opportunity to share additional insight relating to cost reductions, including restructured payment plans. Ideally, this would improve the patient’s compliance with medication adherence and treatment goals.

13.3. Social and Community Services

Health care can be strengthened through local partnerships. Hypertensive patients, particularly patients with lower incomes, have more opportunity to achieve treatment goals with the assistance of strong local partnerships. In patients with low socioeconomic status or patients who are challenged by social situations, integration of social and community services offers complementary reinforcement of clinically identified treatment goals. Social and community services are helpful when explicitly related to medical care.

---

Table 22. Evidence-Based Elements of the Plan of Care for Patients With Hypertension

<table>
<thead>
<tr>
<th>Plan of Care</th>
<th>Associated Section(s) of Guideline and Other Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacological and nonpharmacological treatments</td>
<td></td>
</tr>
<tr>
<td>Medication selection (initial and ongoing)</td>
<td>Section 8.1</td>
</tr>
<tr>
<td>Monitoring for adverse effects and adherence</td>
<td>Sections 8.3.1, 8.3.2, 12.1.1</td>
</tr>
<tr>
<td>Nonpharmacological interventions</td>
<td></td>
</tr>
<tr>
<td>Diet</td>
<td>Sections 6, 12.1.2</td>
</tr>
<tr>
<td>Exercise</td>
<td></td>
</tr>
<tr>
<td>Weight loss if overweight</td>
<td></td>
</tr>
<tr>
<td>Moderate alcohol consumption</td>
<td></td>
</tr>
<tr>
<td>Management of common comorbidities and conditions</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>Section 9.1</td>
</tr>
<tr>
<td>Reduced ejection fraction</td>
<td>Section 9.2</td>
</tr>
<tr>
<td>Preserved ejection fraction</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Section 9.3</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>Section 9.4</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>Section 9.5</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>Section 9.9</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Section 9.8</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>Section 9.9</td>
</tr>
<tr>
<td>Left ventricular hypertrophy</td>
<td>Section 7.3</td>
</tr>
<tr>
<td>Thoracic aortic disease</td>
<td>Section 9.10</td>
</tr>
<tr>
<td>Patient and family education</td>
<td></td>
</tr>
<tr>
<td>Achieving BP control and self-monitoring</td>
<td>Sections 4.2, 8.2</td>
</tr>
<tr>
<td>Risk assessment and prognosis</td>
<td>Section 8.1.2</td>
</tr>
<tr>
<td>Sexual activity and dysfunction</td>
<td>Section 11.4</td>
</tr>
<tr>
<td>Special patient groups</td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Section 10.2.2</td>
</tr>
<tr>
<td>Older persons</td>
<td>Section 10.3.1</td>
</tr>
<tr>
<td>Children and adolescents</td>
<td>Section 10.3.2</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>Section 9.7</td>
</tr>
<tr>
<td>Possible secondary causes of hypertension</td>
<td>Section 5.4</td>
</tr>
<tr>
<td>Resistant hypertension</td>
<td>Section 11.1</td>
</tr>
<tr>
<td>Patients with hypertension undergoing surgery</td>
<td>Section 11.5</td>
</tr>
<tr>
<td>Renal transplantation</td>
<td>Section 9.3.1</td>
</tr>
<tr>
<td>Psychosocial factors</td>
<td></td>
</tr>
<tr>
<td>Sex-specific issues</td>
<td>Section 10.2</td>
</tr>
<tr>
<td>Culturally sensitive issues (race and ethnicity)</td>
<td>Section 10.1</td>
</tr>
<tr>
<td>Resource constraints</td>
<td>Section 12.5</td>
</tr>
<tr>
<td>Clinician follow-up, monitoring, and care coordination</td>
<td>Sections 8.1.3, 8.3.1, 8.3.2</td>
</tr>
<tr>
<td>Follow-up visits</td>
<td>Section 12.2</td>
</tr>
<tr>
<td>Team-based care</td>
<td>Section 12.2</td>
</tr>
</tbody>
</table>

(Continued)
However, additional financial support and financial services are incredibly beneficial to patients, some of whom may choose to skip a doctor’s appointment to pay a residential utility bill.

14. Summary of BP Thresholds and Goals for Pharmacological Therapy

Table 23. BP Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions

<table>
<thead>
<tr>
<th>Clinical Condition(s)</th>
<th>BP Threshold, mm Hg</th>
<th>BP Goal, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical CVD or 10-year ASCVD risk ≥10%</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>No clinical CVD and 10-year ASCVD risk &lt;10%</td>
<td>≥140/90</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Older persons (&gt;65 years of age; noninstitutionalized, ambulatory, community-living adults)</td>
<td>≥130 (SBP)</td>
<td>&lt;130 (SBP)</td>
</tr>
<tr>
<td>Specific comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Chronic kidney disease after renal transplantation</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Heart failure</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Stable ischemic heart disease</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Secondary stroke prevention</td>
<td>≥140/90</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>≥130/80</td>
<td>&lt;130/80</td>
</tr>
</tbody>
</table>

ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CVD, cardiovascular disease; and SBP, systolic blood pressure.

References

Preamble


1. Introduction


S1-5. Effects of treatment on morbidity and mortality in hypertension.:
I. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–34.


2.1. Observational Relationship


2.2. BP Components


2.3. Population Risk


2.4. Coexistence of Hypertension and Related Chronic Conditions


3. Classification of BP


3.1. Accurate Measurement of BP in the Office


3.2. Lifetime Risk of Hypertension


4. Measurement of BP

4.1. Accurate Measurement of BP in the Office


4.2. Out-of-Office and Self-Monitoring of BP


4.3. Masked and White Coat Hypertension


5. Causes of Hypertension

5.1. Secondary Forms of Hypertension

5.1.1. Drugs and Other Substances With Potential to Impair BP Control


5.1.2. Primary Aldosteronism


5.1.3. Renal Artery Stenosis


5.1.4. Obstructive Sleep Apnea


6. Nonpharmacological Interventions


8. Treatment of High BP

8.1. Pharmacological Treatment

8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk


8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension


8.1.3. Follow-Up After Initial BP Evaluation


8.1.4. General Principles of Drug Therapy


8.1.5. BP Goal for Patients With Hypertension

8.2. Follow-Up of BP During Antihypertensive Drug Therapy

8.2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP


9. Hypertension in Patients With Comorbidities

9.1. Stable Ischemic Heart Disease


9.2. Heart Failure


9.2.2.3. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > 0.40 treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80:207–9.


9.3. Chronic Kidney Disease


9.4. Cerebrovascular Disease

9.4.1. Acute Intracerebral Hemorrhage


9.4.2. Acute Ischemic Stroke


9.4.2.3. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective


9.4.3. Secondary Stroke Prevention


S9.4.3.3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.


9.5. Peripheral Artery Disease


9.6. Diabetes Mellitus


9.7. Metabolic Syndrome


9.8. Atrial Fibrillation


9.9. Valvular Heart Disease


9.10. Aortic Disease


10. Special Patient Groups

10.1. Racial and Ethnic Differences in Treatment


10.2. Sex-Related Issues


10.2.2. Pregnancy


10.3. Age-Related Issues

10.3.1. Older Persons


11. Other Considerations

11.1. Resistant Hypertension


11.2. Hypertensive Crises—Emergencies and Urgencies


11.3. Cognitive Decline and Dementia


11.4. Patients Undergoing Surgical Procedures


12. Strategies to Improve Hypertension Treatment and Control

12.1. Adherence Strategies for Treatment of Hypertension

12.1.1. Antihypertensive Medication Adherence Strategies


12.1.2. Strategies to Promote Lifestyle Modification


12.2. Structured, Team-Based Care Interventions for Hypertension Control


12.3. Health Information Technology–Based Strategies to Promote Hypertension Control

12.3.1. EHR and Patient Registries


S12.3.2. Telehealth Interventions to Improve Hypertension Control


12.4. Improving Quality of Care for Patients With Hypertension

12.4.1. Performance Measures


12.4.2. Quality Improvement Strategies


12.5. Financial Incentives


13. The Plan of Care for Hypertension


<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul K. Whelton, Chair</td>
<td>Tulane University School of Hygiene and Tropical Medicine—Show Chwan Professor of Global Public Health</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert M. Carey, Vice Chair</td>
<td>University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Daiichi Sankyo Inc†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Wilbert S. Aronow</td>
<td>Westchester Medical Center and New York Medical College—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Donald E. Casey, Jr</td>
<td>Thomas Jefferson College of Population Health—Adjunct Faculty; Alvarez &amp; Marsal Ipo4health—Principal and Founder</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Karen J. Collins</td>
<td>Collins Collaboration—President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cheryl Dennison Himmelfarb</td>
<td>John Hopkins University—Professor of Nursing and Medicine, Institute for Clinical and Translational Research</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sondra M. DePalma</td>
<td>PinnacleHealth CardioVascular Institute—Physician Assistant; American Academy of PAs—Director, Regulatory and Professional Practice</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Samuel Gidding</td>
<td>Alfred I. DuPont Hospital for Children—Chief, Division of Pediatric Cardiology, Nemours Cardiac Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David C. Goff, Jr*</td>
<td>Colorado School of Public Health—Professor and Dean, Department of Epidemiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kenneth A. Jamerson</td>
<td>University of Michigan Health System—Professor of Internal Medicine and Frederick G.L. Huettwell Collegiate Professor of Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Daniel W. Jones</td>
<td>University of Mississippi Medical Center—Professor of Medicine and Physiology; Metabolic Diseases and Nutrition—University Sanderson Chair in Obesity Mississippi Center for Obesity Research—Director, Clinical and Population Science</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric J. MacLaughlin</td>
<td>Texas Tech University Health Sciences Center—Professor and Chair, Department of Pharmacy Practice, School of Pharmacy</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paul Muntner</td>
<td>University of Alabama at Birmingham—Professor, Department of Epidemiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
## Appendix 1. Continued

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruce Ovbiagele</td>
<td>Medical University of South Carolina—Phil Professor and Chairman of Neurology</td>
<td>None</td>
<td>• Boehringer Ingelheim Korea Ltd</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sidney C. Smith, Jr</td>
<td>University of North Carolina at Chapel Hill—Professor of Medicine; Center for Cardiovascular Science and Medicine—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Crystal C. Spencer</td>
<td>Spencer Law, PA—Attorney at Law</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Randall S. Stafford</td>
<td>Stanford Prevention Research Center—Professor of Medicine; Program on Prevention Outcomes—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sandra J. Taler</td>
<td>Mayo Clinic—Professor of Medicine, College of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Randal J. Thomas</td>
<td>Mayo Clinic—Medical Director, Cardiac Rehabilitation Program</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kim A. Williams, Sr</td>
<td>Rush University Medical Center—James B. Herrick Professor; Division of Cardiology—Chief</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeff D. Williamson</td>
<td>Wake Forest Baptist Medical Center—Professor of Internal Medicine; Section on Gerontology and Geriatric Medicine—Chief</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jackson T. Wright, Jr</td>
<td>Case Western Reserve University—Professor of Medicine; William T. Dahms MD Clinical Research Unit—Program Director; University Hospitals Case Medical Center—Director, Clinical Hypertension Program</td>
<td>None</td>
<td>• Amgen†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

We gratefully acknowledge the contributions of Dr. Lawrence Appel, who served as a member of the Writing Committee from November 2014 to September 2015.

*Dr. David C. Goff resigned from the writing committee in December 2016 because of a change in employment before the recommendations were balloted. The writing committee thanks him for his contributions, which were extremely beneficial to the development of the draft.

†Significant relationship.

AAPA indicates American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; NMA, National Medical Association; and PCNA, Preventive Cardiovascular Nurses Association.
<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim K. Bircher</td>
<td>Official Reviewer—TFPU Lead Reviewer</td>
<td>University of Houston College of Pharmacy—Clinical Professor, Department of Pharmacy Practice and Translational Research</td>
<td>• Jones &amp; Bartlett Learning</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Accreditation Council for Clinical Lipidology†</td>
<td>None</td>
<td>• Walgreens*</td>
</tr>
<tr>
<td>Roger Blumenthal</td>
<td>Official Reviewer—Prevention Subcommittee</td>
<td>Johns Hopkins Hospital—Kenneth Jay Pollin Professor of Cardiology; Ciccarone Center for the Prevention of Heart Disease—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Anna Dominiczak</td>
<td>Official Reviewer—AHA</td>
<td>University of Glasgow—Regus Professor of Medicine; Vice-Principal and Head of College of Medical, Veterinary and Life Sciences</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Carlos M. Ferrario</td>
<td>Official Reviewer—AHA</td>
<td>Wake Forest School of Medicine—Professor, of Physiology and Pharmacology; Hypertension and Vascular Disease Center—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
| Eugene Yang                      | Official Reviewer—ACC-BOS | University of Washington School of Medicine—Associate Clinical Professor of Medicine; UW Medicine Eastside Specialty Center—Medical Director | • RubiconMD*  
• Regeneron*  
• Amgen Inc.*  
• Gilead Sciences, Inc. (DSMB)* | None          | None                          | None              | • Third party, CAD, 2016*       | None           | None    |
| Robert Jay Amrani               | Organizational Reviewer—AAPA | Massachusetts General Hospital—Clinical Physician Assistant, Chelsea Health Center; Bryant University—Physician Assistant Program | None        | None          | None                          | None              | • Defendant, aortic dissection, 2016*                  | None           | None    |
| Greg Holzman                     | Organizational Reviewer—ACPM | Montana Department of Public Health and Human Services—State Medical Officer | None        | None          | None                          | None              | • American Academy of Family Medicine†  
• American College of Preventive Medicine† | None           | None    |
| Martha Gulati                    | Organizational Reviewer—ASPC | University of Arizona College of Medicine—Professor of Medicine; Chief, Division of Cardiology; University Medicine Cardiovascular Institute in Phoenix—Physician Executive Director, Banner | None        | None          | None                          | None              | • BEATA (spouse)*                                       | None           | None    |
| Wallace Johnson                  | Organizational Reviewer—NMA | University of Maryland Medical Center—Assistant Professor of Medicine | None        | None          | None                          | None              | None                                                   | None           | None    |
| Nancy Houston Miller            | Organizational Reviewer—PCNA | The Lifecare Company—Associate Director | • Moving Analytics* | None          | None                          | None              | None                                                   | None           | None    |
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldo J. Peixoto</td>
<td>Organizational Reviewer—ASH</td>
<td>Yale University School of Medicine—Professor of Medicine (Nephrology); Associate Chair for Ambulatory Services Operations and Quality; Department of Internal Medicine; Clinical Chief, Section of Nephrology</td>
<td>Lundbeck Inc.</td>
<td>None</td>
<td>None</td>
<td>Bayer Healthcare Pharmaceuticals†</td>
<td>None None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Carlos Rodriguez</td>
<td>Organizational Reviewer—ABC</td>
<td>Wake Forest University—Professor, Epidemiology and Prevention</td>
<td>Amgen Inc.</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None None None None None None None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joseph Saseen</td>
<td>Organizational Reviewer—APhA</td>
<td>University of Colorado Anschutz Medical Campus—Vice-Chair, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>National Lipid Association†</td>
<td>Defendant, statin use, 2016</td>
<td>None</td>
</tr>
<tr>
<td>Mark Supiano</td>
<td>Organizational Reviewer—AGS</td>
<td>University of Utah School of Medicine—D. Keith Barnes, MD, and Dottie Barnes Presidential Endowed Chair in Medicine; Chief, Division of Geriatrics; VA Salt Lake City Geriatric Research—Director, Education, and Clinical Center; University of Utah Center on Aging Executive—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None None</td>
<td>None</td>
</tr>
<tr>
<td>Sana M. Al-Khatib</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Duke Clinical Research Institute—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AHRQ*</td>
<td>Elsevier*</td>
<td>Third party, implantable cardioverter defibrillators, 2017</td>
<td>None</td>
</tr>
<tr>
<td>George Bakris</td>
<td>Content Reviewer</td>
<td>University of Chicago Medicine—Professor of Medicine; Director, Hypertensive Diseases Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AbbVie, Inc.</td>
<td>Eli Lilly and Company</td>
<td>None None</td>
<td>None</td>
</tr>
<tr>
<td>Jan Basile</td>
<td>Content Reviewer</td>
<td>Medical University of South Carolina—Professor of Medicine, Senoheiser Cardiovascular Health Program; Ralph H Johnson VA Medical Center—Internist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Amgen Inc.</td>
<td>Eli Lilly and Company</td>
<td>None None</td>
<td>None</td>
</tr>
<tr>
<td>Joshua A. Beckman</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Vanderbilt University Medical Center—Director, Cardiovascular Fellowship Program</td>
<td>AstraZeneca*</td>
<td>None</td>
<td>None</td>
<td>EMR†</td>
<td>Bristol Myers Squibb*</td>
<td>None</td>
<td>2015 Defendant; Venous thromboembolism*</td>
</tr>
<tr>
<td>John Bisognano</td>
<td>Content Reviewer</td>
<td>University of Rochester Medical Center—Cardiologist</td>
<td>CVRx</td>
<td>None</td>
<td>None</td>
<td>CVRx*</td>
<td>NIH*</td>
<td>None None</td>
<td>None</td>
</tr>
<tr>
<td>Biykem Bozkurt</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Baylor College of Medicine—Medical Care Line Executive, Cardiology Chief, Gordon Cannon Chair, Professor of Medicine, DeBakey</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Navartis Corporation</td>
<td>None None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership</th>
<th>Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Calhoun</td>
<td>Content Reviewer</td>
<td>University of Alabama, Birmingham School of Medicine—Professor, Department of Cardiovascular Disease</td>
<td>Novartis, Valencia Technologies*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>MEDTRONIC*</td>
<td>ReCor Medical*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joaquin E. Cigarroa</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Oregon Health and Science University—Clinical Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH</td>
<td>ACC/AHA Taskforce on Clinical Practice Guidelines†</td>
<td>NIH, Board of Directors, Western Affiliate†</td>
<td>American Stroke Association, Cryptogenic Stroke Initiative Advisory Committee†</td>
<td>Catheterization and Cardiovascular Intervention†</td>
</tr>
<tr>
<td>William Cushman</td>
<td>Content Reviewer</td>
<td>Memphis VA Medical Center—Chief, Preventive Medicine Section; University of Tennessee College of Medicine—Professor, Medicine, Preventive Medicine, and Physiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Lilly</td>
<td>Novartis Corporation†</td>
<td>Takeda†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Anita Deswal</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Baylor College of Medicine—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH*</td>
<td>bAurora Health Care Inc.</td>
<td>American Heart Association†</td>
<td>AHA Committee on Heart Failure and Transplantation—Chair†</td>
<td>Heart Failure Society of America†</td>
</tr>
<tr>
<td>Dave Dixon</td>
<td>Content Reviewer—Cardiovascular Team</td>
<td>Virginia Commonwealth University School of Pharmacy—Associate Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ross Feldman</td>
<td>Content Reviewer</td>
<td>Winnipeg Regional Health Authority—Medical Director, Cardiac Sciences Program; University of Manitoba—Professor of Medicine</td>
<td>GSK*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Keith Ferdinand</td>
<td>Content Reviewer</td>
<td>Tulane University School of Medicine—Professor of Clinical Medicine</td>
<td>Amgen Inc.*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Stephan Fihn</td>
<td>Content Reviewer</td>
<td>University of Washington—Professor of Medicine, Health Services; Division Head, General Internal Medicine; Director, Office of Analytics and Business Intelligence for the Veterans Health Administration; VA Puget Sound Health Care System—General Internist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>University of Washington</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawrence Fine</td>
<td>Content Reviewer</td>
<td>National Heart, Lung and Blood Institute—Chief, Clinical Applications and Prevention Branch, Division of Prevention and Population Sciences</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>John Flack</td>
<td>Content Reviewer</td>
<td>Southern Illinois University School of Medicine—Chair and Professor Department of Internal Medicine; Chief, Hypertension Specialty Services</td>
<td>Regeneron*</td>
<td>None</td>
<td>None</td>
<td>Bayer Healthcare Pharmaceuticals†</td>
<td>American Journal of Hypertension*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NuGrt</td>
<td></td>
<td></td>
<td></td>
<td>CardioRen Medicines†</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>International Journal of Hypertension†</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Southern Illinois University Department of Medicine*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joseph Flynn</td>
<td>Content Reviewer</td>
<td>Seattle Children’s Hospital—Chief of the Division of Nephrology; University of Washington School of Medicine—Professor of Pediatrics</td>
<td>Ultragenyx, Inc. (DSMB)</td>
<td>None</td>
<td>None</td>
<td>UpToDate, Springer*</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Federico Gentile</td>
<td>Content Reviewer</td>
<td>Centro Cardiologico</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joel Handler</td>
<td>Content Reviewer</td>
<td>Kaiser Permanente—Physician; National Kaiser Permanente Hypertension—Clinical Leader</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hani Jneid</td>
<td>Content Reviewer</td>
<td>Baylor College of Medicine—Associate Professor of Medicine, MEDVAMC</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>José A. Joglar</td>
<td>Content Reviewer</td>
<td>UT Southwestern Medical Center—Professor of Internal Medicine; Cardiovascular Clinical Research Center—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Amit Khera</td>
<td>Content Reviewer</td>
<td>University of Texas Southwestern Medical Center—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Glenn N. Levine</td>
<td>Content Reviewer</td>
<td>Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Defendant, catheterization laboratory procedure, 2016</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Defendant, interpretation of ECG of a patient, 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Defendant, interpretation of angiogram (non-ACS), 2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Defendant, out-of-hospital death, 2016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td>Representation</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speakers Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
<td>Salary</td>
</tr>
<tr>
<td>----------</td>
<td>----------------</td>
<td>------------</td>
<td>------------</td>
<td>----------------</td>
<td>-------------------------------</td>
<td>------------------</td>
<td>---------------------------------------------------</td>
<td>----------------</td>
<td>--------</td>
</tr>
<tr>
<td>Giuseppe Mancia</td>
<td>Content Reviewer</td>
<td>University of Milan-Bicocca—Professor of Medicine; Chairman, Department of Clinical Medicine, Prevention and Applied Biotechnologies</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Andrew Miller</td>
<td>Content Reviewer—Geriatric Cardiology Section</td>
<td>Cardiovascular Associate—Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis Corporation†</td>
<td>Pfizer Inc†</td>
<td>Bristol-Myers Squibb Company</td>
<td>none</td>
</tr>
<tr>
<td>Pamela Morris</td>
<td>Content Reviewer—Prevention Council, Chair</td>
<td>Seiserimer Cardiovascular Health Program—Director; Women’s Heart Care Medical University of South Carolina—Co-Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Martin Myers</td>
<td>Content Reviewer</td>
<td>Sunnybrook Health Sciences Centre—Affiliate Scientist; University of Toronto—Professor, Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Rick Nishimura</td>
<td>Content Reviewer</td>
<td>Mayo Clinic College of Medicine—Judd and Mary Morris Leighton Professor of Medicine; Mayo Clinic—Division of Cardiovascular Diseases</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick T. O’Gara</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Harvard Medical School—Professor of Medicine; Brigham and Women’s Hospital—Director, Strategic Planning, Cardiovascular Division</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>MEDITRONIC</td>
<td>NIH*</td>
<td>None</td>
</tr>
<tr>
<td>Suzanne Gopari</td>
<td>Content Reviewer</td>
<td>University of Alabama at Birmingham—Distinguished Professor of Medicine; Professor of Cell, Developmental and Integrative Biology, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH/NHLBI</td>
<td>Takeda WHF/ESH/EPH</td>
<td>None</td>
</tr>
<tr>
<td>Carl Pepine</td>
<td>Content Reviewer—CV Disease in Women Committee</td>
<td>Shands Hospital at University of Florida—Professor of Medicine, Chief of Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Capricor, Inc.</td>
<td>NIH</td>
<td>None</td>
</tr>
<tr>
<td>Mahboob Rahman</td>
<td>Content Reviewer</td>
<td>Case Western Reserve University School of Medicine—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vankata Ram</td>
<td>Content Reviewer</td>
<td>UT Southwestern Medical Center; Apollo Institute for Blood Pressure Clinics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Co-Investigator-mentor</td>
<td>NIH</td>
<td>None</td>
</tr>
<tr>
<td>Barbara Riegel</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>University of Pennsylvania School of Nursing—Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis Corp†</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Roccella</td>
<td>Content Reviewer</td>
<td>National Heart, Lung, and Blood Institute—Coordinator, National High Blood Pressure Education Program</td>
<td>Medical University of South Carolina</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>American Society of Hypertension†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ernesto Schiffrin</td>
<td>Content Reviewer</td>
<td>Jewish General Hospital—Physician-in-Chief, Chief of the Department of Medicine and Director of the Cardiovascular Prevention Centre; McGill University—Professor, Department of Medicine, Division of Experimental Medicine</td>
<td>Novartis Servier</td>
<td>None</td>
<td>None</td>
<td>Servier*</td>
<td>Canadian Institutes for Health Research†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Raymond Townsend</td>
<td>Content Reviewer</td>
<td>University of Pennsylvania School of Medicine—Professor of Medicine; Director, Hypertension Section, Department of Internal Medicine/Renal; Institute for Translational Medicine and Therapeutics—Member</td>
<td>MEDTRONIC</td>
<td>None</td>
<td>None</td>
<td>NIH*</td>
<td>ASN; UpToDate</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael Weber</td>
<td>Content Reviewer</td>
<td>SUNY Downstate College of Medicine—Professor of Medicine</td>
<td>Ablative Solutions*; Allergan, Inc; Astellas Pharma US*; Boston Scientific*; Eli Lilly and Company; MEDTRONIC*; Novartis; Recor</td>
<td>None</td>
<td>None</td>
<td>Memarios*</td>
<td>Merck &amp; Co., Inc.*</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to [http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy](http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy) for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

AHRQ indicates Agency for Healthcare Research and Quality; AAPA, American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APHA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; BOG, Board of Governors; CME, continuing medical education; DSMB, Data and Safety Monitoring Board; FDA, US Food and Drug Administration; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NBA, National Medical Association; PCNA, Preventive Cardiovascular Nurses Association; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiovascular Angiography and Interventions; SUNY, State University of New York; TFG, Task Force on Practice Guidelines; and UT, University of Texas.


Hypertension. 2018;71:1269-1324; originally published online November 13, 2017; doi: 10.1161/HYP.0000000000000066

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/71/6/1269

An erratum has been published regarding this article. Please see the attached page for:
/content/71/6/e136.full.pdf

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2017/11/13/HYP.0000000000000066.DC2
http://hyper.ahajournals.org/content/suppl/2017/11/13/HYP.0000000000000066.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/


1. On page 1269, in the author list, “FACC” has been removed after Dr. Giddings’ name.
2. On page 1270, in the Table of Contents and on page 1295, the 9.5. heading read, “9.5. Peripheral Arterial Disease.” It has been updated to read, “9.5. Peripheral Artery Disease.” It has also been updated on page 1303 in Table 22 and on page 1304 in Table 23.
3. On page 1276, in the footnote for Table 5, second paragraph, last sentence, the reference 3 citation has been removed from the end of the sentence.
4. On page 1278, the heading “4.3. Ambulatory BP Monitoring” has been deleted. The heading “4.4. Masked and White Coat Hypertension” now reads, “4.3. Masked and White Coat Hypertension.”
5. On page 1279, Figure 1, bottom row, needed the following changes:
   • The third box from the left (“Masked Hypertension”) was labeled as Class IIb. It has been updated to Class IIa. The shading of the box has been updated also.
   • The fourth box from the left (“Elevated BP”) was labeled as Class IIb. It has been updated to Class IIa. The shading of the box has been updated also.
6. On page 1280, Figure 2, bottom row, the second box from the left read, “Continue current therapy (Class IIa).” It has been updated to read, “Continue current therapy”; the Class of Recommendation color has been removed.
7. On page 1284, in Table 14, the text in the first column, last row read, “Angiogenesis inhibitor (e.g., bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenib).” It has been updated to read, “Angiogenesis inhibitor (eg, bevacizumab) and tyrosine kinase inhibitors (eg, sunitinib, sorafenib).”
8. On page 1287, legend to Figure 4, the third sentence, read, “*Using the ACC/AHA Pooled Cohort Equations (57).” It has been updated to read, “*Using the ACC/AHA Pooled Cohort Equations, 38.1.2-14,38.1.2-15.”
9. On page 1287, the section “8.1.3. Follow-Up After Initial BP Evaluation” recommendation table title read, “Recommendations for Follow-Up After Initial BP Elevation.” It has been updated to read, “Recommendations for Follow-Up After Initial BP Evaluation.”
10. On pages 1288–1290, in “Table 18. Oral Antihypertensive Drugs,” the following updates have been made:
   • In the “Primary agents” section, the first row “Thiazide or thiazide-type diuretics,” the “Metolazone” section, the “Usual Dose, Range (mg/d)” column read, “2.5–30.” It has been updated to read, “2.5–5.”

(Hypertension. 2018;71:e136-e139. DOI: 10.1161/HYP.0000000000000075.)
© 2018 American Heart Association, Inc.
Hypertension is available at http://hyper.ahajournals.org DOI: 10.1161/HYP.0000000000000075
• In the “Primary agents” section, the second row “ACE inhibitors,” the “Ramipril” section, the “Usual Dose, Range (mg/d)*” column read, “2.5–10.” It has been updated to read, “2–20.”
• In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Felodipine” section, the “Usual Dose, Range (mg/d)*” column read, “5–10.” It has been updated to read, “2.5–10.”
• In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nicardipine SR” section, the “Usual Dose, Range (mg/d)*” column read, “5–20.” It has been updated to read, “60–120.” The “Daily Frequency” column read, “1.” It has been updated to read, “2.”
• In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nifedipine LA” section, the “Usual Dose, Range (mg/d)*” column read, “60–120.” It has been updated to read, “30–90.”
• In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nisoldipine” section, the “Usual Dose, Range (mg/d)*” column read, “30–90.” It has been updated to read, “17–34.”
• In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil SR” section, the “Usual Dose, Range (mg/d)*” column read, “120–480.” It has been updated to read, “120–360.”
• In the “Primary agents” section, the fifth row “CCB—nondihydropyridines,” the “Verapamil-delayed onset ER” section, the “Usual Dose, Range (mg/d)*” column read, “100–480.” It has been updated to read, “100–300.”
• In the “Secondary agents” section, the first row “Diuretics—loop,” the “Bumetanide” section, the “Usual Dose, Range (mg/d)*” column read, “0.5–4.” It has been updated to read, “0.5–2.”
• In the “Secondary agents” section, the third row “Diuretics—aldosterone antagonists,” the “Eplerenone” section, the “Daily Frequency” column read, “12.” It has been updated to read, “1 or 2.”
• In the “Secondary agents” section, the fourth row “Beta blockers—cardioselective,” the “Atenolol” section, the “Daily Frequency” column read, “12.” It has been updated to read, “2.”
• In the “Secondary agents” section, the fourth row “Beta blockers—cardioselective,” the “Metoprolol tartrate” section, the “Usual Dose, Range (mg/d)*” column read, “100–400.” It has been updated to read, “100–200.”
• In the “Secondary agents” section, the sixth row “Beta blockers—noncardioselective,” the “Propranolol IR” section, the “Usual Dose, Range (mg/d)*” column read, “160–480.” It has been updated to read, “80–160.”
• In the “Secondary agents” section, the sixth row “Beta blockers—noncardioselective,” the “Propranolol LA” section, the “Usual Dose, Range (mg/d)*” column read, “320–80.” It has been updated to read, “80–160.”
• In the “Secondary agents” section, the seventh row “Beta blockers—intrinsic sympathomimetic activity,” the “Carteolol” section has been deleted.
• In the “Secondary agents” section, the tenth row “Alpha-1 blockers,” the “Doxazosin” section, the “Usual Dose, Range (mg/d)*” column read, “1–8.” It has been updated to read, “1–16.”
• In the “Secondary agents” section, the penultimate row, the “Class” column read, “Central alpha₁-agonist and other centrally acting drugs.” It has been updated to read, “Central alpha₁-agonist and other centrally acting drugs.”
• In the “Secondary agents” section, the last row “Direct vasodilators,” the “Hydralazine” section, the “Usual Dose, Range (mg/d)*” column read, “250–200.” It has been updated to read, “100–200.”
11. On page 1291, the heading “8.3.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP” has been renumbered as “8.2.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP.”

12. On page 1295, Figure 9, fourth row, the first box on the left read, “Aim for BP <140/90 mm Hg (Class IIb).” It has been updated to read, “Aim for BP <130/80 mm Hg (Class IIb).”

13. On page 1304, Table 23, in the “Specific comorbidities” section, the penultimate row “Secondary stroke prevention (lacunar)” has been deleted.

14. On page 1304, in the “Presidents and Staff” section for the American Heart Association, Ms. Hundley’s title is updated to read, “Manager, Production and Operations.”

15. On page 1310, in the References for section “8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension,” the following changes were made:

16. On page 1317, in Appendix 1, for Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6 “Personal Research” read, “None.” It has been updated to read, “Daiichi Sankyo Inc†”

17. On page 1318, in Appendix 1, for Dr. Ovbiagele, column 4, “Speakers Bureau,” read, “None.” It has been updated to read, “Boehringer Ingelheim Korea Ltd.”

18. On page 1318, in Appendix 1, for Dr. Wright, column 4, “Speakers Bureau,” read, “None.” It has been updated to read, “Amgen†.”

19. On page 1318, in the Appendix 1 footnotes, the first paragraph has been deleted. It read:
   This table represents the relationships of committee members with industry and other entities (RWI) that are considered relevant to this document. Although most ACC/AHA guideline writing committees are constituted such that no more than half the members may have relevant RWI for 1 year before and during development of the guideline, rules for the prevention guidelines require that no members have relevant RWI from 1 year before appointment until 1 year after publication of the guideline. Members’ RWI were reviewed and updated at all meetings and conference calls of the writing committee during the document development period. The complete ACC/AHA policy on RWI is available at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy.

   It has been updated with 2 new paragraphs to read:
   This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

   According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s
household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.

20. On page 1318, in the Appendix 1 footnotes, “†Significant relationship.” has been added.

21. In the Comprehensive RWI Data Supplement for the writing committee, the following updates have been made:

- For Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6, “Personal Research” read, “None.” It has been updated to read, “Daiichi Sankyo Inc*.”
- For Dr. Ovbiagele, column 4, “Speakers Bureau” read, “None.” It has been updated to read, “Boehringer Ingelheim Korea Ltd.”
- For Dr. Wright, column 4, “Speakers Bureau” read, “None.” It has been updated to read, “Amgen*.”

These corrections have been made to the print version and the current online version of the article, which is available at http://hyper.ahajournals.org/lookup/doi/10.1161/HYP.0000000000000066.
2017 Hypertension Guideline Data Supplements

(Section numbers correspond to the full-text guideline.)

Table of Contents

Data Supplement 1. Coexistence of Hypertension and Related Chronic Conditions (Section 2.4) ................................................................................................................................................................. 7
Data Supplement 2. Definition of High BP (Section 3.1) .................................................................................................................................................................................................................. 8
Data Supplement 3. Out-of-Office and Self-Monitoring of BP (Section 4.2) .................................................................................................................................................................................................. 18
Data Supplement 4. White Coat Hypertension (Section 4.4) ........................................................................................................................................................................................................ 21
Data Supplement 5. White Coat Hypertension (Prevalence) (Section 4.4) .................................................................................................................................................................................................. 23
Data Supplement 6. White Coat Hypertension (Correlation with Clinical Outcomes) (Section 4.4) ........................................................................................................................................................................... 25
Data Supplement 7. Renal Artery Stenosis (Section 5.4.3) .................................................................................................................................................................................................. 27
Data Supplement 8. RCTs Comparing Obstructive Sleep Apnea (Section 5.4.4) .................................................................................................................................................................................................. 29
Data Supplement 9. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Fiber Intake) (Section 6.2) ........................................................................................................................................................................... 31
Data Supplement 10. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Fish Oil) (Section 6.2) ........................................................................................................................................................................... 33
Data Supplement 11. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Potassium Supplementation to Placebo or Usual Diet) (Section 6.2) ........................................................................................................................................................................... 34
Data Supplement 12. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Protein Intake on BP) (Section 6.2) ........................................................................................................................................................................... 36
Data Supplement 13. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Sodium Reduction to Placebo or Usual Diet) (Section 6.2) ........................................................................................................................................................................... 38
Data Supplement 14. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Stress Reduction) (Section 6.2) ........................................................................................................................................................................... 43
Data Supplement 15. RCTs and Meta-analyses Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Patterns) (Section 6.2) ........................................................................................................................................................................... 44
Data Supplement 16. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Alcohol Reduction) (Section 6.2) ........................................................................................................................................................................... 51
Data Supplement 17. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Calcium Supplementation) (Section 6.2) ........................................................................................................................................................................... 55
Data Supplement 18. RCTs and Meta-analyses RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Physical Activity) (Section 6.2) ........................................................................................................................................................................... 56

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
2017 Hypertension Guideline Data Supplements

Data Supplement 19. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Magnesium Supplementation) (Section 6.2) ................................................. 59
Data Supplement 20. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Weight Loss) (Section 6.2) ........................................................................................................ 61
Data Supplement 21. RCTs and Systematic Reviews for RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Section 6.2) ................................................................. 64
Data Supplement 22. Observational Studies of CV Target Organ Damage Including LVH (Section 7.2) ............................................................................................................................... 66
Data Supplement 23. RCTs on Use of Risk Estimation to Guide Treatment of Hypertension (Section 8.1.2) ................................................................................................................... 67
Data Supplement 24. Follow-Up After Initial BP Evaluation (Section 8.1.3) .......................................................................................................................... 81
Data Supplement 25. RCTs for General Principles of Drug Therapy (Combination Therapies that Inhibit the RAAS) (Section 8.1.4) ................................................................................. 83
Data Supplement 26. BP Goal for Patients with Hypertension (Section 8.1.5) .......................................................................................................................... 85
Data Supplement 27. Choice of Initial Medication (Section 8.1.6) .......................................................................................................................... 92
Data Supplement 28. Follow-Up After Initiating Antihypertensive Drug Therapy (Section 8.3.1) ........................................................................................................................... 95
Data Supplement 29. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP (Section 8.3.2) ....................................................................................... 97
Data Supplement 30. RCTs Comparing Stable Ischemic Heart Disease (Section 9.1) .............................................................................................................................. 100
Data Supplement 31. Meta-analyses of ischemic heart disease (Section 9.1) .......................................................................................................................... 110
Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Ischemic Heart Disease (Section 9.1) .............................................................................................. 111
Data Supplement 33. RCTs Comparing Heart Failure (Section 9.2) .............................................................................................................................. 112
Data Supplement 34. RCTs Comparing HFrEF (Section 9.2.1) .............................................................................................................................. 113
Data Supplement 35. RCTs Comparing HFrEF (Section 9.2.2) .............................................................................................................................. 119
Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of HFrEF (Section 9.2.2) ................................................................. 122
Data Supplement 37. RCTs Comparing CKD (Section 9.3) .............................................................................................................................. 123
Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries of CKD (Section 9.3) .............................................................................................................................. 133
Data Supplement 39. RCTs Comparing Hypertension after Renal Transplantation (Section 9.3.1) .............................................................................................................................. 137
Data Supplement 40. Nonrandomized Trials, Observational Studies, and/or Registries for Hypertension after Renal Transplantation (Section 9.3.1) .............................................................................................................................. 140
Data Supplement 41. RCTs Comparing Acute Intracerebral Hemorrhage Outcomes (Section 9.4.1) .............................................................................................................................. 143
Data Supplement 42. RCTs Comparing Acute Ischemic Stroke Outcomes (Section 9.4.2) .............................................................................................................................. 147
Data Supplement 43. RCTs Comparing Secondary Stroke Prevention (Section 9.4.3) .............................................................................................................................. 158
Data Supplement 44. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Stroke Prevention (Section 9.4.3) .............................................................................................................................. 161

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Data Supplement</th>
<th>Title and Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>RCTs and Meta-analysis Comparing PAD (Section 9.5)</td>
<td>168</td>
</tr>
<tr>
<td>46</td>
<td>RCTs and Meta-analyses Comparing BP Targets in DM (Section 9.6)</td>
<td>174</td>
</tr>
<tr>
<td>47</td>
<td>Nonrandomized Trials, Observational Studies, and/or Registries in DM (Section 9.6)</td>
<td>183</td>
</tr>
<tr>
<td>48</td>
<td>Atrial Fibrillation (Section 9.8)</td>
<td>190</td>
</tr>
<tr>
<td>49</td>
<td>Valvular Heart Disease (Section 9.9)</td>
<td>191</td>
</tr>
<tr>
<td>50</td>
<td>RCTs and Meta-analysis Comparing Valvular Heart Disease (Section 9.9)</td>
<td>194</td>
</tr>
<tr>
<td>51</td>
<td>RCTs Comparing Race/Ethnicity (Section 10.1)</td>
<td>197</td>
</tr>
<tr>
<td>52</td>
<td>RCTs Comparing Women With Hypertension (Section 10.2.1)</td>
<td>201</td>
</tr>
<tr>
<td>53</td>
<td>RCTs Comparing Pregnancy (Section 10.2.2)</td>
<td>203</td>
</tr>
<tr>
<td>54</td>
<td>RCT for Older Persons (Section 10.3.1)</td>
<td>204</td>
</tr>
<tr>
<td>55</td>
<td>RCTs Comparing Hypertensive Crises and Emergencies (Section 11.2)</td>
<td>204</td>
</tr>
<tr>
<td>56</td>
<td>RCTs Assessing Impact of Hypertension Therapy on Dementia Incidence (Section 11.3)</td>
<td>207</td>
</tr>
<tr>
<td>57</td>
<td>RCTs for Patients Undergoing Surgical Procedures (Section 11.5)</td>
<td>210</td>
</tr>
<tr>
<td>58</td>
<td>Observational and Nonrandomized Studies for Patients Undergoing Surgical Procedures (Section 11.5)</td>
<td>211</td>
</tr>
<tr>
<td>59</td>
<td>RCTs of Adherence and Compliance with Fixed Dose Combinations Regimens (Section 12.1.1)</td>
<td>213</td>
</tr>
<tr>
<td>60</td>
<td>Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Medication Adherence Strategies (Section 12.1.1)</td>
<td>214</td>
</tr>
<tr>
<td>61</td>
<td>RCTs and Meta-analysis on Strategies to Promote Lifestyle Modification (Section 12.1.2)</td>
<td>220</td>
</tr>
<tr>
<td>62</td>
<td>RCTs, Meta-analyses, and Systematic Reviews on the Effect of Structured, Team-based Care Interventions for Hypertension Control (Section 12.2)</td>
<td>220</td>
</tr>
<tr>
<td>63</td>
<td>Electronic Health Records and Patient Registries (Section 12.3.1)</td>
<td>227</td>
</tr>
<tr>
<td>64</td>
<td>RCTs, Meta-analyses, and Systematic Reviews on the Effect of Telehealth Interventions to Improve Hypertension Control (Section 12.3.2)</td>
<td>232</td>
</tr>
<tr>
<td>65</td>
<td>RCTs and Observational Studies that Report on the Effect of Performance Measures and on Hypertension Control (Section 12.4.1)</td>
<td>236</td>
</tr>
<tr>
<td>66</td>
<td>RCTs, Meta-analyses, and Systematic Reviews on Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2)</td>
<td>238</td>
</tr>
<tr>
<td>67</td>
<td>Nonrandomized Trials, Observational Studies, and/or Registries of Effect of Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2)</td>
<td>244</td>
</tr>
<tr>
<td>68</td>
<td>RCTs Comparing Financial Incentives (Section 12.5)</td>
<td>245</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
### 2017 Hypertension Guideline Data Supplements

<table>
<thead>
<tr>
<th>Data Supplement</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Treatment of HFrEF Stages C and D</td>
<td>252</td>
</tr>
<tr>
<td>B</td>
<td>Medication Adherence Assessment Scales</td>
<td>253</td>
</tr>
<tr>
<td>C</td>
<td>Categories Defining Normal BP, Elevated BP, and Stages 1, 2, and 3 Hypertension</td>
<td>253</td>
</tr>
<tr>
<td>D</td>
<td>Fixed-Dose Combination Antihypertensive Drugs</td>
<td>255</td>
</tr>
<tr>
<td>E</td>
<td>Examples of Hypertension Quality Improvement Strategies</td>
<td>256</td>
</tr>
<tr>
<td>F</td>
<td>Barriers and Improvement Strategies in Antihypertensive Medication Adherence</td>
<td>257</td>
</tr>
<tr>
<td>G</td>
<td>Examples of Strategies to Promote Lifestyle Modification Interventions in Patients With Hypertension</td>
<td>258</td>
</tr>
<tr>
<td>H</td>
<td>Responsibilities and Roles of the Hypertension Team</td>
<td>259</td>
</tr>
<tr>
<td>I</td>
<td>Examples of Telehealth Strategies and Technologies to Promote Effective Hypertension Management</td>
<td>260</td>
</tr>
<tr>
<td>J</td>
<td>Publicly Available Performance Measures Used to Assess Hypertension Care Quality Services</td>
<td>261</td>
</tr>
<tr>
<td>K</td>
<td>Online Quality Improvement Resources for Treatment and Control of Hypertension</td>
<td>263</td>
</tr>
</tbody>
</table>

### Search Terms:

An extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted between February and August 2015. Key search words included but were not limited to the following: adherence; aerobic; alcohol intake; ambulatory care; antihypertensive: agents, drug, medication, therapy; beta adrenergic blockers; blood pressure: arterial, control, determination, devises, goal, high, improve, measurement, monitoring, ambulatory; calcium channel blockers; diet; diuretic agent; drug therapy; heart failure: diastolic, systolic; hypertension: white coat, masked, ambulatory, isolated ambulatory, isolated clinic, diagnosis, reverse white coat, prevention, therapy, treatment, control; intervention; lifestyle: measures, modification; office visits; patient outcome; performance measures; physical activity; potassium intake; protein intake; renin inhibitor; risk reduction: behavior, counseling; screening; sphygmomanometers; spironolactone; therapy; treatment: adherence, compliance, efficacy, outcome, protocol, regimen; weight. Additional relevant studies published through June 2016, during the guideline writing process, were also considered by the writing committee, and added to the evidence tables when appropriate.
Abbreviations:

1°, primary; 2°, secondary; AASK, African American Study of Kidney Disease and Hypertension; ABI, ankle-brachial index; ABCD, Appropriate Blood Pressure Control in Diabetes; ABPM, ambulatory blood pressure monitoring; ACCESS, Acute Candesartan Cilexetil Evaluation in Stroke Survivors; ACCOMPLISH, Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension; ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACE, angiotensin-converting enzyme; ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ADVANCE, Action in Diabetes and Vascular Disease; AF, atrial fibrillation; AFL, atrial flutter; AHR, adjusted hazard ratio; AIPRD, Angiotensin-Converting Enzyme Inhibition in Progressive Renal Disease; ALLHAT, Antihypertensive Lipid Lowering Treatment to Prevent Heart Attack Trial; AMI, acute myocardial infarction; ARB, angiotensin-receptor blocker; ARIC, Atherosclerosis Risk in Communities; ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; BB, beta blocker; BMI, body mass index; BP, blood pressure; BPLTTC, Blood Pressure Lowering Treatment Trials’ Collaboration; bpm, beats per minute; BUN, blood urea nitrogen; CABB, coronary artery bypass graft; CAD, coronary artery disease; CATIS, China Antihypertensive Trial in Acute Ischemic Stroke; CCB, calcium-channel blocker; CCU, coronary care unit; CHD, coronary heart disease; CHF, congestive heart failure; CHHIPS, Controlling Hypertension and Hypotension Immediately Post-Stroke; CI, confidence interval; CKD, chronic kidney disease; COMFORT, Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Mediation Compliance Trial; COSSACS, the Continue or Stop Post-Stroke Antihypertensives Collaborative Study; CPAP, continuous positive airway pressure; Cr, creatinine; CrCl, creatinine clearance; CRP, C-reactive protein; CR/XL, metoprolol controlled release/extended release; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; DM, diabetes mellitus; DM-1, diabetes mellitus type-1; DM-2, diabetes mellitus type-2; ECG, electrocardiogram; ED, emergency department; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; FC, functional class; FDC, fixed dose combination; FEVER, Felodipine Event Reduction; GITS, gastrointestinal therapeutic system; GFR, glomerular filtration rate; HBPM, home blood pressure monitoring; HCTZ, hydrochlorothiazide; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; HEDIS, Healthcare Effectiveness Data and Information Set; HF, heart failure; HFrEF, reduced ejection fraction; HFrPEF, heart failure with preserved ejection fraction; HIV, human immunodeficiency virus; HR, hazard ratio; HTN, hypertension; ICD, implantable cardioverter-defibrillator; ICH, intracerebral hemorrhage; IDACO, International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome; IHD, ischemic heart disease; IMT, intimal media thickness; INDANA, Individual Data Analysis of Anti-hypertensive Drug intervention trials; INTERACT2, the second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial; INVEST, International Verapamil-Trandolapril Study; INWEST, the Intravenous Nimodipine West European Stroke Trial; IQI, interquartile interval; IQR, interquartile range; IRR, incidence rate ratio; ISDN, isosorbide dinitrate; IV, intravenous; JNC-7, 7th Report of the Joint National Committee; KPNC, Kaiser Permanente Northern California; LDL, low-density lipoprotein; LGSAS, low-gradient severe aortic stenosis; LIFE, Losartan Intervention For Endpoint Reduction in Hypertension; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVMi, left ventricular mass index; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiac events; MAP, mean arterial pressure; MD, mean difference; MDPIT, Multicenter Diltiazem Postinfarction Research Group; MDRD, Modification of Diet in Renal Disease; MERIT, Metoprolol CR/XL Randomised Intervention Trial; MESA, Multi-Ethnic Study of Atherosclerosis; MH, masked hypertension; MI, myocardial infarction; MOSES, The Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention; MPR, medication possession ratio; MRFIT, Multiple Risk Factor Intervention Trial; MRI, magnetic resonance imaging; N/A, not available; NCQA, National Committee for Quality Assurance; NEMESIS, North East Melbourne Stroke Incidence Study; NHANES, National Health and Nutrition Examination Surveys; NIH, National Institute of Health; NNT, number needed to treat; NR, not relative;
## Data Supplement 1. Coexistence of Hypertension and Related Chronic Conditions (Section 2.4)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Wilson PW, et al., 1999 (1) 10335688   | **Study type:** Nonrandomized  
**Size:** 2,406 men, 2,569 women (1,759 men, 1,818 women with follow-up)  
**Inclusion criteria:** Men and women 18–74 y and free of CHD at baseline, from the Framingham Offspring Study  
**Exclusion criteria:** N/A | **1st endpoint:** Total CHD (first occurrence of angina, UA, MI, and coronary death), Hard CHD (first MI and coronary death)  
**Results:** Presence of ≥3 risk factors was associated with a 2.39 times greater risk of CHD in men (95% CI: 1.56–3.36; p<0.001) and a 5.90 increased risk of CHD in women (95% CI: 2.54–13.73; p<0.001) | • CVD risk factors infrequently occur in isolation (only 28%–30% of the time); presence of ≥3 risk factors occurred 17% of the time in both men and women; presence of ≥3 risk factors associated with high risk of CHD and coronary death (attributable risk of 20% in men and 48% in women) |
| Berry JD, et al., 2012 (2) 22276822     | **Study type:** Nonrandomized  
**Size:** 257,384 black and white men and women, including 67,890 pts (from 17 meta-analysis) and 189,494 pts (from MRFIT)  
**Inclusion criteria:** Meta-analysis of 18 cohort studies  
**Exclusion criteria:** N/A | **1st endpoint:** Fatal CHD, nonfatal MI, fatal or nonfatal stroke  
**Results:** Participants with optimal RF profile (total cholesterol <180 mg/dL, untreated BP <120 mm Hg systolic, and <80 mm Hg diastolic, nondiabetic, nonsmoker) compared to participants with ≥2 risk factors had lower risk of CVD through the age of 80 y (4.7% vs. 29.6% for men, 6.4% vs. 20.5% for women), lower lifetime risk of fatal heart disease and nonfatal MI (3.6% vs. 37.5% for men, <1% vs. 18.3% for women), and lower lifetime risk of fatal or nonfatal stroke (2.3% vs. 8.3% for men, 5.3% vs. 10.7% for women) | • Increased burden of 80 risk factors associated with higher lifetime risk of CVD |
### Data Supplement 2. Definition of High BP (Section 3.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; and CI; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Lewington S, et al., 2002 12493255    | Study type: Meta-analysis of 61 observational cohort studies | **Inclusion criteria:** Men and women with no history of previous CVD and record of key study variables. **Exclusion criteria:** Prior CVD | **1° endpoint:** Cause-specific mortality  
**Results:** 958,074 persons followed for a mean of 12 y to death (12.7 million person-y at risk. Number of deaths attributed to:  
- Stroke: 11960  
- IHD: 34,283  
- Other vascular:10092  
- Non-vascular: 60797  
Above a SBP ≥115 mm Hg and DBP ≥75 mm Hg, there was a progressive rise in vascular death with progressively high BP with no evidence of a J-curve (approximately doubling of stroke and IHD mortality for a 20 mm Hg higher level of SBP or 10 mm Hg higher level of DBP, in those 40–69 y). With progressively higher age, the BP-related proportional risk of vascular mortality was somewhat reduced but the corresponding absolute risk was much higher. | • In adults aged 40–89 y, usual BP is strongly related to vascular (and overall) mortality, without evidence of a threshold down to at least an SBP/DBP of 115/75 mm Hg. |
| Rapsomaniki E, et al., 2014 24881994 | Study type: Observational cohort study  
**Size:** 1.25 million patients, in 225 primary care practices in the UK, followed for a median of 5.2 y using electronic medical records. | **Inclusion criteria:** Men and women ≥30 y, with no previous diagnosis of CVD, who had been registered at their practices for ≥1 year. **Exclusion criteria:** N/A | **1° endpoint:** 12 acute and chronic CVD outcomes  
**Results:** 83,098 initial CVD events recorded. Within each of 3 age groups (30–59, 60–79, and ≥80 y), the lowest risk for CVD was in those with a SBP 90–114 mm Hg and DBP 60–74 mm Hg. There was a direct relationship between level of BP and most CVD outcomes, with no evidence of J-curve, with the strongest relationship for SBP and stroke and weakest for abdominal aneurysm. | • Despite modern treatments, the lifetime burden of BP-related CVD was substantial. |
| Wilson PW, et al., 1999 (1) 10335688 | Study type: Nonrandomized  
**Inclusion criteria:** Men and women 18–74 y and free of CHD at baseline, from the Framingham Offspring Study | **Inclusion criteria:** Men and women 18–74 y and free of CHD at baseline, from the Framingham Offspring Study | **1° endpoint:** Total CHD (first occurrence of angina, UA, MI, and coronary death), Hard CHD (first MI and coronary death)  
**Results:** | • CVD risk factors infrequently occur in isolation (only 28%–30% of the time) |
| Study type               | Size: 2,406 men, 2,569 women (1,759 men, 1,818 women with follow-up) | Exclusion criteria: N/A | Results: Presence of ≥3 risk factors was associated with a 2.39 times greater risk of CHD in men (95% CI: 1.56–3.36; p<0.001) and a 5.90 increased risk of CHD in women (95% CI: 2.54–13.73; p<0.001) | • Presence of ≥3 risk factors occurred 17% of the time in both men and women  
• Presence of ≥3 risk factors associated with high risk of CHD and coronary death (attributable risk of 20% in men and 48% in women) |
|-------------------------|-------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Guo X, et al., 2013 (3) | Study type: Meta-analysis of nonrandomized studies                 | Inclusion criteria: Studies reporting adjusted risk for CVD or mortality with pre-HTN          | 1° endpoint: CVD and all-cause mortality                                                                                              | • SBP/DBP of 120–129/80–84 mm Hg associated with increased risk for all-cause or CVD mortality.  
• SBP/DBP of 130–139/85–89 mm Hg associated with an increased risk for CVD mortality. |
|                         | Size: 870,678 pts                                                  | Exclusion criteria: N/A                                                                 | Results: SBP/DBP 120–129/80–84 mm Hg compared to <120/80 mm Hg:  
• All-cause mortality: RR: 0.91; 95% CI: 0.81–1.02  
• CVD mortality: RR: 1.10 (95% CI: 0.92, 1.30)  
SBP/DBP 130–139/85–89 mm Hg compared to <120/80 mm Hg:  
• All-cause mortality: 1.00; 95% CI: 0.95–1.06  
• CVD mortality: RR: 1.26; 95% CI: 1.13–1.41 |
| Guo X, et al., 2013 (4) | Study type: Meta-analysis of nonrandomized studies                 | Inclusion criteria: Studies reporting adjusted risk for fatal and nonfatal stroke, CHD, MI and total CVD events with pre-HTN, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg | 1° endpoint: Fatal and nonfatal stroke, CHD, MI and total CVD events                                                                  | • Compared to pts with SBP/DBP<120/80 mm Hg, the RR for CVD, MI and stroke were larger for pts with SBP/DBP of 130–139/85–89 mm Hg vs. SBP/DBP of 120–129/80–84 mm Hg. |
|                         | Size: 1,010,858 pts                                               | Exclusion criteria: N/A                                                                 | Results: SBP/DBP 120–129/80–84 mm Hg compared to <120/80 mm Hg:  
• CVD RR: 1.24; 95% CI: 1.10–1.39  
• MI RR: 1.43; 95% CI: 1.10–1.86  
• Stroke RR: 1.35; 95% CI: 1.10–1.66  
SBP/DBP 130–139/85–89 mm Hg compared to <120/80 mm Hg:  
• CVD RR: 1.56; 95% CI: 1.36–1.78  
• MI RR: 1.99; 95% CI: 1.59–2.50  
• Stroke RR: 1.95; 95% CI: 1.69–2.24 |
| Huang Y, et al., 2013 (5)| Study type: Meta-analysis of nonrandomized studies                 | Inclusion criteria: Studies reporting risk for CVD, CHD and stroke, with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg  
Adults ≥18 y BP evaluated at baseline                                                                                               | 1° endpoint: CVD, CHD, and stroke                                                                                                   | • Compared to pts with SBP/DBP <120/80 mm Hg, the RR for CVD was larger for pts with SBP/DBP of 130–139/85–89 mm Hg vs. SBP/DBP of 120–129/80–84 mm Hg. |
|                         | Size: 468,561 pts from 18 prospective cohort studies              | Exclusion criteria: N/A                                                                 | Results: Comparing SBP/DBP 120–129/80–84 mm Hg to <120/80 mm Hg:  
• CVD RR: 1.46; 95% CI: 1.14–1.78  
• CHD RR: 1.26; 95% CI: 1.00–1.58  
• Stroke RR: 1.48; 95% CI: 1.32–1.62 |

Guo X, et al., 2013 (3)  
Study type: Meta-analysis of nonrandomized studies  
Size: 870,678 pts  
Inclusion criteria: Studies reporting adjusted risk for CVD or mortality with pre-HTN  
Exclusion criteria: N/A  
1° endpoint: CVD and all-cause mortality  
Results: SBP/DBP 120–129/80–84 mm Hg compared to <120/80 mm Hg:  
  • All-cause mortality: RR: 0.91; 95% CI: 0.81–1.02  
  • CVD mortality: RR: 1.10 (95% CI: 0.92, 1.30)  
SBP/DBP 130–139/85–89 mm Hg compared to <120/80 mm Hg:  
  • All-cause mortality: 1.00; 95% CI: 0.95–1.06  
  • CVD mortality: RR: 1.26; 95% CI: 1.13–1.41  

Guo X, et al., 2013 (4)  
Study type: Meta-analysis of nonrandomized studies  
Size: 1,010,858 pts  
Inclusion criteria: Studies reporting adjusted risk for fatal and nonfatal stroke, CHD, MI and total CVD events with pre-HTN, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg  
Exclusion criteria: N/A  
1° endpoint: Fatal and nonfatal stroke, CHD, MI and total CVD events  
Results: SBP/DBP 120–129/80–84 mm Hg compared to <120/80 mm Hg:  
  • CVD RR: 1.24; 95% CI: 1.10–1.39  
  • MI RR: 1.43; 95% CI: 1.10–1.86  
  • Stroke RR: 1.35; 95% CI: 1.10–1.66  
SBP/DBP 130–139/85–89 mm Hg compared to <120/80 mm Hg:  
  • CVD RR: 1.56; 95% CI: 1.36–1.78  
  • MI RR: 1.99; 95% CI: 1.59–2.50  
  • Stroke RR: 1.95; 95% CI: 1.69–2.24  

Huang Y, et al., 2013 (5)  
Study type: Meta-analysis of nonrandomized studies  
Size: 468,561 pts from 18 prospective cohort studies  
Inclusion criteria: Studies reporting risk for CVD, CHD and stroke, with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg  
Adults ≥18 y BP evaluated at baseline  
1° endpoint: CVD, CHD, and stroke  
Results: Comparing SBP/DBP 120–129/80–84 mm Hg to <120/80 mm Hg:  
  • CVD RR: 1.46; 95% CI: 1.14–1.78  
  • CHD RR: 1.26; 95% CI: 1.00–1.58  
  • Stroke RR: 1.48; 95% CI: 1.32–1.62  

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>1° Endpoint</th>
<th>Results</th>
<th>2° Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huang Y, et al., 2014 (6) 24074825 Study type: Meta-analysis of nonrandomized studies Size: 1,003,793 pts were derived from 6 prospective cohort studies Inclusion criteria: Studies reporting adjusted risk for ESRD with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg Adults ≥18 y BP evaluated at baseline ≥ 1 y follow-up for ESRD Results reported with adjustment Exclusion criteria: 1) enrollment depended on having a condition or risk factor, 2) the study reported only age- and sex-adjusted RRs, and 3) data were derived from the same cohort or from a 2° analysis</td>
<td>1° endpoint: ESRD</td>
<td>Results: Comparing SBP/DBP 120–129/80–84 mm Hg to &lt;120/80 mm Hg: ESRD RR: 1.44; 95% CI: 1.19–1.74 Comparing SBP/DBP 130–139/85–89 mm Hg to &lt;120/80 mm Hg: ESRD RR: 2.02; 95% CI: 1.70–2.40; p value comparing these risk ratios=0.01</td>
<td>Compared to pts with SBP/DBP &lt;120/80 mm Hg, the RR for ESRD was larger for pts with SBP/DBP of 130–139/85–89 mm Hg vs. SBP/DBP of 120–129/80–84 mm Hg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang Y, et al., 2013 (7) 24623843 Study type: Meta-analysis of nonrandomized studies Size: 762,393 pts from 19 prospective cohort studies Inclusion criteria: Studies reporting adjusted risk for stroke with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg Adults ≥18 y BP evaluated at baseline ≥ 1 y follow-up for stroke Results reported with adjustment Exclusion criteria: Enrollment depended on having a specific risk factor condition (e.g., DM or other baseline chronic diseases) The RR was unadjusted or only adjusted for age and sex Data were derived from the same cohort or meta-analysis of other cohort studies.</td>
<td>1° endpoint: Stroke</td>
<td>Results: Comparing SBP/DBP 120–129/80–84 mm Hg to &lt;120/80 mm Hg: Stroke: RR: 1.44; 95% CI: 1.27–1.63 Comparing SBP/DBP 130–139/85–89 mm Hg to &lt;120/80 mm Hg: Stroke: RR: 1.95; 95% CI: 1.73–2.21 p value comparing these risk ratios ≤0.001</td>
<td>Compared to pts with SBP/DBP &lt;120/80 mm Hg, the RR for stroke was larger for pts with SBP/DBP of 130–139/85–89 mm Hg vs. SBP/DBP of 120–129/80–84 mm Hg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study type: Meta-analysis of nonrandomized studies</td>
<td>Size: 1,129,098 pts from 20 prospective cohort studies</td>
<td>Inclusion criteria:</td>
<td>1° endpoint: All-cause and CVD mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huang Y, et al., 2014 (8) 24439976</td>
<td>Studies reporting adjusted risk for all-cause/CVD mortality with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg</td>
<td>Adults ≥18 y BP evaluated at baseline ≥2 y follow-up for mortality Results reported with adjustment</td>
<td>Comparing SBP/DBP 120–129/80–84 mm Hg to &lt;120/80 mm Hg:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• All-cause mortality RR: 0.96; 95% CI: 0.85–1.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• CVD mortality RR: 1.08; 95% CI: 0.98–1.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>p value comparing these risk ratios:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• All-cause mortality p=0.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• CVD mortality p=0.01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type: Meta-analysis of nonrandomized studies</th>
<th>Size: 591,664 pts from 17 prospective cohort studies</th>
<th>Inclusion criteria:</th>
<th>1° endpoint: CHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huang Y, et al., 2015 (9) 25699996</td>
<td>Studies reporting adjusted risk for CHD with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg</td>
<td>Adults ≥18 y BP evaluated at baseline Results reported with adjustment</td>
<td>Comparing SBP/DBP 120–129/80–84 mm Hg to &lt;120/80 mm Hg:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• CHD RR: 1.27; 95% CI: 1.07–1.50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>p value comparing these RR:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• 0.15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type: Meta-analysis of nonrandomized studies</th>
<th>Size: 21956722</th>
<th>Inclusion criteria:</th>
<th>1° endpoint: Incident stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee M, et al., 2011 (10) 21956722</td>
<td>Studies reporting adjusted risk for stroke with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg</td>
<td>Adults ≥18 y</td>
<td>Comparing SBP/DBP 120–129/80–84 mm Hg to &lt;120/80 mm Hg:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Stroke RR: 1.22; 95% CI: 0.95–1.57</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Size</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>1° Endpoint</th>
<th>Results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta-analysis of nonrandomized studies</td>
<td>518,520 pts from 18 prospective cohort studies</td>
<td>BP evaluated at baseline, Results reported with adjustment</td>
<td>Exclusion criteria:</td>
<td>Comparing SBP/DBP 130–139/85–89 mm Hg to &lt;120/80 mm Hg: Stroke RR: 1.79; 95% CI: 1.49–2.16</td>
<td>Shen L, et al., 2013 (11) 23608614</td>
<td>SBP/DBP of 120–129/80–84 mm Hg</td>
</tr>
<tr>
<td>Meta-analysis of nonrandomized studies</td>
<td>934,106 pts from 18 prospective cohort studies</td>
<td>BP evaluated at baseline, 95% CI not reported</td>
<td>Exclusion criteria:</td>
<td>Comparing SBP/DBP 130–139/85–89 mm Hg to &lt;120/80 mm Hg: Stroke RR: 1.79; 95% CI: 1.49–2.16</td>
<td>Wang S, et al., 2013 (12) 23932039</td>
<td></td>
</tr>
<tr>
<td>2° analysis of an RCT</td>
<td>33,357 pts in the ALLHAT</td>
<td>BP evaluated at baseline, Results reported with adjustment</td>
<td>Exclusion criteria:</td>
<td>Comparing SBP/DBP 130–139/85–89 mm Hg to &lt;120/80 mm Hg: Stroke RR: 1.79; 95% CI: 1.49–2.16</td>
<td>Cushman WC, et al., 2002 (13) 12461301</td>
<td></td>
</tr>
</tbody>
</table>

Shen L, et al., 2013 (11) 23608614
Study type: Meta-analysis of nonrandomized studies
Size: 934,106 pts from 18 prospective cohort studies
Inclusion criteria: Studies reporting adjusted risk for CHD with 120–139/80–89 mm Hg, 120–129/80–84 mm Hg or 130–139/85–89 mm Hg
BP evaluated at baseline
95% CI was reported
Exclusion criteria: N/A
1° endpoint: CHD
Results: Comparing SBP/DBP 120–129/80–84 mm Hg to <120/80 mm Hg:
CHD RR: 1.16; 95% CI: 0.96–1.42
Comparing SBP/DBP 130–139/85–89 mm Hg to <120/80 mm Hg:
CHD RR: 1.53; 95% CI: 1.19–1.97)

Wang S, et al., 2013 (12) 23932039
Study type: Meta-analysis of nonrandomized studies
Size: 396,200 pts from 13 prospective cohort studies
Inclusion criteria: Prospective cohort studies reporting risk for outcomes with 120–139/80–89 mm Hg
Pts free of CVD at baseline,
Follow-up ≥5 y
Adjusted results reported
95% CI was reported
Exclusion criteria: N/A
1° endpoint: CVD, CVD mortality, all-cause mortality
Results: Comparing SBP/DBP 120–129/80–84 mm Hg to <120/80 mm Hg:
CVD RR: 1.41; 95% CI: 1.25–1.59
CVD mortality RR: 1.18; 95% CI: 0.98–1.42
All-cause mortality RR: 0.99; 95% CI: 0.88–1.13
Comparing SBP/DBP 130–139/85–89 mm Hg to <120/80 mm Hg:
CVD RR: 1.74; 95% CI: 1.51–2.01
CVD mortality RR: 1.33; 95% CI: 1.13–1.58
All-cause mortality RR: 1.02; 95% CI: 0.97–1.08

Cushman WC, et al., 2002 (13) 12461301
Study type: 2° analysis of an RCT
Size: 33,357 pts in the ALLHAT
Inclusion criteria: Men and women ≥55 y with HTN and 1 additional CHD risk factor
Exclusion criteria: Pts randomized to doxazosin
1° endpoint: Achieving SBP/DBP<140/90 mm Hg, use of ≥2 drug classes
Results: BP control (<140/90 mm Hg) can be achieved in most pts ≥2 or more drug classes are often required.
**Results:** SBP/DBP control was achieved by 66% at 5 y of follow-up and 63% of pts were on ≥2 drug classes.

1° endpoint: Following a titration schedule to reach a target SBP/DBP <140/90 mm Hg

**Results:** Mean SBP/DBP at baseline was 174/98 mm Hg. Over 90% of pts required ≥2 drug classes during follow-up.

**Results:** Combination therapy vs. monotherapy produced larger SBP reductions:

- Thiazide alone (7.3 mm Hg)
- Thiazide+second drug class (14.6 mm Hg)
- BB alone (9.3 mm Hg)
- BB +second drug class (18.9 mm Hg)
- ACE-inhibitor alone (6.8 mm Hg)
- ACE-inhibitor+second drug class (13.9 mm Hg)
- CCB alone (8.4 mm Hg)
- CCB +second drug class (14.3 mm Hg)

**Results:** Throughout middle and old age, usual BP is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.

**Study type:** Meta-analysis of cohort studies

**Size:** 61 prospective studies with 12.7 million person-y of observation, 56,000 vascular deaths in 40–89 y.

**Inclusion criteria:** Collaboration was sought from the investigators of all prospective observational studies in which data on BP, blood cholesterol, date of birth (or age), and sex had been recorded at a baseline screening visit, and in which cause and date of death (or age at death) had been routinely sought for all screens during more than 5,000 person-y of follow-up (see appendix A). Relevant studies were identified through computer searches of Medline and Embase, by hand-searches of meeting abstracts, and by extensive discussions with investigators.

**Exclusion criteria:** To minimize the effects of reverse causality (whereby

1° endpoint: Not completely clear, but for our purposes, stroke and IHD death would be co-1°. Also looked at other vascular deaths.

- HRs for stroke mortality for a 20 mm Hg lower SBP by age-group
  40–49: 0.36 (95% CI: 0.32–0.40)
  50–59: 0.38 (95% CI: 0.35–0.40)
  60–69: 0.43 (95% CI: 0.41–0.45)
  70–79: 0.50 (95% CI: 0.48–0.52)
  80–89: 0.67 (95% CI: 0.63–0.71)

- HRs for IHD mortality for a 20 mm Hg lower SBP by age-group
  40–49: 0.49 (95% CI: 0.45–0.53)
  50–59: 0.50 (95% CI: 0.49–0.52)
  60–69: 0.54 (95% CI: 0.53–0.55)
  70–79: 0.60 (95% CI: 0.58–0.61)
established disease could change the usual BP), studies were excluded if they had selected pts on the basis of a positive history of stroke or heart disease, and individuals from contributing studies were excluded from the present analyses if they had such a history recorded at baseline.

<table>
<thead>
<tr>
<th>Intention</th>
<th>Inclusion criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aim: This systematic review and meta-analysis aims to combine data from all published large-scale BP-lowering trials to quantify the effects of BP reduction on CV outcomes and death across various baseline BP levels, major comorbidities, and different pharmacological interventions.</td>
<td></td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td></td>
</tr>
<tr>
<td>RCTs of BP-lowering treatment that included a minimum of 1,000 pt-y of follow-up in each study arm. No trials were excluded because of presence of baseline comorbidities, and trials of antihypertensive drugs for indications other than HTN were eligible.</td>
<td></td>
</tr>
<tr>
<td>Eligible studies fell into 3 categories: 1st, random allocation of pts to a BP-lowering drug or placebo; 2nd, random allocation of pts to different BP-lowering drugs; and third, random allocation of pts to different BP-lowering targets.</td>
<td></td>
</tr>
</tbody>
</table>

| Exclusion criteria: |
| <1,000 pt-y of follow-up in each treatment group. |

| Intervention: |
| BP-lowering meds |

| Comparator: |
| Placebo, active comparator or less intensive treatment |

| 1st endpoint: |
| CVD. |
| Major CVD events, CHD, stroke, HF, renal failure, and all-cause mortality. |
| Standardized RR for 10 mm Hg difference in SBP |
| CVD RR: 0.80 (95% CI: 0.77–0.83) |

| Other endpoints: |
| CHD RR: 0.83 (95% CI: 0.78–0.88) |
| Stroke RR: 0.73 (95% CI: 0.68–0.77) |
| HF RR: 0.72 (95% CI: 0.67–0.78) |
| Total deaths RR: 0.87 (95% CI: 0.84–0.91) |

| Other results: |
| Benefit for CVD and other endpoints not different by baseline SBP, including <130 mm Hg fig 4 in paper |
| CVD: 0.63; 95% CI: 0.50–0.80; p=0.22 |
| CHD: 0.55; 95% CI: 0.42–0.72; p=0.093 |
| Stroke: 0.65, 95% CI: 0.27–1.57; p=0.38 |
| HF: 0.83; 95% CI: 0.41–1.70; p=0.27 |
| Total deaths: 0.53; 95% CI: 0.37–0.76; p=0.79 |
| More precision around estimates of benefits in SBP 130–139 at baseline, fig 4 in paper |
| Results similar in trials of people with and without CVD at baseline figure 5 |
| CVD+ 0.77 (95% CI: 0.71–0.81) |

| Limitations: |
| BP-lowering significantly reduces vascular risk across various baseline BP levels and comorbidities. Our results provide strong support for lowering BP to SBP<130 mm Hg and providing BP-lowering treatment to individuals with a history of CVD, CHD, stroke, DM, HF, and CKD. |
| In stratified analyses, we saw no strong evidence that proportional effects were diminished in trials that included people with lower baseline SBP (<130 mm Hg), and major CV events were clearly reduced in high-risk pts with various baseline comorbidities. Both of these major findings—the efficacy of BP-lowering below 130 mm Hg and the similar proportional effects in high risk populations—are consistent with and extend the findings of the SPRINT trial. |
### Law MR, et al., 2009 (18)

**Study type:** Meta-analysis of use of BP-lowering drugs in prevention of CVD from 147 randomized trials

**Size:** Of 147 randomized trials of 464,000 pts, 37 trials of BBs in CAD included 38,892 pts, and 37 trials of other antihypertensive drugs in CAD included 85,395 pts

**Inclusion criteria:** The database search used Medline (1966 to Dec. 2007) to identify randomized trials of BP-lowering drugs in which CAD events or strokes were recorded. The search also included the Cochrane Collaboration and Web of Science databases and the citations in trials and previous meta-analyses and review articles.

**Exclusion criteria:** Trials were excluded if there were <5 CAD events and strokes or if treatment duration was <6 mo.

**1° endpoint:** CAD events; stroke

**Results:** In 37 trials of pts with a history of CAD, BB reduced CAD events 29% (95% CI: 22%–34%). In 27 trials in which BBs were used after acute MI, BB reduced CAD events 31% (95% CI: 24%–38%), and in 11 trials in which BB were used after long-term CAD, BB insignificantly reduced CAD events 13%. In 7 trials, BB reduced stroke 17% (95% CI: 1%–30%). CAD events were reduced 14% (95% CI: 2%–25%) in 11 trials of thiazide diuretics, 17% (95% CI: 11%–22%) in 21 trials of ACEIs, insignificantly reduced in 4 trials of angiotensin receptor blockers, and 15% (95% CI: 8%–22%) in 22 trials of CCB. Stroke was reduced 38% (95% CI: 28%–47%) in 10 trials of thiazide diuretics, 22% (95% CI: 8%–34%) in 13 trials of ACEI, and 34% (95% CI: 25%–42%) in 9 trials of CCB.

**Outcome measures:**
- CVD- 0.74 (95% CI: 0.67–0.83)
- CVD+ 0.90 (95% CI: 0.83–0.98)
- Other outcomes similarly in figure 5

- In appendix, in general, benefits for CVD prevention seen in groups with and without baseline CHD, Stroke, DM, CKD and HF when examined separately, but no absolute risks provided to enable estimation of how far down the absolute risk curve these findings have been demonstrated.
- Some evidence of BB inferiority to other med classes in figure 6.
- Did not report absolute risks so do not know lower level of risk in treated populations.
- Lack of individual pt data, which would have allowed a more reliable assessment of treatment effects in different pt groups.
- Interpretation: Lowering of BP into what has been regarded the normotensive range should therefore be routinely considered for the prevention of CVD among those deemed to be of sufficient absolute risk.

### Sundstrom J, et al., 2015 (19)

**Aim:** To investigate whether pharmacologic BP reduction prevents CV events and deaths in pts with grade 1 HTN.

**Inclusion criteria:** RCTs of at least 1 y duration; pts ≥18 y, at least 80% of whom had grade 1 HTN and no previous CVD (MI, angina pectoris, CABG, PCI, stroke, TIA, carotid surgery, peripheral arterial

**1° endpoint:** Total major CV events, comprising stroke (nonfatal stroke or death from cerebrovascular disease), coronary events (nonfatal MI or death from CHD, including sudden death), HF (causing death or resulting in

**Outcome measures:**
- BP-lowering therapy is likely to prevent stroke and death in pts with uncomplicated grade 1 HTN.
<table>
<thead>
<tr>
<th>Study type: Meta-analysis of RCTs</th>
<th>Size: 10 RTCs with 15,266 pts</th>
<th>surgery, intermittent claudication, or renal failure; and compared an antihypertensive drug provided as monotherapy or a stepped-care algorithm vs. placebo or another control regimen.</th>
<th>Exclusion criteria: Excluded trials did not contribute an event for any of the outcomes of interest.</th>
<th>Other endpoints: Each of the above outcomes independently; and total deaths.</th>
<th>CHD 0.91 (95% CI: 0.74–1.12) Stroke 0.72 (95% CI: 0.55–0.99) HF 0.80 (95% CI: 0.57–1.12) CVD deaths 0.75 (95% CI: 0.57–0.98) Total deaths 0.78 (95% CI: 0.67–0.92) Only the first event for a pt was used for the analysis of each outcome, but a pt who had &gt;1 outcome type could contribute to more than 1 analysis. They also tabulated overall withdrawals and withdrawals due to adverse events.</th>
<th>• 5 y risks in BPLTTC control groups CVD events 7.4%, CVD deaths 3.1%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomopoulos C, et al., 2014 (20) 25269547</td>
<td><strong>Aim:</strong> Investigating whether all grades of HTN benefit from BP-lowering treatment and which are the target BP levels to maximize outcome reduction.</td>
<td><strong>Study type:</strong> Meta-analysis of RCTs</td>
<td><strong>Size:</strong> 32 RCTs with 104,359 pts</td>
<td><strong>Inclusion criteria:</strong> Intentional BP-lowering comparing active drug treatment with placebo, or less active treatment (intentional BP-lowering trials), or comparison of an active drug with placebo over baseline antihypertensive treatment, resulting in a BP difference of at least 2 mm Hg in either SBP or DBP (nonintentional BP-lowering trials); enrolling of hypertensive individuals only or a high proportion (at least 40%) of them.</td>
<td><strong>1º endpoint:</strong> • As some trials were done on low-risk pts, others on higher risk pts, no evaluation of absolute risk-reduction was made. However, a 2º analysis was done including trials or trial subgroups with mean baseline SBP/DBP values in grade 1 range and a low-to-moderate risk (&lt;5% CV deaths in 10 y in controls): FEVER stratum with baseline SBP below the median (&lt;153 mm Hg); HTN Detection and Follow-up Program stratum with baseline DBP 90–94 mm Hg and no CVD; OSLO (e17); TOMHS (e28) and USPHS. Risks of stroke, CHD, the composite of stroke and CHD, and all-cause death were significantly reduced by BP-lowering in these low-to-moderate risk pts (control group: average CV mortality 4.5% in10 y) with a moderate BP elevation (average SBP/DBP 145.5/91 mm Hg) at randomization. Standardized RR associated with 10/5 reduction in BP: stroke 0.33 (95% CI: 0.11–0.98) CHD 0.68 (95% CI: 0.48–0.95)</td>
<td>• Meta-analyses favor BP-lowering treatment even in grade 1 HTN at low-to-moderate risk, and lowering SBP/DBP to &lt;140/90 mm Hg. • Achieving &lt;130/80 mm Hg appears safe, but only adds further reduction in stroke.</td>
</tr>
</tbody>
</table>
| Xie X, et al., 2015 (21) 26559744 | **Aim:** To assess the efficacy and safety of intensive BP-lowering strategies.  
**Study type:** Meta-analysis of RCTs  
**Size:** 19 RCTs with 44,989 pts | **Inclusion criteria:** RCTs with at least 6 mo follow-up that randomly assigned pts to more intensive vs. less intensive BP-lowering treatment, with different BP targets or different BP changes from baseline. Reference lists from identified trials and review articles were manually scanned to identify any other relevant studies.  
**Exclusion criteria:** N/A  
**Intervention:** BP-lowering meds  
**Comparator:**  
- Less intensive treatment  
- BP difference 6.8/3.5  
- The mean follow-up BP levels in the less intensive BP-lowering treatment  
**1st endpoint:**  
- CVD, other major CV events, defined as a MI, stroke, HF, or CV death, separately and combined; nonvascular and all-cause mortality; ESKD, and adverse events. Progression of albuminuria (defined as new onset of micro-albuminuria/macro-albuminuria or a change from micro-albuminuria to macro-albuminuria) and retinopathy (retinopathy progression of 2 or more steps) were also recorded for trials that were done in pts with DM  
- CVD RR: 0.86 (95% CI: 0.78–0.96)  
**Other endpoints:**  
- MI RR: 0.87 (95% CI: 0.76–1.00) p=0.042  
Stroke RR: 0.78 (95% CI: 0.68–0.90)  
HF RR: 0.85 (95% CI: 0.66–1.11)  
CVD death RR: 0.91 (95% CI: 0.74–1.11)  
Total deaths RR: 0.91 (95% CI: 0.81–1.03)  
**Limitations:**  
- Intensive BP-lowering, including to <130 mm Hg, provided greater vascular protection than standard regimens.  
- In high-risk pts, there are additional benefits from more intensive BP-lowering, including for those with SPB <140 mm Hg at baseline.  
- The net absolute benefits of intensive BP-lowering in high-risk individuals are large.  
- Lack of individual pt data, which would have allowed a more reliable assessment of net clinical benefits.
regimen group were 140/81 mm Hg, compared with 133/76 mm Hg in the more intensive treatment group.

Other results:
- Benefit for CVD not different by baseline SBP
  120–139: 0.89 (95% CI: 0.76–1.05)
  140–160: 0.83 (95% CI: 0.68–1.00)
  >160: 0.89 (95% CI: 0.73–1.09)
  p-heterogeneity: 0.60
- Benefit for CVD not different for more intensive and less intensive targets in intensive group
  <140 or <150 mm Hg: 0.76 (95% CI: 0.60–0.97)
  <120–<130 mm Hg: 0.91 (95% CI: 0.84–1.00; p-hetero: 0.06)
- Absolute benefits were proportional to absolute risk.
- For trials in which all pts had vascular disease, renal disease, or DM at baseline, the average control group rate of major vascular events was 2.9% per y compared with 0.9% per y in other trials, and the numbers needed to treat were 94 (95% CI: 44–782) in these trials vs. 186 (95% CI: 107–708) in all other trials.
- Increase in Severe hypotension: 0.3% vs. 0.1% per person y OR: 2.68 (95% CI: 1.21–5.89)

Interpretation: Supports treating pt with and without CVD at threshold of 130 to <130. Supports treating at threshold of about 130 even down to a CVD event rate of 0.9% per y.

### Data Supplement 3. Out-of-Office and Self-Monitoring of BP (Section 4.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population (N)</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Pickering TG, et al., 1988 (22) 3336140 | **Study type:**
  ● Observational Cohort
  ● 24-h ABPM <134/90
  ● Systematic review
  ● Office vs. ABPM or HBPM
  **Size:** 292 pts | N/A | **1° endpoint:** WCH=21% | ● Multiple methodologies used to define MH. Prevalence 8.5%–16.6% (general population), 14.7%–30.4% (nonelevated clinic population) |
<table>
<thead>
<tr>
<th>Study type:</th>
<th>Inclusion criteria:</th>
<th>1° endpoint:</th>
<th>2° endpoint:</th>
</tr>
</thead>
<tbody>
<tr>
<td>McManus RJ, et al., 2014 (24) 25157723</td>
<td>Study type: RCT  ● Self-monitoring with self-titration vs. usual care.</td>
<td>Inclusion criteria: SBP/DBP ≥130/85 mm Hg</td>
<td>1° endpoint: Change in SBP/DBP at 12 mo</td>
</tr>
<tr>
<td>Margolis KL, et al., 2013 (25) 23821088</td>
<td>Study type: Cluster RCT  ● Home BP tele-monitoring with pharmacist case management vs. usual care.</td>
<td>Inclusion criteria: Uncontrolled BP</td>
<td>1° endpoint: SBP/DBP &lt;140/90 mm Hg (&lt;130/80 mm Hg in DM or CKD) at 6 and 12 mo.</td>
</tr>
<tr>
<td>Margolis KL, et al., 2013 (25) 23821088</td>
<td>Study type: RCT  ● Home BP tele-monitoring with pharmacist case management vs. usual care.</td>
<td>Inclusion criteria: Uncontrolled BP</td>
<td>2° endpoint: Change in BP, pt satisfaction, and BP control at 18 mo (6 mo after intervention stopped).</td>
</tr>
<tr>
<td>Uhlig K, et al., 2012 (23) 22439158</td>
<td>Study type: Systematic review  ● Self-monitoring vs. usual care vs. self-monitoring+support</td>
<td>N/A</td>
<td>1° endpoint: Change in clinic SBP/DBP</td>
</tr>
</tbody>
</table>

McManus RJ, et al., 2014 (24) 25157723

Aim: Assess impact of follow-up and monitoring system including home BP tele-monitoring and pharmacist case management on BP control in pts treated for HTN

Study type: RCT

Size: 450 pts
<table>
<thead>
<tr>
<th>Study type: U.S. Preventive Services Task Force commissioned systematic review and meta-analysis of office and out of office BP relationships for diagnostic accuracy of diagnosing high BP after an initial office-based classification of high BP.</th>
<th>Inclusion criteria: Adults ≥18 y. 24 studies based on “confirmation” by means of ABPM and 6 by means of HBPM.</th>
<th>1° endpoint: ABPM or HBPM conformation of office-based diagnosis of high BP. CVD risk-relationships for ABPM, HBPM and office-based BPs also reviewed. ABPM was recommended as the best method to confirm an office-based diagnosis of high BP, with HBPM an acceptable alternative, based on “over diagnosis” of high BP with office BP measurements (White coat hypertension) and stronger relationships between out of office BP measurements (especially ABPM) with vascular events.</th>
<th>Screen for high BP in adults ≥18 y and confirm office-based high BP using out of office BP measurements (preferably ABPM).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type: Systematic review Self-monitoring vs. usual care vs. self-monitoring+support</td>
<td>N/A</td>
<td>1° endpoint: Change in clinic SBP/DBP</td>
<td>Self-monitoring vs. usual care resulted in lower SBP/DBP (-3.1/-2.0 mm Hg) at 6 mo. Self-monitoring + support vs. usual care resulted in lower SBP/DBP SBP/DBP -3.4– -8.9/-1.9– -4.4 mm Hg up to 12 mo. Self-monitoring may confer a small benefit for BP control.</td>
</tr>
<tr>
<td>Study type: RCT Self-monitoring of BP vs. usual care.</td>
<td>Size: 900 pts</td>
<td>1° endpoint: Change in clinic SBP/DBP and HTN control (SBP/DBP &lt;140/90 mm Hg) Decline in SBP at 9 mo was 14.7 mm Hg and 14.1 mm Hg in the intervention and usual care groups (p=0.70); HTN was controlled in 38.9% and 39.1% in the intervention and control groups (p=0.91).</td>
<td>Self-monitoring of BP by itself does not improve BP above usual care.</td>
</tr>
<tr>
<td>Study type: Systematic review</td>
<td>N/A</td>
<td>1° endpoint: Change in clinic SBP/DBP and MAP</td>
<td>Self-monitoring is associated with a reduction in BP. This effect is larger when accompanied by telemonitoring.</td>
</tr>
</tbody>
</table>
2017 Hypertension Guideline Data Supplements

- Self-monitoring vs. usual care vs. self-monitoring+telemonitoring
  
  **Size:** 9,446 pts

- Mean reduction in SBP, DBP and MAP with home monitoring was 2.63 mm Hg (95% CI: 4.24–1.02), 1.68 (95% CI: 2.58–0.79), 4.0 (95% CI: 1.79–6.22). The effect for SBP was larger when accompanied by telemonitoring (3.20; 95% CI: 4.66–1.73 vs. 1.26; 95% CI: 2.20–0.31).

Fagard RH, et. al., 2007 (28)  
**Study type:** Systematic review  
**MH and WCH vs. sustained normotension**  
**Size:** 11,502 pts

1\(^{o}\) **endpoint:** CVD events. The adjusted HR for CVD events was 1.12 (95% CI: 0.84–1.50) for WCH vs. sustained normotension (p=0.59) and 2.00 (95% CI: 1.58–2.52) for MH vs. sustained normotension (p<0.001)

MH is associated with increased CVD risk but WCH is not associated with increased risk.

---

**Data Supplement 4. White Coat Hypertension (Section 4.4)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Definitions</th>
<th>Patient Population (N)</th>
<th>HBPM (%)</th>
<th>Daytime ABPM (%)</th>
<th>24-h ABPM (%)</th>
<th>Results/Comments</th>
</tr>
</thead>
</table>
| Viera AJ, et al., 2010 (29) 20671718   | Office BP ×3  
Duplicate measures of:  
24-h ABPM >130/80  
Daytime ABPM >135/85  
HBPM >135/85  
50 pts  
Untreated  
Borderline HTN and BP >110/70 and <160/110  
MH=43/35 | 50 pts  
MH=54/53 |  
MH=51/45 |  
For MH diagnosis  
95% agreement daytime and 24-h ABPM  
Only 47%–53% agreement between HBPM and either daytime or 24-h ABPM |
Duplicate measures of:  
24-h ABPM >130/80  
Daytime ABPM >135/85  
HBPM >135/85  
420 pts  
Untreated  
Borderline HTN and BP >120/80 and <149/95  
MH=15–17 | 420 pts  
MH=43–44 |  
MH=48–50 |  
For MH Diagnosis  
92%–94% agreement daytime and 24-h ABPM  
70% agreement between HBPM and either daytime K=0.3–0.36 |
| Bayo B, et al., 2006 (31) 16534404    | Office BP ×3  
HBPM ×3 d  
190 untreated pts  
Spanish  
Borderline  
WCH=35 (95% CI: 28–42) | 190 untreated pts  
WCH=42 (95% CI: 34, 48) |  
WCH=42 (95% CI: 34, 48) |  
Compared to ABPM, HBPM pulse pressure variation: 59% negative predictive value: 69% |
<table>
<thead>
<tr>
<th>Study Authors</th>
<th>Year</th>
<th>IDACO Cohorts</th>
<th>Office BP × 2 &gt; 140/90</th>
<th>HBPM &gt; 135/85</th>
<th>Daytime ABPM &gt; 135/85</th>
<th>Number of Untreated Patients</th>
<th>ABPM Measured</th>
<th>Agreement</th>
<th>Weighted kappa (k)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asayama K, et al., 2015 (32)</td>
<td>2017</td>
<td>Obs (IDACO) database</td>
<td>CV outcomes risk by WCH, MH, NTN ABPM measured: Office BP × 2 &gt;140/90 (office) &gt;130/80 (24-h ABPM) &gt;135/85 (daytime ABPM) &gt;120/70 (nighttime ABPM)</td>
<td>8,237 untreated pts</td>
<td>N/A</td>
<td>WCH=9.1</td>
<td>WCH=10.7</td>
<td>MH=13.4</td>
<td>MH=9.7</td>
</tr>
<tr>
<td>Conen D, et al., 2014 (33)</td>
<td>2014</td>
<td>Obs 13 IDACO Cohorts</td>
<td>Office × 2</td>
<td>Awake ABPM &gt;135/85</td>
<td>24-h ABP &gt;130/80</td>
<td>Analyzed by decade in y</td>
<td>7,506 untreated pts</td>
<td>WCH=2.2% age 18–30, increasing to 19.5% in both sexes age &gt;70 y</td>
<td>MH=inverted U distribution (13% and 11% in 18–30 y 18% and 20% in those 30–50 y)</td>
</tr>
<tr>
<td>Nasothimiou EG, et al., 2012 (34)</td>
<td>2012</td>
<td>Office BP × 3 × &gt;140/90</td>
<td>HBPM &gt;135/85</td>
<td>Daytime ABPM &gt;135/85</td>
<td>613 pts (66% untreated, 34% treated)</td>
<td>WCH=15%</td>
<td>WCH=14%</td>
<td>MH=15%</td>
<td>MH=16%</td>
</tr>
<tr>
<td>Coll de TG, et al., 2011 (35)</td>
<td>2011</td>
<td>Office × 2 &gt;140/90</td>
<td>Daytime ABPM &gt;135/85</td>
<td>HBPM &gt;135/85</td>
<td>403 untreated pts</td>
<td>WCH=24%</td>
<td>WCH=8.1%</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Stergiou GS, et al., 2005 (36)</td>
<td>2005</td>
<td>Office × 3 × 2 &gt;140/90</td>
<td>HBPM ≥135/85 awake</td>
<td>ABPM ≥135/85</td>
<td>438 untreated/ treated pts</td>
<td>MH=12%</td>
<td>MH=14%</td>
<td>WCH=16%</td>
<td>WCH=15%</td>
</tr>
</tbody>
</table>

• Similar prevalence using either 24-h or awake ABPM

• No difference between treated and untreated. However, only 44% overlap for MH, but 90%–95% if 5 mm Hg zone of uncertainty added.
<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>● Office ×3 &gt;140/90</td>
<td>● Office ×3 &gt;140/90</td>
<td>● Office ×3 &gt;140/90</td>
<td>● Office ×3 &gt;140/90</td>
</tr>
<tr>
<td></td>
<td>● ABPM &gt;125/79</td>
<td>● ABPM &gt;125/79</td>
<td>● ABPM &gt;125/79</td>
<td>● ABPM &gt;125/79</td>
</tr>
<tr>
<td></td>
<td>● LVMI by echo</td>
<td>● LVMI by echo</td>
<td>● LVMI by echo</td>
<td>● LVMI by echo</td>
</tr>
<tr>
<td></td>
<td>● WCH=12%</td>
<td>● WCH=12%</td>
<td>● WCH=12%</td>
<td>● WCH=12%</td>
</tr>
<tr>
<td></td>
<td>● MH=9%</td>
<td>● MH=9%</td>
<td>● MH=9%</td>
<td>● MH=9%</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>● 70% agreement between ABPM and HBPM for WCH and 57% for MH</td>
<td>● 70% agreement between ABPM and HBPM for WCH and 57% for MH</td>
<td>● 70% agreement between ABPM and HBPM for WCH and 57% for MH</td>
<td>● 70% agreement between ABPM and HBPM for WCH and 57% for MH</td>
</tr>
</tbody>
</table>

Data Supplement 5. White Coat Hypertension (Prevalence) (Section 4.4)
<table>
<thead>
<tr>
<th>Study type</th>
<th>Inclusion criteria</th>
<th>1st endpoint</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conen D, et al., 2014 (33)</td>
<td>&gt;18 y, untreated</td>
<td>WCH=2.2% age 18–30 y, increasing to 19.5% both sexes age &gt;70 y</td>
<td>Increase in WCH prevalence with increasing age in both sexes</td>
</tr>
<tr>
<td>Alwan H, et al., 2014 (40)</td>
<td>&gt;18 y, untreated</td>
<td>WCH=2.6%</td>
<td>Pts with pre-HTN had 7 times higher rate of MH</td>
</tr>
<tr>
<td>Stergiou GS, et al., 2014 (41)</td>
<td>&gt;18 y, untreated</td>
<td>MH=15.8%</td>
<td>WCH=13.8%</td>
</tr>
<tr>
<td>Pierdomenico SD, et al., 2011 (42)</td>
<td>&gt;18 y, untreated</td>
<td>Long-term follow-up for CVD events</td>
<td>WCH=16.1%</td>
</tr>
<tr>
<td>Hansen TW, et al., 2007 (43)</td>
<td>78% untreated</td>
<td><em>Study endpoints</em>: F/NF CVD, Median follow-up =9.5 y</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Study type*: Observational, SKIPOGH, 5 IDACO cohort Studies, Office ×2 >140/90, Home >135/85, Median 8.3-y follow-up, Meta-analysis of observational cohort studies (8 WCH, 5 MH) 24-h ABPM >130/80 Daytime >135/85, 4 observational studies Office <140/90, 24-h ABPM >135/85.

*Study endpoints*: F/NF CVD, Median follow-up =9.5 y.

*N/A*: Not applicable.
### Data Supplement 6. White Coat Hypertension (Correlation with Clinical Outcomes) (Section 4.4)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Endpoints and Length of Follow-up</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusions/Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICE 2011 (44) 22855971</td>
<td>Study type: Systematic Review 3 Meta-analyses 11 observational studies &quot;best method&quot; comparison of office vs. HBPM or ABPM that best predicted (i.e., statistically significant predictors and higher HR values) clinical outcomes (after adjustment for covariates in multivariate analyses)</td>
<td>• Home vs. office (n=7,685) • ABPM vs. office (n=33,158) • Home vs. ABPM vs. Office (n=2,442)</td>
<td>• Outcomes of interest: mortality, stroke, MI, HF, DM, vascular procedures, hospitalization for angina, and other MACCE</td>
<td>For predicting clinical outcomes: ABPM vs. office (9 studies): • ABPM superior to office (8 studies) • No difference between ABPM and office (1 study) HBPM vs. office (3 studies): • HBPM superior to office (2 studies) • No difference between HBPM and office (1 study) HBPM vs. ABPM vs. office (2 studies): • HBPM similar to ABPM and both superior to office (1 study) • No difference between HBPM, ABPM and office (1 study)</td>
<td>• Overall recommendation for ABPM to confirm HTN diagnosis (HBPM recommended if ABPM not practical)</td>
</tr>
<tr>
<td>Pierdomenico SD, et al., 2011 (42) 20847724</td>
<td>Study type: Meta-analysis (8 studies) NTN vs. WCH or MH based mostly on daytime ABPM &lt;135/85 Size: 7,961 Inclusion criteria: Untreated</td>
<td>• Follow-up 3.2–12.8 y • Composite CVD</td>
<td>• WCH vs. NTN: OR: 0.96; 95% CI: 0.65–1.42 • MH vs. NTN: OR: 2.09; 95% CI: 1.55–2.81 • SH vs. NTN: OR: 2.59; 95% CI: 2.00–3.35</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Asayama K, et al., 2014 (32) 25135185</td>
<td>Study type: Observational (IDACO) database CV outcomes risk by WCH, MH, NTN • ABPM measured: Office BP ×2 &gt;140/90 (office) Inclusion criteria: &gt;18 y, untreated</td>
<td>• F/NF CVD/stroke, 729 CV events • Follow-up 10.6 y</td>
<td>• WCH adjusted HR: 1.2; 95% CI: 0.93–1.54; p=0.16 • MH adjusted HR: 1.81; 95% CI: 1.41–2.32; p&lt;0.0001 • SH adjusted HR: 2.31; 95% CI: 1.91–2.80; p&lt;0.0001</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>
### 2017 Hypertension Guideline Data Supplements

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Population-based (4 international cohorts)</th>
<th>Size: 8,237</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verdecchia P, et al., 2005 (45) 15596572</td>
<td>(24-h ABPM) &gt;130/80 (daytime ABPM) &gt;135/85 (nighttime ABPM) &gt;120/70</td>
<td>26% NTN</td>
</tr>
<tr>
<td></td>
<td>• Office ×3 &gt;140/90</td>
<td>Stroke</td>
</tr>
<tr>
<td></td>
<td>• Awake ABPM &gt;130/80</td>
<td>Follow-up 5.4 y</td>
</tr>
<tr>
<td></td>
<td>Size: 5,955</td>
<td>• WCH adjusted HR: 1.15; 95% CI: 0.61–2.16; p=0.66</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• SH adjusted HR: 2.01; 95% CI: 1.31–3.08; p&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Stroke not increased in WCH but tended to approach systolic HTN risk 6 y after baseline ABPM.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Observational</th>
<th>Size: 7,030</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hansen TW, et al., 2007 (43) 17620947</td>
<td>4 studies</td>
<td>78% untreated</td>
</tr>
<tr>
<td></td>
<td>• Office &lt;140/90</td>
<td>F/NF CVD</td>
</tr>
<tr>
<td></td>
<td>• 24-h ABPM &gt;135/85</td>
<td>Median follow-up=9.5 y</td>
</tr>
<tr>
<td></td>
<td>Size: 11,502</td>
<td>• WCH adjusted HR: 1.22 (95% CI: 0.96, 1.53), p=0.09</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• MH adjusted HR: 1.62; 95% CI: 1.35–1.96; p&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• SH adjusted HR: 1.80; 95% CI: 1.59–2.03; p&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Meta-analysis</th>
<th>Size: 2,051</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fagard RH, et al., 2007 (28) 17921809</td>
<td>7 studies</td>
<td>22% treated</td>
</tr>
<tr>
<td></td>
<td>• Office &lt;140/90</td>
<td>F or F/NF CVD</td>
</tr>
<tr>
<td></td>
<td>• 24-h ABPM or HBPM</td>
<td>Follow-up 3.2–12.3 y (mean=8 y)</td>
</tr>
<tr>
<td></td>
<td>Size: 11,502</td>
<td>• WCH adjusted HR: 1.12 (95% CI: 0.84–1.50), p=0.59</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• MH adjusted HR: 2.0; 95% CI: 1.58–2.52; p&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Systolic HTN adjusted HR: 2.28; 95% CI: 1.87–2.78; p&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Observational PAMELA Study</th>
<th>Size: 2.58</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mancia G, et al., 2013 (46) 23716584</td>
<td>Office ×3&lt;140/90</td>
<td>22% treated</td>
</tr>
<tr>
<td></td>
<td>• HBPM&gt;135/85 and-24-h • ABPM&gt;130/80</td>
<td>CV and all-cause mortality</td>
</tr>
<tr>
<td></td>
<td>Size: 2.58</td>
<td>Follow-up 16 y</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CV mortality in WCH adjusted HR: 2.04 (95% CI: 0.87–4.78), p=0.10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• All-cause mortality in WCH adjusted HR: 1.50; 95% CI: 1.03–2.18; p=0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Trend but insignificant increase in CV mortality and significant increase in total mortality in WCH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Risk of developing systolic HTN greater in those with WCH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Cross-sectional study assessing target organ damage by BP control status. Control: Office &lt;140/90, daytime &lt;135/85.</th>
<th>Size: 332</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomiyama M, et al., 2006 (47) 16942927</td>
<td>Treated pts</td>
<td>LVMI, carotid IMT, UAE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cross-sectional</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• LVMI, carotid IMT and UAE increased in masked uncontrolled HTN compared to controlled HTN. LVMI and UAE increased in SH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• SH and masked uncontrolled HTN but not WCE associated with increased target organ damage</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc. 26
<table>
<thead>
<tr>
<th>Study Acronym (if applicable)</th>
<th>Author Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawes CM, et al., 2003 (50)</td>
<td>12658016</td>
<td>Study type: Meta-analysis of RCTs of BP drugs recording CHD events and strokes</td>
<td>N/A</td>
<td>CHD RR or 46% Stroke 64%</td>
<td>All classes of BP meds confer benefit while BB confer greater benefit in those with CAD</td>
</tr>
<tr>
<td>Riaz IB, et al., 2014 (51)</td>
<td>25145333</td>
<td>Study type: 540 studies and 7 RCTs</td>
<td>N/A</td>
<td>Incidence of nonfatal MI 6.74% in both the stenting and medical therapy groups: OR: 0.99; 95% CI: 0.70–1.43; p=0.99, incidence of renal events in stenting population was found to be 19.58% vs. 20.53% in medical therapy OR: 0.95; 95% CI: 0.76–1.18; p=0.62.</td>
<td>BP effect, CV accident not specifically reported</td>
</tr>
<tr>
<td>Cooper CJ, et al., 2014 (52)</td>
<td>24245566</td>
<td>Study type: Residential treatment center medical therapy with or without renal stent</td>
<td>N/A</td>
<td>Composite endpoint of death from CV or renal causes, MI, stroke, hospitalization for congestive HF, progressive renal insufficiency, or the need for renal-replacement therapy. 35.1% and 35.8%, respectively; HR with stenting: 0.94; 95% CI: 0.76–1.17; p=0.58 Difference in SBP favoring the stent group: -2.3 mm Hg; 95% CI: -4.4– -0.2; p=0.03.</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Data Supplement 7. Renal Artery Stenosis (Section 5.4.3)**
| Study type                  | Size     | Analysis                                                                 | Achieved BP 133/76 mm Hg (intensive) 140/81 (less intense) | Major CV events: 14%; 95% CI: 4%–22% | MI: 13%; 95% CI: 0%–24% | Stroke: 22%; 95% CI: 10%–32% | Albuminuria: 10%; 95% CI: 3%–16% | Retinopathy progression: 19%; 95% CI: 0%–34% | More intensive had no effects on HF: 15%; 95% CI: -11%–34% | CV death: 9%; 95% CI: –11%–26% | Total mortality: 9%; 95% CI: -3%–19% | ESKD: 10%; 95% CI: -6%–23% | More intensive approach reduced major CV events (stroke and MI) except heat failure, CVD, ESRD, and total mortality. |
|----------------------------|----------|--------------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------|--------------------------|-------------------------------|--------------------------------|--------------------------------|---------------------------------|-------------------------------|-----------------------------|-----------------------------|--------------------------------|--------------------------------|
| Xie X, et al., 2015 (21)    | 44,989   | MA of RTC that randomly assigned individuals to different target BP levels | 19 trials                                                  | 19 trials                          | 19 trials                  | 19 trials                    | 19 trials                      | 19 trials                      | 19 trials                       | 19 trials                     | 19 trials                    | 19 trials                   | 19 trials                      | 19 trials                      |
| Brunström M, et al., 2016 (53) | 73,738   | Meta-analysis of levels of BP control in DM hypertensives.               | 49 trials (most pts with DM-2)                                | 49 trials                          | 49 trials                  | 49 trials                    | 49 trials                      | 49 trials                      | 49 trials                       | 49 trials                     | 49 trials                    | 49 trials                   | 49 trials                      | 49 trials                      |
| Ettehad D, et al., 2015 (17) | 613,815  | Meta-analysis of large RTCs of antihypertensive treatment                | 123 studies                                                | 123 studies                        | 123 studies                | 123 studies                  | 123 studies                    | 123 studies                    | 123 studies                      | 123 studies                   | 123 studies                  | 123 studies                | 123 studies                    | 123 studies                    |
Thomopolous C, et al., 2016 (54) 26848994

**Study type:** Meta-analysis of RTCs of more vs. less intense BP control

- 16 trials (52,235 pts) compared more vs. less intense treatment
- 34 (138,127 pts) active vs. placebo

More intense BP
- Stroke RR: 0.71; 95% CI: 0.60–0.84
- CHD RR: 0.80; 95% CI: 0.68–0.95
- Major CV events RR: 0.75; 95% CI: 0.68–0.85
- CV mortality RR: 0.79; 95% CI: 0.63–0.97

Stratification of SBP cutoffs (150,140 and 130 mm Hg) showed that a SBP/DBP difference of 10/5 mm Hg across each cutoff reduced risk of all outcomes

- Intensive BP reduction improves CV outcomes compared to less intense
- Achieved BP <130/80 may be associated with CV benefit.

Julius S, et al., 2006 (55) 16537662

**Study type:** RCT in pre-HTN; 16 mg candesartan vs. placebo

- Size: 809 pts

- 58% men

- During the first 2 y, HTN developed in 154 (40.4%) pts in the placebo group compared with only 53 (13.6%) of those in the candesartan group, for RR: 66.3% (p<0.0001). After 4 y, HTN developed in 240 (63.0%) in the placebo group vs. only 208 (53.2%) in the candesartan group RR: 15.6% (p<0.0069).

- 2/3 of those with pre-HTN develop HTN within 4 y. Candesartan interrupts the onset and reduced by 15.6%

Ference BA, et al., 2014 (56) 24591335

**Study type:** Evaluated the effect of 12 polymorphisms (associated with BP) on the odds of CHD and compared it with the effect of lower SBP observed in both prospective cohort studies and BP-lowering randomized trials

- Size: 199,477 pts

- 63 studies

- 12 polymorphisms were associated with a 0.32 mm Hg lower SBP (p=1.79×10^{-7}) and a 0.093-mm Hg/decade slower age-related rise in SBP (p=3.05×10^{-5}). The effect of long-term exposure to lower SBP on CHD mediated by these polymorphisms was 2-fold greater than that observed in prospective cohort studies (p=0.006) and 3-fold greater than that observed in short-term BP treatment trials (p=0.001).

- SBP may be causally associated with the rate of rise in SBP with age and has a cumulative effect on the risk of CHD.

Data Supplement 8. RCTs Comparing Obstructive Sleep Apnea (Section 5.4.4)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barb F, et al., 2010 (57) 20007932</td>
<td>Aim: Assess the effect on BP of 1 y of treatment with CPAP in nonsleepy pts with HTN and OSA.</td>
<td>Inclusion criteria: Pts with HTN (on medications or ≥140/90) and Intervention: CPAP Comparator: Conservative treatment</td>
<td>1° endpoint: Decrease in BP Results: At 12 mo, CPAP decreased SBP by 1.89 mm Hg (95% CI: 3.90–0.11 mm Hg; p=0.065) and DBP 2.19 mm Hg</td>
<td>Limitations: Not blinded; both groups consisted of pts with severe sleep-apnea.</td>
<td></td>
</tr>
<tr>
<td>Study type</td>
<td>Size</td>
<td>Inclusion criteria</td>
<td>Intervention</td>
<td>Comparator</td>
<td>1st endpoint</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>--------------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------</td>
</tr>
<tr>
<td>RCT</td>
<td>359 pts; 12 mo of follow-up</td>
<td>apnea-hypopnea index &gt;19</td>
<td>(dietary counseling and sleep hygiene advice).</td>
<td>(95% CI: 3.46– -0.93 mm Hg; p=0.001). The most significant reduction in BP was in pts who used CPAP for more than 5.6 h/night.</td>
<td>CPAP</td>
</tr>
<tr>
<td>Martinez-Garcia MA, et al., 2013 (58) 24327037</td>
<td>Aim: Assess the effect of CPAP on BP in pts with OSA and resistant hypertension.</td>
<td>Inclusion criteria: Pts with resistant hypertension and OSA.</td>
<td>Intervention: CPAP</td>
<td>Comparator: No therapy</td>
<td></td>
</tr>
<tr>
<td>RCT</td>
<td>194 pts; 3 mo follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lozano L, et al., 2010 (59) 20577130</td>
<td>Aim: Assess effect of CPAP on pts with OSA and resistant hypertension.</td>
<td>Inclusion criteria: Pts with resistant hypertension and OSA.</td>
<td>Intervention: CPAP + conventional drug treatment</td>
<td>Comparator: Conventional drug treatment alone</td>
<td>1st endpoint: Decrease in 24-h ABPM from baseline to 12 wk.</td>
</tr>
</tbody>
</table>
Muxfeldt ES, et al., 2015 (60) 25601933

**Aim:** Evaluate the effect of CPAP on pts with resistant hypertension and OSA.

**Study type:** RCT

**Size:** 434 pts; 6 mo of follow-up

**Inclusion criteria:** Pts with resistant hypertension and OSA

**Intervention:** CPAP + conventional antihypertensive therapy

**Comparator:** Antihypertensive therapy alone. Conventional antihypertensive therapy included spironolactone.

**1° endpoint:** BP reduction at 6 mo via ABPM

**Results:**
- On an intention-to-treat analysis, there was no significant difference in any BP change, neither in nocturnal BP fall, between CPAP and control groups. The best effect of CPAP was on night-time SBP in per-protocol analysis, with greater reduction of 4.7 mm Hg (95% CI: -1.6%–5.8%; p=0.25, in comparison with the control group.
- Median use of CPAP was 4.8 h.

**Limitations:** Nonblinded design; per protocol analysis underpowered to show the prespecified outcome of 6–7 mm Hg SBP differences between CPAP and control groups.

**Conclusions:** CPAP had no significant effect on clinic or ambulatory BP in pts with resistant hypertension and moderately severe to severe OSA. However, in the specific subgroup of pts with uncontrolled ambulatory BP, CPAP may modestly reduce night-time SBP and improve the nocturnal BP fall pattern. The reason for lack of BP reduction in the overall study may have been due to excellent control of BP with median 5 medications, including spironolactone, in the majority of pts.

---

Pedrosa RP, et al., 2013 (61) 23598607

**Aim:** Evaluate the effect of CPAP on pts with resistant hypertension and OSA.

**Study type:** RCT with

**Size:** 40 pts; 6 mo follow-up

**Inclusion criteria:** Pts with resistant hypertension and OSA

**Intervention:** CPAP + conventional antihypertensive therapy (n=20)

**Comparator:** Antihypertensive therapy alone (n=20).

**1° endpoint:** BP reduction at 6 mo by ABPM.

**Results:** BP was 162±4/97±2 mm Hg prior to randomization. CPAP was used for 6 h/night. Compared with the control group, awake SBP/DBP decreased significantly in the CPAP group (-6.5±3.3/-4.5±1.9 vs. +3.1±3.3/2.1±2.7 mm Hg; p<0.05). BP changes were significant only when pts were awake but not at night by ABPM.

**Limitations:** Small; but strength was rigorous exclusion of pts who were nonadherent; control arm did not undergo placebo treatment; nonblinded.

**Conclusions:** Treatment of OSA with CPAP significantly reduces daytime BP in pts with resistant hypertension.

---

### Data Supplement 9. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Fiber Intake) (Section 6.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevance Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
### Whelton SP, et al., 2005 (62) 15716684

**Aim:** Study the effect of dietary fiber intake on BP  
**Study type:** Systematic review and meta-analysis  
**Size:**  
- 21 RCTs (25 comparisons) with 1,477 pts  
- 20 of the RCTs were conducted in nonhypertensive persons  
- 13 double-blind; 3 single blind and 9 open label  
**Inclusion criteria:**  
- RCT  
- ≥16 y  
- English language publication before Feb. 2004  
- No concurrent interventions  
**Exclusion criteria:**  
- Missing key data  
**Intervention:** Fiber supplementation, either as a pill (8 trials), cereal/fruit/veg (15 trials), Pectin (1 trial), Guar gum (1 trial)  
**Comparator:** Placebo or no fiber supplementation  

1° endpoint: In a pooled analysis of the overall group (hypertensive and normotensive persons), the mean for change in SBP was -1.15 mm Hg; 95% CI: -2.68–0.39 mm Hg and for DBP was -1.65 mm Hg; 95% CI: -2.70–-0.61 mm Hg. In the subgroup of 20 trials conducted in nonhypertensives, the mean change in SBP was -0.14 mm Hg; 95% CI: -1.10–0.86 mm Hg. In the subgroup of 5 trials conducted in hypertensives, the mean change in BP was -5.95 mm Hg; 95% CI: -9.50–-2.40 mm Hg.  

1° Safety endpoint: N/A  

- This is the most detailed and comprehensive review of the topic.  
- It provides limited evidence, overall, that fiber supplementation results in a significant in BP and suggests no evidence in support of an effect in normotensives.

### Streppel MT, et al., 2005 (63) 15668359

**Aim:** Study the effect of fiber supplementation on BP  
**Study type:** Systematic review and meta-analysis  
**Size:**  
- 23 RCTs (25 comparisons) in 1,404 pts  
- Mean duration=9 wk  
- Mean age=42 y  
- 16 double-blind, with 14 (67%) of the 21 comparisons conducted in normotensive pts  
- 3 trials based on plant protein and 4 trials based on animal protein  
**Inclusion criteria:**  
- Human RCT  
- BP 1° or 2° outcome  
**Exclusion criteria:**  
- Inadequate reporting of the data  
- Concurrent intervention  
**Intervention:** Fiber supplementation (average dose=11.5 g/d); soluble fiber in 11 trials, insoluble fiber in 7 trials, and a mixture in the remaining trials  
**Comparator:** Placebo or no fiber supplementation  

1° endpoint: In the overall group (hypertensive and normotensive pts), a pooled analysis identified a MD for change in SBP of -1.13 mm Hg; 95% CI: -2.49–0.23. In a subgroup of 17 trials conducted in “nonhypertensives” (mean baseline BP<140/90 mm Hg or <50% receiving antihypertensive medication), the mean treatment effect was -0.23 mm Hg; 95% CI: -1.43–0.98 in univariate analysis and -1.00 mm Hg; 95% CI: -1.94–-0.06 mm Hg in multivariate analysis that adjusted for age, sex, study design, duration of intervention, and fiber dose. The corresponding effects in 8 trials conducted in hypertensives were -4.53 mm Hg; 95% CI: -6.69–-2.38 mm Hg; and -2.42 mm Hg; 95% CI: -5.28–-0.45 mm Hg.  

**Safety endpoint:** N/A  

- Findings consistent with experience in the meta-analysis by Whelton et al.
### Data Supplement 10. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Fish Oil) (Section 6.2)

| Study Acronym; Author; Year Published | Aim: Study the effect of fish oil supplementation on BP | Study Type: Systematic review and meta-analysis | Size: 17 RCTs (25 comparisons) with 1,524 pts. 9 trials were conducted in normotensives (1,049 pts.) | Inclusion criteria:  • RCT  • English language publication before January 2011  • Duration ≥8 wk | Intervention: Fish oil given in capsule form, with doses varying from 0.8–13.33 g/d. | Comparator: Placebo (usually corn oil, olive oil, or safflower oil). | Endpoint Results (Absolute Event Rates, P value; OR or RR; & 95% CI): 1° endpoint: In a pooled analysis of the 8 trials conducted in hypertensive pts, the mean for change in SBP was -2.56 mm Hg; 95% CI: -4.53– -0.58 mm Hg. The corresponding SBP change for the 9 trials conducted in normotensives was -0.50 mm Hg; 95% CI: -1.44– 0.45. | Relevant 2° Endpoint (if any); Study Limitations; Adverse Events:  • This is the most recent of many that have been published.  • Previous meta-analyses have been conducted by Appel et al (1993), Morris et al. (1993), Gueijnse et al (2002) and Dickinson et al. (2006).  • In general, the findings have been fairly consistent in demonstrating a relatively small (2 3/4 mm Hg SBP) but significant effect, with most of this being attributable to the results in trials conducted in hypertensive pts. |
Rodriguez-Leyva D, et al., 2013 (66) 24126178

**Aim:** Study the effect of flaxseed on BP in hypertensive pts  
**Study type:** RCT  
**Size:** 110 pts with PAD

**Inclusion criteria:**  
- <40 y  
- PAD for >6 mo, ABI <0.9

**Exclusion criteria:**  
- Inability to walk, bowel disease, moderate to severe renal failure, life expectancy <2 y with high cardiac risk, allergy to any of the study products, pts who plan to undergo surgery during the course of the trial, and no more than 2 fish meals per wk

**Intervention:** Pts given 1 food item per day for 6 mo, containing either 30 g of milled flax seed or placebo. Flaxseed contains omega-3 fatty acids, lignans, and fiber.  

**Comparator:** Placebo

**1° endpoint:** SBP and DBP consistently decreased in the flaxseed group over the course of the study. After 6 mo, SBP in the flaxseed group dropped significantly to 136±22 mm Hg (p=0.04). On the contrary, in the placebo group, SBP rose slightly to 146±21 mm Hg. After 6 mo of intervention, DBP in the flaxseed group fell to 72±11 mm Hg (p=0.004), whereas DBP in the placebo group remained the same (79±10 mm Hg).

- Based on this 1 RCT, flaxseed appeared to have a significant BP lowering effect

**Data Supplement 11. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Potassium Supplementation to Placebo or Usual Diet) (Section 6.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Whelton PK, et al., 1997 (67) 9168293 | **Aim:** Study the effect of potassium supplementation on BP  
**Study type:** Systematic review and meta-analysis  
**Size:** | **Inclusion criteria:**  
- Human RCT  
- Without HTN  
- Potassium supplementation vs. control  
- No concurrent interventions  
**Exclusion criteria:** Missing key data  
**Intervention:** Potassium supplementation in 1,049 pts (potassium chloride tabs in 10 RCTs with 618 pts and diet in 2 RCT with 431 pts)  
**Comparator:** No potassium supplementation  
1° endpoint:  
- Significant reduction in BP.  
- Overall (hypertensives and normotensives), mean: 3.11 mm Hg; 95% CI: -4.32– -1.91 mm Hg.  
- In the 12 trials conducted in normotensives, mean: -1.8 mm Hg; 95% CI: -2.9– -0.6 mm Hg for SBP and -1.0 mm Hg; 95% CI: -2.1–0.0 for DBP | • This is the most comprehensive presentation of the effects of potassium on BP, including experience in normotensives.  
• Significant reduction in SBP overall and in the subgroups with and without HTN.  
• In a subsequent meta-analysis of 23 trials, Geleijnse JM, Kok FJ, and Grobbee DE (J Hum Hypertens. 2003;17:471-480) reported a similar effect of potassium on SBP in both hypertensives and nonhypertensives (mean of -3.2 and -1.4 mm Hg, respectively). |
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Safety endpoint</th>
<th>1° endpoint</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Aburto NJ, et al., 2013 (68) | **Aim:** Study the effect of potassium supplementation on BP | Systematic review and meta-analysis | 21 RCTs (n=1,892); 16 in pts with HTN (n=818) and 3 RCTs in pts without HTN (n=757) | **Inclusion criteria:**  
- RCT in humans  
- Duration ≥4 wk  
- 24-h collections of urinary potassium  
- No concomitant interventions  
**Exclusion criteria:**  
- Pts who were acutely ill, HIV positive, hospitalized, or had impaired urinary excretion of potassium | **Intervention:** Potassium supplementation in 20 trials, supplements plus diet/education in 1 trial, and diet/education alone in 2 trials. | No potassium supplementation (placebo or usual diet) | N/A | **Overall change in SBP= -5.93; 95% CI: -10.15– -1.70.** After removing outlier trials, the change was -3.49 mm Hg; 95% CI: -5.15– -1.82 mm Hg.  
- In 16 trials conducted in hypertensives, change in SBP was -5.32 mm Hg; 95% CI: -7.20– -3.43.  
- In the 3 trials conducted in persons without HTN, change in SBP was 0.09 mm Hg; 95% CI: -0.77–0.95. | **1° endpoint:** N/A | • The 1 RCT conducted in African-Americans (n=87) identified a mean treatment effect size of -6.9 mm Hg; 95% CI: -9.3– -4.4 for SBP (p<0.001) and -2.5 mm Hg; 95% CI: -4.3– -0.8 for DBP (p=0.004).  
- In the entire cohort (trials conducted in pts with HTN and normotension), net changes in SBP and DBP were directly related to level of urinary sodium excretion during the trial.  
- 1 trial (TOHP Phase I) incorrectly entered twice so only 2 trials really available. However, this does not change overall finding.  
- The negative results for normotensives in this meta-analysis (and difference with the findings by Whelton et al) probably reflects the requirement for a duration of ≥4 wk and the fact that few trials of this duration have been conducted in normotensives. |
| Geleijnse JM, et al., 2003 (69) | **Aim:** Study the effect of potassium supplementation on BP | Systematic review and meta-regression analysis | 27 RCTs; 19 in pts with HTN and 11 RCTs in pts without HTN | **Inclusion criteria:**  
- RCT in adults  
- Published after 1966  
- Duration ≥2 wk  
- No concomitant interventions  
**Exclusion criteria:**  
- Disease  
- Outlier results (1 trial) | **Intervention:** Potassium supplementation | No potassium supplementation | N/A | **Overall change in SBP= -2.42; 95% CI: -3.75– -1.08.**  
- In the 19 trials conducted in hypertensives, change in SBP was -3.51 mm Hg; 95% CI: -5.31– -1.72  
- In the 3 trials conducted in persons without HTN, change in SBP was 0.97 mm Hg; 95% CI: -3.07–1.14 | **1° endpoint:** N/A | • Imputation for missing data  
- In addition to the treatment effect difference by presence/absence of HTN, there was a trend toward a larger treatment effect in older age (≥45 y), and to a lesser extent higher baseline urinary Na (>150 mmol/24 h) and greater increase in urinary K (>44 mmol/24 h) |
### Data Supplement 12. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Protein Intake on BP) (Section 6.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Rebholz CM, et al., 2012 (70) 23035142 | **Aim:** Study the effect of protein intake on BP  
**Study type:** Systematic review and meta-analysis  
**Size:**  
- 40 RCTs (44 comparisons) with 3,277 pts  
- 32 comparisons of protein vs. carbohydrate  
- 12 comparisons of vegetable vs. animal protein  
- 35 of the RCTs were conducted in normotensive persons (28 with SBP in the prehypertensive range) | Inclusion criteria:  
- RCT in humans  
- ≥18 y  
- Publication between January 1,1950 and April 1, 2011  
- No concurrent interventions  
- No more than 10% difference in calories, sodium, potassium, fiber between the treatment arms  
- Duration ≥1 wk  
**Exclusion criteria:** Missing key data | Intervention:  
- Protein intake  
- 1st meta-analysis: any source of protein, with a median protein supplementation dose of 40 g/d (20–66 g/d)  
- 2nd meta-analysis: specifically vegetable or animal protein  
**Comparator:**  
- 1st meta-analysis: carbohydrate  
- 2nd meta-analysis: vegetable or animal protein | 1° endpoint:  
- 1st meta-analysis  
There was a fairly consistent trend for a small BP lowering effect of protein compared to carbohydrate intake (86% of the trials). In a pooled analysis of the overall group (hypertensive and normotensive persons), the mean for change in SBP was -1.76 (95% CI: -2.33– -1.20). In a subgroup of 15 trials in which none of the participants were receiving antihypertensive medication, the mean change in SBP was -1.95 (95% CI: -2.62– -1.29).  
- 2nd meta-analysis  
For the comparison of vegetable vs. animal protein, there was no evidence of a difference in BP. In a pooled analysis of the overall group (hypertensive and normotensive pts) the mean change in SBP was -0.10 (95% CI: -2.31–2.11) mm Hg. In a subgroup of 8 trials in which none of the pts were receiving antihypertensive medication, the mean change in SBP was -0.55 (95% CI: -3.06–1.96). | ● This is the most detailed and comprehensive review of the topic.  
● It provides strong evidence that protein supplementation results in a significant but modest reduction in BP and suggests that the effect size is similar following supplementation with protein from vegetables or animals. |
| Tielemans SM, et al., 2013 (71) 23514841 | **Aim:** Study the effect of protein intake on BP  
**Inclusion criteria:** RCTs, in “generally healthy adults”  
**Exclusion criteria:** N/A |  
- At baseline, the mean for age and SBP were 50 (range: 31–74) and 128  
- Findings consistent with experience in the meta-analysis by Rebholz et al. | 1° Safety endpoint: N/A |
<table>
<thead>
<tr>
<th>Study type</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Safety endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review and meta-analysis</td>
<td>RCTs in adults with DM-2</td>
<td>High protein diet intervention and ≥5% difference in dietary protein intake between intervention and control groups</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Study type: Systematic review and meta-analysis</td>
<td>All but 1</td>
<td>Probiotic fermented milk (100–450 g/d)</td>
<td>Not specified but all of the trials reported to be</td>
<td>N/A</td>
</tr>
</tbody>
</table>
(cross-over) trial said to use a parallel design. Antihypertensive drug use reported in 3 trials and in an additional 3 trials mean SBP exceeded 150 mm Hg at baseline.

**Size:** 14 RCTs with 702 pts (median size=40).

- Intervention with enzymatically hydrolysed milk
- Cointervention

Placebo controlled. However, 2 were single blind and 1 was open label.

lactotripeptides Valine-Proline-Proline and Isolucine-Proline-Proline.

- These findings may have special relevance for countries, like Japan, where consumption of fermented milk products is common.

**Data Supplement 13. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Sodium Reduction to Placebo or Usual Diet) (Section 6.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| NUTRICODE Mozaffarian D, et al., 2014 (74) 25119608 | **Aim:** Study the effect of sodium reduction on BP and CVD mortality  
**Study type:** Meta-regression analysis  
**Size:** 103 RCTs (107 comparisons) with 6,970 pts; 38 of the 107 comparisons were conducted in normotensive pts | **Inclusion criteria:** RCT in 2 previous Cochrane meta-analyses  
**Exclusion criteria:**  
- Duration <1 wk  
- Mean 24-h collections or estimates of urinary sodium reduced <20 mmol in the intervention group compared to control  
- Concomitant interventions | **Intervention:** Sodium reduction  
**Comparator:** No sodium reduction | **1° endpoint:**  
- Strong evidence for a linear relationship between reduction in sodium intake and lower levels of SBP throughout the entire distribution of sodium studied, with larger reductions in older persons, blacks (compared to whites) and hypertensives (compared to normotensives). For a white, normotensive population at age 50 y, each reduction of 100 mmol/d (2.3 g/d) in dietary sodium lowered SBP by a mean: 3.74 (95% CI: 5.18–2.29).  
- Modeling based on global estimates of sodium intake, effect of sodium reduction on BP, and effect of BP reduction on CVD mortality attributed 1.65 million CVD deaths annually due sodium intake >2 g/d. this would represent 9.5% (95% CI: 6.4–12.8) of all CVD mortality. Estimates were not | **RCT meta-regression analysis that provides evidence for BP lowering following a reduction in dietary sodium intake, overall and in normotensive persons, with a more pronounced effect in those who were older, black and had a higher starting level of BP.**  
- These findings are consistent with other reports.  
- The modeling analysis suggested sodium reduction would yield important population health benefits but did not specify the magnitude of the potential benefit for pts within the normal BP range. |
<table>
<thead>
<tr>
<th>Study Reference</th>
<th>Aim</th>
<th>Study Type</th>
<th>Size</th>
<th>Inclusion Criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Endpoint</th>
<th>Safety Endpoint</th>
</tr>
</thead>
</table>
| Aburto NJ, et al., 2013 (68) | **Aim**: Study the effect of sodium reduction on BP | **Study type**: Systematic review and meta-analysis | **Size**: Overall study included 36 trials (49 comparisons) conducted in 6,736 pts. Of these, 3,263 were nonhypertensive. The results in normotensives in this table are based on experience in 7 RCTs conducted in 3,067 normotensive pts. | **Inclusion criteria**:  
- RCT in humans  
- Trial duration ≥4 wk  
- 24-h urinary sodium ≥40 mmol/d less in treatment compared to control group  
- No concurrent interventions  
- Not acutely ill  
 **Exclusion criteria**: Lack of above | **Intervention**: Sodium reduction | **Comparator**: No sodium reduction | **1° Endpoint**: In pooled analysis, the overall change in SBP was -3.39 (95% CI: -4.31– -2.46) mm Hg. In the pts with HTN, the change was -4.06 (95% CI: -5.15– -2.96). In the normotensives, the change was -1.38 (95% CI: -2.74–0.02).  
 **Safety endpoint**: In the small number of relevant trials, there was no significant effect of sodium reduction on lipid levels (Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride levels; 11 trials) or on plasma (7 trials) or urinary catecholamine levels (2 trials). Experience in 4 trials (3 which could not be included in the meta-analysis) suggested a beneficial effect of sodium reduction on urinary protein excretion. |  

| He FJ, et al., 2013 (75) | **Aim**: Study the effect of sodium reduction on BP | **Study type**: Systematic review, meta-analysis and meta-regression analysis | **Size**: Overall study included 34 trials (37 comparisons) conducted in 3,230 pts. | **Inclusion criteria**:  
- RCTs  
- Healthy adults ≥18 y  
- Trial duration ≥4 wk  
- Sodium intake only difference between treatment and control group  
- 24-h urine sodium ≥40 mmol less in treatment compared to control  
 **Exclusion criteria**: Lack of above | **Intervention**: Sodium reduction | **Comparator**: No sodium reduction | **1° Endpoint**: In an overall pooled analysis, the change for SBP was -4.18 (95% CI: -5.18– -3.18) mm Hg. In the trials of persons with HTN, the mean change was -5.39 (95% CI: -6.62– -4.15) mm Hg. In the trials conducted in normotensives, the change in SBP was -2.42 (95% CI: -3.56– -1.29) mm Hg.  
- In meta-regression analysis, change in 24-h urinary sodium was significantly associated with reduction in SBP (4.3 mm Hg for a 100 mmol reduction in 24-h urinary sodium).  
 **Safety endpoint**: In this context, reduced sodium intake resulted in a statistically significant but small reduction in SBP.  
 **Study inclusion/exclusion criteria designed to yield a group of trials that would provide results that have relevance for clinical practice and public health. In this context, reduced sodium intake resulted in a significant and potentially important reduction in SBP.  
 **The meta-regression results were consistent with a dose-response relationship in normotensive pts |  

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
pts. 12 of the RCTs (14 comparisons) were conducted in 2,240 normotensive pts.

Safety endpoint:
In the small number of relevant trials (which included both hypertensive and normotensive pts) that provided safety endpoint measurements (4–14 trials), there was no change in total, LDL- or HDL-cholesterol, or triglyceride levels. There were small significant increases in plasma renin activity, aldosterone, and noradrenaline levels but these were consistent with expected physiologic responses to sodium reduction.

Graudal NA, et al., 2012 (76) 22068710

| Aim: Study the effect of sodium reduction on BP |
| Study type: Systematic review and meta-analysis |
| Size: Overall study included 167 trials. Of these, 71 RCTs were conducted in 5,577 normotensive pts, with the following characteristics: |
| ● Median age: 27 y (13–67 y) |
| ● Median trial duration: 7 d (4–1,100 d) |
| ● 5,292 Whites (71 studies) |
| ● 268 Blacks (7 studies) |
| ● 215 Asians (3 studies) |

| Inclusion criteria: |
| ● RCTs |
| ● 24-h collections or estimates from ≥8 h collections of urinary sodium excretion |

| Exclusion criteria: |
| Systematic studies in unhealthy pts with diseases other than HTN |

| Intervention: Sodium reduction |
| Comparator: No sodium reduction |

| 1st endpoint: The overall effect of sodium reduction was not presented. |

A forest plot of 71 comparisons (from 61 trials) in the 4,919 normotensive whites assigned to sodium reduction compared to usual sodium intake identified a trend towards lower SBP in 50 (70%), no difference in 8 (11%), and higher SBP in 13 (19%). In a pooled analysis, sodium reduction compared to usual sodium intake in the normotensives yielded the following MDs in SBP:

- Whites: -1.27 (95% CI: -1.88 - -0.66)
- Blacks: -4.02 (95% CI: -7.37 - -0.68)
- Asians: -1.27 (95% CI: -3.07 - -0.54)

A corresponding analysis in the hypertensives yielded the normotensives yielded the following MDs in SBP:

- Whites: -5.48 (95% CI: -6.53 - -4.43)
- Blacks: -6.44 (95% CI: -8.85 - -4.03)
- Asians: -10.21 (95% CI: -16.98 - -3.44)

Safety endpoint: In the relevant trials (all cross-over studies and including

Heterogeneous group of trials that included many small studies of short duration in young persons.

Overall finding of lower BP in those assigned to a reduced intake of dietary sodium, with an apparently greater effect in Blacks compared to Whites and Asians.

The hormone changes in this meta-analysis likely reflect a physiologic response to sodium reduction, especially in studies of short duration and rapid changes in sodium intake. The increases in total cholesterol and triglyceride levels were not noted in the meta-analyses conducted by Aburto et al. and He et al.
comparisons in both hypertensive and normotensive participants) that provided safety endpoint measurements, significant increases in the standard MD for plasma renin activity (70 trials), aldosterone (51 trials), noradrenaline (31 trials), adrenaline (14 trials), and weighted MD for total cholesterol (24 trials), and triglyceride (18 trials) levels. There was no significant effect of sodium reduction on LDL-cholesterol (15 trials) and HDL-cholesterol (17 trials).

### DASH-Sodium Trial

**Aim:** Study the effect of sodium reduction on BP  
**Study type:** Randomized, controlled crossover trial  
**Size:** Overall study based on 412 pts, of whom 243 were normotensive

**Inclusion criteria:**  
Adults ≥22 y

**Exclusion criteria:**  
- Taking antihypertensive medication, heart disease, renal disease, poorly controlled hyperlipidemia or DM, DM requiring insulin, special dietary requirements, >14 drinks/wk

**Intervention:** Feeding study in which pts were randomized to a DASH or control diet at 3 levels of assigned dietary sodium intake: High=210 mmol/d; Intermediate=100 mmol/d; Low=50 mmol/d

**Comparator:** Each pt served as their own control (crossover design)

**1° endpoint:**  
- Reduced sodium intake resulted in a significant reduction in SBP, with a greater reduction during assignment to the Low compared to the Intermediate sodium intake diet. At every level of sodium intake, the achieved reduction in SBP was greater on the control group compared to the DASH diet and for Blacks compared to other pts.  
- Reducing sodium intake from the high to intermediate level decreased SBP by 2.1 mm Hg (p<0.001) during the control diet and 1.3 mm Hg (p=0.03) during the DASH diet.  
- Reducing sodium intake from the intermediate low level decreased SBP by a further 4.6 mm Hg (p<0.001) during the control diet and 1.7 mm Hg (p<0.01) during the DASH diet.

**Safety endpoint:** N/A

- This trial provides the best (direct) evidence for a dose-response treatment relationship between sodium intake and level of BP.  
- It also suggests the relative effect of reduced sodium intake is greater in persons with a typical U.S. diet but the combination of sodium reduction and consumption of a DASH-type diet results in a lower level of BP than can be achieved with either dietary modification on its own.  
- Consistent with other trials and meta-analyses, it suggests the effect of a reduced sodium intake is greater in Blacks compared to others, especially for those consuming a typical U.S. diet.

### TOHP II Trial (Sodium component)

**Aim:** Study the effect of sodium reduction on BP and prevention of HTN.  
**Study type:** Randomized,  
**Inclusion criteria:**  
- Healthy community-dwelling adults 30–54 y  
- BMI between 110% and 165% of desirable body weight

**Intervention:** Behavior change intervention aimed at studying the effects of modest (25%–30%) reductions in dietary sodium intake during

**1° endpoint:**  
- Compared to usual care, the sodium reduction group experienced a significant mean reduction of 51 mmol for 24-h urinary excretion and -2.9 (SD: 0.5) mm Hg (p<0.001) in SBP at 6 mo (-5.1 mm Hg in

- This was the largest trial of sodium reduction in HTN prevention and also provides the longest duration of follow.  
- The assumptions for a main effects factorial analysis (independence of the
controlled factorial trial.

**Size:** 2,382 pts, of whom 594 were randomized to sodium reduction (alone) and 596 were randomized to usual care.

- Not taking BP-lowering medication
- Mean SBP <140 mm Hg and DBP 83–89 mm Hg

**Exclusion criteria:**
- Taking antihypertensive medication,
- Heart disease, renal disease, poorly controlled hyperlipidemia or DM, DM requiring insulin, special dietary requirements, >14 drinks/wk.

**Comparator:** Usual care group

up to 48 mo (minimum 36 mo) of follow-up.

the sodium reduction group and -2.2 mm Hg in the usual care group).

- A progressive reduction in effect size for urinary sodium excretion and BP was noted over time, with mean for SBP at 18, 36 mo and termination of -2.0 (SD: 0.5) mm Hg (p<0.001), -1.2 (SD: 0.5) mm Hg (p=0.02), and -1.0 (SD: 0.5) mm Hg (p=0.5).

**Prevention of HTN**

- At 6 mo of follow-up the incidence of new onset HTN was 39% lower in the pts randomized to reduced dietary sodium intake compared to the usual care group (p=0.04).
- During more prolonged follow-up, the effect size decreased but remained significant after 48 mo of follow-up (14% reduction; p=0.04). Overall, the incidence of HTN was reduced by 18% (p=0.048).

**Safety endpoint:** N/A

---

**TOHP Phase I**

1992 (79)

**Aim:** Study the effect of sodium reduction on BP and prevention of HTN

**Study type:** Randomized, controlled factorial trial.

**Size:** Overall, 2,182 adults, with the 327 assigned to sodium reduction compared

**Inclusion criteria:**
- Community-dwelling adults 30–54 y
- Not on antihypertensive medication
- DBP 80-89 mm Hg
- Healthy

**Exclusion criteria:**
- Disease
- Inability to comply with the protocol

**Intervention:** Behavior change intervention

**Comparator:** Usual care

**1° endpoint:** Change in DBP

**2° endpoint:** Change in SBP

**Safety endpoint:** CVD events, symptoms and general and well being

- Significantly lower DBP (0.9 mm Hg; p<0.05) and SBP (1.7 mm Hg; p<0.01) in the sodium reduction group compared to usual care
- Few CVD events
- No difference in symptoms
- Significant improvement in general well-being at 6 and 18 mo (p<0.05)
### Data Supplement 14. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Stress Reduction) (Section 6.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Canter PH, et al., 2004 (81) 15480084 | Aim: Study the effect of transcendental meditation on BP  
Study type: Systematic review  
Size: | Inclusion criteria:  
• RCT in humans  
• Publication in any language until May 2004  
• No concurrent interventions | Intervention:  
• Use of transcendental meditation techniques as taught by Maharishi Mahesh Yogi  
• Practiced on a regular basis over an extended period | 1° endpoint: Statistically significant reduction in SBP reported in 3 of 5 trials that provided such information.  
1° Safety endpoint: N/A | • Only a handful of RCTs available from the large number of publications on this topic.  
• Trials had methodological weaknesses and were subject to potential bias due to the affiliation of authors to the transcendental meditation organization. |
| Cook NR, et al., 2007 (80) 17449506 | Aim: Study the effect of sodium reduction on CVD morbidity and mortality.  
Study type: 10–15 y post-trial follow-up of TOHP I and TOHP II pts that took advantage of the randomized trial design. Vital status was obtained for 100% of the pts and information on morbidity was obtained from 2,415 (77%) of the pts.  
Size: 744 TOHP Phase I and 2,382 TOHP Phase II pts | Inclusion criteria: Assigned to dietary sodium reduction or control in TOHP Phase I or TOHP Phase II.  
Exclusion criteria: None | Intervention: Behavior change intervention aimed at studying the effects of modest (25%–30%) reductions in dietary sodium intake during TOHP Phase I or TOHP Phase II.  
Comparator: No sodium reduction intervention. | 1° endpoint:  
• 200 CVD events and 77 deaths during follow-up  
• Kaplan-Meier plots identified trends toward less morbidity and mortality in those who had been randomized to sodium reduction compared to usual care, with a consistent pattern for the TOHP I and TOHP II participants  
• Risk of a CVD event was 30% lower (RR: 0.70; 95% CI: 0.53–0.94; p=0.018) among those randomized to sodium reduction compared to usual care, after adjustment for trial, clinic, age, race, sex, baseline weight and sodium excretion  
• RR for total mortality was 0.80 (95% CI: 0.51–1.26).  
Safety endpoint: N/A | • Dietary sodium reduction, previously shown to reduce BP and prevent HTN in the TOHP I and TOHP II trials, appeared to reduce CVD events during extended post-trial follow-up of the pts from these 2 trials. |
Data Supplement 15. RCTs and Meta-analyses Studying the Effect of Nonpharmacologic Interventions on BP (Dietary Patterns) (Section 6.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appel LJ, et al., 1997 (82) 9099655</td>
<td>Aim: Study the effect of dietary patterns on BP</td>
<td>Inclusion criteria:</td>
<td>Intervention:</td>
<td>1° endpoint: Compared to the control diet, both intervention diets reduced BP, with an overall mean (95% CI) reduction of:</td>
<td>● This trial was the first of several to document the value of the combination diet (later renamed the DASH diet). ● The BP reductions noted with the DASH (combination) diet were substantial and well maintained. ● Generalizability was limited due to the nature of the intervention (feeding study) and the relatively short period of intervention experience (8 wk)</td>
</tr>
<tr>
<td></td>
<td>Study type: Multicenter RCT 3 arm parallel design 3 wk pre- randomization run-in phase Feeding study with 8 wk of intervention Size: 459 adults, mean age 44 y. (326 normotensive)</td>
<td>● Adults ≥22 y ● SBP&gt;160 mm Hg and DBP 80–95 mm Hg ● No antihypertensive medication</td>
<td>● Diet high in fruits and vegetables “Combination” diet high in fruits, vegetables, low-fat dairy products, and reduced total fat, saturated fat and cholesterol. Comparator: Usual U.S. diet</td>
<td>1° endpoint: Compared to the control diet, both intervention diets reduced BP, with an overall mean (95% CI) reduction of:</td>
<td>● Fruits and Veg. Diet: SBP: -2.8 (95% CI: -4.7– -0.9) DBP: -1.1 (95% CI: -2.4– -0.3) ● Combination Diet: SBP: -5.5 (95% CI: -7.4– -3.7) DBP: -3.0 (95% CI: -4.3– -1.6) The BP changes in the subgroup with HTN were:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exclusion criteria:</td>
<td></td>
<td>● Fruits and Veg. Diet: SBP: -7.2 (-11.4, -3.0) DBP: -2.8 (-5.4, -0.3) ● Combination Diet: SBP: -11.4 (-15.9, -6.9) DBP: -5.5 (-8.2, -2.7)</td>
<td></td>
</tr>
</tbody>
</table>
### 2017 Hypertension Guideline Data Supplements

| Study | Aim: Study the effect of different levels of sodium intake on BP during consumption of a DASH or usual U.S. diet | Inclusion criteria: | Intervention: 3 levels of dietary sodium while consuming a DASH or usual U.S. diet. The target sodium intake levels for a daily energy intake of 2,100 kcal were:  
High: 150 mmol (3,450 mg)/d  
Intermediate: 100 mmol (2,300 mg)/d  
Low: 50 mmol (1,150 mg)/d  
The mean achieved levels of sodium during the high, intermediate and low sodium periods were 144, 107 and 67 mmol/d in the DASH diet group and 141, 106, and 64 mmol/d in the usual U.S. diet group. | Comparator: See description above | 1° endpoint:  
- At each level of sodium intake, SBP and DBP were lower during consumption of the DASH diet compared to the usual U.S. diet, the difference being greatest with high sodium intake and lowest with low sodium intake, with the mean SBP difference between the DASH and usual US diets during high, intermediate and low sodium intake being -5.9 (95% CI: -8.0– -3.7), -5.0 (95% CI: -7.6– -2.5), and -2.2 (95% CI: -4.4– -0.1). The corresponding differences for DBP were -2.9 (95% CI: -4.3– -1.5), -2.5 (95% CI: -4.1– -0.8), and -1.0 (95% CI: -2.5, 0.4).  
- In both the DASH and usual U.S. diet arms, SBP and DBP were significantly lower during intermediate compared to high sodium intake, and during low compared to intermediate sodium intake, with the decrement being greater for the latter change.  
- In comparison to consumption of a usual U.S. diet at the high level of sodium intake. |
| --- | --- | --- | --- | --- | --- |
| Sacks FM, et al., 2001 (77) | | • Adults ≥22 y  
• Average SBP between 120–159 mm Hg and average DBP between 80–95 mm Hg  
• No use of antihypertensive medication  
Exclusion criteria: Heart disease, renal insufficiency, poorly controlled hyperlipidemia or DM, DM requiring insulin, special dietary requirements, >14 alcoholic drinks /wk. | The corresponding changes in the subgroup of normotensives were:  
• Fruits and Veg. Diet:  
SBP: -0.8 (-2.7, 1.1)  
DBP: -0.3 (-1.9, 1.3)  
• Combination Diet:  
SBP: -3.5 (-5.3, -1.6)  
DBP: -2.1 (-3.6, -0.5) | | This trial provided additional documentation of the effectiveness of a DASH diet in lowering BP in normotensives (and hypertensives) and the complementary benefit of consuming a reduced intake of sodium. |
**Aim:** Study the effect of 2 behavioral interventions, aimed at dietary change, on BP

**Study type:**
- Multicenter RCT with 3 parallel arms:
  - Established
  - Established plus DASH diet
  - Advice only

**Size:**
810 adults, with 62% (506) normotensive. At baseline, mean age, BMI and SBP/DBP were 50 y, 33 kg/m², and 135/85 mm Hg, respectively.

**Duration:** 6 mo, with observations at 3 and 6 mo.

**Inclusion criteria:**
- Adults ≥25 y
- Average SBP between 120–159 mm Hg and average DBP between 80–95 mm Hg
- No use of antihypertensive medication
- BMI between 18.5 and 45 kg/m²

**Exclusion criteria:**
- Regular use of drugs that affect BP
- Target organ damage or DM
- Use of weight-loss meds
- HF, angina, cancer, within 2 y
- Consumption of >21 alcoholic drinks /wk
- Pregnancy, planned pregnancy, lactation

**Intervention:**
- Structured behavioral interventions that used an identical format (4 individual and 14 group sessions) to facilitate adoption of “established” dietary recommendations for reduction in BP or “established” plus the DASH diet. The “established” dietary recommendations used in PREMIER were a) weight loss in overweight participants, b) sodium reduction, increased physical activity, reduced alcohol intake in pts consuming alcohol.
- Compared to experience in the advice only (control) group, there was only modest achievement of BP endpoints.

**1° endpoint**
- Compared to control (advice only), SBP and DBP were significantly reduced with both active interventions but there was no significant difference in the effect size between the 2 active intervention groups. This was true for both the normotensive and hypertensive pts, with the effect size being larger in the hypertensive group. In the normotensives, the MD for change in SBP was identical for the “established” compared to “established plus DASH Diet” groups: -3.1 (95% CI: -5.1– -1.1) mm Hg

The corresponding changes for DBP were -1.6 (95% CI: -2.9-- -0.2) for the “established” intervention group and -2.0 (95% CI: -3.4-- -0.6) for the “established intervention plus DASH Diet” group.
- Overall, the incidence of HTN was lowest and the percent with optimal BP was highest in the “established plus DASH Diet” but the incidence of sodium intake, the normotensive group consuming the DASH diet at the low level of sodium intake had a mean SBP difference of 7.1 mm Hg (p<0.001).

**1° Safety endpoint:** Participants tended to report less symptoms during periods of reduced sodium intake, with a statistically significant reduction in reports of headache (p<0.05) consistent with prior experience in the TONE trial.

This was an interesting trial which employed a behavior change approach to implement both active interventions.
- The investigators goal was to determine the additive value of the DASH Diet in persons already following key elements of conventional (established) recommendations for nonpharmacologic intervention to lower BP.
- The intervention approach in this trial was less effective in achieving weight loss and reduction in dietary sodium compared to the corresponding experience in the TOHP and TONE trials and the DASH Diet effects on intermediate variables (such as fruit and vegetable consumption) was less than that achieved in the DASH Diet feeding studies.
- Despite the modest intervention effects, both SBP and DBP were significantly reduced with the conventional intervention approach (in normotensives as well as overall) and addition of the DASH diet did not have a
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim: Compare effects of 3 diets, each with a reduced intake of saturated fats, on BP and serum lipids</th>
<th>Inclusion criteria:</th>
<th>Interventions:</th>
<th>Comparator: Advice only</th>
<th>Safety endpoint: N/A</th>
<th>Significant effect on reduction of SBP or DBP.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appel LJ, et al., 2005 (84) 16287956</td>
<td>HTN was significantly less and the percent with optimal BP was higher in both active intervention groups compared to advice only. The difference between the 2 active intervention groups was not significant. In the normotensives, there was a nonsignificant trend towards less HTN and a significantly higher percent with optimal BP in both active intervention groups compared to advice only, with no significant difference for percent with optimal BP in the 2 active intervention groups.</td>
<td>HTN was significantly less and the percent with optimal BP was higher in both active intervention groups compared to advice only. The difference between the 2 active intervention groups was not significant. In the normotensives, there was a nonsignificant trend towards less HTN and a significantly higher percent with optimal BP in both active intervention groups compared to advice only, with no significant difference for percent with optimal BP in the 2 active intervention groups.</td>
<td>Comparator: Advice only</td>
<td>Safety endpoint: N/A</td>
<td>Significant effect on reduction of SBP or DBP.</td>
<td></td>
</tr>
</tbody>
</table>

- Weight loss was somewhat greater in the “established” plus DASH diet group, with a MD of 4.8 kg (10.6 lbs) for body weight. This group also manifested expected effects of the DASH diet, with significantly higher urinary potassium and phosphorous levels, greater consumption of fruits and vegetables, dietary calcium, dairy products, and a lower consumption of total fat and saturated fat.

1° Safety endpoint: N/A
### Study type:
- 2 center RCT
- 3 period crossover design
- Each 8 wk period was separated by a 2–4 wk wash-out phase

### Size:
161–164 included in analyses (191 pts randomized).

132 (80.5%) of the 164 included in the BP analyses were normotensive. Mean age and BMI were 54 y and 30.2 kg/m², respectively.

### Exclusion criteria:
- DM, CVD (current or H/O), LDL cholesterol >220 mg/dL, fasting triglycerides >750 mg/dL, weight >350 lb., taking that effect BP or lipids, unwillingness to stop vitamin/mineral supplements, >14 alcoholic drinks/wk.
- High unsaturated fats (predominantly monounsaturated fat) with low saturated fat content

### Comparator:
- High carbohydrate with reduced fat/saturated fat content

### Intervention:
- Reduced SBP by -1.4 mm Hg (p=0.002) overall and by -0.9 mm Hg (p=0.047) in the normotensives
- Reduced LDL cholesterol by 3.3 mg/dL (p=0.01) overall and by -2.1 mg/dL (p=0.14) in the normotensives
- Reduced HDL-C by -1.3 mg/dL (p=0.02) overall
- Reduced serum Triglycerides by -15.7 mg/dL (p<0.001) overall

Compared with the high carbohydrate diet, the high unsaturated fat diet:
- Reduced SBP by -1.3 mm Hg (p=0.005) overall and by -0.9 (p=0.06) in the normotensives
- Reduced LDL cholesterol by -1.5 mg/dL (p=0.01) and by -2.1 (p=0.14) in the normotensives
- Increased HDL-C by 1.1 mg/dL (p=0.03) overall
- Reduced serum Triglycerides by -9.6 (p=0.02) overall

This clinical trial provides 1 of the longest follow-up experiences related to the topic.
- It suggests low carbohydrate diets may be somewhat better than traditional low fat diets in achievement of weight loss, improvement of lipid profile, inflammation, and CHD risk.
- Although the BP differences were not significant, there was a consistent trend toward lower BPs in the low-carbohydrate diet group.

---

**Bazzano LA, et al., 2014 (85) 251786568**

**Aim:** Compare the effects of a low-carbohydrate and a low-fat diet on body weight and CVD risk factors (including BP)

**Study type:** Single center parallel arm RCT that compared the 2 diets over 12 mo of intervention.

**Size:** 148 pts, with a mean age of 46.8 y at baseline.

**Inclusion criteria:**
- 22–75 y
- BMI: 30–45 kg/m²

**Exclusion criteria:**
- CVD
- DM-2
- Kidney disease
- Use of prescription weight loss meds/surgery
- Weight loss >6.8 kg during prior 6 mo

**Intervention:**
- Low-carbohydrate diet, with digestible carbohydrate (total carbohydrate minus total fiber) <40 g/d
- Behavioral counselling that employed a mix of 20 individual and group meetings

**Comparator:**
- Low fat diet, with <30% of daily energy from fat

**1° endpoint:**
- Compared to the low-fat diet group, the low-carbohydrate diet group had a mean decrease at 12 mo of:
  - Body weight: -3.5 (95% CI: -5.6– -1.4) kg
  - Fat mass: -1.5 (95% CI: -2.6– -0.4) kg
  - HDL-C: 7.0 (11.0–3.0) mg/dL
  - Ratio total/HDL-C: -0.44 (95% CI: -0.71– -0.16)
  - Triglycerides: -14.1 (95% CI: -27.4– -0.8) mg/dL

- This clinical trial provides 1 of the longest follow-up experiences related to the topic.
- It suggests low carbohydrate diets may be somewhat better than traditional low fat diets in achievement of weight loss, improvement of lipid profile, inflammation, and CHD risk.
- Although the BP differences were not significant, there was a consistent trend toward lower BPs in the low-carbohydrate diet group.
baseline. Mean SBP/DBP at baseline were 124.9/79.4 and 120.3/77.5 mm Hg in the low-fat and low-carbohydrate groups, respectively. The corresponding BMIs were 97.9 and 96.3 kg/m². All 148 pts were included in the analysis (intention to treat)

| Aim: Compare effects of low-carbohydrate and low-fat diets on weight loss and CVD risk factors |
| Study type: |
| • Systematic review and meta-analysis |
| • Cochrane Collaboration strategy |
| Size: 5 trials (447 pts) |
| Inclusion criteria: |
| • RCT |
| • Adults ≥16 y |
| • Low-carbohydrate diet and low-fat diet interventions |
| • BMI ≥25 kg/m² |
| • Follow-up ≥6 m |
| Exclusion criteria: |
| • Cross-over or sequential design |
| • Missing data |
| Intervention: Low-carbohydrate diet: maximum of 60 g/d carbohydrate |
| Comparator: Low-fat diet: maximum of 30% energy from fat |

| 1° endpoint: At 6 mo, the low-carbohydrate diet pts, compared to the low-fat diet participants, had a mean reduction in body weight that was greater by -3.3 (95% CI: -5.3– -1.4) kg, and a more favorable profile for HDL-cholesterol and triglyceride levels. In contrast, the profile for total-cholesterol and HDL-cholesterol was more favorable in those assigned to a low-fat diet. The profile for SBP tended to be better in the low carbohydrate diet pts but the differences were not significant: MD at 6 mo: -2.4 (95% CI: -4.9–0.1) mm Hg. |

| 1° Safety endpoint: No serious side effects noted |

| Nordmann AJ, et al., 2006 (86) 16476868 |
| 1° Safety endpoint: N/A |

| Intake from fat (<7% from saturated fat) |

| At 3, 6, and 12 mo, BP tended to be lower in the low-carbohydrate group but none of the differences in SBP or DBP were significant. |
| CRP was reduced in both diet groups but to a significantly greater extent in the low-carbohydrate group. |
| At 6 and 12 mo pts in the low carbohydrate group experienced a significant improvement in their 10-y Framingham CHD risk score. In contrast, there was no change in Framingham CHD risk in the low-fat diet group. |

| 1° Safety endpoint: No serious side effects noted |

<p>| This systematic review/meta-analysis tends to suggest low-carbohydrate diets are somewhat more effective in reducing body weight compared to the traditionally recommended low-fat diets. |
| Although the BP differences were not significant they would probably have reached a conventional level of significance had subsequent clinical trials (including the Bazzano et al. trial) been included in the analysis. |</p>
<table>
<thead>
<tr>
<th>Source</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1° endpoint</th>
<th>Safety endpoint</th>
<th>Notes</th>
</tr>
</thead>
</table>
| Nordmann AJ, et al., 2011 (87) 21854893 | Compare effects of Mediterranean and low-fat diets on weight loss and CVD risk factors | - RCT  
- Intent to treat analysis  
- Overweight/obese with at least 1 additional CVD risk factor  
- Follow-up ≥6 mo | Mediterranean diet: moderate fat intake (main sources olive oil and nuts), rich in vegetables, and low in red meat. | Compared to the low-fat diet, the Mediterranean diet resulted in MDs of:  
- Body weight: -2.2 (95% CI: -3.9 – -0.6) kg  
- BMI: -0.6 (95% CI: -1.0– -0.1) kg/m²  
- SBP: -1.7 (95% CI: -3.3– -0.05) mm Hg  
- DBP: -1.5 (95% CI: -2.1– -0.8) mm Hg  
- Fasting Plasma Glucose: -3.8 (95% CI: -7.0– -0.6) mg/dL  
- Total-Cholesterol.: -7.4 (95% CI: -10.3– -4.4)  
- CRP: -1.0 (95% CI: -1.5– -0.5) | N/A | Overall, this study suggests the Mediterranean diet compared to the traditional low fat diet results in greater weight loss, a better CVD risk factor profile (including better BP control), and less inflammation.  
- The number of eligible trials was small and the study samples were heterogeneous (2 2º and 4 1° prevention trials). |
| Yokoyama Y, et al., 2014 (88) 24566947 | Compare the effects of vegetarian and omnivorous diets on BP | - Adults ≥20 y  
- English language publications between Jan 1946-Nov 2013  
- Twin pt studies  
- Multiple interventions  
- Only categorical BP results | Lacto-ovo in 4 trials  
Lacto in 1 trial  
Vegan in 2 trials | Compared to the omnivorous diet, the vegetarian diet resulted in MDs of:  
SBP: -4.8 (95% CI: -6.6– -3.1) mm Hg  
DBP: -2.2 (95% CI: -3.5– -1.0) mm Hg  
Total Cholesterol.: -7.4 (95% CI: -10.3– -4.4)  
CRP: -1.0 (95% CI: -1.5– -0.5) | N/A | Overall, this meta-analysis of clinical trials suggested BP was lower in those who consumed a vegetarian diet compared to their counterparts who consumed an omnivorous diet.  
- The number of eligible trials was small and the study samples were heterogeneous (2 2º and 4 1° prevention trials).  
- The number of eligible trials was small and the number of trials was small and the study samples were heterogeneous (2 2º and 4 1° prevention trials).  
- Even greater reductions in SBP and DBP were noted in a MA of 32 observational studies. |
| PREDIMED  
Toledo E, et al., 2013 (89) 24050803 | Compare the effects of a Mediterranean and lower-fat diet on BP | - Adults, men 5,580 y, women 60–80 y  
- Free from CVD | Pts assigned to a control group or to 1 of 2 Mediterranean diets. | The percentage of pts with controlled BP increased in all 3 intervention groups (p-value for within-group changes: p<0.001). Pts | N/A | Both the traditional Mediterranean diet and a low-fat diet exerted beneficial effects on BP and could be part of advice to pts for controlling BP. |
**Study type:** RCT, single-blinded, in Spanish primary healthcare centers

**Size:** 7,447 men (55–80 y) and women (60–80 y) at high risk for CVD.

**Exclusion criteria:** Do not meet criteria listed above

**Comparator:** Lower fat diet

The control group received education on following a low-fat diet, while the groups on Mediterranean diets received nutritional education and also free foods; either extra virgin olive oil, or nuts.

Allocated to either of the 2 Mediterranean diet groups had significantly lower DBP than the pts in the control group (-1.53 mm Hg (95% CI: -2.01 – -1.04) for the Mediterranean diet supplemented with extra virgin olive oil, and -0.65 mm Hg (95% CI: -1.15 – -0.15) mm Hg for the Mediterranean diet supplemented with nuts). No between-group differences in changes of SBP were seen.

**Data Supplement 16. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Alcohol Reduction) (Section 6.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Xin X, et al., 2001 (90) 11711507     | **Aim:** Study the effect of alcohol reduction on BP  
**Study type:** Systematic review and meta-analysis  
**Size:**  
- 15 RCTs (25 comparisons) with 2,234 pts.  
- 6 trials were conducted in normotensives (269 pts with a mean age ranging from 26.5–45.5 y). Average | **Inclusion criteria:**  
- RCT in humans  
- Publication between 1966-1999  
- Duration ≥1 wk  
- Only pts regularly consuming alcohol  
- Only difference between the comparison groups was alcohol intake  
**Exclusion criteria:** Comparison of different doses of alcohol intake | **Intervention:** Reduction in alcohol consumption. In most trials this was achieved by randomization to “light” alcohol but some RCT were based on a behavioral intervention aimed at reducing the number of drinks consumed.  
**Comparator:** Usual consumption of alcohol | **1° endpoint:**  
- Overall, alcohol reduction was associated with a significant reduction in mean SBP of -3.31 (95% CI: -4.10 – -2.52) and DBP of -2.04 (95% CI: -2.58 – -1.49).  
- In the subgroup of 7 RCTs in persons with HTN, the mean changes in SBP and DBP were -3.9 (95% CI: -5.04 – -2.76) and -2.41 (95% CI: -3.25 – -1.57).  
- In the subgroup of 6 RCTs in normotensives the corresponding changes in SBP and DBP were -3.5 (95% CI: -4.61 – -2.51) and -1.80 (95% CI: -3.03 – -0.58). | **This is the most recent meta-analysis of this topic. Although this meta-analysis reports % reduction in alcohol intake, most trials aimed at reducing the number of alcoholic drinks consumed achieved a reduction of about 3 drinks/d.**  
**The intervention results were consistent with the relationship alcohol and BP in observational epidemiology – about a 1 mm Hg higher SBP per alcoholic drink consumed. In observational studies, type of alcohol does not seem to matter and at lower levels of alcohol consumption (<1 standard size alcoholic drink per day in women and <2 in men) there does not
### Aim: Study the effect of reduced alcohol intake on BP.

**Study type:** Randomized, controlled factorial trial.

**Size:** 1,383 pts.

**Inclusion criteria:**
- Alcohol dependence.
- 4—21 d of abstinence.
- Men: >21 drinks/wk; Women >14 drinks/wk.
- At least 2 heavy drinking days within a consecutive 30-d period during 90 d prior to baseline.

**Exclusion criteria:**
- Other substance abuse.
- Psychiatric disorder requiring medication.
- Unstable medical condition

**Intervention:**
Pharmacotherapy (naltrexone, acamprosate, or both) and counseling strategies (behavioral and/or medical management).

**Comparator:** Placebo.

**Change in BP:**
- Based on up to 5 repeated measures of BP over 16 wk. Data modeled to estimate change in BP over time.
- For pts with higher than average baseline SBP (>132 mm Hg), SBP declined by an average of 12 mm Hg (149—137) in the intervention arm compared to placebo, with a corresponding decline in DBP of 8 mm Hg. For those with a baseline SBP ≤132 mm Hg there was no change in SBP (120—121 mm Hg) or DBP.

**Safety endpoint:** N/A

---

### Aim: Study effectiveness of lifestyle

**Inclusion criteria:**
- Only parallel trials

**Intervention:** Lifestyle change aimed at reduced consumption of alcohol

**1° endpoint:**
- Net reduction (95% CI): SBP -3.8 (-6.1—-1.4)

**Safety endpoint:** N/A

---

### Notes:

- The relationship between alcohol consumption and BP is predictable and consistent in observational and RCT studies. However, the relationship between alcohol consumption and CVD is more complex as alcohol is associated with an apparently beneficial effect on CVD risk, possibly mediated by an increase in HDL-cholesterol.
- Pregnant women, pts with HTN and those at risk of a drinking problem should not drink alcohol. Established light drinkers (<2 standard drinks/d in men and <1/d in women) who are normotensive are in a favorable risk category for CVD.
<table>
<thead>
<tr>
<th>Study type</th>
<th>Study type</th>
<th>Size</th>
<th>Size</th>
<th>Inclusion criteria</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Comparator</th>
<th>Endpoints</th>
<th>Endpoints</th>
<th>Safety endpoint</th>
<th>Safety endpoint</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 of 10 meta-analyses</td>
<td>1 of 10 meta-analyses</td>
<td>4 trials which collectively studied 305 pts</td>
<td>909 adults (641 men and 268 women)</td>
<td>Heavy drinking during wk prior to screening interview.</td>
<td>Heavy drinking during wk prior to screening interview.</td>
<td>Physician counselling aimed at reduced consumption of alcohol.</td>
<td>Physician counselling aimed at reduced consumption of alcohol.</td>
<td>Usual care</td>
<td>Usual care</td>
<td>DBP -3.2 (-5.0 — -1.4)</td>
<td>DBP -3.2 (-5.0 — -1.4)</td>
<td>N/A</td>
<td>N/A</td>
<td>The goal was to blind those conducting the outcome assessment to treatment assignment but by 6 mo assignment was known in 20-30% of the participants.</td>
</tr>
</tbody>
</table>

**Wallace P, et al., 1988 (93) 3052668**

**Aim:** Study effectivenes of general practitioner advice to reduce heavy drinking.

**Study type:** RCT

**Size:** 909 adults (641 men and 268 women)

**Inclusion criteria:** Heavy drinking during wk prior to screening interview.

**Exclusion criteria:** None mentioned

**Intervention:** Physician counselling aimed at reduced consumption of alcohol.

**Comparator:** Usual care

**Endpoints:**
- 1° outcome was reduction in percent with heavy consumption of alcohol (mean net change=46%). Liver enzymes and BP also measured at 6 and 12 mo.
- Pretreatment SBP/DBP=133.5/79.9 mm Hg.
- Net reduction SBP= -2.12 (95% CI: -4.19 — -0.00)

**Safety endpoint:** N/A

---

**Lang T, et al., 1995 (94) 8596098**

**Aim:** Worksite study of reduced alcohol intake effect on BP in heavy drinkers with HTN.

**Study type:** RCT

**Size:** 14 site physicians; 129 adults (95% men)

**Inclusion criteria:** Heavy drinking (documented by history and liver enzyme elevation). HTN (SBP/DBP >140/90 mm Hg)

**Exclusion criteria:** 2° HTN
- Severe liver disease
- Planned move/retirement.

**Intervention:** Physician and worker counselling aimed at reduced consumption of alcohol.

**Comparator:** Usual care.

**Duration:** Follow-up visits at 1, 3, 6, and 18 mo.

**Endpoints:**
- Baseline SBP/DBP=162.5/98.0. Although all of the workers had HTN, only about 20% were being treated with antihypertensive medications at baseline.
- At 1 y, the net change in SBP= -5.5 (p<0.05). When 5 sites with <5 workers/site were excluded, the net change in SBP= -7.3 mm Hg (p<0.01).
- At 2 y, the net change in SBP= -6.6 (p<0.05).

**Safety endpoint:** N/A

---

● Behavioral intervention state of the art for its time
● Careful measurements of BP using Hawksley RZ sphygmanometer.
● Main analyses do not seem to have accounted for cluster design.
Roerecke M, et al., 2017  

| Aim: Study the effect of reduced alcohol intake on BP. | Inclusion criteria:  
- RCT in adult humans  
- Publication on or before July 13, 2016.  
- Full text articles.  
- Change in alcohol intake for ≥1 wk | Intervention: Reduction in alcohol consumption. Strategy varied from controlled inpatient administration to randomization to “light” alcohol to pragmatic primary care trials with counselling to reduce alcohol intake. | Safety endpoint: N/A |
|---|---|---|---|
| Study type: Systematic review and meta-analysis. | Size: 36 RCT with 2865 participants. | Duration: Follow-up from 1 wk to 2 y (median 4 wk). | 1st endpoint:  
- Overall, alcohol reduction was associated with a significant reduction in mean SBP of -3.31 (95% CI: -4.10– -2.52) and DBP of -2.04 (95% CI: -2.58– -1.49).  
- In the subgroup of 7 RCTs in persons with HTN, the mean changes in SBP and DBP were SBP: -3.13 (95% CI: -3.93– -2.32)  
DBP: -2.00 (95% CI: -2.65– -1.35).  
- In meta-regression analysis, there was a strong relationship between the extent of BP reduction and change in BP, with no reduction in BP for those consuming 2 or less drinks at baseline but increasing reductions in BP for those with progressively higher intakes of alcohol at baseline. For instance, in those consuming ≥6 drinks/day and reducing their alcohol intake by approximately 50%, the estimated reduction in SBP and DBP were:  
SBP: -5.5 (95% CI: -6.70– -4.30)  
DBP: -3.97 (95% CI: -4.70– -3.25). Similar patterns of the effect of baseline alcohol intake on treatment effect were noted for a variety of subgroups. | 1st Safety endpoint: N/A |
| Setting:  
- 13 in hypertension  
- 13 in normotension  
- 12 HTN and NT  
- Only 3 trials presented data for women. | | | N/A |
Data Supplement 17. RCTs and Meta-analysis RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Calcium Supplementation) (Section 6.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Van Mierlo LA, et al., 2006 (95) 16673011 | Aim: Study the effect of calcium supplementation on BP  
**Study type:** Systematic review and meta-analysis  
**Size:**  
- 40 RCTs with 2,492 pts.  
- 27 RCTs in pts <140/90 mm Hg (n=1,728)  
- Follow-up varied from 3–208 wk (median=8.5 wk)  
- Age range 11–77 y (mean=43.7 y)  
**Inclusion criteria:**  
- RCT in humans  
- Publication between 1996 and 2003  
- Nonpregnant normotensive pts or hypertensive pts  
- Only difference between the comparison groups was magnesium intake  
- Follow-up ≥2 wk  
**Exclusion criteria:** Study pts having renal disease or hyperparathyroidism | **Intervention:** increased calcium intake, with a range from 355–2,000 mg/d (mean=1,200 mg/d; median=1,055 mg/d), primarily as a gluconate or carbonate salt.  
**Comparator:** Placebo or usual intake – 32 double-blind. | **1° endpoint:**  
- Overall, increased calcium intake was associated with a significant reduction in mean SBP of -1.86 (95% CI: -2.91– -0.81) and DBP of -0.99 (95% CI: -1.61– -0.37).  
- The reduction was slightly less but still significant in the subset of 32 double-blind trials, with a mean SBP of -1.67 (95% CI: -2.87– -0.47) and DBP of -0.93 (95% CI: -1.64– -0.22).  
- There was no significant difference between the effect size in those with a baseline BP ≥ or<140/90 mm Hg.  
- The mean change in SBP and DBP for those with a baseline BP>140/90 mm Hg (23 comparisons) was -2.17 (95% CI: -3.78– -0.55) and -0.95 (95% CI: -1.89– -0.01), respectively.  
- The mean in SBP and DBP for those with a baseline BP<140/90 mm Hg was -1.67 (95% CI: -3.01– -0.27) and -1.02 (95% CI: -1.85– -0.19) mm Hg, respectively.  
- The authors reported slightly larger effect sizes in those with a lower initial calcium intake, in trials that employed a dietary  
**This is the most recent SR/MA on this topic to include RCT conducted in both normotensive and hypertensive pts. The authors interpreted their results as being consistent with a beneficial effect of calcium supplementation on BP, with about a 2 mm Hg reduction in SBP for a 1 g increase in calcium intake. This is slightly larger effect size than noted in several earlier meta-analyses.**  
**A subsequent Cochrane Collaboration meta-analysis was confined to 13 RCT in 485 adults (≥18 y) with HTN studied for ≥8 wk (Dickinson HO et al. Cochrane Database of Systematic Reviews. 2006; CD004639). The authors noted a significant reduction in mean of -2.5 (95% CI: -4.5– -0.6) for SBP but a more modest insignificant change of -0.8 (95% CI: -2.1– 0.4) for DBP. Due to the poor quality of the RCT and heterogeneity of the results, the authors concluded the reduction in SBP was likely an artifact due to bias.**  
**Although not included in most meta-analyses, calcium supplementation has been effective as a treatment in pregnant women at risk for pre-eclampsia.**  
**Several of the meta-analyses (including the 1 by van Mierlo et al) have suggested a bigger effect size in persons with a lower intake of calcium at baseline and in trials that utilized a dietary intervention.** | |
Most of the trials were of short duration and did not (have the capacity) report on potential adverse effects such renal stones.

- In addition to being small, several trials were of uncertain quality.
- Overall, RCT experience provides limited and inconsistent evidence from trials of variable quality in support of calcium supplementation for prevention (or treatment) of HTN. Better evidence supports the role of calcium supplements, in conjunction with vitamin D, in strengthening bone density.

### Data Supplement 18. RCTs and Meta-analyses

**RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Physical Activity) (Section 6.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Whelton SP, et al., 2002 (96) 11926784 | **Aim:** Study the effect of aerobic exercise on BP  
**Study type:** Systematic review and meta-analysis  
**Size:** 38 reports (54 comparisons) with 2,419 pts; 27 of the comparisons were conducted in normotensive pts | **Inclusion criteria:**  
- English language publication between 1966–2001  
- RCT in adults ≥18 y  
- Duration ≥2 wk  
- No concurrent interventions  
**Exclusion criteria:** Missing BP data | **Intervention:** Aerobic exercise  
**Comparator:** No exercise prescribed | **1° endpoint:**  
- For the overall group, a pooled analysis of experience in 53 trials identified a mean net change in SBP of -3.84 (95% CI: -4.97– -2.72). In subgroup analysis, the effect was noted in different ethnic groups, in trials that employed different designs, durations, and sample sizes, in trials with obese, overweight or normal weight pts, and in trials that employed different types, intensity levels, and duration of aerobic exercise.  
- In the subgroup of 15 trials in hypertensives, the mean net change in SBP was -4.94 (95% CI: -7.17– -2.70). | **This meta-analysis provides the most comprehensive analysis of the effect of aerobic exercise on BP and provides strong evidence in support of aerobic exercise as an intervention to lower BP in normotensives.**  
- Recognizing this, many of the trials were small and of short duration.
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1° endpoint</th>
<th>Safety endpoint</th>
</tr>
</thead>
</table>
| Cornelissen VA, et al., 2013 (97) 23525435 | Study the effect of different types of physical activity on BP | • Parallel arm RCTs  
• Adults≥18 y  
• Peer reviewed journals up to February 2012  
• Trial duration ≥4 wk | Physical activity  
Comparator: No prescription of physical activity | Overall (trials in hypertensives and normotensive), pooled experience identified a significant reduction in BP with all forms of physical activity (aerobic and both forms of resistance training), with mean reductions in SBP of -3.5 mm Hg following aerobic endurance training, -1.8 mm Hg following dynamic resistance training, and -10.9 mm Hg following static (isometric) resistance training (p<0.001 for the difference between the effect size following static [isometric] and other forms of physical activity). In subgroup analysis, dynamic aerobic endurance and dynamic resistance training resulted in mean SBP changes of -2.1 (95% CI: -3.3– -0.83) and -4.3 (95% CI: -7.7– -0.90), respectively, in the pts with pre-HTN and smaller, nonsignificant reductions in the remaining pts with a normal BP. | N/A |
| Rossi AM, et al., 2013 (98) 23541664 | Study the effect of resistance exercise on BP | RCTs in adults (≥18 y)  
BP-lowering 1° outcome | Dynamic resistance training but overall reporting of the details was poor. | Pooled experience (hypertensive and normotensive pts) identified a small, nonsignificant reduction in mean SBP of -1.03 (95% CI: -3.44–0.39). The corresponding finding | N/A |
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>1° endpoint</th>
<th>Safety endpoint</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garcia-Hermosa A, et al., 2013 (99) 23786645</td>
<td>Study the effect of exercise on BP in obese children.</td>
<td>Systematic review and meta-analysis.</td>
<td>9 RCTs (410 pts).</td>
<td>Children ≤14 y with obesity</td>
<td>Physical activity, principally aerobic exercise.</td>
<td>No physical exercise, nutrition, education, or dietary restriction intervention</td>
<td>Change in SBP: In pooled analysis, mean change in SBP was -0.4 (95% CI: -0.66 – -0.24).</td>
<td>N/A</td>
<td>This meta-analysis focused specifically on the effect of physical activity on BP in children with obesity. Although it is not stated explicitly, it seems likely that all of the participants were normotensive and not receiving medication that could influence level of BP. The findings are consistent with other meta-analyses of the effect of physical activity on BP. Only limited information regarding study details is provided in this publication. The interventions were heterogeneous in type, duration, and quality.</td>
</tr>
<tr>
<td>Carlson DJ, et al., 2014 (100) 24582191</td>
<td>Study the effect of physical activity on BP in children with obesity.</td>
<td>Systematic review and meta-analysis.</td>
<td>9 RCTs (223 pts: 127 intervention and 96 controls): 6 were conducted in normotensives.</td>
<td>Adults ≥18 y</td>
<td>Pure isometric exercise.</td>
<td>Use of a control group was a requirement but no additional specific information provided.</td>
<td>In the overall pooled analysis (hypertensive and normotensive trials), mean change in SBP was -6.77 (95% CI: -7.93 – -5.62) mm Hg. In the subgroup of 3 trials with hypertensive pts (all on antihypertensive medication), the mean change in SBP was -4.31 (95% CI: -6.42 – -2.21) mm Hg. In the subgroup of 6 trials with normotensive pts, the mean change in SBP was -7.83 (95% CI: -9.21 – -6.45) mm Hg.</td>
<td>N/A</td>
<td>This study provides information regarding the effect of pure isometric exercise interventions on BP in adults. The BP reductions reported in this meta-analysis are surprisingly large but the overall effect pattern is quite consistent with other meta-analyses of isometric exercise.</td>
</tr>
</tbody>
</table>
Cornelissen VA, et al., 2011 (101) 21896934

Aim: Study the effect of resistance training on BP.

Study type: Meta-analysis

Size: 28 randomized, controlled trials, involving 33 study groups and 1,012 pts.

Inclusion criteria:
- Adults ≥18 y
- RCT, including cross-over trials.
- Duration ≥4 wk
- Published in a peer reviewed journal up to June 2010

Exclusion criteria: Interventions other than pure isometric exercise (e.g., dynamic resistance)

Intervention: Resistance training, including isometric and dynamic modalities.

Comparator: Use of a control group was a requirement but no additional specific information provided.

1° endpoint: Resistance training induced a significant SBP/DBP reduction in 28 normotensive or prehypertensive study groups of -3.9 (-6.4, -1.2)/-3.9 (-5.6, -2.2) mm Hg. In the 5 hypertensive study groups, the change in mean SBP/DBP was -4.1 (95% CI: -0.63–1.4)/-1.5 (95% CI: -3.4–0.40) mm Hg. When the study groups were divided according to the mode of training, isometric handgrip training in 3 groups resulted in a larger decrease in SBP/DBP (-13.5 [95% CI: -16.5– -10.5]/-6.1 [95% CI: -8.3– -3.9] mm Hg) than dynamic resistance training in 30 groups (-2.8 [95% CI: -4.3– -1.3]/-2.7 [95% CI: -3.8– -1.7] mm Hg).

Safety endpoint: N/A

● This meta-analysis supports the BP-lowering potential of dynamic resistance training and isometric handgrip training.
● Results further suggest that isometric handgrip training may be more effective for reducing BP than dynamic resistance training.
● However, given the small amount of isometric studies available, additional studies are warranted to confirm this finding.

Kass L, et al., 2012 (102) 22318649

Aim: Study the effect of magnesium supplementation on BP

Study type: Systematic review and meta-analysis

Inclusion criteria:
- RCT in humans
- Parallel or cross-over design
- Publication before July 2010
- Adults >18 y
- Only difference between the

Intervention: Increased magnesium intake, with a range in elemental magnesium of 120 to 973 mg/d and a mean of 410 mg/d.

Comparator: Placebo or usual intake

1° endpoint: Overall, increased magnesium intake was associated with a small nonsignificant reduction in mean SBP of -0.32 (95% CI: -0.41– -0.23) and DBP of -0.36 (95% CI: -0.44– -0.27).

Safety endpoint: N/A

● This is the most recent systematic review/meta-analysis on this topic. The authors interpreted their results as being consistent with a beneficial effect of magnesium supplementation on BP. However, this interpretation seems at odds with the data.
● In an earlier meta-analysis of 20 RCT (6 in normotensives) by Jee Systolic...
**Size:** 22 RCTs (23 comparisons) with 1,173 pts. Data for RCTs conducted in normotensive pts were not presented. However, most RCTs were conducted in normotensives and only 6 of the RCTs included some (or all) pts who were being treated with antihypertensive medication. Overall mean age was ~50 y. Follow-up varied from 3–24 wk, with a mean of 11.3 wk.

**Comparison groups** was magnesium intake

**Exclusion criteria:** Comparison of different doses of alcohol intake

- Forest plots revealed considerable heterogeneity in effect size.
- The authors reported slightly larger effect sizes in subgroup analysis of cross-over RCT and RCT that employed a dose of magnesium >370 mg/d.

1° Safety endpoint: N/A

HTN et al (Am J Hypertens. 2002;15:691-696) magnesium supplementation resulted in small mean NS reductions of -0.6 (95% CI: -2.2–1.0) mm Hg in SBP and -0.8 (95% CI: -1.9–0.4) in DBP. In meta-regression analysis, there was an apparent dose-response with SBP and DBP reductions of -4.3 (95% CI: -6.3–-2.2) and -2.3 (95% CI: -4.9–0) mm Hg for each 10 mmol/d higher level of magnesium intake.

- A Cochrane systematic review/meta-analysis of magnesium supplementation for treatment of HTN in adults (Dickinson HO et al. Cochrane Database Systematic Review 2006: CD 004640) included 12 RCT (n=545) with follow-up of 8–26 wk. Overall, mean SBP and DBP were reduced by -1.3 (95% CI: -4.0–1.5) and -2.2 (95% CI: -3.4–-0.9) mm Hg, respectively. The authors noted the studies were of poor quality, with considerable heterogeneity, and felt the results were likely biased.
- Some authors have suggested there may be a greater BP effect when the intervention is by means of diet change but there is insufficient RCT evidence to support this position.
- Magnesium sulfate is the drug of choice for prevention of seizures in the pre-eclamptic woman, or prevention of recurrence of seizures in the eclamptic woman, as demonstrated in RCT and a 2010 Cochrane review (Duley L et al. Cochrane Database of Systematic Reviews. CD000127, 2010).
- Overall, RCT experience provides insufficient evidence to recommend oral
Data Supplement 20. RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Weight Loss) (Section 6.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; and 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Neter JE, et al., 2003 (103) 12975389 | **Aim**: Study the effect of weight loss on BP  
**Study type**: Systematic review and meta-analysis  
**Size**: 25 RCTs (34 comparisons) with 4,874 pts; 17 of the comparisons were conducted in normotensive pts | **Inclusion criteria**:  
- RCT in humans  
- English language publication between 1966–2002  
- Nonpharmacologic intervention  
**Exclusion criteria**:  
- Duration <8 wk  
- Missing data  
- Objective not weight loss  
- Concomitant intervention(s) | **Intervention**: Weight loss (calorie reduction, physical activity, or combination of both)  
**Comparator**: No weight loss prescription | **1° endpoint**:  
- For the overall group, mean baseline body weight was 88.3 kg and mean change in body weight following the application of the weight loss intervention was -5.1 (95% CI: -6.03–-4.25) kg. This represents a mean percent change of -5.8%.  
- There was strong evidence for a BP lowering effect of weight loss on BP, overall and in normotensive subgroup. In the normotensive group, the mean for change in SBP was 4.08 (95% CI: -6.01–-2.16).  
- Overall, a 1 kg reduction in body weight was associated with a mean change in SBP of -1.05 (95% CI: -1.43–-0.66) mm Hg. | **Safety endpoint**: N/A  
- Substantial evidence for a reduction in BP, overall and in normotensives.  
- With the exception of the mean (95% CI) changes in BP, this paper provides limited data for the normotensive group |

| Ho M, et al., 2012 (104) 23166346 | **Aim**: Study the effect of lifestyle weight loss interventions in obese/overweight children on weight  
**Inclusion criteria**:  
- RCTs, in obese/overweight children and adolescents ≤18 y | **Intervention**: Lifestyle weight loss program with a dietary component  
**Comparator**: No treatment, usual care or | **1° endpoint**: Pooled experience in the 7 RCTs with BP experience identified a significant reduction in mean SBP of -3.40 (95% CI: -5.19–-1.61). The pooled SBP MD was -3.72 (95% CI: -4.74–-2.69) in the 3 RCTs with a duration >1 y | **Safety endpoint**: N/A  
- Findings in children are consistent with experience in adult normotensives and with experience in hypertensive pts. |
<table>
<thead>
<tr>
<th><strong>Aim</strong></th>
<th><strong>Study type</strong></th>
<th><strong>Size</strong></th>
<th><strong>Inclusion criteria</strong></th>
<th><strong>Intervention</strong></th>
<th><strong>1° endpoint</strong></th>
<th><strong>Safety endpoint</strong></th>
<th><strong>Comments</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study the effect of childhood obesity prevention programs on BP</td>
<td>Systematic review and meta-analysis</td>
<td>Overall study included 23 studies (28 comparisons) conducted in 18,925 pts.</td>
<td>RCTs, quasi-experimental studies, and natural experiments in humans</td>
<td>Weight loss</td>
<td>Pooled experience in 19 studies (20 comparisons) identified a small but significant reduction in mean SBP of -1.65 (95% CI: -2.56– -0.71). The effect size was greater in studies that employed an intervention that combined diet and physical activity (mean change in SBP of -2.11 mm Hg).</td>
<td>N/A</td>
<td>Considerable heterogeneity in the data</td>
</tr>
</tbody>
</table>

**Cai L, et al., 2014 (105) 24552832**

<table>
<thead>
<tr>
<th><strong>Aim</strong></th>
<th><strong>Study type</strong></th>
<th><strong>Size</strong></th>
<th><strong>Inclusion criteria</strong></th>
<th><strong>Intervention</strong></th>
<th><strong>1° endpoint</strong></th>
<th><strong>Safety endpoint</strong></th>
<th><strong>Comments</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study the effect of weight loss on BP and prevention of HTN.</td>
<td>Behavior change intervention (combination of diet change and physical activity) aimed at</td>
<td>Healthy community-dwelling adults 30–54 y</td>
<td>Behavior change intervention (combination of diet change and physical activity) aimed at</td>
<td>Change in SBP</td>
<td>Compared to usual care, the weight loss group experienced a significant mean reduction of -4.5 kg in body</td>
<td>N/A</td>
<td>Largest trial of weight loss in prevention of HTN and also provides the longest duration of follow-up</td>
</tr>
</tbody>
</table>

**TOHP, Phase II Hypertension Prevention Collaborative Research Group,**
### Study type: Randomized, controlled factorial trial.  
**Size:** 2,382 pts, of whom 1,192 were randomized to a weight loss intervention and 1,190 were randomized to a no weight loss intervention.  

**Inclusion criteria:**  
- BMI between 110% and 165% of desirable body weight  
- Not taking BP-lowering medication  
- Mean SBP <140 mm Hg and DBP 83-89 mm Hg  

**Exclusion criteria:**  
- Taking antihypertensive medication  
- Heart disease, renal disease, poorly controlled hyperlipidemia or DM, DM requiring insulin, special dietary requirements  
- >14 drinks/wk  

**Comparator:** Usual care group

**Comparing the effects of a modest reduction in body weight during up to 48 mo (minimum 36 mo) of follow-up.**  

**Comparator:** Usual care group

**Prevention of HTN**  
- At 6 mo of follow-up the incidence of new onset HTN was 42% lower in the participants randomized to weight loss compared to the usual care group (p=0.02).  
- During more prolonged follow-up, the effect size decreased but remained borderline significant after 48 mo of follow-up (13% reduction; p=0.06). Overall, the incidence of HTN was reduced by 21% (p=0.02).  

**Safety endpoint:** N/A

---

### TOHP, Phase I  
**1992 (79)  
1586398**

**Aim:** Study the effect of weight loss on BP and prevention of HTN  

**Study type:** Randomized, controlled factorial trial.  

**Size:** Overall, 2,182 adults, with the 308

**Inclusion criteria:**  
- Community-dwelling adults 30–54 y  
- Not on antihypertensive medication  
- DBP 80-89 mm Hg  
- Healthy  

**Exclusion criteria:**  
- Disease

**Intervention:** Behavior change intervention (combination of diet change and physical activity)  

**Comparator:** Usual care

**1° endpoint:** Change in DBP  

**2° endpoint:** Change in SBP  

**Safety endpoint:** CVD events, symptoms and general and well being  

- Significantly lower DBP (2.3 mm Hg; p<0.01) and SBP (2.9 mm Hg; p<0.01) in the weight loss group compared to usual care.  
- Few CVD events  
- No difference in symptoms  
- Significant improvement in general well-being at 6 and 18 mo (p<0.05)
assigned to weight loss compared to 256 usual care controls

- Inability to comply with the protocol

**TONE**
Whelton PK, et al.,
1998 (107) 9515998

**Aim:** Study the effect of weight loss on BP and need for antihypertensive drug therapy

**Study type:** RCT, factorial design

**Size:** 585 (obese) participants

**Inclusion criteria:**
- Community-dwelling adults 60–80 y
- SBP <145 mm Hg and DBP <85 mm Hg on 1 antihypertensive medication

**Exclusion criteria:**
- Heart attack or stroke within 6 mo
- Current angina, HF, insulin-dependent DM
- Inability to comply with protocol

**Intervention:** Behavior change intervention (combination of diet change and physical activity)

**Comparator:** Usual care, with similar level of contact compared to active intervention group

**1° endpoint:** Recurrence of HTN following withdrawal of antihypertensive medication (or CVD event)

**2° endpoint:** BP (while still on antihypertensive medication prior to tapering of medication)

**Safety endpoint:** CVD events, symptoms (including headaches), dietary composition

- Significant reduction in SBP prior to withdrawal of antihypertensive medication (mean±SE=-4.0±1.3 mm Hg)
- 1° outcome significantly less common in weight loss group compared to usual care – Rel. HR: 0.70; 95% CI, 0.57–0.87; p<0.001
- No overt evidence for adverse effects of intervention

---

**Data Supplement 21. RCTs and Systematic Reviews for RCTs Studying the Effect of Nonpharmacologic Interventions on BP (Section 6.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOHP, Phase II (Weight Loss component) 1997 (1) 9080920</td>
<td><strong>Aim:</strong> Study the effect of weight loss on BP and prevention of HTN.  <strong>Study type:</strong> Randomized, controlled factorial trial.</td>
<td>Healthy community-dwelling adults 30–54 y  BMI between 110% and 165% of desirable body weight  Not taking BP-lowering medication  Mean SBP &lt;140 mm Hg and DBP 83-89 mm Hg</td>
<td>Behavior change intervention (combination of diet change and physical activity) aimed at studying the effects of a modest reduction in body weight during up to 48 mo (minimum 36 mo) of follow-up.</td>
<td><strong>1° endpoint:</strong> Change in SBP  - Compared to usual care, the weight loss group experienced a significant mean (standard error) reduction of -4.5 kg in body weight and -3.7 (0.5) (p&lt;0.001) mm Hg in SBP at 6 mo (-6.0 mm Hg in the weight loss group and -2.2 mm Hg in the usual care group).  - A progressive reduction in the effect sizes for body weight and BP</td>
<td>This was the largest trial of weight loss in prevention of HTN and also provides the longest duration of follow-up  The assumptions for a main effects factorial analysis (independence of the interventions) were not demonstrated. Given this finding, the most reliable analysis of this trial was comparison of the experience in each active intervention group with the usual care group. This results in a reduction in statistical power.</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc. 64
### TONE (Weight Loss component) Whelton PK, et al., 1998 (3) 9515998

**Aim:** Study the effect of weight loss on BP and need for antihypertensive drug therapy  
**Study type:** RCT, factorial design  
**Size:** 585 (obese) participants

| Size: 2,382 pts, of whom 1,192 were randomized to weight loss and 1,190 were randomized to no weight loss intervention | Exclusion criteria:  
- Taking antihypertensive medication  
- Heart disease, renal disease, poorly controlled hyperlipidemia or DM, DM requiring insulin, special dietary requirements  
- >14 drinks/wk. | Comparator: Usual care group | was noted over time, with mean (SD) for SBP at 18, 36 mo and termination of -1.8 (0.5) (p<0.001), -1.3 (0.5) (p=0.01), and -1.1 (0.5) (p=0.04).  
**Prevention of HTN**  
- At 6 mo of follow-up the incidence of new onset HTN was 42% lower in the participants randomized to weight loss compared to the usual care group (p=0.02).  
- During more prolonged follow-up, the effect size decreased but remained borderline significant after 48 mo of follow-up (13% reduction; p=0.06). Overall, the incidence of HTN was reduced by 21% (p=0.02).  
**Safety endpoint:** N/A  
- Consistent with the pattern in the proceeding TOHP I trial weight loss reduced BP and the incidence of HTN but the effect sizes for weight loss and BP as well as the difficulty of maintaining the intervention in highly motivated and extensively counselled participants underscores the difficulty of achieving and maintaining ideal body weight in the general population by means of lifestyle change.

### TOHP, Phase I (Weight Loss component) 1992 (4) 1586398

**Aim:** Study the effect of weight loss on BP and prevention of HTN

| Inclusion criteria:  
- Community-dwelling adults 60-80 y  
- SBP <145 mm Hg and DBP <85 mm Hg on 1 antihypertensive medication | Comparator: Usual care, with similar level of contact compared to active intervention group | 1° endpoint: Recurrence of HTN following withdrawal of antihypertensive medication (combination of diet change and physical activity)  
- Significant reduction in SBP prior to withdrawal of antihypertensive medication (mean±standard error=-4.0±1.3 mm Hg)  
- 1° outcome significantly less common in weight loss group compared to usual care – Rel. HR: 0.70; 95% CI: 0.57–0.87; p<0.001  
- No overt evidence for adverse effects of intervention | 2° endpoint: BP (while still on antihypertensive medication prior to tapering of medication)  
- Few CVD events

| Exclusion criteria:  
- Heart attack or stroke within 6 mo  
- Current angina, HF, insulin-dependent DM  
- Inability to comply with protocol | Intervention: Behavior change intervention (combination of diet change and physical activity) | Safety endpoint: CVD events, symptoms (including headaches), dietary composition | Significant reduction in DBP  
- Change in DBP (p<0.01) and SBP (2.9 mm Hg; p<0.01) in the weight loss group compared to usual care  
- Few CVD events

| Inclusion criteria:  
- Community-dwelling adults 30–54 y | 2° endpoint: Change in SBP |
Study type: Randomized, controlled factorial trial.

Size: Overall, 2,182 adults, with the 308 assigned to weight loss compared to 256 usual care controls.

Exclusion criteria: Not on antihypertensive medication, DBP 80-89 mm Hg, Healthy.

Comparator: Usual care

Safety endpoint: CVD events, symptoms and general and well-being

- No difference in symptoms
- Significant improvement in general well-being at 6 and 18 mo

Data Supplement 22. Observational Studies of CV Target Organ Damage Including LVH (Section 7.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIFE</td>
<td>Devereux RB, et al., 2004 (108) 15547162</td>
<td>Study Type: Sub-study of pts with HTN and ECG LVH Size: 941</td>
<td>Inclusion criteria: • 55–80 y • BP 160–200/95–115 mm Hg • No MI or stroke within 6 mo • Had echo • Did not require treatment with BB, ACE or AT-1 antagonist for other reasons Intervention: Treatment to BP of 140/90 mm Hg beginning with pts randomized to losartan or atenolol</td>
<td>1° endpoint: Change in LV mass assessed by echo and change in BP in relation to CVD events Results: • Composite endpoint of CV death, MI, or stroke reached in 104 in 4.8 y of follow-up • Reduction in 1° endpoint per SD reduction in LV mass independent of BP change OR: 0.74 (95% CI: 0.6–0.91; p=0.003) • Reductions for each composite endpoint component and total mortality were also significant; results independent of change in ECG LVH</td>
</tr>
<tr>
<td>CARDIA</td>
<td>Armstrong AC, et al., 2014 (109) 24507735</td>
<td>Study Type: Observational study of population-based cohorts</td>
<td>Inclusion criteria: African American and white men and women stratified by education (above/below high school) 18–30 y at study start and followed for over 20 y; previously healthy</td>
<td>1° endpoint: Composite of hard CVD events Results: • LV mass indexed to body surface area or to height predicted CV events independently of the Framingham risk score (HR: 1.21; 95% CI: 1.05–1.39; p&lt;0.007)</td>
</tr>
</tbody>
</table>
Net reclassification improvement for LVM/height was 0.13 (p<0.01) and for LVM/BSA was 0.11 (p=0.02).

**ARIC**
Okwuosa TM, et al., 2015 (110)

- **Study type:** Observational study of population-based cohorts
- **Size:** 14,489
- **Inclusion criteria:** African American and white men and women population-based cohort mean age 54.7 ± 5.7 y at study start and followed for over 25 y; previously healthy
- **1° endpoint:** Pooled cohort CV events and 10-y Framingham CVD events
- **Results:**
  - 792 (5.5%) 10-y Pooled Cohort CV events and 690 (4.8%) 10-y Framingham CHD events.
  - LVH was associated with CVD events (HR: 1.62; 95% CI: 1.38–1.90) and CHD events (HR: 1.56; 95% CIs: 1.32–1.86).
  - LVH by ECG did not significantly reclassify or improve C statistic compared with Framingham risk score (C statistics 0.767/0.719; net reclassification index =0.001 [p=not significant]), compared with (C statistics 0.770/0.718), respectively.
- **Summary:** ECG LVH does not improve risk reclassification

**MESA**
Zalawadiya SK, et al., 2015 (111)

- **Study type:** Observational study of population-based cohorts
- **Size:** 4,921
- **Inclusion criteria:** Multi-ethnic cohort of men and women followed for a mean follow-up of 4.5 y
- **1° endpoint:** Hard CVD endpoints
- **Results:** MRI calculated LVH (indexed to BSA or height; >95th percentile) predicted hard CVD events (LVH-BSA: HR: 2.36; 95% CI: 1.37–4.04; p=0.002; LVH-height [1.7]: HR: 1.95; 95% CI: 1.17–3.26; p=0.01), but did not improve risk reclassification beyond conventional risk factors
- **Summary:** Though LVH predicted events it did not improve risk reclassification

### Data Supplement 23. RCTs on Use of Risk Estimation to Guide Treatment of Hypertension (Section 8.1.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events Summary</th>
</tr>
</thead>
</table>
| Sundstrom J, et al., 2014 (112) 25131978 | **Aim:** We aimed to investigate whether the benefits of BP-lowering drugs are proportional to baseline CV risk, to | **Inclusion criteria:** BPLTTCC: trials were eligible if they met the original inclusion criteria specified in the protocol, 11 and were part of the subset of studies that randomly allocated | **Intervention:** BP-lowering meds | **1° endpoint:**
  - Total major CV events, consisting of stroke (nonfatal stroke or death from cerebrovascular disease), CHD (nonfatal MI or death from CHD) | **Summary:**
  - Lowering BP provides similar relative protection at all levels of baseline CV risk, but progressively greater absolute risk reductions as baseline risk |
establish whether absolute risk could be used to inform treatment decisions for BP-lowering therapy, as is recommended for lipid-lowering therapy.

**Study type:** Meta-analysis of RCTs  
**Size:** 11 trials and 26 randomized groups with 67,475 pts (51,917 pts data available for the calculation of the risk equations)

| Sundstrom J, et al., 2015 (19) | **Aim:** To investigate whether pharmacologic BP reduction prevents CV events and deaths in pts with grade 1 HTN.  
**Study type:** Meta-analysis of RCTs  
**Size:** 10 RTCs with 15,266 pts |
|---|---|
| Inclusion criteria: RCTs of at least 1 y duration; pts ≥18 y, at least 80% of whom had grade 1 HTN and no previous CVD (MI, angina pectoris, CABG, PCI, stroke, TIA, carotid surgery, peripheral arterial surgery, intermittent claudication, or renal failure); and compared an antihypertensive drug provided as monotherapy or a stepped-care algorithm vs. placebo or another control regimen.  
**Exclusion criteria:** Excluded trials did not contribute an event |
| Intervention: BP-lowering meds  
**Comparator:**  
- Placebo or less intensive treatment  
- The difference in average achieved BP between the active and control groups was 3.6/2.4 mm Hg in the BPLTTC (Appendix Table 2, available at www.annals.org) but is unknown for the other contributing trial subgroups.  
**1st endpoint:** Total major CV events, comprising stroke (nonfatal stroke or death from cerebrovascular disease), coronary events (nonfatal MI or death from CHD, including sudden death), HF (causing death or resulting in hospitalization), or CV death; OR: 0.86 (95% CI: 0.74–1.01)  
Other endpoints: Each of the above outcomes independently; and total deaths.  
- CHD 0.91 (95% CI: 0.74–1.12)  
- Stroke 0.72 (95% CI: 0.55–0.99)  
- HF 0.80 (95% CI: 0.57–1.12)  
- CVD deaths 0.75 (95% CI: 0.57–0.98)  
| Summary:  
- BP-lowering therapy is likely to prevent stroke and death in pts with uncomplicated grade 1 HTN.  
- 5 y risks in BPLTTC control groups CVD events 7.4% CVD deaths 3.1%  

including sudden death), HF (resulting in death or admission to hospital), or CV morbidity.  
- The mean estimated baseline levels of 5-y CV risk for each of the 4 risk groups were 6.0% (SD: 2–0), 12.1% (1–5), 17.7% (1–7), and 26.8% (5–4).  
- In each consecutive higher risk group, BP-lowering treatment reduced the risk of CV events relatively by 18% (95% CI: 7–27), 15% (95% CI: 4–25), 13% (95% CI: 2–22), and 15% (95% CI: 5–24), respectively (p=0.30 for trend) in each group with BP-lowering treatment for 5 y would prevent 14 (95% CI: 8–21), 20 (95% CI: 8–31), 24 (95% CI: 8–40), and 38 (95% CI: 16–61) CV events, respectively (p=0.04 for trend).  

Increases. These results support the use of predicted baseline CVD risk equations to inform BP-lowering treatment decisions.  
- Lowest risk group had >83% with a risk that exceeds 4%.
### Aim:
To evaluate the effect of antihypertensive treatment on 2nd prevention of CVD events and all-cause mortality among pts without clinically defined HTN.

### Study type:
Meta-analysis of RCTs

### Size:
25 RCTs with 64,162 pts

### Inclusion criteria:
Studies were eligible for inclusion if they were RCTs of antihypertensive treatment among pts with BP <140 mm Hg systolic or <90 mm Hg diastolic for the prevention of CVD events (fatal or nonfatal stroke, fatal or nonfatal MI, CHF, or CVD mortality).

### Exclusion criteria:
Studies were excluded if CVD events were not reported by HTN status in studies that included pts with and without HTN; the study population did not include pts with BP in the normal or prehypertensive ranges; the study population did not include pts with preexisting CVD or CVD equivalents, such as diabetes; antihypertensive treatment was not part of the intervention; treatment allocation was not random; a measure of variance (p-value or CI) was not reported or could not be calculated from the information provided; pts <18 y; or there were differences between Intervention and Comparator.

### Intervention:
BP-lowering meds, the majority were studies of ACEI, next most common were BBs.

### Comparator:
Placebo or active comparator

### 1° endpoint:
- Composite CVD (fatal or nonfatal stroke, fatal or nonfatal MI, CHF, or CVD mortality):
  - CVD RR: 0.85 (95% CI: 0.80–0.90), absolute risk reduction: 27.1/1,000.
  - This implies that a 2.7% absolute risk reduction reflects a 15% RR reduction, so the baseline risk for CVD would have been about 18%, but the follow-up interval is unclear.

### Other endpoints:
- Stroke RR: 0.77 (95% CI: 0.61, 0.98)
- MI RR: 0.80 (95% CI: 0.69, 0.93)
- HF RR: 0.71 (95% CI: 0.65, 0.77)
- CVD death RR: 0.83 (95% CI: 0.69, 0.99)
- Total deaths RR: 0.87 (95% CI: 0.80, 0.95)

### Other results:
Table 4 shows similar results for CVD from studies of pts with CAD vs. other, HF vs. other, and DM vs. non-DM. Similar results from studies of ACEI vs. other. These results support the Summary:
Among pts with clinical history of CVD but without HTN, antihypertensive treatment was associated with decreased risk of stroke, CHF, composite CVD events, and all-cause mortality.

### Limitations:
- Difference in achieved BP was not reported.
- Average baseline SBP not reported. No information on the entry levels of BP other than not hypertensive. Difficult to use to establish a treatment threshold or goal.
- Many of these studies were designed to try to demonstrate specific drug benefits rather than BP-lowering benefits. Can we attribute the benefits to BP-lowering? We know these pts did not have HTN but we do not know the lower limit of the BP inclusion ranges or the treatment associated difference in SBP between groups making it difficult to...
<table>
<thead>
<tr>
<th>Xie X, et al., 2015 (21) 26559744</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To assess the efficacy and safety of intensive BP-lowering strategies.</td>
</tr>
<tr>
<td><strong>Study type:</strong> Meta-analysis of RCTs</td>
</tr>
<tr>
<td><strong>Size:</strong> 19 RCTs with 44,989 pts</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> RCTs with at least 6 mo follow-up that randomly assigned pts to more intensive vs. less intensive BP-lowering treatment, with different BP targets or different BP changes from baseline. Reference lists from identified trials and review articles were manually scanned to identify any other relevant studies.</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong> N/A</td>
</tr>
<tr>
<td><strong>Intervention:</strong> BP-lowering meds</td>
</tr>
<tr>
<td><strong>Comparator:</strong></td>
</tr>
<tr>
<td>• Less intensive treatment</td>
</tr>
<tr>
<td>• BP difference 6.8/3.5</td>
</tr>
<tr>
<td>• The mean follow-up BP levels in the less intensive BP-lowering regimen group were 140/81 mm Hg, compared with 133/76 mm Hg in the more intensive treatment group.</td>
</tr>
<tr>
<td><strong>1st endpoint:</strong></td>
</tr>
<tr>
<td>• CVD, other major CV events, defined as a MI, stroke, HF, or CV death, separately and combined; nonvascular and all-cause mortality; ESKD, and adverse events. Progression of albuminuria (defined as new onset of micro-albuminuria/macro-albuminuria or a change from micro-albuminuria to macro-albuminuria) and retinopathy (retinopathy progression of 2 or more steps) were also recorded for trials that were done in pts with DM</td>
</tr>
<tr>
<td>• CVD RR: 0.86 (95% CI: 0.78–0.96)</td>
</tr>
<tr>
<td><strong>Other endpoints:</strong></td>
</tr>
<tr>
<td>MI RR: 0.87 (95% CI: 0.76–1.00; p=0.042)</td>
</tr>
<tr>
<td>Stroke RR: 0.78 (95% CI: 0.68–0.90)</td>
</tr>
<tr>
<td>HF RR: 0.85 (95% CI: 0.66–1.11)</td>
</tr>
<tr>
<td>CVD death RR: 0.91 (95% CI: 0.74–1.11)</td>
</tr>
<tr>
<td>Total deaths RR: 0.91 (95% CI: 0.81–1.03)</td>
</tr>
<tr>
<td><strong>Other results:</strong></td>
</tr>
<tr>
<td>• Benefit for CVD not different by baseline SBP</td>
</tr>
<tr>
<td>120–139: 0.89 (95% CI: 0.76–1.05)</td>
</tr>
<tr>
<td>140–160: 0.83 (95% CI: 0.68–1.00)</td>
</tr>
<tr>
<td>&gt;160: 0.89 (95% CI: 0.73–1.09)</td>
</tr>
<tr>
<td><strong>Summary:</strong> Intensive BP-lowering, including to &lt;130 mm Hg, provided greater vascular protection than standard regimens. In high-risk pts, there are additional benefits from more intensive BP-lowering, including for those with SPB &lt;140 mm Hg at baseline. The net absolute benefits of intensive BP-lowering in high-risk individuals are large.</td>
</tr>
<tr>
<td><strong>Limitations:</strong></td>
</tr>
<tr>
<td>• Lack of individual pt data, which would have allowed a more reliable assessment of treatment effects in different pt groups.</td>
</tr>
<tr>
<td>• Interpretation: Supports treating pt with and without CVD at threshold of 130 to &lt;130. Supports treating at threshold of about 130 even down to a CVD event rate of 0.9% per y.</td>
</tr>
</tbody>
</table>
### Aim:
This systematic review and meta-analysis aims to combine data from all published large-scale BP-lowering trials to quantify the effects of BP reduction on CV outcomes and death across various baseline BP levels, major comorbidities, and different pharmacological interventions.

### Inclusion criteria:
- RCTs of BP-lowering treatment that included a minimum of 1,000 pt-y of follow-up in each study arm. No trials were excluded because of presence of baseline comorbidities, and trials of antihypertensive drugs for indications other than HTN were eligible.
- Eligible studies fell into 3 categories: 1st, random allocation of pts to a BP-lowering drug or placebo; 2nd, random allocation of pts to different BP-lowering meds
- Comparator: Placebo, active comparator or less intensive treatment

### Intervention:
BP-lowering meds

### 1st endpoint:
- CVD.
- Major CVD events, CHD, stroke, HF, renal failure, and all-cause mortality.
- Standardized RR for 10 mm Hg difference in SBP
- CVD RR: 0.80 (95% CI: 0.77–0.83)

### Other endpoints:
- CHD RR: 0.83 (95% CI: 0.78–0.88)
- Stroke RR: 0.73 (95% CI: 0.68–0.77)

### Summary:
BP-lowering significantly reduces vascular risk across various baseline BP levels and comorbidities. Our results provide strong support for lowering BP to SBP <130 mm Hg and providing BP-lowering treatment to individuals with a history of CVD, CHD, stroke, DM, HF, and CKD.
- In stratified analyses, we saw no strong evidence that proportional effects were diminished in trials that included people with lower
<table>
<thead>
<tr>
<th>Study type: Meta-analysis of RCTs</th>
<th>Size: 123 studies with 613,815 pts</th>
<th>lowering drugs; and third, random allocation of pts to different BP-lowering targets.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion criteria: &lt;1,000 pt-y of follow-up in each treatment group.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **HF RR:** 0.72 (95% CI: 0.67–0.78)
- **Total deaths RR:** 0.87 (95% CI: 0.84–0.91)

**Other results:**
- Benefit for CVD and other endpoints not different by baseline SBP, including <130 mm Hg fig 4 in paper
  - CVD: 0.63; 95% CI: 0.50–0.80; p=0.22
  - CHD: 0.55; 95% CI: 0.42–0.72; p=0.93
  - Stroke: 0.65; 95% CI: 0.27–1.57; p=0.38
  - HF: 0.83; 95% CI: 0.41–1.70; p=0.27
  - Total deaths: 0.53; 95% CI: 0.37–0.76; p=0.79
- More precision around estimates of benefits in SBP 130–139 at baseline, fig 4 in paper
- Results similar in trials of people with and without CVD at baseline figure 5
  - CVD+ 0.77 (95% CI: 0.71–0.81)
  - CVD- 0.74 (95% CI: 0.67–0.83)
  - Total deaths
  - CVD+ 0.90 (95% CI: 0.83–0.98)
  - CVD- 0.84 (95% CI: 0.75–0.93)
- Other outcomes similarly in figure 5
  - In appendix, in general, benefits for CVD prevention seen in groups with and without baseline CHD, Stroke, DM, CKD and HF when examined separately, but no absolute risks provided to enable estimation of how far down the absolute risk curve these findings have been demonstrated.

**Limitations:**
- Lack of individual pt data, which would have allowed a more reliable assessment of treatment effects in different pt groups.
- Interpretation: Lowering of BP into what has been regarded the normotensive range should therefore be routinely considered for the prevention of CVD among those deemed to be of sufficient absolute risk.

Baseline SBP (<130 mm Hg), and major CV events were clearly reduced in high-risk pts with various baseline comorbidities. Both of these major findings—the efficacy of BP-lowering below 130 mm Hg and the similar proportional effects in high risk populations—are consistent with and extend the findings of the SPRINT trial.
### SPRINT

**Wright JT Jr, et al., 2015**

**Aim:** To test the effectiveness of a goal SBP <120 mm Hg vs. a goal SBP <140 mm Hg for the prevention of CVD in pts with SBP ≥130 mm Hg at baseline.

**Study type:** RCT

**Size:** 9361 pts followed median of 3.26 y.

**Inclusion criteria:**
- SBP ≥130 mm Hg, with upper limit varying as number of pre-trial BP-lowering meds increased.
- Age ≥50 y
- Presence of at least 1 of the following:
  - Clinical or subclinical CVD
  - CKD stage ≥3
  - Age ≥75
  - Framingham General CVD risk ≥15% in 10 y

**Exclusion criteria:** DM, history of stroke, ESRD (eGFR <20)

**Intervention:** Intensive BP-lowering treatment to goal SBP <120 mm Hg

**Comparison:**
- Standard BP-lowering treatment to goal SBP <140 mm Hg
- Net treatment difference ~3 drugs (2.8) on average vs. 2 drugs (1.8) on average
- During the trial, mean SBP was 121.5 vs. 134.6.

**1° endpoint:** CVD (MI, ACS, stroke, HF, CVD death)

HR: 0.75 (95% CI: 0.64, 0.89)

**Other endpoints:**
- Total deaths HR: 0.73 (95% CI: 0.60–0.90)
- 1° or death HR: 0.78 (95% CI: 0.67–0.90)
- Components of 1° composite mostly consistent in direction other than ACS – no difference.

**CKD outcomes:**
- 1° in CKD pts: reduction in GFR of ≥50% or ESRD HR: 0.89 (95% CI: 0.42, 1.87)
- Incident albuminuria HR: 0.72 (95% CI: 0.48, 1.07)
- In pts without CKD: reduction in GFR ≥30% and to <60
  - HR: 3.49 (95% CI: 2.44–5.10)
  - Incident albuminuria HR: 0.81 (95% CI: 0.63–1.04)

**Adverse events:**
- SAEs: 1.04; p=0.25
- Significant absolute increases seen in intensive group for hyponatremia (1%), syncope (0.6%), electrolyte abnormality (0.8%), acute kidney injury/acute renal failure (1.6%) over the study period.

**Summary:**
- More intensive SBP lowering to a goal of <120 mm Hg with achieved mean of approximately 121 mm Hg resulted in less CVD and lower total mortality over 3.26 y in comparison with a goal SBP <140 mm Hg and achieved SBP of ~135 mm Hg.
- There were small increases in some expected SAEs. Perhaps unexpected, a sizable increase in reduced eGFR in the non-CKD group and AKI/ARF overall was observed in the intensive group. While of uncertain etiology and significance, there is speculation this could be an acute hemodynamic effect, especially given the findings regarding albuminuria.

**Limitations:** Few pts were untreated at baseline ~9%, so SPRINT provides little if any insight at present regarding BP-lowering medication initiation for untreated people with SBP 130–139.
Aim: To determine the quantitative efficacy of different classes of BP-lowering drugs in preventing CHD and stroke, and who should receive treatment.

5 questions encapsulate this uncertainty. 1st, do BBs have a special effect over and above lowering BP in preventing CHD events in people with a history of CHD? 2nd, does the effect of BP-lowering drugs in preventing CHD and stroke differ in people with and without a history of CVD (i.e., is there a different effect in 2nd and 1st prevention)? 3rd, does BP reduction alone explain the effect of BP-lowering drugs in preventing CHD and stroke? 4th, should the use of BP-lowering drugs be limited to people with high BP and not given to those at high risk of CVD?

Inclusion criteria: The database search (by MRL) used Medline (1966 to December 2007; any language) to identify randomized trials of BP-lowering drugs in which CHD events or strokes were recorded (irrespective of whether BP reduction was considered the mechanism of action). Search terms were “antihypertensive agents” or “HTN” or “diuretics, thiazide” or “adrenergic beta-antagonists” or “angiotensin-converting enzyme inhibitors” or “receptors, angiotensin/antagonists & inhibitors” or “tetrazoles” or “CCB s” or “vasodilator agents” or the names of all BP-lowering drugs listed in the British National Formulary as keywords or text words. Limits were Medline publication type “clinical trial” or “controlled clinical trial” or “RCT” or “meta-analysis”. We also searched the Cochrane Collaboration and Web of Science databases and the citations in trials and previous meta-analysis and review articles.

Exclusion criteria: We excluded nonrandomized trials and trials in which treated groups but not control groups

Intervention: BP-lowering medications

Comparison: Placebo or less intensive treatment

1st endpoint: CHD and stroke co-1st

Standardized to a 10/5 mm Hg BP reduction

Overall

CHD: 0.78 (95% CI: 0.73–0.83)

Stroke: 0.59 (95% CI: 0.52–0.67)

In absence of vascular disease

CHD: 0.79 (95% CI: 0.72–0.86)

Stroke: 0.54 (95% CI: 0.45–0.65)

History of CHD

CHD: 0.76 (95% CI: 0.68–0.86)

Stroke: 0.65 (95% CI: 0.53–0.80)

History of stroke

CHD: 0.79 (95% CI: 0.62–1.00)

Stroke: 0.66 (95% CI: 0.56–0.79)

No big drug class effects except more benefit for BBs shortly after MI.

Treatment benefits seen down to pre-treatment SBP of 110–119 mm Hg for CHD events RR: 0.78 (95% CI: 0.63–0.96) and 130–139 mm Hg for stroke RR: 0.75 (95% CI: 0.63–0.89)

Summary: The effect of BP-lowering drugs in reducing the risk of disease is entirely or largely due to BP reduction, with 1 main exception, a special extra effect of BBs in people who have had a recent MI. The proportional reduction in CHD events and stroke for a given reduction in BP, an approximate halving in risk for each 10 mm Hg diastolic reduction, is the same in people with and without a history of vascular disease and in people without high BP as well as in those with high BP. There is benefit in lowering BP in anyone at sufficient CV risk whatever their BP, so avoiding the need to measure BP routinely.

Limitation:

- Most of the pts without HTN were in the trials of people with pre-existing CVD; hence, most of the results of BP lowering in people with SBP<140 are in people with CVD.

- No absolute risks or benefits provided. Not possible to estimate how far down the risk curve these results apply.

Interpretation: This MA provides stronger support for
who have a lower BP? A corollary is whether BP should be reduced to a limited extent only, a treat to target approach. Although cohort (prospective/observational) studies do not show a lower BP limit below which risk ceases to decline (“the lower the better”), this has not been shown in randomized trials across a wide range of BP. Finally, what is the quantitative effect of taking ≥1 BP-lowering drugs in lowering BP and preventing CHD events and stroke according to dose, pretreatment BP, and age? To date no such quantitative summary of effect, taking account of these determining factors, has been made.

**Study type:** Meta-analysis of RCTs

**Size:** 147 RCTs of BP-lowering meds and CHD events (22,000) and stroke (12,000).

had other interventions as well as BP reduction, such as cholesterol reduction. We excluded trials in pts with chronic renal failure because these pts typically have high BP and high rates of CVD and their response to standard BP-lowering therapy may differ from other people. We also excluded trials in which fewer than 5 CHD events and strokes were recorded or the duration of treatment was less than 6 mo, as these data would contribute little to the overall results and substantially increase the complexity of the analyses. RCTs were otherwise included irrespective of pt age, disease status, BP before treatment, or use of other drugs.

<table>
<thead>
<tr>
<th>treating at levels &lt;140 for people with CVD than for people without CVD.</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Lewington S, et al., 2002 (16) 12493255 | **Aim:** To describe the age-specific relevance of BP to cause-specific mortality  
**Study type:** Meta-analysis of cohort studies  
**Size:** 61 prospective studies with 12.7 million person-y of observation, 56,000 vascular deaths in 40–89 y.  
**Inclusion criteria:** Collaboration was sought from the investigators of all prospective observational studies in which data on BP, blood cholesterol, date of birth (or age), and sex had been recorded at a baseline screening visit, and in which cause and date of death (or age at death) had been routinely sought for all screens during more than 5,000 person-y of follow-up (see appendix A; http://image.thelancet.com/extras/01art8300webappendixa.pdf). Relevant studies were identified through computer searches of Medline and Embase, by hand-searches of meeting abstracts, and by extensive discussions with investigators.  
**Exclusion criteria:** To minimize the effects of reverse causality (whereby established disease could change the usual BP), studies were excluded if they had selected pts on the basis of a positive history of stroke or heart disease, and individuals from contributing studies were excluded from the present analyses if they had such a history recorded at baseline.  
**Intervention:** N/A  
**Comparator:** N/A  
- The exposures of interest were the level of SBP and DBP and age-group.  
1° endpoint:  
- Not completely clear, but for our purposes, stroke and IHD death would be co-1°. Also looked at other vascular deaths.  
- HRs for stroke mortality for a 20 mm Hg lower SBP by age-group  
  40–49: 0.36 (95% CI: 0.32–0.40)  
  50–59: 0.38 (95% CI: 0.35–0.40)  
  60–69: 0.43 (95% CI: 0.41–0.45)  
  70–79: 0.50 (95% CI: 0.48–0.52)  
  80–89: 0.67 (95% CI: 0.63–0.71)  
- HRs for IHD mortality for a 20 mm Hg lower SBP by age-group  
  40–49: 0.49 (95% CI: 0.45–0.53)  
  50–59: 0.50 (95% CI: 0.49–0.52)  
  60–69: 0.54 (95% CI: 0.53–0.55)  
  70–79: 0.60 (95% CI: 0.58–0.61)  
  80–89: 0.67 (95% CI: 0.64–0.70)  
- HRs for other vascular mortality for a 20 mm Hg lower SBP by age-group  
  40–49: 0.43 (95% CI: 0.38–0.48)  
  50–59: 0.50 (95% CI: 0.47–0.54)  
  60–69: 0.53 (95% CI: 0.51–0.56)  
  70–79: 0.64 (95% CI: 0.61–0.67)  
  80–89: 0.70 (95% CI: 0.65–0.75)  
- Similar results for DBP also in figure 1.  
- Similar results for men and women separately for stroke, figure 3, and IHD, figure 5.  
**Summary:** Throughout middle and old age, usual BP is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg. |
| Thomopoulos C, et al., 2014 (20) 25259547 | **Aim:** Investigating whether all grades of HTN benefit from BP-lowering treatment and which are the target  
**Inclusion criteria:** Intentional BP-lowering comparing active drug treatment with placebo, or less active treatment (intentional BP-lowering trials), or comparison of an active drug  
**Intervention/Comparator:** Criteria of eligibility were intentional BP-lowering comparing active drug treatment with placebo, or less active treatment  
1° endpoint:  
- As some trials were done on low-risk pts, others on higher risk pts, no evaluation of absolute risk-reduction was made. However, a 2° analysis was done including  
**Summary:** Meta-analyses favor BP-lowering treatment even in grade 1 HTN at low-to-moderate risk, and lowering SBP/DBP to <140/90 mm Hg. Achieving <130/80 mm Hg. |
<table>
<thead>
<tr>
<th>Study type: Meta-analysis of RCTs</th>
<th>Study type: Meta-analysis of RCTs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 32 RCTs with 104,359 pts</td>
<td>Size: 32 RCTs with 104,359 pts</td>
</tr>
<tr>
<td>BP levels to maximize outcome reduction.</td>
<td>BP levels to maximize outcome reduction.</td>
</tr>
<tr>
<td>with placebo over baseline antihypertensive treatment, resulting in a BP difference of at least 2 mm Hg in either SBP or DBP (nonintentional BP-lowering trials); enrolling of hypertensive individuals only or a high proportion (at least 40%) of them.</td>
<td>(intentional BP-lowering trials), or comparison of an active drug with placebo over baseline antihypertensive treatment, resulting in a BP difference of at least 2 mm Hg in either SBP or DBP (nonintentional BP-lowering trials); enrolling of hypertensive individuals only or a high proportion (at least 40%) of them.</td>
</tr>
<tr>
<td>Exclusion criteria: N/A</td>
<td>Exclusion criteria: N/A</td>
</tr>
<tr>
<td></td>
<td>trials or trial subgroups with mean baseline SBP/DBP values in grade 1 range and a low-to-moderate risk (&lt;5% CV deaths in 10 y in controls): FEVER stratum with baseline SBP below the median (&lt;153 mm Hg) (e7); HTN Detection and Follow-up Program stratum with baseline DBP 90–94 mm Hg and no CVD (e9); OSLO (e17); TOMHS (e28) and USPHS (e29). Risks of stroke, CHD, the composite of stroke and CHD, and all-cause death were significantly reduced by BP-lowering in these low-to-moderate risk pts (control group: average CV mortality 4.5% in 10 y) with a moderate BP elevation (average SBP/DBP 145.5/91 mm Hg) at randomization. Standardized risk ratio associated with 10/5 reduction in BP: stroke 0.33 (95% CI: 0.11–0.98) CHD 0.68 (95% CI: 0.48–0.95) CVD death 0.57 (95% CI: 0.32–1.02) total death 0.53 (95% 0.35–0.80) • Compared outcomes of achieved on study SBP &lt;130 vs. ≥130 Standardized Risk ratio associated with 10/5 reduction in BP: stroke 0.68 (95% CI: 0.57, 0.83) CHD 0.87 (95% CI: 0.76, 1.00) HF 0.92 (95% CI: 0.47, 1.77) CVD 0.81 (95% CI: 0.67, 1.00) CVD death 0.88 (95% CI: 0.77, 1.01) total death 0.88 (95% CI: 0.77, 0.99) • Outcomes of achieved on study SBP 130–139 vs. ≥140 appears safe, but only adds further reduction in stroke.</td>
</tr>
<tr>
<td>Study Reference</td>
<td>Aim</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----</td>
</tr>
<tr>
<td>Lonn EM et al., 2016 (116)</td>
<td>To assess efficacy of fixed-dose antihypertensive therapy in adults with intermediate CVD risk.</td>
</tr>
<tr>
<td>Neaton JD et al., 1993 (117)</td>
<td>To compare 6 antihypertensive drugs (representing different drug classes)</td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
</tr>
<tr>
<td>--------</td>
<td>------</td>
</tr>
<tr>
<td>Van Dieren S, et al., 2012</td>
<td>(118)</td>
</tr>
</tbody>
</table>
| Montgomery AA, et al., 2003 | (119) | 12923409 | Markov decision analysis model comparing treatment and nontreatment of HTN. | Hypothetical cohorts for 20 different strata of sex, age (30–79 y in 10-y bands), and CV risk (low and high) | We created models for 20 different strata of sex, age (age 30–70 y in 10-y bands), and 2 risk profiles (designated as ‘low’ and ‘high’ risk). These example risk profiles represent the extremes of absolute CV risk, based on data from the Health Survey for England and using a Framingham risk function. We recognize that the risk of most individuals seen in primary care will be somewhere between the examples presented here. The data included were as follows: age- and sex-specific mean SBP of untreated individuals with SBP>0.160 mm Hg were used for both high-risk and low-risk profiles. In addition, low-risk profile was defined as nonsmoker, 10th percentile total cholesterol 90th percentile HDL | Treatment and nontreatment of HTN. | Life expectancy, and incremental cost: effectiveness ratios for treatment and nontreatment strategies | Incremental cost per quality-adjusted life y among low-risk groups ranged from £1,030 to £3,304. Cost-effectiveness results for low-risk pts were sensitive to the utility of receiving antihypertensive treatment. Treatment of high-risk individuals was highly cost-effective, such that it was the dominant strategy in the oldest age group, and resulted in incremental costs per quality-adjusted life y ranging from £34–£265 in younger age groups. | Policy decisions about which pts to treat depend on whether a life-expectancy or cost-
cholesterol, no DM, and no LVH, and high-risk profile was defined as smoker, 90th percentile total cholesterol, 10th percentile HDL cholesterol, DM, and LVH.

**Exclusion criteria:** N/A

**Inclusion criteria:** To estimate the rate of cv and non-CV deaths in a hypothetical U.S. population of untreated hypertensive pts, we used the following procedure: age-specific death rates in the U.S. general population were obtained from national vital statistics (1994), and in untreated hypertensive population they were obtained from the control groups of the INDANA database. This latter group represents a unique cohort of 14,942 untreated or placebo-treated hypertensive pts, 26-96 y with an average follow-up of 5 y

**Exclusion criteria:** N/A

**Intervention:** The gain in life expectancy without stroke, CHD, and CV events was estimated from the area between the 2 survival curves of treated and control groups. The relative gain in life expectancy was defined as the ratio of gain in life expectancy to life expectancy.

**1° endpoint:** Stroke and CHD co-

**Results:**

<table>
<thead>
<tr>
<th>CHD</th>
<th>Age</th>
<th>ABb</th>
<th>RGL Ee</th>
<th>Y</th>
<th>RRa (%)</th>
<th>NNTc</th>
<th>GLe d (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>0.86</td>
<td>0.3</td>
<td>333</td>
<td>20</td>
<td>4.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>0.88</td>
<td>1.0</td>
<td>100</td>
<td>17</td>
<td>4.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>0.90</td>
<td>1.9</td>
<td>53</td>
<td>13</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>70</td>
<td>0.91</td>
<td>3.9</td>
<td>26</td>
<td>10</td>
<td>5.4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stroke</th>
<th>Age</th>
<th>ABb</th>
<th>RGL Ee</th>
<th>Y</th>
<th>RRa (%)</th>
<th>NNTc</th>
<th>GLe d (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>40</td>
<td>0.80</td>
<td>0.4</td>
<td>250</td>
<td>32</td>
<td>5.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>0.84</td>
<td>1.0</td>
<td>100</td>
<td>26</td>
<td>5.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>0.86</td>
<td>2.3</td>
<td>44</td>
<td>21</td>
<td>7.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>70</td>
<td>0.87</td>
<td>5.7</td>
<td>18</td>
<td>17</td>
<td>9.1</td>
<td></td>
</tr>
</tbody>
</table>

a RR at 10 y
b Absolute benefit at 10 y
c NNT to avoid 1 event.
d Gain in life expectancy in mo without events.

**Summary:** Absolute gains in life expectancy are likely to be greater for younger, lower risk people with HTN than for older, higher risk people with HTN. However, the NNT to prevent an event will likely be greater especially in the short term in younger, lower risk people. This modeling analysis provides support for treating younger, lower risk individuals with HTN, but relies on the assumption that the relative benefits of treatments observed in short-term trials of higher risk individuals applies over a longer term to lower risk individuals.
survival curve of the life-long treated population. Gains in event-free life expectancy were estimated from survival curves. A sensitivity analysis was performed to assess the impact of possible death misclassifications.

**Size:** 6 RCTs, ~30,000 pts

Relative gain in life expectancy without events.

### Czernichow S et al., 2011 (121) 20881867

**Aim:** The objective of this systematic review and meta-analysis was to compare the relative reductions in risk achieved with different starting levels of BP (and treatment regimens).

**Study type:** Meta-analysis of RCTs

**Size:** 32 trials with 201,566 pts (20,079 1° outcome events)

**Inclusion criteria:** RCTs of BP-lowering (drug vs. control or less intensive treatment) or different classes of drug therapy that included a minimum of 1,000 pt-y of follow-up in each study arm.

**Exclusion criteria:** <1,000 pt-y of follow-up in each treatment group.

**Intervention:** BP-lowering meds

**Comparator:** Placebo, active comparator or less intensive treatment

**1° endpoint:**
- Major CVD events (stroke, CHD, and HF).
- No evidence of differences in the ratio of risk across varying levels of baseline BP (with all classes of BP-lowering medications).

**Summary:**
- Effectiveness of BP-lowering regiments in reducing RR of major CVD events does not seem to be influenced by starting level of BP.

**Limitations:**
- The majority of the participants studied were at high risk for CVD.
- Information pertaining to the effect of treatment on absolute risk was not presented in this manuscript.

---

### Data Supplement 24. Follow-Up After Initial BP Evaluation (Section 8.1.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
### Ambrosius WT, et al., 2014 (122) 24902920

**Aim:** To describe the study design of the SPRINT Study

**Study type:** SPRINT RCT

**Inclusion criteria:** Adults ≥50 y, average SBP ≥130 mm Hg and evidence of CVD, CKD, or 10-y Framingham risk score ≥15%, or ≥75 y

**Intervention:** 9,361 pts randomized to 2 treatment groups:
- **Standard treatment group:** SBP target <140 mm Hg
- **Intensive treatment group:** SBP target <120 mm Hg.

**1° endpoint:** MI, ACS, stroke, HF, or CVD death.

**Relevant 2° endpoint:** All-cause mortality, decline in kidney function or development of ESRD, incident dementia, decline in cognitive function, and small-vessel cerebral ischemic disease

**Summary:** This paper describes the protocol followed in the SPRINT trial that was successful in helping participants to attain and maintain BP targets in the study groups. Once treated, participants had follow-up visits to assess BP control monthly until BP was at target. Medications were titrated and added as per protocol, when target BP was not attained.

### Cushman WC, et al., 2007 (123) 17599425

**Aim:** To describe the study design of the BP trial of the ACCORD Trial

**Study type:** Description of study design and protocol for the ACCORD RCT

**Inclusion criteria:** Adults with a diagnosis of DM-2 for at least 3 mo and at high risk for CVD events, who meet the following BP criteria: (1) SBP 130–160 mm Hg and taking 0–3 antihypertensive medications; (2) SBP 161–170 and on 0–2 antihypertensive medications; or (3) SBP 171-180 and taking 0-1 antihypertensive medication. Other entry criteria included spot urine sample <2+, protein–Cr ratio <700 mg protein/1 g Cr, or 24-h protein excretion <1.0 g/24 h.

**Intervention:**
- **Unmasked, open-label, factorial design, randomized trial with a sample size of 4,733 pts**
- **Pts randomized to intensive SBP control (<120 mm Hg) or standard control (<140 mm Hg)**

**1° endpoint:** Major CVD event (nonfatal MI or stroke, or CV death)

**Relevant 2° endpoint:** Expanded macrovascular outcome (1° outcome plus coronary revascularization or HF hospitalization), total mortality, each of the separate components of the 1° outcome, HF death or hospitalization, and composite microvascular disease outcome (kidney and eye disease).

**Summary:** This paper describes the protocol followed in the ACCORD trial that was successful in helping participants to attain and maintain BP targets in the study groups. Once treated, participants had follow-up visits to assess BP control monthly until BP was at target. Medications were titrated and added as per protocol, when target BP was not attained.
### Data Supplement 25. RCTs for General Principles of Drug Therapy (Combination Therapies that Inhibit the RAAS) (Section 8.1.4)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VA NEPHRON-D</strong> Fried LF, et al., 2013 (124)</td>
<td><strong>Aim:</strong> Assess the efficacy of combination of an ACEI and an ARB vs. ARB monotherapy in reducing the progression of proteinuric diabetic nephropathy</td>
<td><strong>Study type:</strong> Multicenter, double-blind, RCT at 32 VA Medical Centers</td>
<td><strong>Inclusion criteria:</strong> Pts with type 2 DM, a urinary albumin-to-creatinine ratio of ≥300, and an eGFR 30.0–89.9 mL/min/1.73 m²</td>
<td><strong>Intervention:</strong> Losartan 100 mg daily plus lisinopril 10–40 mg daily (n=724)</td>
<td><strong>1° endpoint:</strong> After a median follow-up of 2.2 y, the study was stopped early due to safety concerns. There was no difference in the 1° outcome of first occurrence of change in eGFR (decrease of ≥30 mL/min/1.73 m² if initial GFR was ≥60 mL/min/1.73 m² or a decline of ≥50% if initial eGFR was &lt;60 mL/min/1.73 m²), ESRD, or death (HR with combination therapy: 0.88; 95% CI: 0.70–1.12; p=0.30).  <strong>Safety endpoint:</strong> Combination therapy increased the risk of hyperkalemia (HR: 2.8; 95% CI: 1.8–4.2; p&lt;0.001) and acute kidney injury (HR: 1.7; 95% CI: 1.3–2.2; p&lt;0.001).</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Exclusion criteria:</strong> • Subjects with known nondiabetic kidney disease • Serum K+ &gt;5.5 mmol/L • Current treatment with sodium polystyrene sulfonate • Inability to stop prescribed medication that increases the risk of hyperkalemia</td>
<td><strong>Comparator:</strong> Losartan 100 mg daily plus placebo (n=724)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>2° endpoint:</strong> There was no difference in the 2° endpoint of first occurrence of change in eGFR or ESRD (HR: 0.78; 95% CI: 0.58–1.05; p=0.10). There were no differences between combination therapy or losartan monotherapy for the endpoints of ESRD, death, composite of MI, HF, or stroke, MI, CHF, and stroke (p&gt;0.05 for all).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALTITUDE</strong> Parving HH, et al., 2012 (125)</td>
<td><strong>Aim:</strong> Determine if addition of aliskiren as an adjunct to an ACEI or ARB reduces the risk of CV and renal events in pts with type 2 DM</td>
<td></td>
<td><strong>Inclusion criteria:</strong> • ≥35 y with type 2 DM • On ACEI or ARB • At least 1 of the following: persistent macroalbuminuria (urine microalbumin to creatinine ratio ≥200 mg/g) and eGFR ≥30 mL/min/1.73 m², persistent microalbuminuria (≥20 mg/g and &lt;200 mg/g) and a mean eGFR ≥30 and &lt;60</td>
<td><strong>Intervention:</strong> Aliskiren 300 mg daily added to conventional treatment with an ACEI or ARB (n=4,274)</td>
<td><strong>1° endpoint:</strong> After a median follow-up of 32.9 mo the study was stopped early. There was no difference in the 1° composite outcome death from CV causes or first occurrence of cardiac arrest with resuscitation; nonfatal MI; nonfatal stroke (n=4,287)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Exclusion criteria:</strong></td>
<td></td>
<td></td>
<td><strong>2° endpoint:</strong> There was no difference in the 2° outcome of first occurrence of change in eGFR or ESRD (HR: 0.78; 95% CI: 0.58–1.05; p=0.10). There were no differences between combination therapy or losartan monotherapy for the endpoints of ESRD, death, composite of MI, HF, or stroke, MI, CHF, and stroke (p&gt;0.05 for all).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Subjects with known nondiabetic kidney disease • Serum K+ &gt;5.5 mmol/L • Current treatment with sodium polystyrene sulfonate • Inability to stop prescribed medication that increases the risk of hyperkalemia</td>
<td><strong>Comparator:</strong> Placebo</td>
<td></td>
<td><strong>Summary:</strong> Combination therapy of losartan plus lisinopril did not improve renal outcomes compared to losartan alone, and was associated with greater risk of acute kidney injury and hyperkalemia.</td>
</tr>
</tbody>
</table>
### Study type: Doubled-blind, multicenter RCT

**Size:** 8561

**Exclusion criteria:**
- Serum K+ >5.0 mmol/L
- Type 1 DM
- Unstable serum Cr
- CV history (NYHA Class III or IV, SBP ≥170 mm Hg or DBP ≥110 mm Hg or SBP ≥135 and <170 mm Hg or DBP ≥82 and <100 mm Hg with at least 3 agents, 2nd or third degree heart block, renal artery stenosis
- Surgical or medical conditions (malignancy in last 5 y, <2 y life expectancy, renal transplant or immunosuppressive therapy, drug/alcohol abuse, hypersensitivity/allergy/contraindication to study drugs, pregnancy)
- Concomitant treatment with ≥2 agents blocking RAAS or K+-sparing diuretics.

### Aim:
Evaluate whether use of an ARB was noninferior to ACEI, and whether the combination was superior to ACEI alone in the prevention of vascular events in pts with CVD or DM but not HF.

**Study type:** Multi-center, double-blind, RCT

**Inclusion criteria:**
- ≥55 y
- Coronary, peripheral, or cerebrovascular disease or DM with end-organ damage

**Exclusion criteria:**
- Inability to discontinue ACEI or ARB
- Known hypersensitivity or intolerance to ACEI or ARB
- Selected CVDs (congestive HF, hemodynamically significant valvular or outflow tract obstruction, constrictive pericarditis, complex congenital heart disease, syncopal episodes of unknown etiology <3 mo, planned cardiac surgery

### Intervention:
Ramipril 10 mg daily (n=8,576)

**Comparator:**
- Telmisartan 80 mg daily (n=8,542)
- Combination of telmisartan and ramipril (n=8,502)

**1° endpoint:** After a median follow-up of 56 mo, there was no difference between ramipril vs. telmisartan or combination therapy vs. ramipril in the 1° composite outcome of death from CV causes, MI, stroke, or hospitalization for HF (RR: 1.01; 95% CI: 0.94–1.09 and RR: 0.99; 95% CI: 0.92–1.07, respectively)

**Safety endpoint:**
- Combination therapy was associated with a greater risk of hyperkalemia than

### 2° endpoint:
- There was no difference in composite of death from CV causes, MI, or stroke in the ramipril vs. telmisartan groups RR: 0.99; 95% CI: 0.9–1.07; p=0.001 or ramipril vs. combination RR: 1.00; 95% CI: 0.93–1.09
- There were no differences between ramipril vs. telmisartan or ramipril vs. combination therapy in 2° outcomes including MI, stroke, hospitalization for HF, death from CV causes, death from non-CV causes, or death from any cause (p>0.05 for all).

### Summary:
Aliskiren added to background treatment of an ACEI or ARB did not decrease CV or renal outcomes, and was associated with increased risk of cardiac arrest with resuscitation, hyperkalemia, and hypotension.
or PTCA <3 mo, uncontrolled HTN on treatment [e.g., BP >160/100 mm Hg], heart transplant recipient, stroke due to subarachnoid hemorrhage
• Other conditions (significant renal artery disease, hepatic dysfunction, uncorrected volume or sodium depletion, 1° hyperaldosteronism, hereditary fructose intolerance, other major noncardiac illness or expected to reduce life expectancy or significant disability interfere with study participation, simultaneously taking another experimental drug, unable to provide written informed consent).

• Hypotensive symptoms were cited as reason for permanent discontinuing more in telmisartan vs. ramipril (RR: 1.54; p<0.001)
• Combination therapy vs. ramipril monotherapy (RR: 2.75; p<0.001)
• Renal impairment was more common in combination therapy vs. ramipril monotherapy RR: 1.33; 95% CI: 1.2–1.44

Summary: Combination therapy with telmisartan and ramipril did not decrease the risk of CV events in pts at high risk compared to monotherapy with ramipril. In addition, combination therapy was associated with increased risk of hypotension, hyperkalemia, and renal impairment.

Data Supplement 26. BP Goal for Patients with Hypertension (Section 8.1.5)

<table>
<thead>
<tr>
<th>Study Acronym (if applicable)</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) Study Comparator (# patients)</th>
<th>Primary Endpoint and Results (include P value; OR or RR &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawes CM, et al., 2003 (50) 12658016</td>
<td>Study type: Meta-analysis of RCTs of BP drugs recording CHD events and strokes Size: 464,000 pts</td>
<td>N/A</td>
<td>N/A</td>
<td>• CHD RR or 46% Stroke 64%</td>
<td>• All classes of BP meds confer benefit while BB confer greater benefit in those with CAD</td>
</tr>
<tr>
<td>LV J, et al., 2013 (127) 237968459</td>
<td>Study type: MA of RTC that randomly assigned individuals to different target BP levels Size: 15 trials including a total of 37,348 pts</td>
<td>N/A</td>
<td>N/A</td>
<td>7.5/4.5 mm Hg BP difference. Intensive BP lowering achieved. RR for • Major CV events: 11%; 95% CI: 1%–21% • MI: 13%; 95% CI: 0%–25%</td>
<td>• More intensive strategy for BP control reduced cardio-renal endpoint</td>
</tr>
</tbody>
</table>
| Xie X, et al., 2015 (21) 26559744 | **Study type:** MA of RTC that randomly assigned individuals to different target BP levels  
**Size:** 19 trials (n=44,989) | N/A | N/A | Achieved BP 133/76 mm Hg (intensive) 140/81 (less intense)  
- Major CV events: 14%; 95% CI: 4%–22%  
- MI: 13%; 95% CI: 0%–24%  
- Stroke: 22%; 95% CI: 10%–32%  
- Albuminuria: 10%; 95% CI: 3%–16%  
- Retinopathy progression: 19%; 95% CI: 0%–34%.  
- More intensive had no effects on HF: 15%; 95% CI: -11%–34%  
- CV death: 9%; 95% CI: -11%–26%  
- Total mortality: 9%; 95% CI: -3%–19%  
- ESKD: 10%; 95% CI: -6%–23%  
- More intensive approach reduced major CV events (stroke and MI) except heat failure, CVD, ESRD, and total mortality. |
| Study type: Cumulative meta-analysis of RCTs to study benefit of more vs. less intensive BP lowering | N/A | N/A | Stroke, MI, HF, CVD mortality, and all-cause mortality  
Difference in achieved SBP/DBP=7.6/4.5 mm Hg  
For stroke and MI the cumulative Z score crossed the efficacy boundary after addition of the SPRINT results  
For CVD mortality and HF, the cumulative Z curve crossed the conventional significance boundary (but not the sequential monitoring boundary)  
For all-cause mortality, the cumulative Z curve did not reside in the futility area but did not cross the conventional significance boundary  
The results strongly supported the benefit of intensive BP reduction for prevention of stroke and MI and suggested benefit for prevention of CVD mortality and HF |
| Study type: Network meta-analysis in which the authors attempted to compare the benefits and adverse effects resulting from intensive reduction in SBP | N/A | N/A | There was a significant reduction in stroke (RR: 0.54) and MI (RR: 0.68)  
The point estimate favored all-cause mortality, CVD mortality and HF but the results did not achieve significance  
SBP targets <120 and <130 mm Hg ranked #1 and #2 as the most efficacious  
Serious adverse effects were more common at a lower SBP (120 vs. 150 or 140 mm Hg)  
Overall, the beneficial effects of treatment were consistent with other reports. The cluster plots of treatment benefit vs. risk are difficult to interpret due to limitations of the available data base and the authors' decision to weight treatment benefits and potential adverse effects equally. |

Verdecchia P et al., 2016  
Bangalore S, et al., 2017
| Bundy JD, et al., 2017 28564682 | **Study type:** Systematic review and network meta-analysis to assess the benefits of intensive SBP reduction during treatment of hypertension  
**Size:** 42 trials (n=144,220) | N/A | N/A | • Cluster plots for combined efficacy and safety suggested a SBP <130 mm Hg as the optimal target for SBP reduction during treatment  
• In general, there were linear associations between achieved SBP and risk of CVD and all-cause mortality, with the lowest risk at a SBP of 120–124 mm Hg.  
• This was by far the largest and best powered meta-analysis to assess the relationship between SBP reduction and major outcomes during treatment of hypertension. The findings provided strong evidence for the “lower is better” approach to treatment in patients with a high SBP who are at high risk for CVD. |
| Lawes CMM, et al., 2002 16222626 | **Study type:** Review of observational reports and randomized controlled trials | N/A | N/A | • The relative benefits of BP lowering for CHD prevention likely to be consistent across a wide range of different populations  
• Likely to be considerable benefit for BP lowering beyond traditional thresholds, especially in those at high risk for CVD  
• BP lowering is likely to be more important than choice of initial agent  
• A large majority of patients being treated for |

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
hypertension have suboptimal BPs. Initiatives to lower their BP further are essential.

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (include Absolute Event Rates, P value; OR or RR; and 95% CI)</th>
<th>Relevant 2º Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| Xie X, et al., 2015 (21) 26559744     | **Aim:** To assess the efficacy and safety of intensive BP-lowering strategies. **Study type:** Meta-analysis of RCTs **Size:** 19 RCTs with 44,989 pts | **Inclusion criteria:** RCTs with at least 6 mo follow-up that randomly assigned pts to more intensive vs. less intensive BP-lowering treatment, with different BP targets or different BP changes from baseline. Reference lists from identified trials and review articles were manually scanned to identify any other relevant studies. **Exclusion criteria:** N/A | **Intervention:** BP-lowering meds **Comparator:**  
- Less intensive treatment  
- BP difference 6.8/3.5  
- The mean follow-up BP levels in the less intensive BP-lowering regimen group were 140/81 mm Hg, compared with 133/76 mm Hg in the more intensive treatment group. | **1º endpoint:**  
- CVD, other major CV events, defined as a MI, stroke, HF, or CV death, separately and combined; nonvascular and all-cause mortality; ESKD, and adverse events. Progression of albuminuria (defined as new onset of micro-albuminuria/macro-albuminuria or a change from micro-albuminuria to macro-albuminuria) and retinopathy (retinopathy progression of 2 or more steps) were also recorded for trials that were done in pts with DM  
- CVD RR: 0.86 (95% CI: 0.78–0.96) | **Summary:** Intensive BP-lowering, including to <130 mm Hg, provided greater vascular protection than standard regimens. In high-risk pts, there are additional benefits from more intensive BP-lowering, including for those with SPB <140 mm Hg at baseline. The net absolute benefits of intensive BP-lowering in high-risk individuals are large. **Limitations:**  
- Lack of individual pt data, which would have allowed a more reliable assessment of
Other endpoints:
- MI RR: 0.87 (95% CI: 0.76–1.00) p=0.042
- Stroke RR: 0.78 (95% CI: 0.68–0.90)
- HF RR: 0.85 (95% CI: 0.66–1.11)
- CVD death RR: 0.91 (95% CI: 0.74–1.11)
- Total deaths RR: 0.91 (95% CI: 0.81–1.03)

Other results:
- Benefit for CVD not different by baseline SBP 120–139: 0.89 (95% CI: 0.76–1.05) 140–160: 0.83 (95% CI: 0.68–1.00) >160: 0.89 (95% CI: 0.73–1.09) p-heterogeneity: 0.60
- Benefit for CVD not different for more intensive and less intensive targets in intensive group <140 or <150 mm Hg: 0.76 (95% CI: 0.60–0.97) <120–<130 mm Hg: 0.91 (95% CI: 0.84–1.00; p-hetero: 0.06)

- Absolute benefits were proportional to absolute risk.
- For trials in which all pts had vascular disease, renal disease, or DM at baseline, the average control group rate of major vascular events was 2.9% per y compared with 0.9% per y in other trials, and the numbers needed to treat were 94 (95% CI: 0.74–1.11)

Interpretation: Supports treating pt with and without CVD at threshold of 130 to <130. Supports treating at threshold of about 130 even down to a CVD event rate of 0.9% per y.
<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion Criteria</th>
<th>Intervention</th>
<th>1° endpoint</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julius S, et al., 2006 (55) [16537662]</td>
<td>Study type: RCT in pre-HTN16 mg candesartan vs. placebo</td>
<td>809 pts</td>
<td>Men ≥55 y and women ≥60 y at intermediate risk for CVD. No BP restrictions.</td>
<td>FDC of ARB (candesartan 16 mg/d) and diuretic (hydrochlorothiazide 12.5 mg/d) or placebo</td>
<td>1 co-1° CVD composite outcomes</td>
<td><strong>SBP/DBP reduction of 6.0/3.0 mm Hg</strong>&lt;br&gt;• No difference in treatment effect&lt;br&gt;• 1st co-1° 0.93 (0.79–1.10)&lt;br&gt;• 2nd co-1° 0.95 (0.81–1.11)</td>
</tr>
<tr>
<td>Lawes CM, et al., 2003 (50) [12658016]</td>
<td>Study type: Meta-analysis of RCTs of BP drugs recording CHD events and strokes</td>
<td>464,000 pts</td>
<td>CHD RR or 46% Stroke 64%</td>
<td>CHD mortality, nonfatal MI, nonfatal stroke Above plus cardiac arrest, HF, revascularization</td>
<td>All classes of BP meds confer benefit while BB confer greater benefit in those with CAD</td>
<td></td>
</tr>
<tr>
<td>Lonn EM, et al., 2016 (116) [27041480]</td>
<td>Study type: Double-blind, placebo-controlled RCT, factorial design</td>
<td>N/A</td>
<td>Known CVD&lt;br&gt;• Indications or contraindications to study meds&lt;br&gt;• Mod/advanced CKD&lt;br&gt;• Symptomatic hypotension</td>
<td>FDC of ARB (candesartan 16 mg/d) and diuretic (hydrochlorothiazide 12.5 mg/d) or placebo</td>
<td>1 co-1° CVD composite outcomes</td>
<td>SBP/DBP reduction of 6.0/3.0 mm Hg&lt;br&gt;• No difference in treatment effect&lt;br&gt;• 1st co-1° 0.93 (0.79–1.10)&lt;br&gt;• 2nd co-1° 0.95 (0.81–1.11)</td>
</tr>
</tbody>
</table>
### Data Supplement 27. Choice of Initial Medication (Section 8.1.6)

<table>
<thead>
<tr>
<th>Study Acronym</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| Psaty BM, et al., 2003 12759325 | **Study type:** Network meta-analysis to compare value of different first-line antihypertensive drugs in prevention of major CVD and all-cause mortality | N/A | • For all outcomes, low-dose diuretics were better than placebo  
• None of the other first-line agents (β-blockers, ACEI, CCBs, α-receptor blockers and ARBs) were superior to low-dose diuretics  
• For several outcomes, low-dose diuretics were superior to other agents | • Low-dose diuretics were identified as the most effective first-line treatment for prevention of CVD and all-cause mortality during treatment of hypertension | N/A |

**Size:** 902 pts with stage 1 HTN

**Aim:** To compare 6 antihypertensive drugs (representing different drug classes)

**Study type:** Double-blind, placebo-controlled RCT

**Inclusion criteria:**
- Men and women 45–69 y
- Not taking antihypertensive medications, with DBP 90–99 mm Hg
- Taking 1 antihypertensive medication, with DBP <95 mm Hg and between 85–99 mm Hg after withdrawal of BP medications

**Intervention:**
- Treatment (number):
  - Placebo (234)
  - Chlorthalidone 15 mg/d (136)
  - Acebutolol 400 mg/d (132)
  - Doxazosin 2 mg/d (134)
  - Amlodipine 5 mg/d (131)
  - Enalapril 5 mg/d (135)

**Follow-up:** Median=4.4 y

**1° endpoint:** BP, QoL, side effects, chemistries, ECG, clinical events

**Summary:**
- Drugs (plus diet) more effective compared to placebo (plus diet) for control of BP.
- Minimal differences between drug regimens.

- Suggestion of a subgroup effect in tertile with the highest baseline BP and increased CVD risk.
<table>
<thead>
<tr>
<th>Study Reference</th>
<th>Study Type</th>
<th>Size</th>
<th>Baseline SBP &gt;150 RR for</th>
<th>Baseline SBP 140–150 RR of</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunström M, et al., 2016 (53)</td>
<td>Meta-analysis of levels of BP control in DM hypertensives.</td>
<td>73,738 pts</td>
<td>All death: 0.89; 95% CI:0.80–0.99</td>
<td>Death: 0.87; 95% CI: 0.78–0.98</td>
<td>BP lowering reduces major CV events in DM. Caution for initiating treatment in diabetics with SBP &lt;140/90</td>
</tr>
<tr>
<td>Ettehad D, et al., 2015 (17)</td>
<td>Meta-analysis of large RTCs of antihypertensive treatment</td>
<td>123 studies (613,815 pts)</td>
<td></td>
<td></td>
<td>BP lowering reduces CV risk across various baseline BP levels and comorbidities. Suggest lowering SBP &lt;130 mm Hg and BP-lowering treatment to pts with a history of CVD, CHD, stroke, DM, HF, and CKD.</td>
</tr>
<tr>
<td>Thomopolous C, et al., 2016 (54)</td>
<td>Meta-analysis of RTCs of more vs. less intense BP control</td>
<td>16 trials (52,235 pts) compared more vs. less intense treatment 34 (138,127 pts) active vs. placebo</td>
<td>Stroke RR: 0.71; 95% CI: 0.60–0.84</td>
<td>Stroke RR: 0.80; 95% CI: 0.68–0.95</td>
<td>Intensive BP reduction improves CV outcomes compared to less intense</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
| Study | Study type | Size | Major CV events RR: 0.75; 95% CI: 0.68–0.85  
| CV mortality RR: 0.79; 95% CI: 0.63–0.97  
Stratification of SBP cutoffs (150,140 and 130 mm Hg) showed that a SBP/DBP difference of 10/5 mm Hg across each cutoff reduced risk of all outcomes |  
Julius S, et al., 2006 (55)  
16537662  
Study type: RCT in pre-HTN  
16 mg candesartan vs. placebo  
Size: 809 pts  
58% men  
During the first 2 y, HTN developed in 154 (40.4%) pts in the placebo group compared with only 53 (13.6%) of those in the candesartan group, for a RR of 66.3% (p<0.0001). After 4 y, HTN developed in 240 (63.0%) in the placebo group vs. only 208 (53.2%) in the candesartan group RR 15.6% (p<0.0069).  
2/3 of those with pre-HTN develop HTN within 4 y. Candesartan interrupts the onset and reduced by 15.6% |  
Ference BA, et al., 2014 (56)  
24591335  
Study type: Evaluated the effect of 12 polymorphisms (associated with BP) on the odds of CHD and compared it with the effect of lower SBP observed in both prospective cohort studies and BP-lowering randomized trials  
Size: 199,477 pts in 63 studies  
12 polymorphisms were associated with a 0.32 mm Hg lower SBP (p=1.79×10⁻⁷) and a 0.093-mm Hg/decade slower age-related rise in SBP (p=3.05×10⁻⁵). The effect of long-term exposure to lower SBP on CHD mediated by these polymorphisms was 2-fold greater than that observed in prospective cohort studies (p=0.006) and 3-fold greater than that observed in short-term BP treatment trials (p=0.001).  
SBP may be causally associated with the rate of rise in SBP with age and has a cumulative effect on the risk of CHD. |
### Data Supplement 28. Follow-Up After Initiating Antihypertensive Drug Therapy (Section 8.3.1)

<table>
<thead>
<tr>
<th>Study Acronym</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| Ambrosius WT, et al., 2014 (122) 24902920 | **Aim:** To describe the study design of the SPRINT trial  
**Study type:** description of study design and protocol for the SPRINT RCT | **Inclusion criteria:**  
Adults ≥50 y, average SBP ≥130 mm Hg and evidence of CVD, CKD, or 10-y Framingham risk score ≥15%, or age ≥75 y | **Intervention:** 9361 participants randomized to 2 treatment groups: (1) Standard treatment group, SBP target <140 mm Hg, and (2) Intensive treatment group: SBP target <120 mm Hg. | **1° endpoint:** MI, ACS, stroke, HF, or CVD death. | Relevant 2° endpoint: All-cause mortality, decline in kidney function or development of ESRD, incident dementia, decline in cognitive function, and small-vessel cerebral ischemic disease  
**Summary:** This paper describes the protocol followed in the SPRINT trial that was successful in helping participants to attain and maintain BP targets in the study groups. Once treated, participants had follow-up visits to assessment BP control monthly until BP was at target. Medications were titrated and added as per protocol, when target BP was not attained. |
| Cushman WC, et al., 2007 (123) 17599425 | **Aim:** To describe the study design of the BP trial of the ACCORD trial.  
**Study type:** description of study design and protocol | **Inclusion criteria:**  
Adults with a diagnosis of type 2 DM for at least 3 mo and at high risk for CVD events, who meet the following BP criteria: (1) SBP 130–160 mm Hg and taking 0–3 antihypertensive medications; (2) SBP 161–170 and on 0–2 antihypertensive | **Intervention:**  
- Unmasked, open-label, factorial design, randomized trial with a sample size of 4,733 pts  
- Patients were randomized to intensive SBP control (<120 mm Hg) or standard control (<140 mm Hg) | **1° endpoint:** Major CVD event (nonfatal MI or stroke, or CV death) | Relevant 2° endpoint: Expanded macrovascular outcome (1° outcome plus coronary revascularization or HF hospitalization), total mortality, each of the separate components of the 1° outcome, HF death or hospitalization, and |
for the ACCORD RCT medications; or (3) SBP 171–180 and taking 0–1 antihypertensive medication. Other entry criteria included spot urine sample <2+, protein–Cr ratio <700 mg protein/1 g creatinine, or 24-h protein excretion <1.0 g/24 h.

| Xu W, et al., 2015 (128) 25655523 | **Aim:** Retrospective assessment of the impact of follow-up intervals and treatment intensification thresholds on CVD events  
**Study type:** Retrospective cohort  
**Size:** 88,756 adult pts with HTN from The Health Improvement Network database | **Inclusion criteria:** Primary care practices in the U.K., 1986–2010. | N/A | • Median follow-up of 37.4 mo after the treatment strategy assessment period  
• 9,985 (11.3%) pts had an acute CV event or died.  
• No difference in risk of the outcome with systolic intensification thresholds 130–150 mm Hg, but HR: 1.21 for thresholds >150 mm Hg  
• Outcome risk increased progressively from the lowest (0–1.4 mo) to the highest 5th of time to medication intensification (HR: 1.12; 95% CI: 1.05–1.20; p=0.009) for intensification between 1.4 and 4.7 mo after detection of elevated BP). The highest fifth of time to follow-up (>2.7 mo) was also associated with increased outcome risk HR:  
• Increased risk of acute CVD event or death with:  
• Systolic intensification thresholds >150 mm Hg  
• Delays of >1.4 mo before medication intensification after SBP elevation  
• Delays of >2.7 mo before BP follow-up after antihypertensive medication intensification  
• Timely medical management and follow-up impacts outcomes in the treatment of pts with HTN.  
• Retrospective study, but still sheds important light on the impact of follow-up actions |
### Data Supplement 29. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP (Section 8.3.2)

<table>
<thead>
<tr>
<th>Study Acronym</th>
<th>Author</th>
<th>Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (include Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brennan T, et al., 2010 (130)</td>
<td>20415618</td>
<td>Aim: Assess impact of follow-up and monitoring system including home BP monitoring and telephonic nurse case management on BP control in pts treated for HTN</td>
<td>Study type: RCT</td>
<td>Size: 638 African American pts with high BP from a national health maintenance organization plan</td>
<td>Inclusion criteria: HTN</td>
<td>Intervention: intervention group received telephonic nurse care management, pt education materials, lifestyle counseling, and a home BP monitor</td>
<td>Comparator: Control group received a home BP monitor only</td>
</tr>
<tr>
<td>Bosworth, et al., 2009 (131) 19920269</td>
<td><strong>Aim:</strong> Assess impact of telephone follow-up intervention and/or home BP monitoring on BP control in pts with treated HTN</td>
<td><strong>Inclusion criteria:</strong> Pts with HTN, from 2 university-affiliated primary care clinics.</td>
<td><strong>636 pts randomized to usual care or 1 of 3 intervention groups: (1) Nurse-administered telephone intervention targeting HTN-related behaviors, (2) home BP monitoring 3 times weekly, and (3) both interventions</strong></td>
<td><strong>475 pts (75%) completed the 24-mo BP follow-up.</strong></td>
<td><strong>At 24 mo, improvements in the proportion of pts with BP control relative to the usual care group were 4.3% (95% CI: -4.5%, 12.9%) in the behavioral intervention group, 7.6% (95% CI: -1.9%, 17.0%) in the home BP monitoring group, and 11.0% (95% CI: 1.9%, 19.8%) in the combined intervention group.</strong></td>
<td><strong>Home BP monitoring and tailored behavioral telephone intervention improved BP control, SBP, and DBP at 24 mo relative to usual care. Combined therapy was significantly better than either therapy alone.</strong></td>
<td></td>
</tr>
<tr>
<td>Bosworth, et al., 2011 (132) 21747013</td>
<td><strong>Aim:</strong> Assess impact of telephone follow-up interventions on BP control in pts with treated HTN</td>
<td><strong>Inclusion criteria:</strong> Primary care clinics at a VA Medical Center</td>
<td><strong>593 pts randomized to either usual care or to 1 of 3 telephone follow-up groups: (1) nurse-administered behavioral management, (2) nurse- and physician-administered medication management, or (3) a combination of both</strong></td>
<td><strong>1° endpoint: BP control measured every 6 mo for 18 mo</strong></td>
<td><strong>Behavioral management and medication management alone showed significant improvements at 12 mo-12.8% (95% CI: 1.6%, 24.1%) and 12.5% (95% CI: 1.3%, 23.6%), respectively-but not at 18 mo.</strong></td>
<td><strong>Telephone-based case management for high BP control effectively lowers BP for up to 1 y, but then BP control slackens.</strong></td>
<td></td>
</tr>
</tbody>
</table>

Study type: RCT

Size: 636 pts were randomized; 475 pts completed the trial, including 24-mo follow-up period.

Size: Of 1551 eligible pts, 593 randomized

Study type: RCT
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion criteria: Uncontrolled HTN and Internet access</th>
<th>Intention group with all components achieved better BP control vs. usual care</th>
<th>Combination of home BP monitoring, Internet-based BP management tools, and pharmacist case management helped control HTN better than usual care and better than BP monitoring and Internet-based tool alone.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Green BB, et al., 2008 (133) 18577730</td>
<td>Assess impact of follow-up and monitoring system including home BP monitoring, Internet-based BP management tool, and pharmacist care management on BP control in pts treated for HTN</td>
<td>2 intervention groups: one with home BP monitoring and Internet tool, and the other with home BP monitoring, Internet tool, and pharmacist care management</td>
<td>Cluster RCT</td>
<td>778 pts from 16 clinics in integrated group practice in Washington state.</td>
<td>Compare to usual care</td>
<td>56% (95% CI: 49%–62%) or combination intervention group achieved BP control vs. usual care (p&lt;0.001) and intervention with only home BP monitor and Internet tool (p&lt;0.001)</td>
<td></td>
</tr>
<tr>
<td>Heisler M, et al., 2012 (134) 22570370</td>
<td>Assess impact of follow-up pharmacist care management system on BP control in pts treated for HTN</td>
<td>14-mo intervention period</td>
<td>Cluster RCT</td>
<td>1797 intervention and 2303 control pts from 16 primary care clinics at 5 medical centers (3 VA and 2 Kaiser Permanente)</td>
<td>BP 6 mo prior to and 6 mo after intervention period were compared in intervention and control groups</td>
<td>Mean SBP was 2.4 mm Hg lower (95% CI: -3.4– -1.5), p&lt;0.001 in the intervention group immediately after the intervention period, compared to the control group. BP decrease was the same in the intervention and control groups (9 mm Hg).</td>
<td>Pharmacist care management system in a “real world” setting was more effective than usual care in lowering BP in the short-term, but in the longer-term follow-up did not differ significantly from usual care.</td>
</tr>
<tr>
<td>Margolis KL, et al., 2013 (25) 23821088</td>
<td>Assess impact of follow-up and monitoring system including home BP tele-monitoring and pharmacist case management on BP control in pts treated for HTN</td>
<td>222 pts randomized to 8 usual care clinics and 228 randomized to 8 intervention clinics</td>
<td>Cluster RCT</td>
<td>450 pts from 16 clinics in integrated health system in Minneapolis, MN</td>
<td>Intervention included 12 mo of home BP tele-monitoring and pharmacist case management, with 6 mo of follow-up afterward</td>
<td>Combination of home BP tele-monitoring and pharmacist case management helped control HTN better than usual care at 6, 12, and 18 mo</td>
<td></td>
</tr>
</tbody>
</table>
### Data Supplement 30. RCTs Comparing Stable Ischemic Heart Disease (Section 9.1)

| Study Acronym | Author; Year Published | Aim: To investigate optimal BP in pts ≥60 y with CAD and SBP >150 mm Hg treated with antihypertensive drugs | Study Type: Post-hoc analysis of PROBE trial (INVEST study—atenolol/HCTZ or verapamil-SR/trandolapril) | Inclusion criteria: Pts ≥60 y with CAD and SBP >150 mm Hg treated with antihypertensive therapy | Intervention: • 4,787 pts (57%) achieved SBP <140 mm Hg (group 1) • SBP achieved was <140 mm Hg (group 1) Comparator: • 1,747 pts (21%) achieved SBP of 140–149 mm Hg (group 2); 1,820 pts (22%) achieved SBP ≥150 mm Hg (group 3) • SBP achieved was 140–149 mm Hg (group 2) and 150 mm Hg or higher (group 3) | Endpoint Results (Absolute Event Rates, P value; OR or RR; & 95% CI): 1° endpoint: All-cause death, nonfatal MI, or nonfatal stroke. Multiple propensity score-adjusted 1° outcome showed that compared with group 1, the risk of 1° outcome adjusted HR: 1.12 (95% CI: 0.95–1.32; p=0.19); for group 2 adjusted HR: 1.85 (95% CI: 1.59, 2.14), p<0.0001; for group 3 adjusted HR: 1.64 (95% CI: 1.40, 1.93), p<.0001 1° Safety endpoint: No significant difference between the 3 groups | Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary: Relevant 2° endpoint: Multiple propensity score-adjusted analysis: • Compared with group 1, no significant difference in all-cause mortality in group 2 but increased all-cause mortality in group 3 (HR: 1.64; 95% CI: 1.40–1.93; p<0.0001). • Compared with group 1, increase CV mortality in group 2 (HR: 1.34; 95% CI: 1.01–1.77; p=0.04) and in group 3 (HR: 2.29; 95% CI: 1.79–2.93; p<0.0001). • Compared with group 1, total MI was in group 2 (HR: 1.20; 95% CI: 0.90–1.60; p=0.21) but was increased in group 3 (HR: 2.39; 95% CI: 1.87–3.05; p<0.0001). • Compared with group 1, no significant difference with group 2 but an increase in nonfatal MI in group 3 (adjusted HR: 2.45; 95% CI: 1.02–3.71; p<0.0001). • Compared with group 1, an increase in total stroke in group 2 (HR: 1.89; 95% CI: 1.26–2.82; p=0.002) and in group 3 (HR: 2.93; 95% CI: 2.01–4.27; p<0.001). • Compared with group 1, an increase in nonfatal stroke in group 2 (HR: 1.70; 95% CI: 1.06–2.72; p=0.03) and in group 3 (HR: 2.78; 95% CI: 1.80–4.30; p<0.001). • HF and revascularization not significant | Size: 8,354 pts |

**INVEST**
Bangalore S, et al., 2014 (135)

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<p>| Study type: | Meta-analysis of use of BP-lowering drugs in prevention of CVD from 147 randomized trials |
| Size: | Of 147 randomized trials of 464,000 pts, 37 trials of BBs in CAD included 38,892 pts, and 37 trials of other antihypertensive drugs in CAD included 85,395 pts |
| Inclusion criteria: | The database search used Medline (1966 to Dec. 2007) to identify randomized trials of BP-lowering drugs in which CAD events or strokes were recorded. The search also included the Cochrane Collaboration and Web of Science databases and the citations in trials and previous meta-analyses and review articles. |
| Exclusion criteria: | Trials were excluded if there were &lt;5 CAD events and strokes or if treatment duration was &lt;6 mo. |
| N/A | 1&lt;sup&gt;st&lt;/sup&gt; endpoint: CAD events; stroke |
| Law MR, et al., 2009 (18) | <strong>Results:</strong> In 37 trials of pts with a history of CAD, BBs reduced CAD events 29% (95% CI: 22%, 34%). In 27 trials in which BBs were used after acute MI, BBs reduced CAD events 31% (95% CI: 24%–38%), and in 11 trials in which BBs were used after long-term CAD, BBs insignificantly reduced CAD events 13%. In 7 trials, BBs reduced stroke 17% (95% CI: 1%–30%). CAD events were reduced 14% (95% CI: 2%–25%) in 11 trials of thiazide diuretics, 17% (95% CI: 11%–22%) in 21 trials of ACEIs, insignificantly 14% in 4 trials of angiotensin receptor blockers, and 15% (95% CI: 8%–22%) in 22 trials of CCBs. Stroke was reduced 38% (95% CI: 20%–47%) in 10 trials of thiazide diuretics, 22% (95% CI: 8%–34%) in 13 trials of ACEIs, and 34% from antihypertensive treatment. No adverse events were reported. |
| <strong>Summary:</strong> The optimal SBP in pts ≥60 y with CAD and SBP &gt;150 mm Hg treated with antihypertensive therapy was &lt;140 mm Hg |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1st endpoint and results</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOPE</td>
<td>To investigate effect of ACE-I (Ramipril 10 mg) on CV events in high risk pts. over 5y with a mean entry BP of 139/79 mm Hg in both groups</td>
<td>Pts ≥55 y with history of CAD, stroke, PVD or DM with either HTN, elevated total cholesterol, low LDL cholesterol, smoking, or micro albuminuria.</td>
<td>Ramipril (10 mg) (4,645)</td>
<td>Composite of MI, stroke, or mortality from CV causes.</td>
<td>RR 20%; 95% CI: 9%–29%; p=0.003</td>
</tr>
</tbody>
</table>
|      |     |                    | Placebo (4,652) |                      | • Death from cardiac causes reduced (6.1% vs. 8.1%; p<0.001)  
• Death from MI reduced (9.9% vs. 12.3%; p<0.001)  
• Death from any cause (10.4% vs. 12.2%; p=0.005) |
| SAVE | To assess if captopril decrease morbidity and mortality in pts with LV dysfunction after MI. | Pts (21–80 y) surviving 3 d after MI, EF≤40%. | Captopril (titrated doses) (115) | All-cause mortality: 20% vs. 25%, RR: 19%; 95% CI: 3%–32%; p=0.019 |
|      |     |                    | Placebo (1116) |                      | • Captopril vs. Placebo group BP at 1 y (125±18 / 77±10 mm Hg for placebo vs. 119±18/74±10 mm Hg for captopril; p<0.001)  
• Dizziness, alteration in taste, cough and diarrhea were reported significantly more in the captopril group  
• Ventricular size on Echo studies was independent predictor of adverse CV outcomes |
| EUROPA | To investigate efficacy of perindopril in CV events in pts with stable CAD. | Pts ≥18 y (women) with CAD ≥mo before screening, revascularization ≥6 mo before screening, ≥70% narrowing of major | Perindopril (6,110) | Composite of CV death, nonfatal MI, cardiac arrest with successful CPR | RR 20%; 95% CI: 9%–29; p=0.0003 |

(95% CI: 25%–42%) in 9 trials of CCBs.
<table>
<thead>
<tr>
<th>Size: 12,218 pts</th>
<th>coronary artery: Men with history of chest pain, positive ECG, echo or nuclear test</th>
<th>Exclusion criteria: HF, planned revascularization, &lt;110 mm Hg SBP, uncontrolled HTN, &gt;100 mm Hg DBP, &lt;1 mo use of ACEI or ARB, Cr&gt;150 µmol/L, serum K&gt;5.5 mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MERIT-HF</strong> Goldstein S, et al., 1999 (139) 10526701</td>
<td><strong>Aim:</strong> To investigate if metoprolol (CR/XL) once daily with std. treatment lowers mortality in pts with HF/EF</td>
<td><strong>Inclusion criteria:</strong> Pts 40–80 y with NYHA class II-IV HF for 3 mo before randomization and on standard treatment 2 wk before entry, Stable clinical condition during 2 wk run-in phase, EF ≤0.40.</td>
</tr>
<tr>
<td><strong>Study type:</strong> RCT</td>
<td><strong>Exclusion criteria:</strong> Acute MI, UA &lt;28 d of entry, contra to beta blockade &lt;6 mo, HF due to systemic disease/alcohol abuse, heart transplant candidate, ICD, planned revascularization in past 4 mo, decompensated heart, SBP &lt;100 mm Hg, CCB treatment, amiodarone use within 6 mo</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 3,991 pts</td>
<td><strong>Intervention:</strong> Metoprolol CR/XL (1,990)</td>
<td><strong>Comparator:</strong> Placebo (2,001)</td>
</tr>
<tr>
<td></td>
<td><strong>1º endpoint:</strong> All-cause mortality in the intent to treat</td>
<td><strong>Results:</strong> 145 vs. 217 deaths [11.0 %], RR: 0.66 (95% CI: 0.53–0.81; p=0.00009) or adjusted for interim analyses p=0.0062.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Fewer sudden deaths in the metoprolol group (p=0.0002)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lesser deaths from HF/EF in the metoprolol group (p=0.002)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Metoprolol improved survival and was well tolerated</td>
</tr>
<tr>
<td>Study</td>
<td>Aim</td>
<td>Inclusion criteria</td>
</tr>
<tr>
<td>-------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>Packer M, et al., 2001 (140) 11386263</td>
<td><strong>Aim:</strong> To assess survival in severe chronic HF pts by the use of carvedilol.</td>
<td>HF pts with dyspnea/exertion for 2 mo at least and left EF&lt;25% despite treatment clinically euvoletic; allowed on digitalis, nitrates, hydralazine, spironolactone, or amiodarone. Hospitalized pts with no acute illness.</td>
</tr>
<tr>
<td><strong>Study type:</strong> RCT</td>
<td><strong>Size:</strong> 2,289 pts</td>
<td><strong>Exclusion criteria:</strong> HF due to uncorrected prim. valvular disease or reversible cardiomyopathy cardiac transplant pts., coronary revasc. &lt;2 mo, acute MI or stroke, ventricular tachycardia, on alpha blocker or CCB or on antiarrythmics class I &lt;4 wk, SBP &lt;85 mm Hg, serum Cr &gt;2.8 mg/dL, change in body weight &gt;1.5 kg during screening.</td>
</tr>
<tr>
<td>CAPRICORN</td>
<td><strong>Aim:</strong> To investigate outcomes after carvedilol after MI in pts with LV dysfunction.</td>
<td>Pts ≥18 y, MI within 3–21 d of entry, LVEF≤40%, concurrent ACEI stable dose for at least 24 h, HF pts treated and controlled with ACEI and diuretics but not inotropes.</td>
</tr>
<tr>
<td>Dargie HJ, et al., 2001 (141) 11356434</td>
<td><strong>Study type:</strong> RCT</td>
<td><strong>Size:</strong> 1,959 pts</td>
</tr>
</tbody>
</table>
### Exclusion criteria:
- SBP<90 mm Hg,
- uncontrolled HTN,
- bradycardia, insulin-dependent DM,
- BBs not for HF, Beta-2 agonists and steroids

### MERIT-HF HTN
Herlitz J, et al., 2002 (142) 11862577

**Aim:** To assess metoprolol CR/XL influence on mortality and hospitalizations in HF and HTN pts.

**Study type:** RCT

**Size:** 1,747 pts

**Inclusion criteria:**
- Same as above MERIT-HF, 1999 study (HTN subgroup)

**Exclusion criteria:**
- Same as above MERIT-HF

**Intervention:**
- Metoprolol CR/XL (871)

**Comparator:** Placebo (876)

**1° endpoint:** Total mortality

**Results:** RR: 0.61; 95% CI: 0.44–0.84; p=0.0022

- Total mortality reduction was driven by reduction in the SCD and death from worsening HF
- 12.5% pts had earlier discontinuation due to any cause. Lesser no. of pts in the metoprolol group (n=21) discontinued due to worsening HF
- The mean reduction in BP (adjusted) was 1.7 mm Hg in the metoprolol group vs. 4.8 mm Hg in placebo group (p=0.0001)

### CIBIS-II
1999 (143) 10023943

**Aim:** To determine efficacy of bisoprolol in reducing mortality in chronic HF.

**Study type:** RCT

**Size:** 2,647 pts

**Inclusion criteria:**
- 18–80 y, LVEF≤35%, dyspnea, orthopnea, fatigue, NYHA class III-IV

**Exclusion criteria:**
- Uncontrolled HTN, MI, UA <3 mo revascularization, treatment, heart transplant, AV block <1 degree, SBP <100 mm Hg, renal failure, reversible obstructive lung disease

**Intervention:**
- Bisoprolol (1,327)

**Comparator:** Placebo (1,320)

**1° endpoint:** All-cause mortality

**Results:** 11.8% vs. 17.3% deaths with a RR: 0.66; 95% CI: 0.54–0.81; p<0.0001

- The trial stopped early due to benefit. Bisoprolol group had significantly fewer SCDs.
- Mean age was 61 y so more data on elderly pts is needed

### Elkayam U, et al., 1990 (144) 2242521

**Aim:** To assess comparative efficacy and safety of nifedipine and ISDN alone and the combination for treating for chronic CHF.

**Inclusion criteria:**
- 18–75 y HF pts, NYHA class II and III, LVEF<40%, clinically stable, maintenance dose of Digitalis and diuretics.

**Intervention:**
- Nifedipine (21), ISDN (20), Nifedipine+ISDN (23)

**Comparator:** Placebo

**Endpoints and Results:**
- HF-worsening: 9 in Nifedipine group vs. 3 in ISDN group (p<0.09); and 21 in nifedipine-ISDN group (p<0.001 vs. nifedipine, p<0.0001 vs. ISDN)

- In clinical deterioration nifedipine pts (8) vs. rest of the pts (No difference in LVEF or VO2 max)
- Although all the 3 drug regimens improved exercise capacity, nifedipine treatment alone or in combination resulted in clinical deterioration and worsening of CHF
| Study type: RCT with a crossover design | Exclusion criteria: Pregnancy, nursing, history of MI <1 mo before entry, valvular disease, Angina, significant pulmonary, hepatic, renal and hematologic disease, unable to walk on the treadmill, noncompliance | Clinical deterioration discontinuation: Nifedipine 29% vs. ISDN group 5% (p<0.05) |
| Size: 28 pts | | DBP: Nifedipine alone or combination with ISDN (reduction, p<0.05) |

**The Multicenter Dilitiazem Postinfarction Research Group 1988 (145)**

**Aim:** To assess dilitiazem effect on recurrent infarction and death after acute MI

**Study type:** RCT

**Size:** 2,466 pts

**Inclusion criteria:** 25–75 y admitted to CCU, MI with enzyme confirmation.

**Exclusion criteria:**
- Cardiogenic shock,
- Symptomatic hypotension,
- PH with right HF,
- 2nd/3rd degree heart block,
- HR <50 bpm,
- Contraceptives,
- WPW syndrome,
- CCBs,
- Severe comorbidities or
- Cardiac surgery

**Intervention:** Dilitiazem 240 mg (1,234)

**Comparator:** Placebo (1,232)

**1° endpoints and results:**
- Total mortality: identical in both groups
- Cardiac death and nonfatal MI: 11% fewer in dilitiazem but difference was NS

**Follow-up Results:**
- Pts with BL EF<0.40, late CHF in Dilitiazem group (21%) vs. Placebo (12%) [p=0.004].
- Life table analysis confirmed increased frequency of late CHF in pts taking dilitiazem (p=0.0017)
- Dilitiazem related CHF exclusively associated with systolic LVD with or without BBs

---

**MDPIT Goldstein RE, et al., 1991 (146)**

**Aim:** To determine if dilitiazem increases late onset CHF in post-MI pts with early decline in EF.

**Study type:** RCT

**Size:** 2,466 pts

**Inclusion criteria:** Same as above

**Exclusion criteria:** Same as above

**Intervention:** Dilitiazem 240 mg (1,234)

**Comparator:** Placebo (1,232)

**1° endpoint and results:** Same as above

**Follow-up Results:**
- No combined benefit from dilitiazem on mortality or cardiac events
### 2017 Hypertension Guideline Data Supplements

<table>
<thead>
<tr>
<th>Study Ref.</th>
<th>Aim</th>
<th>Study type</th>
<th>Size</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>1st endpoint</th>
<th>Results</th>
<th>Additional Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freemantle N, et al., 1999 (147) 10381708</td>
<td>To evaluate BBs effectiveness for short-term treatment and long-term 2° prevention in acute MI.</td>
<td>Meta-analysis of RCTs</td>
<td>54,234 pts (82 RCTs)</td>
<td>RCTs with treatment lasting &gt;1 d and with follow-ups on clinical effectiveness in pts with MI</td>
<td>BBs (mostly propranolol, timolol, metoprolol)</td>
<td>Controls (placebo/other treatment)</td>
<td>All-cause mortality</td>
<td>Long-term trials RR reduction: 23% (95% CI: 15%–31%) Short-term trials RR reduction: 4%; 95% CI: -8%–5% Meta-regression in long-term trials indicated a near significant trend for decreased benefit in drugs with ISA. NS in withdrawal between BBs of different cardio selectivity.</td>
<td></td>
</tr>
<tr>
<td>de Peuter OR, et al., 2009 (148) 19841485</td>
<td>To determine influence of beta-2 blockade in addition to beta-1 blockade for preventing vascular events in pts with ACS or HF.</td>
<td>Meta-analysis of RCTs</td>
<td>34,360 pts (33 RCTs)</td>
<td>RCTs comparing Beta-1 blockers vs. BBs 1 + 2 directly (5) RCTs comparing Beta-1 blockers vs. Beta 1 + 2 blockers with a control group (28) Studies not pre-specifying total mortality and vascular event as outcomes &lt;3 mo follow-up, duplicate data, sub studies.</td>
<td>Beta-1 blockers</td>
<td>BBs 1+2 with or without control group</td>
<td>Total mortality, vascular events.</td>
<td>ACS Population: 1 study with different BBs underpowered to detect difference. Beta-1 vs. Placebo NS reduced mortality or vascular events HF population: Beta 1 + 2 blockers vs. Beta 1 blockers decreased mortality RR: 0.86; 95% CI: 0.78–0.94 Beta 1 and Beta 1+2 decreased total mortality. Only Beta 1+2 blockers reduced vascular events. Supplementary beta 2 blockade may be more beneficial. Indirect comparisons and heterogeneity among studies</td>
<td></td>
</tr>
<tr>
<td>Leon MB, et al., 1981 (149) 7246435</td>
<td>To evaluate effectiveness of verapamil as a single agent and in combination with propranolol in pts with stable AP.</td>
<td></td>
<td></td>
<td>Symptomatic angina pectoris pts, 1) not sufficiently controlled on BBs and nitrates and noncardiac</td>
<td>Propranolol, verapamil, Combination of propranolol and verapamil</td>
<td>Large dose verapamil significantly lowered BP. Propranolol and verapamil combined (at best dose) further lowered BP, improved HR and pressure-rate product lowered significantly on combination therapy PR interval increased on combination treatment Regarding antianginal properties, verapamil seemed to be more effective than propranolol.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc. 107
<table>
<thead>
<tr>
<th>Study type: RCT (triple crossover)</th>
<th>Comparator: Placebo</th>
<th>effects from propranolol hindering treatment 2) who could stay 4 wk in hospital</th>
<th>exercise time by 4.7 ± 0.7 min (p&lt;0.001)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Size: 11 pts</th>
<th>Exclusion criteria: LVD with CHF or LVEF&lt;30% at rest and &lt;25% for exercise, HR&lt;50 b/min, ≥first degree heart block</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Aim: To determine if active treatment reduces complications from isolated systolic HTN in the elderly.</th>
<th>Inclusion criteria: Pts ≥60 y, sitting SPB 160–219 mm Hg, sitting DBP 95 mm Hg, and standing SBP ≥140 mm Hg.</th>
</tr>
</thead>
</table>

| Exclusion criteria: Systolic HTN 2nd to a disorder, retinal hemorrhages/papilledema, CHF, aneurysms, serum Cr ≥180 µmol/L, history of nosebleed, stroke, MI <1 y, dementia, substance abuse, severe comorbidities |
|---------|-----------------------------------------------------------------------------------------------------|

<table>
<thead>
<tr>
<th>Intervention: Active treatment (2,398)</th>
<th>Comparator: Placebo (2,297)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>1° endpoint: Fatal and nonfatal strokes combined.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Results: 13.7 vs. 7.9 endpoints/ 1,000 pts-y (42% reduction; p=0.003)</th>
</tr>
</thead>
</table>

| Aim: To compare in pts with a SBP of 130–180 mm Hg and an increased CV risk but without DM the effect of a target SBP of <140 mm Hg vs. a target SBP of <120 mm Hg on the 1° composite outcome of MI, other ACSs, |
|----------------------------------|-----------------------------------------------------------------|

<table>
<thead>
<tr>
<th>Inclusion criteria: 9,361 pts, mean 67.9 y (28.2% ≥75 y; 35.6% women; 57.7% non-Hispanic white; 31.5% African American; 10.5% Hispanic) with a SBP of 130–180 mm Hg and an increased CV risk but without DM, history of stroke, symptomatic HF within</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Intervention: 4,678 pts were randomized to intensive BP treatment</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Comparator: Placebo</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>1° endpoint:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>At 1 y, the mean SBP was 121.4 mm Hg with intensive treatment (mean number of antihypertensive drugs was 2.8) and 136.2 mm Hg with standard treatment (mean number of antihypertensive drugs was 1.8)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Results:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>3.26-y median follow-up, compared with standard BP treatment, intensive BP treatment reduced all-cause mortality 27% (p=0.003), HF 38% (p=0.002), CV mortality 43% (p=0.005), and the 1° composite outcome or death 22% (p&lt;0.001)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>• Intensive BP treatment reduced the 1° composite endpoint 33% (14% to 49%) in pts aged 75 y and older and 20% (0% to 36%) in pts 50–74 y</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>• Serious adverse events were similar in both treatment groups. However, intensive BP treatment caused more hypotension (2.4% vs. 1.4%; p=0.001), more syncope (2.3% vs. 1.7%; p=0.05), more</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Wright JT, et al., 2015 (114)</th>
</tr>
</thead>
</table>

| Aim: To compare in pts with a SBP of 130–180 mm Hg and an increased CV risk but without DM the effect of a target SBP of <140 mm Hg vs. a target SBP of <120 mm Hg on the 1° composite outcome of MI, other ACSs, |
|----------------------------------|-----------------------------------------------------------------|

<table>
<thead>
<tr>
<th>Inclusion criteria: 9,361 pts, mean 67.9 y (28.2% ≥75 y; 35.6% women; 57.7% non-Hispanic white; 31.5% African American; 10.5% Hispanic) with a SBP of 130–180 mm Hg and an increased CV risk but without DM, history of stroke, symptomatic HF within</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Intervention: 4,678 pts were randomized to intensive BP treatment</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Comparator: Placebo</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>1° endpoint:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>At 1 y, the mean SBP was 121.4 mm Hg with intensive treatment (mean number of antihypertensive drugs was 2.8) and 136.2 mm Hg with standard treatment (mean number of antihypertensive drugs was 1.8)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Results: 13.7 vs. 7.9 endpoints/ 1,000 pts-y (42% reduction; p=0.003)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>• All fatal and nonfatal cardiac endpoints (with sudden death) decreased in the active treatment group (p=0.03)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>• Cardiac mortality was lower in active treatment (-27%; p=0.07). All-cause mortality was not different.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>• Nitrendipine used for active arm.</th>
</tr>
</thead>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
stroke, HF, or CV death

<table>
<thead>
<tr>
<th>Past 6 mo, LVEF &lt;35%, and eGFR &lt;20 mL/min/1.73 mm²; CVD was present in 20.1%, and the Framingham 10-y CVD risk score was ≥15% in 61.3% of pts</th>
</tr>
</thead>
<tbody>
<tr>
<td>• At 3.26-y median follow-up, the 1° composite outcome was reduced 25% (p&lt;0.001) by intensive BP treatment</td>
</tr>
<tr>
<td>Electrolyte abnormality (3.1% vs. 2.3%; p=0.02), and more acute kidney injury or acute renal failure (4.1% vs. 2.5%; p&lt;0.001). The incidence of bradycardia, injurious falls, and orthostatic hypotension with dizziness was similar in both treatment groups</td>
</tr>
</tbody>
</table>

### ALLHAT Collaborative Research Group, 2003

**Aim:** In a follow-up analysis, to compare diuretic vs. alpha-blocker as first step treatment of hypertension.

**Inclusion criteria:** Men and women ≥ 55 y with BP ≥140/90 mm Hg or on medications for hypertension with at least one additional risk factor for coronary heart disease.

**Intervention:** 15,255 patients were randomized to chlorthalidone and 9,061 to doxazosin and followed for 3.2 y.

**Primary endpoint:** Combined fatal coronary heart disease or non-fatal MI, analyzed by intention to treat.

- There was no difference in primary outcome between the arms (RR: 1.02; 95% CI: 0.94–1.13).
- However, the doxazosin arm compared with the chlorthalidone arm had a higher risk for stroke (RR: 1.26; 95% CI: 1.10–1.46) and combined cardiovascular disease (RR: 1.20; 95% CI: 1.13–1.27).
- The findings confirmed the superiority of diuretic-based over alpha blocker based antihypertensive treatment in the prevention of cardiovascular disease.

### Zanchetti A, et al., 2006

**Aim:** To provide additional analyses of the primary endpoint in the VALUE trial, including sex, age, race, geographic region, smoking status, type 2 diabetes, total cholesterol, left ventricular hypertrophy, proteinuria, serum creatinine, history of coronary heart disease, stroke or transient ischemic attack and history of peripheral artery disease.

**Inclusion criteria:** The 15,245 patients participating in VALUE were divided into subgroups according to baseline characteristics.

**Statistical analysis:** Subgroup interaction analyses were conducted by the Cox proportion hazard model. Within each subgroup, treatment effects were assessed by hazard ratios and 95% CIs.

- For cardiac morbidity and mortality, the only significant subgroup by treatment interaction was of sex (p=0.016) with HR indicating a relative excess of cardiac events in women but not in men, but SBP differences in favor of amlodipine were greater in women.
- In the VALUE cohort, in no subgroup of patients were there differences in the incidence of the composite cardiac endpoint with valsartan and amlodipine treatment despite greater BP reduction in the amlodipine group.
Aim: To compare the long-term relative safety and outcomes of ACE inhibitor- and CCB-based regimens in older hypertensive individuals in ALLHAT.

Inclusion criteria: men and women age ≥55 y with untreated (BP 140–180/90–110 mm Hg) or treated hypertension (BP ≤160/100 mm Hg on ≤2 antihypertensive drugs) with ≥ 1 additional risk factor for coronary heart disease.

Intervention: Patients (were randomized to amlodipine (9,048) or Lisinopril (9,054).

Primary outcome: Combined fatal coronary heart disease or non-fatal MI, analyzed by intention to treat.

Follow-up: 4.9 y

- Risk of coronary heart disease was similar between amlodipine and Lisinopril
- For stroke, combined cardiovascular disease, gastrointestinal bleeding and angioedema, risks are higher with Lisinopril compared to amlodipine.
- For heart failure, risks are higher with amlodipine compared to Lisinopril.

Data Supplement 31. Meta-analyses of ischemic heart disease (Section 9.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; and CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bundy JD, et al., 2017 28564682</td>
<td>Study type: Network meta-analysis. Size: 144,220 patients in 42 RCTs.</td>
<td>Inclusion criteria: Random allocation into an antihypertensive medication, control or treatment target. Allocation to antihypertensive Antihypertensive treatment was independent of other treatment regimens. ≥100 patients in each treatment group. Trial duration ≥ 6 mo. One or more events for each treatment group reported. Minimum 5 mm Hg difference in SBP level between the 2 treatment groups. Outcomes included major CVD, stroke, CHD, CVD mortality or all-cause mortality.</td>
<td>• There were linear associations between mean achieved SBP and risk of cardiovascular disease and mortality, with the lowest risk at 120 to 124 mm Hg. Randomized groups with a mean achieved SBP of 120 to 124 mm Hg had a hazard ratio (HR) for major cardiovascular disease of 0.71 (95% CI: 0.60–0.83) compared with randomized groups with a mean achieved SBP of 130 to 134 mm Hg, an HR of 0.58 (95% CI: 0.48–0.72) compared with those with a mean achieved SBP of 140 to 144 mm Hg, an HR of 0.46 (95% CI: 0.34–0.63) compared with those with a mean achieved SBP of 150 to 154 mm Hg, and an HR of 0.36 (95% CI: 0.26–0.51) compared with those with a mean achieved SBP of 160 mm Hg or more.</td>
<td>• This study suggests that reducing SBP to levels below currently recommended targets significantly reduces the risk of cardiovascular disease and all-cause mortality and strongly support more intensive control of SBP among adults with hypertension.</td>
</tr>
</tbody>
</table>
### Data Supplement 32. Nonrandomized Trials, Observational Studies, and/or Registries of Ischemic Heart Disease (Section 9.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; and 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROVE IT-TIMI 22 Bangalore S, et al., 2010 (151) <strong>21060068</strong></td>
<td>Study type: Nonrandomized trial of optimal BP after ACS</td>
<td>Inclusion criteria: Pts with acute MI or high-risk UA within 10 d randomized to pravastatin or atorvastatin and to gatifloxacin or placebo treated with standard medical and interventional treatment for ACS</td>
<td>1° endpoint: Composite of all-cause death, MI, UA requiring rehospitalization, revascularization after 30 d, and stroke with a mean follow-up of 24 mo</td>
<td>• After an ACS, a J- or U-shaped association existed between BP and the incidence of new CV events. The lowest incidence of CV events occurred with a BP of 130–140/80–90 mm Hg and a relatively flat curve for SBP of 110–130 mm Hg and of DBP of 70–90 mm Hg, suggesting a BP &lt;110/70 mm Hg may be dangerous.</td>
</tr>
</tbody>
</table>

| Law MR, et al., 2009 (18) **19454737** | Study type: Meta-analysis of use of BP-lowering drugs in prevention of CVD from 147 randomized trials | Inclusion criteria: The database search used Medline (1966 to Dec. 2007) to identify randomized trials of BP-lowering drugs in which CAD events or strokes were recorded. The search also included the Cochrane Collaboration and Web of Science databases and the citations in trials and previous meta-analyses and review articles. | 1° endpoint: CAD events; stroke | • With the exception of the extra protective effect of BBs given shortly after a MI and the minor additional effect of CCBs in preventing stroke, all the classes of BP-lowering drugs have a similar effect in reducing CAD events and stroke for a given reduction in BP. |
### Data Supplement 33. RCTs Comparing Heart Failure (Section 9.2)

<table>
<thead>
<tr>
<th>Study Acronym (if applicable)</th>
<th>Author Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; and 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| LV J, et al., 2013 (127)    | 23798459               | Study type: MA of RTC that randomly assigned individuals to different target BP levels  
  **Size:** 37,348 pts | •15 trials  
  7.5/4.5 mm Hg BP difference. Intensive BP lowering achieved.  
  RR for  
  • Major CV events: 11%; 95% CI: 1%–21%  
  • MI: 13%; 95% CI: 0%–25%  
  • Stroke: 24%; 95% CI: 8%–37%  
  • ESRD: 11%; 95% CI: 3%–18%  
  • Albuminuria: 10%; 95% CI: 4%–16%  
  • Retinopathy 19%; 95% CI: 0%–34%  
  p=0.051 | More intensive strategy for BP control reduced cardio-renal endpoint |
| Xie X, et al., 2015 (21)    | 26559744               | Study type: MA of RTC that randomly assigned individuals to different target BP levels  
  **Size:** 44,989 pts | •19 trials  
  Achieved BP  
  133/76 mm Hg (intensive) 140/81 (less intense)  
  • Major CV events: 14%; 95% CI: 4%–22%  
  • MI: 13%; 95% CI: 0%–24%  
  • Stroke: 22%; 95% CI: 10%–32%  
  • Albuminuria: 10%; 95% CI: 3%–16%  
  • Retinopathy progression: 19%; 95% CI: 0%–34%  
  • More intensive had no effects on HF: 15%; 95% CI: -11%–34%  
  • CV death: 9%; 95% CI: -11%–26%  
  • Total mortality: 9%; 95% CI: -3%–19%  
  • ESKD: 10%; 95% CI: -6%–23% | More intensive approach reduced major CV events (stroke and MI) except heat failure, CVD, ESRD, and total mortality. |
| Thomopolous C, et al., 2016 (54) | 26848994 | Study type: Meta-analysis of RTCs of more vs. less intense BP control  
  •16 trials (52,235 pts) compared more vs. less intense treatment  
  34 (138,127 pts) active vs. placebo | More intense BP  
  • Stroke RR: 0.71; 95% CI: 0.60–0.84  
  • CHD RR: 0.80; 95% CI: 0.68–0.95  
  • Major CV events RR: 0.75; 95% CI: 0.68–0.85  
  • CV mortality RR: 0.79; 95% CI: 0.63–0.97  
  Stratification of SBP cutoffs (150,140 and 130 mm Hg) showed that a SBP/DBP difference of 10/5 mm Hg across each cutoff reduced risk of all outcomes | Intensive BP reduction improves CV outcomes compared to less intense Achieved BP <130/80 may be associated with CV benefit. |
## Data Supplement 34. RCTs Comparing HFrEF (Section 9.2.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study</th>
<th>Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| Herlitz J, et al., 2002 (142) 113862577 | **Aim:** To see effect of metoprolol vs. placebo on mortality and hospitalizations among pts with history of HTN and HF with reduced LVEF  
**Study type:** RCT  
**Size:** 1,747 pts | **Inclusion criteria:** NYHA class II–IV HF with LVEF ≤40% within 3 mo of enrollment; supine resting HR ≥68 bpm; stable clinical condition  
**Exclusion criteria:** Acute MI or UA within 28 d of randomization; indication or contraindication for treatment with BBs or drugs with beta-blocking properties; poor compliance; CABG surgery or PTCA in past 4 mo | **Intervention:**  
• Administration of metoprolol  
• 871 pts randomized to metoprolol  
**Comparator:**  
• Administration of placebo  
• 876 pts randomized to placebo | **1° endpoint:** At 1-y follow-up, compared with placebo, metoprolol reduced all-cause mortality 39% (95% CI: 16%–56%; p=0.002) and all-cause mortality or all-cause hospitalization 24% (95% CI: 11%–35%; p=0.0007)  
**1° Safety endpoint:** Early permanent cessation of drug was 12.5% for metoprolol and 15.9% for placebo (p=0.048); 21 pts on metoprolol and 35 pts on placebo had early cessation because of worsening | **Relevant 2° endpoint:** At 1-y follow-up, compared with placebo, metoprolol reduced CV death 41% (95% CI: 17%–57%; p=0.002), death from HF: 51% (95% CI: 1%–75%; p=0.042), sudden cardiac death 49% (95% CI: 21%–67%; p=0.002), all-cause mortality or HF hospitalization 28% (95% CI: 11%–42%; p=0.002), and cardiac death or nonfatal acute MI 44% (95% CI: 23%–60%; p=0.0003)  
**Study limitations and adverse events:** Early permanent cessation of drug was 12.5% for metoprolol and 15.9% for placebo (p=0.048); 21 pts on M and 35 pts on placebo had early cessation because of worsening HF; all-cause withdrawals were 22% less with metoprolol; (p=0.048); adverse events were 28% less with metoprolol (p=0.026); worsening HF was 41% less with metoprolol (p=0.056)  
**Summary:** In an RCT of pts with HF with reduced EF and a history of HTN, compared with placebo, metoprolol succinate reduced all-cause mortality and all-cause hospitalization |
| Packer M, et al., 2001 (140) 11386263 | **Aim:** To assess survival in severe HF pts with dyspnea/exertion for 2 mo at least and left EF<25% despite | **Inclusion criteria:** HF pts with dyspnea/exertion for 2 mo at least and left EF<25% despite | **Intervention:** Carvedilol (1,156) | **1° endpoint:** Death from any cause 130 vs. 190 deaths (RR: 35%; p=0.0003)  
**Summary:** Study stopped early (1.3 y follow-up) due to benefit on survival | **Relevant 2° endpoint:** At 1-y follow-up, compared with placebo, carvedilol reduced all-cause mortality and all-cause hospitalization  
**Summary:** In an RCT of pts with severe HF, compared with placebo, carvedilol reduced all-cause mortality and all-cause hospitalization |

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Size</th>
<th>Inclusion Criteria</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Endpoints and Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAPRICORN</strong>&lt;br&gt;Dargie HJ, et al., 2001 (141)&lt;br&gt;11356434</td>
<td>1,959 pts</td>
<td>Pts ≥18 y, MI within 3–21 d of entry, LVEF ≤40%, concurrent ACEI stable dose for at least 24 h, HF pts treated and controlled with ACEI and diuretics but not inotropes.</td>
<td>Nifedipine (975)</td>
<td>Placebo (984)</td>
<td>1st endpoint: All-cause mortality or hospital admissions for CV issues&lt;br&gt;Results: 12% vs. 15%; RR: 23% (95% CI: 0.60–0.98; p=0.03) No difference between groups for death or CV hospital admissions&lt;br&gt;&lt;br&gt;• CV mortality, nonfatal MI reduced in the carvedilol group&lt;br&gt;• No difference between groups sudden death and admission due to HF</td>
</tr>
<tr>
<td><strong>Elkayam U, et al., 1990 (144)&lt;br&gt;2242521</strong></td>
<td>18–75 y old HF pts, NYHA class II and III, LVEF&lt;40%, clinically stable, maintenance dose of Digitalis and diuretics.</td>
<td>Nifedipine (21), ISDN (20), Nifedipine+ISDN (23)</td>
<td>Placebo</td>
<td></td>
<td>• In clinical deterioration nifedipine pts (8) vs. rest of the pts (No difference in LVEF or VO² max.)&lt;br&gt;• Although all the 3 drug regimens improved exercise capacity, nifedipine treatment alone or in combination resulted in clinical deterioration and worsening of CHF</td>
</tr>
<tr>
<td>Study type: Crossover RCT</td>
<td>Study type: RCT</td>
<td>Study type: RCT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------------</td>
<td>----------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Size</strong>: 28 pts</td>
<td><strong>Size</strong>: 2,466 pts</td>
<td><strong>Size</strong>: 2,569 pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hepatic, renal and hematologic disease, unable to walk on the treadmill, noncompliance</td>
<td>Inclusion criteria: 18–75 y HF pts, NYHA class II and III, LVEF &lt;40%, clinically stable, maintenance dose of digitalis and diuretics.</td>
<td>Inclusion criteria: 5,010 pts, mean age 63 y, with NYHA class II-IV HF/rEF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nifedipine 29% vs. ISDN group 5% (p&lt;0.05) • DBP: Nifedipine alone or combination with ISDN (reduction, p&lt;0.05)</td>
<td>Intervention: Dilitiazem 240 mg (1,234)</td>
<td>Intervention/Compar ator: 5,010 pts on standard therapy for HF were randomized to valsartan or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1° endpoint and results: • HF-worsening: 9 in Nifedipine group vs. 3 in ISDN group (p&lt;0.09); and 21 in nifedipine-ISDN group (p&lt;0.001 vs. nifedipine, p&lt;0.0001 vs. ISDN)</td>
<td>Comparator: Placebo (1,232)</td>
<td>1° endpoint and results: • At 23-mo follow-up, mortality was similar in pts treated with valsartan or placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At 41.4-mo follow-up, compared with placebo, enalapril reduced mortality by 16% (p=0.0036)</td>
<td>Follow-up Results: Pts with BL EF&lt;0.40, late CHF in Dilitiazem group (21%) vs. Placebo (12%) p=0.004.</td>
<td>• Treatment with valsartan resulted in improvements in NYHA class, LVEF, signs and symptoms of HF, and quality of life compared with placebo (p&lt;0.01).</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MDPIT**
Goldstein RE, et al., 1991 (146) 1984898

**Cohn JN, et al., 2001 (152) 11759645**

**SOLVD Investigators, 1991 (153) 2057034**

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Reference</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention/Comparator</th>
<th>1&lt;sup&gt;st&lt;/sup&gt; endpoint and results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1993 (154)</td>
<td>1993</td>
<td>(154)</td>
<td>To determine the effect of ramipril vs. placebo on mortality in pts with HF r EF</td>
<td>2,006 pts, mean age 65 y, with HF r EF after MI and without NYHA class0HF</td>
<td>2,006 pts were randomized to ramipril or placebo</td>
<td>At 15-mo mean follow-up, compared with placebo, ramipril reduced all-cause mortality 27% (p=0.002). The reduction in mortality was primarily due to a 31% (17%–42%) reduction in death from progressive HF.</td>
<td>Analysis of prespecified 2º outcomes showed that ramipril reduced the first validated outcome (death, severe/resistant HF, MI, or stroke) by 19% (p=0.008).</td>
</tr>
<tr>
<td>Garg R, et al., 1995 (155)</td>
<td>1995</td>
<td>(155)</td>
<td>A meta-analysis was performed to determine the effect of ACEIs vs. placebo on mortality and on mortality plus hospitalization for HF in pts with HF r EF</td>
<td>The meta-analysis included 32 trials of 7,105 pts with HF r EF treated with ACEIs vs. placebo</td>
<td>In 25 trials, pts were treated with digoxin and/or diuretics, 4 trials only used diuretics, 1 trial used only digoxin, and 2 trials used no background therapy</td>
<td>Compared with placebo, ACEIs reduced all-cause mortality 23% (p&lt;0.001) and all-cause mortality or hospitalization for HF 35% (p&lt;0.001).</td>
<td></td>
</tr>
<tr>
<td>Pfeffer MA, et al., 2003 (156)</td>
<td>2003</td>
<td>(156)</td>
<td>To determine the effect of valsartan, captopril, or both on mortality in pts with MI complicated by HF, LV dysfunction, or both</td>
<td>14,703 pts, mean age 65 y, with MI complicated by HF, LV dysfunction, or both</td>
<td>4,909 pts were randomized to valsartan, 4,909 pts were randomized to captopril</td>
<td>At 24.7-mo median follow-up, mortality was similar in the 3 treatment groups. The incidence of adverse events causing discontinuation of drug was 5.8% with valsartan, 7.7% with captopril, and 9.0 % with valsartan plus captopril (p&lt;0.05 comparing valsartan with captopril and valsartan plus captopril with captopril).</td>
<td></td>
</tr>
<tr>
<td>Maggioni AP, et al., 2002 (157)</td>
<td>2002</td>
<td>(157)</td>
<td>A subgroup analysis of the Val-HeFT study was performed to determine the effect of valsartan vs. placebo on mortality and on mortality plus morbidity in pts with HF r EF not receiving ACEIs</td>
<td>366 pts, mean age 67 y, with HF r EF not receiving ACEIs</td>
<td>185 pts were randomized to valsartan and 181 pts were randomized to placebo</td>
<td>Compared with placebo, valsartan reduced first hospital admission for HF 53% (p=0.0006).</td>
<td></td>
</tr>
</tbody>
</table>

HF = heart failure, MI = myocardial infarction, EF = ejection fraction, NYHA = New York Heart Association, ACEI = angiotensin-converting enzyme inhibitor, LV = left ventricular.
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention/Comparator</th>
<th>1° endpoint and results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granger CB, et al., 2003 (158) 13678870</td>
<td>To determine the effect of candesartan vs. placebo on mortality in pts with HF/EF intolerant to ACEIs</td>
<td>2,028 pts, mean age 67 y, with HF/EF intolerant to ACEIs</td>
<td>1,013 pts were randomized to candesartan and 1,015 pts were randomized to placebo</td>
<td>At 33.7-mo median follow-up, compared with placebo, the 1° endpoint of CV death or hospital admission for HF was reduced 30% by candesartan (p&lt;0.0001).</td>
<td>Compared with placebo, candesartan reduced CV death, hospital admission for HF, MI, stroke, or coronary revascularization 24% (p&lt;0.0001).</td>
</tr>
<tr>
<td>Pitt B, et al., 2003 (159) 12668699</td>
<td>To determine the effect of eplerenone vs. placebo on mortality and on CV death or hospitalization for CV events in pts with MI complicated by HF</td>
<td>6,632 pts, mean age 64 y, with HF/EF after MI</td>
<td>3,313 pts were randomized to eplerenone and 3,319 pts were randomized to placebo</td>
<td>At 16-mo mean follow-up, eplerenone reduced mortality 15% (p=0.008) and CV death or hospitalization for CV events 17% (p=0.005).</td>
<td>Compared with placebo, eplerenone reduced death from any cause or any hospitalization 8% (p=0.02) and sudden cardiac death 21% (p=0.03), reduced hypokalemia from 13.1% to 8.4% (p&lt;0.001), and increased serious hyperkalemia from 3.9%–5.5% (p=0.002).</td>
</tr>
<tr>
<td>Taylor AL, et al., 2004 (160) 15533851</td>
<td>To determine the effect of ISDN plus hydralazine vs. placebo on mortality, first hospitalization for HF, and change in quality of life in black pts with HF/EF</td>
<td>1,050 African American pts, mean age 57 y, with HF/EF and NYHA class III or IV HF.</td>
<td>518 pts were randomized to ISDN plus hydralazine and 532 pts were randomized to placebo</td>
<td>At 10-mo mean follow-up, compared with placebo, the mean 1° endpoint of mortality, first hospitalization for HF, and change in quality of life was reduced by ISDN plus hydralazine (p=0.01).</td>
<td>Compared with placebo, ISDN plus hydralazine reduced mortality from 10.2%–6.2% (p=0.02) causing cessation of the study.</td>
</tr>
<tr>
<td>The Multicenter Diltiazem Postinfarction Research Group, 1988 (145) 2899040</td>
<td>To assess diltiazem effect on recurrent infarction and death after acute MI</td>
<td>25–75 y admitted to CCU, MI with enzyme confirmation.</td>
<td>Diltiazem 240 mg (1,234) Comparator: Placebo (1,232)</td>
<td>1° endpoints and results:</td>
<td>No combined benefit from diltiazem on mortality or cardiac events</td>
</tr>
<tr>
<td>ONTARGET Investigators, et al., 2008 (126) 18378520</td>
<td>Evaluate whether use of an ARB was noninferior to ACEI, and whether the combination was</td>
<td>≥55 y</td>
<td>Ramipril 10 mg daily (n=8,576) Comparator: Telmisartan 80 mg daily (n=8,556)</td>
<td>At a median follow-up of 56 mo, there was no difference between ramipril vs. telmisartan or combination therapy vs. ramipril in the 1° endpoint</td>
<td>Telmisartan was equivalent to ramipril in pts with vascular disease or high-risk DM and was associated with less angioedema. The combination of the 2 drugs was associated with more...</td>
</tr>
</tbody>
</table>
superior to ACE alone in the prevention of vascular events in pts with CVD or DM but not HF.

**Study type:** Multi-center, double-blind, RCT

**Size:** 25,620 pts

<table>
<thead>
<tr>
<th>Telmisartan 80 mg daily (n=8,542)</th>
<th>Combination of telmisartan and ramipril (n=8,502)</th>
</tr>
</thead>
<tbody>
<tr>
<td>with end-organ damage</td>
<td>composite outcome of death from CV causes, MI, stroke, or hospitalization for HF (RR: 1.01; 95% CI: 0.94–1.09 and RR: 0.99; 95% CI: 0.92–1.07, respectively)</td>
</tr>
</tbody>
</table>

**Exclusion criteria:**
- Inability to discontinue ACEI or ARB
- Known hypersensitivity or intolerance to ACEI or ARB
- Selected CVDs (congestive HF, hemodynamically significant valvular or outflow tract obstruction, constrictive pericarditis, complex congenital heart disease, syncopal episodes of unknown etiology <3 mo, planned cardiac surgery or PTCA <3 mo, uncontrolled HTN on treatment [e.g., BP >160/100 mm Hg], heart transplant recipient, stroke due to subarachnoid hemorrhage)
- Other conditions (significant renal artery disease, hepatic dysfunction, uncorrected volume or sodium depletion, 1° hyperaldosteronism, hereditary fructose intolerance, other major noncardiac illness or expected to reduce life expectancy or significant disability interfere with study participation, simultaneously taking another experimental drug, unable to provide written informed consent).

**Safety endpoint:**
- Combination therapy was associated with greater risk of hyperkalemia than ramipril monotherapy (480 pts vs. 283 pts; p<0.001)
- Hypotensive symptoms were cited as reason for permanent discontinuing more in telmisartan vs. ramipril (RR: 1.54; p<0.001) and combination therapy vs. ramipril monotherapy (RR: 2.75; p<0.001)
- Renal impairment was more common in combination therapy vs. ramipril monotherapy (RR: 1.33; 95% CI: 1.22–1.44)

adverse events without an increase in benefit
### Study Acronym; Author; Year Published

**TOPCAT**

Pfeffer MA, et al., 2015 (161)  

**Study type:** Post-hoc analysis of prospective, double-blind, RCT  

**Size:** 3,445 pts

### Aim of Study; Study Type; Study Size (N)

**Aim:** To investigate variation in pts and outcome in TOPCAT between pts from the Americas vs. Russia/Georgia  

**Exclusion criteria:** Acute MI or UA within 28 d of randomization; indication or contraindication for treatment with BBs or drugs with beta-blocking properties; poor compliance; CAGB surgery or PTCA in past 4 mo

### Patient Population

**Inclusion criteria:** NYHA class II–IV HF with LVEF ≤40% within 3 mo of enrollment; supine resting heart rate ≥68 bpm; stable clinical condition

### Study Intervention (# patients) / Study Comparator (# patients)

**Intervention:**  
- Americas 886 on spironolactone  
- Russia/Georgia 836 on spironolactone  
- Spironolactone 15–45 mg daily  

**Comparator:**  
- Americas 881 on placebo  
- Russia/Georgia 842 on placebo  
- Placebo

### Endpoint Results (Absolute Event Rates, P value; OR or RR; & 95% CI)

**1° endpoint:** Composite of CV death, aborted cardiac arrest, or HF hospitalization at 3.3 y follow-up was: Americas: 27.3% for spironolactone and 31.8% for placebo HR: 0.82; 95% CI: 0.69–0.98; p=0.026; Russia/Georgia 9.3% for spironolactone and 8.4% for placebo HR: 1.10; 95% CI: 0.79–1.51; p=0.58

**1° safety endpoint:**  
- Doubling of serum creatinine: Americas: 17.8% for spironolactone and 11.6% for placebo HR: 1.60; 95% CI: 1.25–2.05; p<0.001  
- Russia/Georgia 2.0% for S and 2.1% for placebo HR: 0.95; 95% CI: 0.49–1.85; p=0.89  
  
  - Creatinine >3.0 mg/dL  
  - Americas 9.8% for spironolactone and 9.1% for placebo HR: 1.10; 95% CI: 0.81–1.49; p=0.55  
  - Russia/Georgia 0.2% for spironolactone and 0.4% for placebo HR: 0.5; 95% CI: 0.09–2.75; p=0.43  
  - Hyperkalemia (potassium >5.5 mmol/L)  
  - Americas 25.2% for spironolactone and 8.9% for placebo OR: 3.46; 95% CI: 2.62–4.56; p<0.001

**Relevant 2° endpoint:** CV mortality: Americas 10.8% for spironolactone and 14.4% for placebo HR: 0.74; 95% CI 0.57–0.97; p=0.027; Russia/Georgia 7.7% for spironolactone and 5.8% for placebo HR: 1.31; 95% CI: 0.91–1.90; p=0.15. Aborted cardiac arrest: NS between groups. HF hospitalization: 20.8% for spironolactone and 24.5% for placebo HR: 0.82; 95% CI: 0.67–0.99; p=0.042; Russia/Georgia 2.6% for spironolactone and 3.4% for placebo HR: 0.76; 95% CI: 0.44–1.32; p=0.327; Recurrent HF: 361 events for spironolactone and 438 events for placebo (IRR: 0.75; 95% CI: 0.58–0.96; p=0.024) Russia/Georgia 33 events for spironolactone and 37 events for placebo (IRR: 0.83; 95% CI: 0.42–1.62; p=0.58) All-cause mortality: NS between groups in Americas and Russia/Georgia. All-cause hospitalization: NS between groups in Americas and Russia/Georgia. MI: NS between groups; Stroke: NS between groups

### Study limitations and adverse events:

The pts enrolled in Russia/Georgia in the TOPCAT trial did not demonstrate either the expected morbidity and mortality associated with symptomatic HF or
### 2017 Hypertension Guideline Data Supplements

<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention/Comparator</th>
<th>1° endpoint</th>
<th>Relevant 2° endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aronow WS, et al., 1997 (162)</td>
<td>To determine effect of propranolol vs. no propranolol on mortality plus nonfatal MI in pts with prior MI and HFpEF</td>
<td>Pts ≥62 y with MI and LVEF ≥40% and HF NYHA class II or III treated with diuretics and ACEIs for 2 mo</td>
<td>79 pts were randomized to treatment with propranolol</td>
<td>At 32-mo mean follow-up, multivariate Cox regression analysis showed that compared with no propranolol, propranolol reduced mortality 35% (p=0.03) and mortality plus nonfatal MI 37% (p=0.018)</td>
<td>At 1-y follow-up, LVEF was increased by propranolol from 57% to 63% (p&lt;0.001) and LV mass was decreased by propranolol from 312 grams to 278 grams (p=0.001). Propranolol was stopped because of adverse effects in 11 of 79 pts (14%)</td>
</tr>
<tr>
<td>Kostis JB, et al., 1997 (163)</td>
<td>To determine the effect of antihypertensive drug therapy vs. placebo in prevention of HF in pts with isolated systolic HTN</td>
<td>Pts ≥60 y with isolated systolic HTN in the SHEP program</td>
<td>4,736 pts were randomized to antihypertensive drug therapy or placebo</td>
<td>The 1° endpoint of fatal or nonfatal stroke was reduced 30% (p=0.06) by antihypertensive drug therapy</td>
<td>CV mortality and nonfatal hospitalized HF was reduced 30% (p=0.002) by antihypertensive drug therapy</td>
</tr>
<tr>
<td>Beckett NS, et al., 2008 (164)</td>
<td>To determine the effect of antihypertensive drug therapy on fatal or nonfatal stroke in pts ≥80 y</td>
<td>Pts ≥80 y with a SBP≥160 mm Hg</td>
<td>3,845 pts were randomized to antihypertensive drug therapy or placebo</td>
<td>The 1° endpoint of fatal or nonfatal stroke was reduced 30% (p=0.06) by antihypertensive drug therapy</td>
<td>Antihypertensive drug therapy reduced HF 64% (p&lt;0.001) all-cause mortality 21% (p=0.02), and CV death 23% (p=0.06)</td>
</tr>
<tr>
<td>Study Type</td>
<td>Aim: To determine the effect of nebivolol vs. placebo in pts with HFrEF and HFrpEF</td>
<td>Inclusion criteria: Pts ≥70 y, history of HF, and HFrEF or HFrpEF</td>
<td>Intervention/Comparator: 1,359 pts with a history of HFrEF and 752 pts with a history of HFrpEF were randomized to nebivolol or to placebo</td>
<td>1° endpoint: At 21-mo follow-up, the 1° endpoint of all-cause mortality or CV hospitalization was reduced by nebivolol 14% (95% CI: 0.72–1.04) in pts with HFrEF and 19% (95% CI: 0.63, 1.04) in pts with HFrpEF</td>
<td>Relevant 2° endpoint: HR for reduction of all-cause mortality by nebivolol: 0.84 (95% CI: 0.86–1.08) for HFrEF and 0.91 (95% CI: 0.62–1.33) for HFrpEF</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Piller LB, et al., 2011 (168) 21969009</td>
<td>Aim: To determine the effects of candesartan vs. placebo in pts with HFrEF</td>
<td>Inclusion criteria: 3,032 pts, mean age 67 y, with HFrEF and NYHA class II-IV HF</td>
<td>Intervention/Comparator: 3,032 pts were randomized to candesartan or placebo</td>
<td>1° endpoint: At 36.6 m follow-up, the 1° outcome of CV death or hospitalization for HF was reduced 11% (p=0.118) by candesartan</td>
<td>Relevant 2° endpoint: Hospitalization was reduced 16% (p=0.047) by candesartan</td>
</tr>
<tr>
<td>Yusef S, et al., 2003 (166) 13678871</td>
<td>Aim: To determine the effect of irbesartan vs. placebo on all-cause mortality or hospitalization for a CV cause in pts with HFrEF</td>
<td>Inclusion criteria: 4,128 pts were randomized to irbesartan or placebo</td>
<td>1° endpoint: At 49.5-mo follow-up, the 1° outcome of all-cause mortality or hospitalization for CV cause was reduced 5% by irbesartan (p=0.35)</td>
<td>Relevant 2° endpoint: Irbesartan did not significantly reduce the 2° outcomes of death from HF or hospitalization for HF, death from any cause and from CV causes, and quality of life</td>
<td></td>
</tr>
<tr>
<td>Massie BM, et al., 2008 (167) 19001508</td>
<td>Aim: To determine the effect of nebivolol vs. placebo on all-cause mortality or hospitalization for a CV cause in pts with HFrEF</td>
<td>Inclusion criteria: Pts 60 y and older with HFrEF and NYHA class II, III, or IV HF</td>
<td>Intervention/Comparator: 4,128 pts were randomized to irbesartan or placebo</td>
<td>1° endpoint: At 36.6 m follow-up, the 1° outcome of CV death or hospitalization for HF was reduced 11% (p=0.118) by candesartan</td>
<td>Relevant 2° endpoint: Hospitalization was reduced 16% (p=0.047) by candesartan</td>
</tr>
<tr>
<td>Law MR, et al., 2009 (18) 19454737</td>
<td>Study type: Meta-analysis of use of BP-lowering drugs in prevention of CVD from 147 randomized trials</td>
<td></td>
<td>Inclusion criteria: The database search used Medline (1966-Dec. 2007 in any language) to identify randomized trials of BP-lowering drugs in which CAD events or strokes were recorded. The search also included the Cochrane Collaboration and</td>
<td>1° endpoint: CAD events; stroke</td>
<td>Relevant 2° endpoint: All-cause mortality rates were similar for those with HFrEF (84%) and for those with HFrpEF (81%) with no significant differences by randomized treatment arm</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
other antihypertensive drugs in CAD included 85,395 pts

Web of Science databases and the citations in trials and previous meta-analyses and review articles.

**Exclusion criteria:** Trials were excluded if there were <5 CAD events and strokes or if treatment duration was <6 mo.

Insignificantly reduced CAD events 13%. In 7 trials, BBs reduced stroke 17% (95% CI: 1%–30%). CAD events were reduced 14% (95% CI: 2%–25%) in 11 trials of thiazide diuretics, 17% (95% CI: 11%–22%) in 21 trials of ACEIs, insignificantly 14% in 4 trials of angiotensin receptor blockers, and 15% (95% CI: 8%–22%) in 22 trials of CCBs. Stroke was reduced 38% (95% CI: 28%–47%) in 10 trials of thiazide diuretics, 22% (95% CI: 8%–34%) in 13 trials of ACEIs, and 34% (95% CI: 25%–42%) in 9 trials of CCBs.

**Data Supplement 36. Nonrandomized Trials, Observational Studies, and/or Registries of HFrEF (Section 9.2.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Law MR, et al., 2009 (18)</td>
<td><strong>Study type:</strong> Meta-analysis of use of BP-lowering drugs in prevention of CVD from 147 randomized trials. <strong>Size:</strong> Of 147 randomized trials of 464,000 pts, 37 trials of BBs in CAD included 38,892 pts, and 37 trials of other antihypertensive drugs in CAD included 85,395 pts</td>
<td><strong>Inclusion criteria:</strong> The database search used Medline (1966–Dec. 2007 in any language) to identify randomized trials of BP-lowering drugs in which CAD events or strokes were recorded. The search also included the Cochrane Collaboration and Web of Science databases and the citations in trials and previous meta-analyses and review articles.</td>
<td><strong>1st endpoint:</strong> CAD events; stroke <strong>Results:</strong> In 37 trials of pts with a history of CAD, BBs reduced CAD events 29% (95% CI: 22%, 34%). In 27 trials in which BBs were used after acute MI, BBs reduced CAD events 31% (95% CI: 24%, 38%), and in 11 trials in which BBs were used after long-term CAD, BBs insignificantly reduced CAD events 13%. In 7 trials, BBs reduced stroke 17% (95% CI: 1%–30%). CAD events were reduced 14% (95% CI: 2%–25%) in 11 trials of thiazide diuretics, 17% (95% CI: 11%–22%) in 21 trials of ACEIs, insignificantly 14% in 4 trials of angiotensin receptor blockers, and 15% (95% CI: 8%–22%) in 22 trials of CCBs. Stroke was reduced 38% (95% CI: 28%–47%) in 10 trials of CCBs. <strong>With the exception of the extra protective effect of BBs given shortly after a MI and the minor additional effect of CCBs in preventing stroke, all the classes of BP-lowering drugs have a similar effect in reducing CAD events and stroke for a given reduction in BP.</strong></td>
<td></td>
</tr>
</tbody>
</table>
Exclusion criteria: Trials were excluded if there were <5 CAD events and strokes or if treatment duration was <6 mo.

thiazide diuretics, 22% (95% CI: 8%–34%) in 13 trials of ACEIs, and 34% (95% CI: 25%–42%) in 9 trials of CCBs.

Data Supplement 37. RCTs Comparing CKD (Section 9.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| MDRD Klahr S, et al., 1994 (169) 8114857 | **Aim:** To determine whether restricted protein intake or tighter HTN control would delay progression of CKD  
**Study type:** Randomized management to low or usual BP goal and usual, low or very low protein intake  
**Size:**  
- Total n=840  
  Study 1 n=585  
  Study 2 n=255  
  Mean follow-up 2.2 y  
  Mean MAP, mm Hg (SD):  
    Study 1: 98 (11)  
    Study 2: 98 (11)  
  Mean SBP, mm Hg (SD):  
    Study 1: 131 (18)  
    Study 2: 133 (18) | **Inclusion criteria:** Adults 18–70 y, with renal insufficiency (serum Cr 1.2–7.0 mg/dL in women and 1.4–7.0 mg/dL in men or CrCl <70 mL/min per 1.73 m²) and MAP≤125 mm Hg (normotensives included)  
**Exclusion criteria:** Pregnancy, body weight <80% or >160% of standard, DM requiring insulin, urine protein >10 g/d, history of renal transplant, chronic medical conditions, doubts regarding compliance. | **Intervention:**  
- Study 1 included subjects with GFR 25–55 ml/min 1.73 m² (n=585);  
- Study 2 included subjects with GFR 13–24 ml/min 1.73 m² (n=255)  
  Low MAP goal ≤92 mm Hg for those 18–60 y; ≤98 for those ≥61 y  
- Usual: MAP goal ≤107 mm Hg for those 18–60; MAP ≤113 for subjects ≥61  
  2 studies:  
    Study 1: above BP goals plus usual or low protein diet (1.3 or 0.58 g protein per kg of body weight/d)  
    Study 2: above BP goals plus low or very low protein diet (0.58 or 0.28 g per kg/d)  
  Between group difference in MAP, mm Hg 4.7; p<0.001 | **1° endpoint:**  
- Rate of decline in GFR, ml/min (95% CI)  
  - Study 1  
    From baseline to 4 mo  
    Low: 3.4; 95% CI: 2.6–4.1  
    Usual: 1.9; 95% CI: 1.1–2.7  
    p=0.010  
    4 mo to study end,  
    Low: 2.8; 95% CI: 2.2–3.3  
    Usual: 3.9; 95% CI: 3.3–4.5  
    p=0.006  
  - Study 2  
    From baseline to end of study,  
    Low: 3.7; 95% CI: 3.1–4.3  
    Usual: 4.2; 95% CI: 3.6–4.9  
    p=0.28  
  ESRD or death:  
  - Study 2  
    RR for low vs. usual: 0.85; 95% CI: 0.60–1.22  
    p=NR | **Limitations:**  
- Drug therapy was not randomized. Recommended ACEI ± diuretic then CCB and others. More subjects in the low BP goal groups received ACEIs (48%, 51% also reported elsewhere) compared to the usual BP goal group (28%, 32% also reported e/w) (not noted in 1° manuscript but reported in Peterson JC, et al., 1995 (170)). 1.9% study 1, 1.2% study 2 lost to follow-up.  
- Rate of GFR decline was slower than expected in the control groups and was not constant.  
**Summary:** No significant benefits overall from either low protein or lower BP target. There was a significant interaction between baseline urinary protein excretion and BP interventions (p=0.01) indicating that low BP was of benefit to subjects with >1 g proteinuria with slower progression of loss of GFR
<table>
<thead>
<tr>
<th>REIN-2</th>
<th><strong>Aim:</strong> To determine whether intensive BP control will achieve further renoprotection (delayed progression to ESRD) compared to standard BP control in pts with chronic nephropathies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study type:</strong> Multicenter RCT of pts all placed on ACEI (ramipril) at maximum dose tolerated to achieve DBP &lt;90 then assigned to conventional or intensified BP control. Add-on drug was dihydropyridine felodipine 5–10 mg/d</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 335 (median time 19 mo)</td>
<td></td>
</tr>
</tbody>
</table>
| **Inclusion criteria:**  
- Adults, age 18–70 y, with nondiabetic nephropathy, persistent proteinuria (urinary protein excretion >1 g/24 h for ≥3 mo) and not on ACEIs in previous 6 wk  
- Pts with proteinuria 1–3 g/24 h included if CrCl <70 mL/min/1.73 m²  
- For overall population, mean SBP, mm Hg (SD): Intensive: 137.0 (16.7)  
  Conventional: 136.4 (17.0)  
- For overall population, mean DBP, mm Hg (SD): Intensive: 84.3 (9.0)  
  Conventional: 83.9 (10.4) |
| **Intervention:**  
- Intensive: BP goal <130/80 mm Hg  
- Conventional: DBP goal <90 mm Hg, irrespective of SBP  
- For baseline proteinuria subgroups, result BP values NR  
- For the overall population, achieved BP, mm Hg (SD)  
  Intensive: 129.6/79.5 (10.9/5.3)  
  Conventional: 133.7/82.3 (12.6/7.1)  
- **1° endpoint:** Time to ESRD; over 36 mo follow-up, median 19 mo  
  **1° outcome:** ESRD in pts with baseline proteinuria 1–3 g/24 h  
  HR (95% CI): 1.06 (95% CI: 0.51–2.20)  
  p=0.89  
  ESRD in pts with baseline proteinuria >3 g/24 h  
  HR (95% CI): 1.09 (95% CI: 0.55–2.19)  
  p=0.81  
  23% of intensive and 20% of conventional control groups progressed to ESRD.  
  Median rate of GFR decline, mL/min/1.73 m²/mo (IQR) in pts with baseline proteinuria <3 g/24:  
  Intensive: 0.18; 95% CI: 0.03–0.49  
  Conventional: 0.21; 95% CI: -0.03–0.40  
  p=0.89  
  Median rate of GFR decline, mL/min/1.73 m²/mo (IQR) in pts with baseline proteinuria ≥3 g/24:  
  Intensive: 0.51; 95% CI: 0.16–1.05  
  Conventional: 0.39; 95% CI: 0.030.98  
  p=0.39 |
<p>| <strong>Exclusion criteria:</strong> Urinary tract infection, CHF class III–IV, treatment with corticosteroids, NSAIDs, immunosuppression, acute MI or stroke in prior 6 mo, severe uncontrolled HTN, |
| <strong>Comparator:</strong> By BP and protein intake goals |</p>
<table>
<thead>
<tr>
<th>AASK</th>
<th>Aim: To compare the effects of 2 levels of BP and 3 antihypertensive drug classes on GFR decline in HTN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>- Adult African-Americans, 18–70 y, with HTN (DBP ≥ 95) and GFR of 20–65 mL/min/1.73 m², no DM</td>
</tr>
<tr>
<td></td>
<td>- At entry: mean MAP, mm Hg: Low: 115 (27) Usual: 113 (15)</td>
</tr>
<tr>
<td></td>
<td>- Mean SBP, mm Hg (SD): Low: 152 (25) Usual: 149 (23)</td>
</tr>
<tr>
<td></td>
<td>- Mean DBP, mm Hg: Low: 96 (15) Usual: 95 (14)</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong></td>
<td>- DBP &lt; 95, history of DM, Urinary protein/creatinine ratio &gt; 2.5, accelerated or malignant HTN, non-BP related cause of CKD, serious systemic disease, clinical CHF, specific indication or contraindication for a</td>
</tr>
<tr>
<td>Comparator: By BP goals</td>
<td>Intervention:</td>
</tr>
<tr>
<td>Low: MAP goal ≤ 92 mm Hg</td>
<td>- Low: MAP goal ≤ 92 mm Hg</td>
</tr>
<tr>
<td>Usual: MAP goal 102–107 mm Hg</td>
<td>- Initial treatment with a B Blocker (metoprolol), and ACEI (ramipril) or a dihydropyridine (amlodipine) with open label agents added to achieve BP goals</td>
</tr>
<tr>
<td>- Study duration: 3–6.4 y</td>
<td>- BP similar across drug groups except 2 mm Hg lower in amlodipine group</td>
</tr>
<tr>
<td>- Mean from 3 mo to study end</td>
<td>- MAP, mm Hg (SD): Low: 95.8 (8) Usual: 104 (7)</td>
</tr>
<tr>
<td>- SBP/DBP, mm Hg (SD) Low: 128/78 (12/8) Usual: 141/85 (12/7)</td>
<td>- MAP change, mm Hg Low: -20</td>
</tr>
<tr>
<td>- MAP event, ESRD, or death, % risk reduction (95% CI): 2 (95% CI: -22–21) p=0.85</td>
<td>- GFR event or ESRD, % Risk Reduction: -2; 95% CI: -31–20; p=0.87</td>
</tr>
<tr>
<td>- ESRD or death, % risk reduction: 12; 95% CI: -13–32; p=0.31</td>
<td>- ESRD alone, % risk reduction: 6; 95% CI: -29–31; p=0.72</td>
</tr>
<tr>
<td>Limitations:</td>
<td>Based on DSMD recommendation, amlodipine arm halted early and those pts switched to open label Rx, continued study schedule and same BP goals</td>
</tr>
<tr>
<td>Summary:</td>
<td>No difference in GFR decline with lower BP goal and no difference in composite clinical endpoints</td>
</tr>
<tr>
<td></td>
<td>Average rate of GFR decline 2 mL/min/y is similar or slower than previous reports</td>
</tr>
<tr>
<td></td>
<td>There was a trend favoring the lower BP goal in subjects with higher baseline proteinuria and the opposite trend for those without proteinuria</td>
</tr>
<tr>
<td></td>
<td>Ramipril treatment group had slower progression compared with metoprolol and amlodipine combined, less evident between ramipril and metoprolol</td>
</tr>
</tbody>
</table>
### Study Drug or Procedure

<table>
<thead>
<tr>
<th>Comparator: N/A</th>
</tr>
</thead>
</table>

### Usual

- SBP/DBP change, mm Hg
  - Low: -24/-8
  - Usual: -18/-10
- Achieved mean BP difference between groups, mm Hg
  - MAP: 11
  - SBP: 16
  - DBP: 8

###Comparator

- GFR event or ESRD, Amlodipine, Low vs. Usual Goal RR: 32%; 95% CI: -14–60; p=0.14
- Metoprolol, Low vs. Usual Goal RR: 4%; 95% CI: -39–33; p=0.84
- Ramipril, Low vs. Usual Goal RR: -8%; 95% CI: -93–15; p=0.24

### Safety endpoint:

- Acute and chronic rate of change in GFR (slope): NS for chronic and total slope in subgroup analyses by baseline proteinuria strata
- Acute slope: p=0.08 for interaction
- Total slope: p=0.04 for interaction
- Chronic slope: p=0.16 for interaction
- Clinical composite outcome: includes reduction in GFR by 50% or by 25 mL/min/m², ESRD, death, NS in subgroup analyses by baseline proteinuria strata; p=0.007 for interaction

Within each drug group, risk reductions for any 2<sup>nd</sup> clinical outcome of the low vs. usual BP goal were not significantly different between pts with baseline urine protein to creatinine ratio ≤0.22 and >0.22 (p=NS)

### Limitations:

Post-hoc analysis, effects on GFR may have been obscured by early rise and later fall with amlodipine, follow-up only 3–6.4 y, many comparisons so risk for type I error, unable to test ACEI – DHP CCB combination.

### Summary:

- BP effect was similar among drug groups for GFR slope and main clinical composite.

---

**Study Details**

- **Aim:** Within AASK to examine the effect of BP intervention separately in the 3 drug treatment groups

  **Study type:**
  - Randomized 3×2 factorial trial
  - Measured GFR with iothalamate

  **Size:** 1,094

- **Inclusion criteria:**
  - Adult African Americans, ages 18–70, with HTN (DBP ≥95) and GFR of 20–65 mL/min/1.73 m², no DM
  - Mean MAP, mm Hg:
    - Low, Amlodipine: 115.3 (18.3)
    - Usual, Amlodipine: 112.7 (14.7)
    - Low, Metoprolol: 114.5 (17.5)

- **Intervention:**
  - Analysis by initial drug treatment group
  - Low, Amlodipine: MAP goal ≤92 mm Hg, Amlodipine (5–10 mg/d)
  - Usual, Amlodipine: MAP goal 102–107 mm Hg, Amlodipine (5–10 mg/d)
  - Low, Metoprolol: MAP goal ≤92 mm Hg, Metoprolol (50–200 mg/d)

- **1<sup>st</sup> endpoint:**
  - GFR event, ESRD, or death prior to dialysis, Amlodipine, Low vs. Usual Goal RR: 32%; 95% CI: -14–60; p=0.14
  - Metoprolol, Low vs. Usual Goal RR: 4%; 95% CI: -39–33; p=0.84
  - Ramipril, Low vs. Usual Goal RR: -8%; 95% CI: -93–15; p=0.24

  p for interaction=0.17

  - GFR event or ESRD, Amlodipine, Low vs. Usual Goal RR: 26%; 95% CI: -33–58; p=0.32

- **2<sup>nd</sup> outcome:** urine protein excretion

---

**Contreras G, et al., 2005 (173)**

15897360
<table>
<thead>
<tr>
<th>Drug</th>
<th>Usual, Metoprolol: 112.4 (14.1)</th>
<th>Low, Ramipril: 115.2 (15.2)</th>
<th>Usual, Ramipril: 114.0 (16.7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean SBP, mm Hg:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low, Amlodipine: 152.2 (28.2)</td>
<td>Usual, Amlodipine: 147.7 (21.9)</td>
<td>Low, Metoprolol: 152.0 (25.7)</td>
<td></td>
</tr>
<tr>
<td>Low, Metoprolol: 147.7 (21.4)</td>
<td>Usual, Metoprolol: 147.7 (21.4)</td>
<td>Low, Ramipril: 151.0 (22.5)</td>
<td></td>
</tr>
<tr>
<td>Low, Ramipril: 150.9 (24.1)</td>
<td>Mean DBP, mm Hg:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low, Amlodipine: 96.55 (15.1)</td>
<td>Usual, Amlodipine: 94.87 (12.9)</td>
<td>Low, Metoprolol: 95.45 (15.4)</td>
<td></td>
</tr>
<tr>
<td>Low, Metoprolol: 94.47 (12.5)</td>
<td>Low, Ramipril: 96.90 (13.6)</td>
<td>Usual, Ramipril: 95.12 (15.3)</td>
<td></td>
</tr>
</tbody>
</table>

**Exclusion criteria:**
- DBP<95, history of DM,
- Urinary protein/creatinine ratio >2.5, accelerated or malignant HTN,
- Non-BP related cause of CKD, serious systemic

<table>
<thead>
<tr>
<th>Drug</th>
<th>Usual, Metoprolol: MAP goal 102–107 mm Hg, Metoprolol (50–200 mg/d)</th>
<th>Low, Ramipril: MAP goal ≤92 mm Hg, Ramipril (2.5–10 mg/d)</th>
<th>Usual, Ramipril: MAP goal 102–107 mm Hg, Ramipril (2.5–10 mg/d)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note:</strong></td>
<td>Amlodipine arms terminated 1 y early</td>
<td>Achieved MAP difference between groups, mm Hg</td>
<td>Achieved MAP difference between groups, mm Hg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p=NR</td>
<td>p=NR</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Achieved SBP difference between groups, mm Hg</td>
<td>Achieved DBP difference between groups, mm Hg</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Amlodipine, Low vs. Usual: 18.4</td>
<td>Amlodipine, Low vs. Usual: 12.6</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Amlodipine, Low vs. Usual: 13.0</td>
<td>p=NR</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual: 15.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Ramipril, Low vs. Usual: 16.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual: 11.12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual: 10.14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual: 8.86</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Metoprolol, Low vs. Usual Goal RR: 7%; 95% CI: -42–39; p=0.74</th>
<th>Ramipril, Low vs. Usual Goal RR: -42%; 95% CI: -126–11; p=0.14</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>p for interaction=0.20</td>
<td>p for interaction=0.20</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>ESRD or death prior to dialysis, Amlodipine, Low vs. Usual Goal RR: 51%; 95% CI: 13–73; p=0.016</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual Goal RR: 11%; 95% CI: -40–44; p=0.61</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Ramipril, Low vs. Usual Goal RR: -32%; 95% CI: -114–18; p=0.26</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>p for interaction=0.035</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Death alone (prior to dialysis), Amlodipine, Low vs. Usual Goal RR: 48%; 95% CI: -59–83; p=0.25</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual Goal RR: -1; 95% CI: -110–5; p=0.97</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Ramipril, Low vs. Usual Goal RR: 21%; 95% CI: -92–67; p=0.61; p for interaction=0.61</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual Goal RR: 11%; 95% CI: -60–50; p=0.70</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Ramipril, Low vs. Usual Goal RR: -65%; 95% CI: -195–8; p=0.09; p for interaction=0.021</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Death alone (prior to dialysis), Amlodipine, Low vs. Usual Goal RR: 48%; 95% CI: -59–83; p=0.25</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Metoprolol, Low vs. Usual Goal RR: -1; 95% CI: -110–5; p=0.97</td>
</tr>
<tr>
<td></td>
<td>BP effect differed among drug groups for composite of ESRD or death</td>
<td>Ramipril, Low vs. Usual Goal RR: 21%; 95% CI: -92–67; p=0.61; p for interaction=0.61</td>
</tr>
</tbody>
</table>

**Safety endpoint:**
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
- ESRD alone, Amlodipine, Low vs. Usual Goal: RR: 54%; 95% CI: 8–77; p=0.028
### Norris K, et al., 2006 (174) 17059993

**Aim:** Compared effect of treatment on CV event rate during mean follow-up of 4.1 y by drug class and level of BP control. Determined baseline factors that predict CV outcomes

**Study type:** Randomized 3×2 factorial trial

**Measured GFR with iothalamate**

**Size:** 1,094

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>Intervention:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Adult African Americans, 18–70 y, with HTN (DBP ≥95) and GFR of 20–65 mL/min/1.73 m², no DM</td>
<td>- Achieved SBP/DBP, mm Hg (SD)</td>
</tr>
<tr>
<td>- Mean MAP, mm Hg: 114 (16)</td>
<td>Low: 128/78</td>
</tr>
<tr>
<td>- Mean SBP, mm Hg: 150 (24)</td>
<td>Usual: 141/85</td>
</tr>
<tr>
<td>- Mean DBP, mm Hg: 96 (14)</td>
<td>p=NR</td>
</tr>
</tbody>
</table>

**Exclusion criteria:** N/A

**Comparator:** N/A

**1° endpoint:**

- Number of deaths before ESRD, n of events
  - Low: 38
  - Usual: 47; p=NR
- Major CAD events, n of events (rate per person-y)
  - Low: 19 (0.008)
  - Usual: 23 (0.010); p=NS
- Stroke events, number of events (rate per person-y)
  - Low: 26 (0.011)
  - Usual: 29 (0.013); p=NS
- HF events, n of events (rate per person-y)
  - Low: 27 (0.012)
  - Usual: 23 (0.010)
  - p=NS
- CV composite outcome or ESRD, n of events (rate per person-y)
  - Low: 71 (0.032)
  - Usual: 78 (0.035); p=NS

**Limitations:**

- Limited power, only 202 CV events – low incidence. CV outcomes were 2° endpoints of high priority (prespecified).
- >50% had a history of heart disease at entry, 40% with LVH by ECG. 1/3 smokers, almost 50% had income <15K.

**Summary:**

- CV outcome rate was not related to randomized interventions, either drug or BP target.
- 7 baseline risk factors were independently associated with increased risk for CV composite outcome in multivariable analyses after controlling for age, sex, baseline GFR, baseline proteinuria, PP, duration of HTN, protein/creatinine ratio, urine sodium-potassium ratio and annual income <15,000.
### Amlodipine Versus Enalapril in Renal Failure (AVER trial)

**Esnault VL, et al., 2008 (175)**

**18405787**

**Usual: 15 (0.006); p=NS**

| Aim: | To compare GFR decline in nondiabetic, nonnephrotic adults with HTN and estimated CrCl 20–60 mL/min/1.73 m² when randomized to a CCB (amlodipine, 5–10 mg/d) or an ACEI (enalapril, 5–20 mg/d). |
| Inclusion criteria: | ● 18–80 y  
● CrCl 20–60 mL/min/1.73 m² (Cockcroft-Gault)  
● Nondiabetic  
● Enrollment confirmed at end of 4-wk placebo run-in if sitting DBP between 90 and 119 mm Hg  
● Mean SBP, mm Hg (SD):  
  Amlodipine: 165.1 (15.4)  
  Enalapril: 165.2 (16.6)  
● Mean DBP, mm Hg (SD):  
  Amlodipine: 102.0 (6.7)  
  Enalapril: 102.5 (7.1)  
● Mean serum Cr, mg/dL (SD):  
  Amlodipine: 2.00 (0.8)  
  Enalapril: 2.05 (0.7)  |
| Intervention: | ● Amlodipine: 5–10 mg/d  
● Enalapril: 5–20 mg/d  
Therapy initiated with amlodipine 5 mg/d or enalapril 5 mg/d. Drugs up-titrated to amlodipine 10 mg/d or enalapril 20 mg/d at wk 8 and 12 if DBP >90 mm Hg. After 18 wk, if maximal tolerated dose of study drug did not decrease BP to target, add on anti-HTN treatments were the following: atenolol (50–100 mg/d), loop diuretics (furosemide 20–500 mg/d or torsemide, 5–200 mg/d), alpha blockers (prazosin, 2.4–5 mg/d or doxazosin, 1–16 mg/d) and centrally acting drugs (rilmenidine (1–2 mg/d or methyldopa, 250–500 mg/d). |
| Study type: | RCT |
| Size: | Amlodipine: 132  
Enalapril: 131 |
| Exclusion criteria: | ● Nephrotic proteinuria  
● 2º or malignant HTN (DBP >120 mm Hg)  
● A major CV event within 3 mo  
● Angina pectoris  
● Congestive heart disease (NYHA II-IV)  
● Uncontrolled arrhythmias  
● II-III AV block  
● Need for serious steroids, NSAIDS or cytotoxic drugs |
| **1º endpoint:** | Change in GFR from baseline to final assessment |
| **2º Outcome:** | Clinical composite of renal replacement therapy, discontinuation due to deterioration of renal function, 50% decrease in GFR, doubling of serum Cr, hospitalization for transient renal failure. "Other 2º outcome measures" included: changes in serum Cr, sitting DBP and SBP, heart rate, total and HDL cholesterol, 24-h urinary protein excretion, ambulatory BP monitoring, and safety measures. Composite Outcomes: 2º clinical composite |
| Safety endpoint: | Proteinuria subgroup, >1 g/d: protein excretion rate decreased significantly in pts taking enalapril plus diuretic (median -270 mg/d; p<0.001) but not in pts taking amlodipine plus diuretic (-25 mg/d) at last obs |
| Summary: | ● No difference in GFR change or serum creatinine at trial end  
Last observation: mean change in GFR, mL/min/1.73 m²  
Amlodipine -4.92, Enalapril -3.98; p=NS  
● Last observation: mean change in Serum Cr from baseline (mg/d)  
Amlodipine +0.57, Enalapril +0.47; p=NS  
● No difference in composite 2º endpoints.  
● Mean BP (mm Hg): baseline to last observation  
Amlodipine 164.8/101.8 to 140.1/85.4, delta -24.7/16.4  
Enalapril 165.0/102.5 to 140.3/86.4, delta -24.7/16.1 |

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
### ESPIRAL
Marin R, et al., 2001 (176) 11593109

#### Aim:
To investigate in a random comparison the capacity of an angiotensin converting enzyme inhibitor (fosinopril), and that of a long-acting dihydropiridine (nifedipine GITS) to modify the decay in renal function in pts with primary renal disease, exhibiting a progressive increase in serum Cr during the previous 2 y.

#### Study type:
Randomized open label trial

#### Size:
241
- Nifedipine GITS: 112
- Fosinopril: 129

#### Inclusion criteria:
- 18–75 y
- Serum Cr between 1.5 and 5 mg/dL (133–442 µmol/l)
- HTN defined as BP >140/90 mm Hg or by the use of antihypertensive agent(s)
- Proven progression of chronic renal failure in the previous 2 y, defined by increase by >25% or >0.5 mg/dL (44.2 µmol/l) in serum Cr
- Mean SBP, mm Hg (SD):
  - Nifedipine GITS: 157.5 (20)
  - Fosinopril: 155 (17)
- Mean DBP, mm Hg (SD):
  - Nifedipine GITS: 96 (11)
  - Fosinopril: 96 (8)

#### Intervention:
- Nifedipine GITS: 30–60 mg QD
- Fosinopril: 10–30 mg QD
- Drugs added in step-wise fashion to achieve BP goal.
- Step 1: Randomized drug
- Step 2: Furosemide (up to 100 mg)
- Step 3: Atenolol (up to 100 mg)
- Step 4: Doxazosin (up to 12 mg)
- BP goal:
  - Nifedipine GITS: <140/90 mm Hg
  - Fosinopril: <140/90 mm Hg
- Duration of treatment: mean follow-up NR; authors report minimum follow-up of 3 y and this is when most outcome measures reported

#### 1° endpoint:
- 1° Outcome: Time elapsed until serum Cr values doubled, or the need to enter a dialysis program
- 2° Outcome: CV events (including MI, stroke, angina, and death), proteinuria evolution and serum Cr

#### Safety endpoint:
N/A

#### Limitations:
- SBP was 4–6 mm Hg lower with ACEI which may have impacted improved outcomes. Still positive effects remained from fosinopril after adjusted for BP levels.
- Sodium restriction may have favored the ACEI group.

#### Summary:
- Renal survival was significantly better if fosinopril used as first agent, unrelated to the primary renal disease.
- Proteinuria decreased by 57% in the fosinopril group and increased by 7% in the nifedipine GITS group while BP control did not differ between treatment groups for DBP.
- 3-y follow-up
  - Doubling of serum Cr or entering dialysis N (%)
    - Nifedipine GITS: 40 (36%)
    - Fosinopril: 27 (21%)
  - OR: 0.47 (0.26–0.84); p=0.01
  - Decrease in SBP, mm Hg (SD)
    - Nifedipine GITS: 14.0 (22.5)
    - Fosinopril: 19.8 (19.6), p NR
  - Decrease in DBP, mm Hg (SD)
    - Nifedipine GITS: 14.9 (11.8)
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1° endpoint</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCOMPLISH Bakris GL, et al., 2010 (177) 20170948</td>
<td>To examine the effect of initial antihypertensive therapy with benazepril plus amiodipine compared to benazepril plus hydrochlorothiazide on progression of CKD</td>
<td>Males or females ≥55 y. with HTN, high CV risk (history of coronary events, MI, revascularization, stroke, CKD, PAD, LVH, DM)</td>
<td>Initial antihypertensive therapy with benazepril plus amiodipine compared to benazepril plus hydrochlorothiazide</td>
<td>Overall: time to first event of composite CV morbidity and mortality</td>
<td>Initial antihypertensive treatment with benazepril plus amiodipine slowed progression of nephropathy to a greater extent compared to benazepril plus hydrochlorothiazide.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Entry BP for pts with CKD benazepril plus amiodipine: 145.1/78.6 (20.2/11.2)</td>
<td>BP after dose adjustment benazepril plus amiodipine: 131.6/73.3 (18.2/10.3 SD), 4119, (75%) controlled</td>
<td>Progression of CKD, a prespecified endpoint, was defined as doubling of serum creatinine concentration or ESRD (estimated glomerular filtration rate &lt;15 mL/min/1.73 m² or need for dialysis).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>benazepril plus hydrochlorothiazide: 145.0/78.1 (20.5/10.7)</td>
<td>Benazepril plus hydrochlorothiazide: 132.5/74.4 (17.9/11.2 SD), 3963 (72%) controlled</td>
<td>All randomized pts were included in the intention-to-treat analysis. There were 113 (2.0% x 0%) events of CKD progression in the benazepril plus amiodipine group compared with 215 (3.7% x 7%) in the benazepril plus hydrochlorothiazide group HR: 0.52, (95% CI: 0.41–0.65), p&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rate of DM same in CKD and non-CKD pts (58.9% vs. 60.5%; p=0.302)</td>
<td>Benazepril plus hydrochlorothiazide: 132.5/74.4 (17.9/11.2 SD), 3963 (72%) controlled</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exclusion criteria: N/A</td>
<td>BP after dose adjustment benazepril plus amiodipine: 131.6/73.3 (18.2/10.3 SD), 4119, (75%) controlled</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Target &lt;140/90 and &lt;130/80 for DM or CKD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparator: N/A</td>
<td></td>
<td></td>
<td>p&lt;0.0013 Target &lt;140/90 and &lt;130/80 for DM or CKD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety endpoint: N/A</td>
<td></td>
<td></td>
<td>Subset with more advanced CKD analyzed for rate of progression</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Limitations:**
- Trial terminated early (mean follow-up 2.9 y [SD 0.4]) because of superior efficacy of benazepril plus amiodipine compared with benazepril plus hydrochlorothiazide with 20% lower CV risk.
- Very small proportion of study population had albuminuria above 33.9 mg/mmol combined with early trial termination to reduce renal events.
- Funded by Novartis.

**Summary:**
- Initial antihypertensive treatment with benazepril plus amiodipine slowed progression of nephropathy to a greater extent compared to benazepril plus hydrochlorothiazide.

<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1° endpoint</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVOID Parving HH, et al.,</td>
<td>Compare effects of dual blockade of</td>
<td>Pts with HTN, 18–85 y,</td>
<td>All on losartan then aliskiren or</td>
<td>Ratio of albumin to creatinine at 6 mo</td>
<td>No renal endpoints regarding function, survival, CV</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 2008 (178)

<table>
<thead>
<tr>
<th>RAAS by aliskiren 300 mg/d added to maximal dose losartan 100 mg/d and optimal HTN therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study type:</strong> RCT, double-blinded, duration was 6 mo</td>
</tr>
<tr>
<td><strong>Size:</strong> 805 entered open label, 599 randomized, 524 completed.</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> DM-2 and nephropathy (early morning alb/creat &gt;300 mg/g or &gt;200 mg/g in on RAAS blocker already)</td>
</tr>
<tr>
<td><strong>Comparator:</strong> All on losartan, aliskiren or placebo added</td>
</tr>
<tr>
<td><strong>Outcome:</strong> degree of albuminuria. Aliskiren reduced urinary alb/creat ratio by 20% (95% CI 9–30; p&lt;0.001)</td>
</tr>
<tr>
<td><strong>2° endpoint:</strong> First occurrence of a change in eGFR (a decline of ≥30 mL/min/1.73 m² if initial GFR ≥60 or a decline of ≥50% if initial eGFR &lt;60, ESRD or death)</td>
</tr>
<tr>
<td><strong>Safety endpoint:</strong> mortality, hyperkalemia, acute kidney injury</td>
</tr>
</tbody>
</table>

### VA NEPHRON-D

<table>
<thead>
<tr>
<th>Fried LF, et al., 2010 (124)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To test the efficacy of the combination of losartan with lisinopril as compared with standard treatment with losartan alone in slowing the progression of proteinuric diabetic kidney disease</td>
</tr>
<tr>
<td><strong>Study type:</strong> RCT, multi-center, double-blind</td>
</tr>
<tr>
<td><strong>Size:</strong> 1448 were randomized</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> Pts without adverse events on full dose losartan DM-2, eGFR 30–89.9 mL/min/1.73 m² by 4 variable MDRD formula, urinary albumin/creatinine ratio of ≥300 in a random sample</td>
</tr>
<tr>
<td><strong>Intervention:</strong> Pts with DM-2 already taking losartan 100 mg/d with albumin to creatinine ratio of ≥300 were randomized to either lisinopril 10–40 mg/d or placebo.</td>
</tr>
<tr>
<td><strong>1° endpoint:</strong> First occurrence of a change in eGFR (a decline of ≥30 mL/min/1.73 m² if initial GFR ≥60 or a decline of ≥50% if initial eGFR &lt;60, ESRD or death)</td>
</tr>
<tr>
<td><strong>Safety endpoint:</strong> mortality, hyperkalemia, acute kidney injury</td>
</tr>
</tbody>
</table>
### Data Supplement 38. Nonrandomized Trials, Observational Studies, and/or Registries of CKD (Section 9.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upadhyay A, et al., 2011 (179) 21403055</td>
<td>Aim: To summarize trials comparing lower vs. higher BP targets in pts with CKD; focus on proteinuria as an effect modifier</td>
<td><strong>Inclusion criteria:</strong> &gt;50 pts/group, 1 y follow-up, outcomes of death, kidney failure, CV events, change in kidney function, number of antihypertensive agents, adverse events. 3 trials (MDRD, AASK, REIN-2; 8 reports)</td>
<td><strong>Results:</strong> Overall trials did not show that BP target of &lt;125/75–130/80 is more beneficial than a target of &lt;140/90. Lower quality evidence suggests a low target may be beneficial in subgroups with proteinuria &gt;300–1,000/d</td>
<td><strong>Limitations:</strong> No pts with DM-1 included. Duration (mean follow-up 2–4 y) may be too short to detect differences in clinically important outcomes. Reporting of adverse events not uniform. <strong>Summary:</strong> Available evidence is inconclusive but does not prove a BP target &lt;130/80 improves clinical outcomes more than a target of &lt;140/90 in adults with CKD.</td>
</tr>
<tr>
<td>Lv, et al., 2013 (127) 23798459</td>
<td><strong>Aim:</strong> To assess the renal and CV effects of intensive BP lowering in people with CKD</td>
<td><strong>Study type:</strong> Systematic review  <strong>Size:</strong> 9,287 pts with CKD and 1,264 kidney failure events</td>
<td><strong>Inclusion criteria:</strong> • Randomized trials of pts with CKD assigned to different target BP that reported kidney failure and CV events. • 11 trials on 9,287 pts with CKD and 1,264 kidney failure events (doubling of serum creatinine, 50% decline in GFR or ESKD) • Included AASK, REIN-2, MDRD, Wuhl (children), Toto, Schrier plus 5 trials with CKD subgroups, also included the late nonrandomized follow-up studies for AASK and MDRD • BP targets varied substantially between trials. 2 trials targeted mean BP &lt;92 mm Hg for the intensive treatment arm, and 107 mm Hg in the standard treatment arm. 1 trial aimed for BP&lt;130/80 mm Hg vs. a DBP of 90 mm Hg, 1 study targeted &lt;120/80 mm Hg vs.</td>
<td><strong>Results:</strong> Compared with standard regimens, more intensive BP lowering reduced risk of composite endpoint HR: 0.82; 95% CI: 0.68–0.98, and ESKD HR: 0.79; 95% CI: 0.67–0.93. Effect was modified by proteinuria (p=0.006) and markers of trial quality. Intensive BP lowering reduced the risk of kidney failure HR: 0.73; 95% CI: 0.62–0.86 but not in pts without proteinuria at baseline HR: 1.12; 95% CI: 0.67–1.87. No clear effect on CV events or death.</td>
</tr>
</tbody>
</table>
135–140/85–90 mm Hg, and 4 studies had DBP<75–80 mm Hg vs. from 80–90 mm Hg. A trial involving pediatric pts targeted a 24-h mean BP<the 50th percentile, compared with the 50th to 95th percentiles in the control group. 2 trials had more liberal targets for intensive treatment (<140–150 mm Hg systolic, 85 mm Hg diastolic).

- CV outcomes: major CV events reported in 5 trials (472 CV events in 5,308 pts with CKD). Intensive BP lowering did not reduce risk of CV events in pts with CKD, but the CIs remained wide RR: 1.09; 95% CI: 0.83–1.42. 6 trials reported stroke outcomes (197 events in 5,411 pts), 5 trials reported MI (138 events in 4,317 pts), and 5 trials reported HF (118 events in 5,308 pts). They saw no clear effect of intensive treatment on any of these vascular outcomes.
- Death: 10 trials involving 6,788 participants reported 846 deaths. There was no clear effect of intensive BP lowering on risk of all-cause death RR: 0.94; 95% CI: 0.84–1.05) or CV death RR: 1.20; 95% CI: 0.82–1.75.

**Aim:** To determine the levels of BP and urine protein excretion associated with lowest risk for progression of CKD during antihypertensive therapy with and without ACEIs.

**Study type:** 11 RCTs in pts with predominantly nondiabetic kidney disease

**Size:** 1,860 pooled in pt level meta-analysis; mean duration of follow-up 2.2 y

**Inclusion criteria:**
- Pt-level meta-analysis using data from the AIPRD Study Group database to assess relationships among pts with nondiabetic kidney disease across a wide range of urine protein excretion values during antihypertensive therapy with and without ACEIs.
- The AIPRD Study Group database included 1,860 pts with nondiabetic kidney disease enrolled in 11 RCTs of ACEIs to slow the progression of kidney disease. The database contained information on BP, urine protein excretion, serum creatinine, and onset of kidney failure during 22,610 visits.
- Included only randomized trials (with a minimum 1 y follow-up) that compared the effects of antihypertensive regimens that included ACEIs with the effects of regimens that did not include ACEIs. HTN or decreased kidney function was required for entry into all studies.

**Exclusion criteria:** Common to all studies: acute kidney failure, treatment with immunosuppressive meds, clinically significant chronic HF, obstructive uropathy, renal artery stenosis, active systemic disease, DM-1, history of transplantation, history of allergy to

**1st endpoint:** Progression of CKD defined as doubling of serum creatinine or onset of kidney failure

**Results:** Kidney disease progression documented in 311 pts, 124 (13.2%) in the ACEI group and 187 (20.5%) in the control group (p=0.001). 176 (9.5%) developed kidney failure: 70 (7.4%) in the ACEI group and 106 (11.6%) in the control group (p=0.002). SBP of 110–129 mm Hg and urine protein excretion <2.0 g/d were associated with lowest risk for kidney disease progression. ACEI beneficial after adjustment for BP and urine protein excretion (RR: 0.67; 95% CI: 0.53–0.84). The increased risk for kidney progression at higher SBP levels was greater in pts with urine protein excretion >1.0 g/d (p<0.006).

**Limitations:** Studies included were not designed to assess the effect of lowering BP and urine protein excretion on kidney disease progression.

**Conclusions:** Although reverse causation cannot be excluded with certainty, SBP goal between 110 and 129 mm Hg may be beneficial in pts with urine protein excretion >1.0 g/d. SBP <110 mm Hg may be associated with higher risk for kidney disease progression.
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Results</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giatras I, et al., 1997 (181) 9273824</td>
<td>To use meta-analysis to assess effects if ACEIs on development of ESRD in nondiabetic pts</td>
<td>All randomized studies comparing ACEIs with other antihypertensive agents, with at least 1 y of follow-up</td>
<td>Among 806 pts receiving ACEIs, 52 (6.4%) developed ESRD and 17 (2.1%) died. In 788 controls, 72 (9.1%) developed ESRD and 12 (1.5%) died. The pooled RR were 0.70; 95% CI: 0.51–0.97 for ESRD and 1.24; CI: 0.55–2.83 for death. The decreases in weighted mean systolic and DBPs during follow-up were 4.9 and 1.2 mm Hg greater, respectively, in the pts who received ACEIs.</td>
<td>Included studies through 5/1996, published (7) and nonpublished (3) study results. Did not require that pts have HTN or renal insufficiency at baseline. Did not report results by severity of proteinuria related to the diseases included many of which are not characterized by proteinuria.</td>
</tr>
<tr>
<td>ONTARGET Investigators, et al., 2008 (126) 18378520</td>
<td>Evaluate whether use of an ARB was noninferior to ACEI, and whether the combination was superior to ACEI alone in the prevention of vascular events in pts with CVD or DM but not HF.</td>
<td>≥55 y; Coronary, peripheral, or cerebrovascular disease or DM with end-organ damage</td>
<td>No difference between ramipril vs. telmisartan or combination therapy vs. ramipril in the 1° composite outcome of death from CV causes, MI, stroke, or hospitalization for HF: RR: 1.01; 95% CI: 0.94–1.09 and RR: 0.99; 95% CI: 0.92–1.07, respectively</td>
<td>Combination therapy was associated with greater risk of hyperkalemia than ramipril monotherapy (480 pts vs. 283 pts; p&lt;0.001)</td>
</tr>
</tbody>
</table>

### Notes
- **ACEIs** and pregnancy.
- **Study type:** Meta-analysis
- **Size:** 1,594 pts from 10 studies
- **Exclusion criteria:** Studies of diabetic renal disease and renal transplants were excluded.

### Summary
ACEIs are more effective than other antihypertensive agents in reducing the development of end-stage nondiabetic renal disease, and they do not increase mortality. It could not be determined whether this beneficial effect is due to the greater decline in BP or to other effects of ACE inhibition.

### Safety endpoint:
- Combination therapy was associated with greater risk of hyperkalemia than ramipril monotherapy (480 pts vs. 283 pts; p<0.001)
- Hypotensive symptoms were cited as reason for permanent discontinuing more in telmisartan vs. ramipril RR: 1.54; p<0.001 and combination therapy vs. ramipril monotherapy RR: 2.75; p<0.001
- Renal impairment was more common in combination therapy vs. ramipril monotherapy RR: 1.33; 95% CI: 1.22–1.44.
| VALIANT | **Aim:** Evaluate whether use of an ARB or the combination of an ACEI and an ARB was superior to a proven effective dose of an ACEI after AMI in pts with HF and/or LVEF <40%. |
|  | **Study type:** Multi-center, double-blind, RCT |
|  | **Size:** 14,703 pts |
|  | **Inclusion criteria:**  |
|  | • ≥18 y  |
|  | • Between 12 h and 10 d after AMI  |
|  | • Clinical or radiological signs of HF and/or evidence of depressed LV systolic function with EF<40% or reduced echo wall motion index  |
|  | **Exclusion criteria:**  |
|  | • Cardiogenic shock  |
|  | • Serum creatinine >2.5 mg/dL  |
|  | • Known hypersensitivity or intolerance to ACEI or ARB  |
|  | • SBP<100 mm Hg  |
|  | • Known or suspected bilateral renal artery stenosis  |
|  | • Stroke or TIA within previous 3 mo  |
|  | • Refractory ventricular arrhythmia  |
|  | • Refractory angina  |
|  | • Right ventricular MI  |
|  | • Mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation of hemodynamic significance  |
|  | • Obstructive cardiomyopathy  |
|  | • Previous major organ transplant  |
|  | • Conditions likely to lead to poor adherence  |
|  | **Intervention:** Valsartan 160 mg bid  |
|  | **Comparator:**  |
|  | • Captopril 50 mg tid  |
|  | • Combination of captopril 50 mg tid and valsartan 160 mg bid  |
|  | **1° endpoint:** All-cause mortality  |
|  | **2° endpoint:**  |
|  | • Composite of CV mortality or emergency treatment or hospitalization for new or worsening HF, reinfarction, stroke, and resuscitated cardiac arrest  |
|  | • On 3-y multivariable analysis, each 10-y age increase was associated with HR: 1.49; 95% CI: 1.43–1.56); p<0.0001 for mortality and an OR: 1.38; 95% CI: 1.31–1.46; p<0.0001 for readmission with HF.  |
|  | • Similar but slightly smaller trend for composite endpoint, higher mainly in the oldest group.  |
|  | • Valsartan was at least as effective as captopril in reducing mortality and other adverse outcomes in all age groups and combination therapy with both agents added no incremental benefit.  |
|  | • Combination therapy increased the incidence of adverse effects leading to discontinuation in all age groups  |
|  | **Safety endpoint:**  |
|  | • Adverse events associated with captopril and valsartan were more common in the elderly and in pts receiving combination therapy.  |
|  | • Renal dysfunction was more common with older age and combination therapy.  |
### Data Supplement 39. RCTs Comparing Hypertension after Renal Transplantation (Section 9.3.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim:</th>
<th>Inclusion criteria:</th>
<th>Intervention:</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Midtvedt K, et al., 2001 (183) 11468543</td>
<td>To compare the effect of an ACEI (lisinopril) with a CCB (controlled release nifedipine) in the treatment of post-transplant HTN focusing on changes in LVH.</td>
<td>All RTx pts with HTN by DBP ≥95 in first 3 wk after transplant</td>
<td>Renal transplant recipients with HTN (DBP ≥95 mm Hg) in the first 3 wk after Transplant were randomized to double-blind nifedipine CR 30 mg or lisinopril 10 mg daily.</td>
<td>1° endpoint: BP controlled in both groups (mean 140 ± 16/87 ± 8 with nifedipine, 136 ± 17/85 ± 8 with lisinopril, NS). LV mass reduced by 15% (p&lt;0.001) in both groups (from 153 ± 43 to 131 ± 38 g/m² with nifedipine and from 142 ± 35 to 121 ± 34 g/m² with lisinopril) with no difference between groups at baseline or at follow-up.</td>
<td>Summary: In renal transplant pts with HTN with well-controlled BP, there is regression of LV mass after renal transplantation which is observed to be similar in pts treated with lisinopril or nifedipine.</td>
</tr>
<tr>
<td>Midtvedt K, et al., 2001 (184) 11740389</td>
<td>To examine whether graft function as determined by GFR was better maintained with a CCB (controlled release nifedipine) as compared to an ACEI (lisinopril) in hypertensive renal transplant recipients treated with cyclosporine.</td>
<td>All renal transplant pts with HTN (DBP ≥95 mm Hg) in the first 3 wk after transplant</td>
<td>Renal transplant pts with HTN (DBP ≥95 mm Hg) in the first 3 wk after transplant were randomized to double-blind nifedipine CR 30 mg or lisinopril 10 mg daily.</td>
<td>1° endpoint: ● GFR baseline at 3–5 wk after entry, and at 1 and 2 y ● Nifedipine: baseline GFR 46 mL/min, at 1 y 56 ● Lisinopril: baseline GFR 43, at 1 y 44 ● delta N vs. L: 9.6 at 1 y (95% CI: 5.5–13.7 mL/min; p=0.0001), 10.3 at 2 y (95% CI: 4.0–16.6 mL/min; p=0.0017) ● Baseline GFR similar, change in GFR significant after 1 y and remained statistically significant after 2 y</td>
<td>Summary: Both nifedipine and lisinopril were safe and effective in treatment of HTN in renal transplant pts treated with cyclosporine. Pts receiving nifedipine but not lisinopril had improved renal function over 2 y.</td>
</tr>
<tr>
<td><strong>Suwelack B, et al., 2000 (185)</strong></td>
<td><strong>Aim:</strong> To compare the structural and functional cardiac changes of quinapril vs. atenolol administered to hypertensive kidney transplant recipients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study type:</strong> Prospective RCT</td>
<td><strong>Inclusion criteria:</strong> Cyclosporine-based immunosuppression, stable graft function with serum creatinine &lt;2.5 mg/dL.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 31 cyclosporine treated stable function recipients with HTN 6–12 wk after transplant</td>
<td><strong>Exclusion criteria:</strong> Pts with severe aortic or mitral regurgitation or with heart rates &gt;100 beats/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Intervention:</strong> Cyclosporine treated stable function pts with HTN 6–12 wk after transplant randomized to double-blinded quinapril or atenolol to target DBP&lt;90.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
|  | ● Echo within 24 h of first dose and at 24 mo  
|  | ● Stepwise increase in dose, could then add furosemide 40–80 mg/d, third-line CCB |
|  | **Comparator:** 2 treatment arms |
|  | **1° endpoint:** BP was lower in the atenolol group, delta 10.7 ± 3.4 mm Hg vs. 4.5 ± 2.9 mm Hg with quinapril  
|  | ● E/A ratio (impaired relaxation) increased (improved) only in quinapril group (+0.11; p<0.05) and decreased by 0.03 (p>0.05 vs. start of treatment) in the atenolol group. Difference in E/A ratio alterations was significant (p<0.05). |
|  | ● LV mass index decreased only in quinapril group (p<0.05) from entry to 24 mo. |
|  | **Summary:** In hypertensive renal allograft recipients, quinapril in contrast to atenolol provided a sufficient reduction in LVH and a concomitant improvement in LV diastolic cardiac relaxation and these effects occurred independently from BP reduction. |
| **Paoletti E, et al., 2007 (186)** | **Aim:** To assess the effectiveness of ACEIs in regressing LVH persisting after renal transplantation during an 18-mo observation period. To assess the impact of cyclosporine vs. tacrolimus in affecting LVH outcome. |
| **Study type:** Prospective RCT | **Inclusion criteria:** Renal transplant pts with serum creatinine <2.5 mg/dL, urine protein excretion not exceeding 1 g/d and with persistent LVH at 3–6 mo after transplant.  
|  | ● Previously randomized to either cyclosporine or tacrolimus immunosuppression.  
|  | ● All were pts of deceased donor transplants. |
| **Size:** 70 renal transplant recipients at 3–6 mo after transplant. | **Exclusion criteria:** |
|  | **Intervention:** RCT Lisinopril (n=36) vs. placebo (n=34), also used other agents to treat HTN  
|  | ● Endpoint LVMI at 18 mo  
|  | ● Echo at 3–6 mo and at 18 mo |
|  | **Comparator:** Treatment vs. placebo |
|  | **1° endpoint:** Change in LV mass index at 18 mo.  
|  | ● BP decreased in both groups (p=NS, between group differences SBP -1.7 ± 3.3 mm Hg; 95% CI: -4.8–-8.2; and DBP 0.3 ± 2.2 mm Hg; 95% CI: -4.8–-4.1).  
|  | ● LVMI regressed more in ACEI group (-9.1 ± 13.3 g/m²; p<0.001) but only in those on cyclosporine immunosuppression. Interaction of LVMI effect and |
|  | **Summary:** LVMI regressed more in ACEI group but only in those on cyclosporine immunosuppression. Interaction of LVMI effect and cyclosporine in post hoc analysis. |
| **VA NEPHRON-D**  
Fried LF, et al., 2010 (124)  
20728887 | **Aim:** To test the efficacy of the combination of losartan with lisinopril as compared with standard treatment with losartan alone in slowing the progression of proteinuric diabetic kidney disease  
**Study type:** RCT, multi-center, double-blind  
**Size:** 1,448 were randomized | **Inclusion criteria:** Pts without adverse events on full dose losartan DM-2, eGFR 30–89.9 mL/min/1.73 m² by 4 variable MDRD formula, urinary albumin/creatinine ratio of ≥300 in a random sample  
**Exclusion criteria:** Known nondiabetic kidney disease, serum potassium >5.5 mmol/L, current treatment with sodium polystyrene sulfonate or inability to stop prescribed medications increasing risk of hyperkalemia.  
**Intervention:**  
● Pts with DM-2 already taking losartan 100 mg/d with albumin to creatinine ratio of ≥300 were randomized to either lisinopril 10–40 mg/d or placebo.  
● 132 1° endpoints in the combination therapy group  
No benefit to mortality or CV events.  
● Combination therapy increase risk of hyperkalemia 6.3 events/100 person-y vs. 2.6 events/100 person-y (p<0.001) and acute kidney injury 12.2 vs. 6.7 events/100 person-y (p<0.001)  
**Comparator:** 152 1° endpoints in monotherapy group  
**1° endpoint:** First occurrence of a change in eGFR (a decline of ≥30 mL/min/1.73 m² if initial GFR ≥60 or a decline of ≥50% if initial eGFR <60, ESRD or death  
**2° endpoint:** First occurrence of decline in eGFR or ESRD  
**Safety endpoint:** Mortality, hyperkalemia, acute kidney injury  
**Summary:** Study stopped early due to safety concerns. Combination of ACEI and ARB was associated with increased risk of adverse events among pts with diabetic nephropathy.
### Data Supplement 40. Nonrandomized Trials, Observational Studies, and/or Registries for Hypertension after Renal Transplantation (Section 9.3.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Cross NB, et al., 2009 (187) 19588343 | **Study type:** Comparative assessment by drug class using RCTs and quasi-RCTs lasting at least 2 wk in kidney transplant pts  
**Size:**  
- 60 studies, 3,802 pts, most taking cyclosporine based immunosuppression  
- 29 studies (n=2,262) compared CCB to placebo, 10 (n=445) ACEI to placebo, 7 (n=405) CCB to ACEI | **Inclusion criteria:** 21 studies for HTN, 6 for erythrocytosis, 2 CAN, 2 LVH, 30 not specified  
**Exclusion criteria:** N/A | **1° endpoint:** To assess comparative effects of antihypertensive agents in kidney transplant pts  
**Results:** Used random effects meta-analysis, risk ratios for dichotomous outcomes and MD for continuous outcomes, both with 95% CI. Stratified analyses and meta-regression to investigate heterogeneity.  
- CCBs vs. placebo or no treatment had strongest results: improved GFR MD: 4.45 mL min (95% CI: 2.22–6.68), reduced graft loss RR: 0.75, (95% CI: 0.57–0.99).  
- ACEI vs. placebo inconclusive for GFR MD: -8.07 mL/min (95% CI: -18.57–2.43) and variable for graft loss.  
- Compared to CCB, ACEI decreased GFR MD: -11.48 mL/min (95% CI: -5.75– -7.21), proteinuria MD: -0.28 g/24 h (95% CI: -0.47– -0.10), also reduced hemoglobin MD: -12.96 g/L (95% CI: -5.72– -10.21) and increased hyperkalemia RR: 3.74 (95% CI: 1.89– 7.43). Graft loss data were inconclusive.  
- CCB may be preferred as first line for HTN after kidney transplant. ACEI may have some detrimental effects. There were not enough studies with other agents. | |
| Jennings DL, et al., 2008 (188) 18094340 | **Study type:** Literature review  
**Size:** 5 studies with 3 reporting safety endpoints and 2 reporting clinical efficacy endpoints | **Inclusion criteria:** Studies using either ACEI or ARB initiated within the first 12 wk after renal transplant | **1° endpoint:** Safety or efficacy  
**Results:**  
- No significant increase in serum creatinine or potassium after up to 9 mo Rx  
- Early initiation of ACEI may be more effective than BB in reducing LVH and proteinuria after 24 mo treatment | Conclusion: Reasonable to consider RAAS inhibitors as first-line treatment in pts with HTN and compelling indications i.e., DM, HF in first 12 wk after renal transplant. |
| Ninomiya T, et al., 2013 (189) 24092942 | **Aim:** To define CV effects of lowering BP in pts with CKD  
**Study type:**  
**Inclusion criteria:** Had to meet 1 of the following criteria: Pts randomized to a BP-lowering drug/regimen or a control group (placebo or less intensive BP lowering regimen) or pts randomized | **Results:** Compared with placebo, BP lowering regimens reduced the risk of major CV events by about a sixth per 5 mm Hg reduction in SBP in individuals with (HR: 0.83; 95% CI)  
**Limitations:**  
- Limited numbers with CKD and most were stage 3a:  
- There were 121,995 pts (80%) with eGFR ≥60 mL/min/1.73 m² (mean eGFR 81 (SD 17) |
Meta-analysis of RCTs
Individual pt data available for 23 trials, with summary data from another 3. Meta-analysis was performed according to baseline kidney function.

**Size:** 26 trials (152,290 pts), including 30,295 pts with reduced eGFR, defined as eGFR <60 mL/min/1.73 m².

between regimens based on different classes of drugs to lower BP. Trials required to have at least 1,000 pt-y of planned follow-up in each randomized arm and not to have presented or published their main results before finalization of the overview protocol in July 1995.

**Exclusion criteria:** Trials prior to July 1995.

There was no evidence that the effects of different drug classes on major CV events varied between pts with different eGFR (all p>0.60 for homogeneity).

<table>
<thead>
<tr>
<th>ONTARGET Investigators, et al., 2008 (126)</th>
<th>18378520</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> Evaluate whether use of an ARB was noninferior to ACEI, and whether the combination was superior to ACE alone in the prevention of vascular events in pts with CVD or DM but not HF.</td>
<td></td>
</tr>
<tr>
<td><strong>Study type:</strong> Multi-center, double-blind, RCT</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 25,620</td>
<td></td>
</tr>
</tbody>
</table>
| **Inclusion criteria:**  
• ≥55 y  
• Coronary, peripheral, or cerebrovascular disease or DM with end-organ damage | |
| **Exclusion criteria:**  
• Inability to discontinue ACEI or ARB  
• Known hypersensitivity or intolerance to ACEI or ARB  
• Selected CVDs (congestive HF, hemodynamically significant valvular or outflow tract obstruction, constrictive pericarditis, complex congenital heart disease, syncopal episodes of unknown etiology <3 mo, planned cardiac surgery or PTCA <3 mo, uncontrolled HTN on treatment [e.g., BP >160/100 mm Hg], heart transplant recipient, | |
| **Intervention:** Ramipril 10 mg daily (n=8,576) | |
| **Comparator:**  
• Telmisartan 80 mg daily (n=8,542)  
• Combination of telmisartan and ramipril (n=8,502) | |
| **1° endpoint:** After a median follow-up of 56 mo, no difference between ramipril vs. telmisartan or combination therapy vs. ramipril in the 1° composite outcome of death from CV causes, MI, stroke, or hospitalization for HF  
RR: 1.01 (95% CI: 0.94–1.09) and RR: 0.99 (95% CI: 0.92–1.07), respectively. | |
| **Safety endpoint:**  
• Combination therapy was associated with greater risk of hyperkalemia than ramipril monotherapy (480 pts vs. 283 pts; p<0.001)  
• Hypotensive symptoms were cited as reason for permanent discontinuing more in telmisartan vs. ramipril RR: 1.54, p<0.001; and combination therapy vs. ramipril monotherapy RR: 2.75, p<0.001  
• Renal impairment was more common in combination therapy vs. ramipril monotherapy RR: 1.33; 95% CI: 1.22–1.44 | |
stroke due to subarachnoid hemorrhage
• Other conditions (significant renal artery disease, hepatic dysfunction, uncorrected volume or sodium depletion, 1° hyperaldosteronism, hereditary fructose intolerance, other major noncardiac illness or expected to reduce life expectancy or significant disability interfere with study participation, simultaneously taking another experimental drug, unable to provide written informed consent).

| VALIANT | Aim: Evaluate whether use of an ARB or the combination of an ACEI and an ARB was superior to a proven effective dose of an ACEI after AMI in pts with HF and/or LVEF <40%. | Inclusion criteria: |
| VALIANT | Study type: Multi-center, double-blind, RCT | • ≥18 y |
| VALIANT | Size: 14,703 | • Between 12 h and 10 d after AMI |
| VALIANT | | • Clinical or radiological signs of HF and/or evidence of depressed LV systolic function with EF<40% or reduced echo wall motion index |
| VALIANT | | Exclusion criteria: |
| VALIANT | | • Cardiogenic shock |
| VALIANT | | • Serum creatinine >2.5 mg/dL |
| VALIANT | | • Known hypersensitivity or intolerance to ACEI or ARB |
| VALIANT | | • SBP<100 mm Hg |
| VALIANT | | • Known or suspected bilateral renal artery stenosis |
| VALIANT | | • Stroke or TIA within previous 3 mo |
| VALIANT | | • Refractory ventricular arrhythmia |
| VALIANT | | • Refractory angina |
| VALIANT | | • Right ventricular MI |
| VALIANT | | • Mitral stenosis, mitral regurgitation, aortic stenosis, aortic regurgitation of hemodynamic significance |
| VALIANT | | • Obstructive cardiomyopathy |
| VALIANT | | • Previous major organ transplant |
| VALIANT | Intervention: Valsartan 160 mg bid | Comparator: |
| VALIANT | | • Captopril 50 mg tid |
| VALIANT | | • Combination of captopril 50 mg tid and valsartan 160 mg bid |
| VALIANT | | • Analyzed by prespecified age groups of <65 (n=6,988) 65 to 74 (n=4,555) 75 to 84 (n=2,777) ≥85 y (n=383) |

1° endpoint: All-cause mortality

2° endpoint: 
• Composite of CV mortality or emergency treatment or hospitalization for new or worsening HF, reinfarction, stroke, and resuscitated cardiac arrest
• On 3-y multivariable analysis, each 10-y increase was associated with HR: 1.49 (95% CI: 1.43–1.56), p<0.0001 for mortality and OR: 1.38 (95% CI: 1.31–1.46; p<0.0001) for readmission with HF.
• Similar but slightly smaller trend for composite endpoint, higher mainly in the oldest group. Valsartan was at least as effective as captopril in reducing mortality and other adverse outcomes in all age groups and combination therapy with both agents added no incremental benefit. Combination therapy increased the incidence of adverse effects leading to discontinuation in all age groups

Safety endpoint: 
• Adverse events associated with captopril and valsartan were more common in the elderly and in pts receiving combination therapy.
• Renal dysfunction was more common with older age and combination therapy.
### Data Supplement 41. RCTs Comparing Acute Intracerebral Hemorrhage Outcomes (Section 9.4.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERACT2 Anderson CS, et al., 2013 (191) 23713578</td>
<td><strong>Aim:</strong> To assess whether rapid lowering of elevated BP would improve the outcome in pts with ICH.  <strong>Study type:</strong> Phase III RCT  <strong>Study size:</strong> 2,839 pts</td>
<td><strong>Inclusion criteria:</strong> Pts with spontaneous ICH within the previous 6 h with elevated SBP</td>
<td><strong>Design:</strong> Intensive treatment to lower BP (with a target systolic level of &lt;140 mm Hg within 1 h) vs. guideline-recommended treatment (with a target SBP &lt;180 mm Hg) among pts with SBP between 150 and 220 mm using agents of the physician’s choosing.</td>
<td>1° outcome: Death or major disability (score of 3 to 6 on the modified Rankin scale) at 90 d.  Pre-specified 2° outcome: Ordinal analysis of the modified Rankin score.</td>
<td>Summary:  ● In pts with ICH, intensive lowering of BP did not result in a significant reduction in the rate of death or severe disability.  ● However, there may be improved functional outcomes with intensive lowering of BP.  ● INTERACT-2 is so far the largest (and only phase 3) RCT evaluating efficacy of intensive BP lowering.</td>
</tr>
</tbody>
</table>
### ATACH-1

**Aim:** To determine the feasibility and acute (i.e., within 72 h) safety of 3 levels of SBP reduction in subjects with supratentorial ICH treated within 6 h after symptom onset.

**Study type:** Phase I, dose-escalation, multicenter prospective study.

**Study size:** 60

**Inclusion criteria:** Pts with ICH with elevated SBP ≥170 mm Hg who presented to the ED within 6 h of symptom onset.

**Design:**
- IV nicardipine to reduce SBP to a target of:
  - #1: 170–200 mm Hg in the first cohort of pts
  - #2: 140–170 mm Hg in the 2nd cohort
  - #3: 110–140 mm Hg in the third cohort.
- Each subject was followed-up for 3 mo to preliminarily assess mortality and the clinical outcomes. A total of 18, 20, and 22 pts were enrolled in the respective 3 tiers of SBP treatment goals.

**1° outcome:** Treatment feasibility (achieving and maintaining the SBP goals for 18–24 h)

**2° outcomes:**
- #1: Neurologic deterioration within 24 h;
- #2: Serious adverse events within 72 h.

**Key findings:**
- Overall, 9 of 60 pts had treatment failures (all in the last tier). A total of 7 subjects with neurologic deterioration were observed: 1 (6%), 2 (10%), and 4 (18%) in tier 1, 2, and 3, respectively.
- Serious adverse events were observed in 1 subject (5%) in tier 2 and in 3 subjects (14%) in tier 3. However, the safety stopping rule was not activated in any of the tiers.
- 3 (17%), 2 (10%), and 5 (23%) subjects in tiers 1, 2, and 3, respectively, died within 3 mo.

**Summary:**
- Observed proportions of neurologic deterioration and serious adverse events were below the prespecified safety thresholds, and the 3-mo mortality rate was lower than expected in all SBP tiers.

### INTERACT-1

**Aim:** To assess the safety and efficiency of early intensive lowering of BP (target SBP)

**Inclusion criteria:** Pts with supratentorial ICH presenting to the ED within 6 h of symptom onset.

**Design:** Early intensive BP-lowering treatment is clinically effective in reducing hematoma growth, with a proportional change in hematoma volume at 24 h.

**Summary:** Early intensive BP-lowering treatment is clinically

---

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<p>| Anderson CS, et al., 2008 (193) | this treatment, as a run-in phase to a larger trial. | acute spontaneous ICH diagnosed by CT within 6 h of onset, elevated SBP (150–220 mm Hg), and no definite indication or contraindication to treatment | 140 mm Hg; n=203) vs. standard guideline-based management of BP (target SBP 180 mm Hg; n=201). | 2° outcomes: Measurements of hematoma volume. | Safety and clinical outcomes: Assessed for up to 90 d. |
| Study type: Randomized pilot trial | Study size: 404 | 140 mm Hg; n=203) vs. standard guideline-based management of BP (target SBP 180 mm Hg; n=201). | 2° outcomes: Measurements of hematoma volume. | Safety and clinical outcomes: Assessed for up to 90 d. |
| Key findings: | | | | |
| • Mean hematoma volumes were smaller in the guideline group (12.7 mL, SD 11.6) than in the intensive group (14.2 mL, SD 14.5). | | | |
| • From randomization to 1 h, mean SBP was 153 mm Hg in the intensive group and 167 mm Hg in the guideline group (difference 13.3 mm Hg (95% CI: 8.9–17.6) mm Hg; p&lt;0.0001); from 1 h to 24 h, BP was 146 mm Hg in the intensive group and 157 mm Hg in the guideline group (10.8 mm Hg; 95% CI: 7.7–13.9 mm Hg; p&lt;0.0001). | | | |
| • Mean proportional hematoma growth was 36.3% in the guideline group and 13.7% in the intensive group (difference 22.6%; 95% CI: 0.6%–44.5%; p=0.04) at 24 h. | | | |
| • After adjustment for initial hematoma volume and time from onset to CT, median hematoma growth differed between the groups with p=0.06; the absolute difference in volume between groups was 1.7 mL (95% CI: -0.5–3.9; p=0.13). RR of hematoma growth ≥33% or ≥12.5 mL was 36% lower (95% CI: 0%–59%; p=0.05) in the intensive group than in the guideline group. Adjusted RR: 8% (95% CI: -1.0%–17%; p=0.05). | | | |
| • Intensive BP-lowering treatment did not alter the risks of adverse events or 2° clinical outcomes at 90 d. | | | |
| feasible, well tolerated, and might reduce hematoma growth in ICH. | | | |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Key findings</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tsivgoulis G, et al., 2014 (194)</td>
<td>To evaluate the safety and efficacy of intensive BP reduction in pts with acute-onset ICH</td>
<td>Pts with acute ICH randomized to either intensive or guideline BP-reduction protocols.</td>
<td>Death rates similar between pts randomized to intensive BP-lowering treatment and those receiving guideline BP-lowering treatment OR: 1.01; 95% CI: 0.83–1.23; p=0.914.</td>
<td>Intensive BP management in pts with acute ICH is safe.</td>
</tr>
<tr>
<td></td>
<td>Study type: Systematic review and meta-analysis of RCTs.</td>
<td></td>
<td>Intensive BP-lowering treatment associated with strong trend towards lower 3-mo death or dependency vs. guideline treatment OR: 0.87; 95% CI: 0.76–1.01; p=0.062.</td>
<td>Intensively treated ICH pts tended to have more favorable 3-mo functional outcome.</td>
</tr>
<tr>
<td></td>
<td>Study size: 4 eligible studies, including a total of 3,315 pts</td>
<td>Intensive early BP lowering after acute ICH onset compared with guideline-based treatment</td>
<td>Intensive BP reduction was also associated with a greater attenuation of absolute hematoma growth at 24 h (standardized MD± standard error: -0.110 ± 0.053; p=0.038).</td>
<td>Intensive BP reduction associated with a greater attenuation of absolute hematoma growth at 24 h.</td>
</tr>
<tr>
<td>ATACH2 Qureshi AI, et al., 2016</td>
<td>To determine the relative efficacy of intensive vs. standard antihypertensive treatment that was initiated within 4.5 H after symptom onset and continued for the next 24 H in patients with spontaneous supratentorial intracerebral hemorrhage</td>
<td>Pts with spontaneous ICH (volume, &lt;60 cm3) and a Glasgow Coma Scale (GCS) score of 5 or more</td>
<td>Among 1,000 participants with a mean (±SD) systolic BP of 200.6±27.0 mm Hg at baseline, 500 were assigned to intensive treatment and 500 to standard treatment. Enrollment was stopped because of futility.</td>
<td>Treatment of patients with spontaneous ICH to achieve a target systolic BP of 110 to 139 mm Hg did not result in a lower rate of death or disability compared to conventional reduction to a target of 140–179 mm Hg. Furthermore, there was more than twice the frequency of renal adverse events in the more intensively treated arm within a week of treatment initiation.</td>
</tr>
<tr>
<td></td>
<td>Study type: Phase III RCT</td>
<td>Design: Intravenous nicardipine administered within 4.5 H after symptom onset and continued for the next 24 H to lower BP</td>
<td>Death or disability occurred in 38.7% of patients in the intensive treatment group and 37.7% in the standard-treatment group. RR: 1.04; 95% CI: 0.85–1.27.</td>
<td>Starting antihypertensive treatment in the initial 5–10 d after ICH may have a different outcome from that seen after an ischemic stroke because of 2º edema formation and hemodynamic changes.</td>
</tr>
<tr>
<td></td>
<td>Study size: 1,000 pts</td>
<td>1ª outcome: Moderately severe or severe disability or who had died (modified Rankin scale score, 4 to 6) at 3 months</td>
<td>Serious adverse events occurring within 72 H after randomization were reported in 1.6% of the patients in the intensive-treatment group and 1.2% of those in the standard-treatment group.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Key findings:</td>
<td>Renal adverse events within 7 d after randomization were significantly higher in the intensive-treatment group than in the</td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
### Data Supplement 42. RCTs Comparing Acute Ischemic Stroke Outcomes (Section 9.4.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| COSSACS Robinson TG, et al., 2010 20621562 | **Aim:** Assess the efficacy and safety of continuing or stopping pre-existing antihypertensive drugs in patients with acute stroke  
**Study type:** RCT  
**Size:** 763 | **Inclusion criteria:**  
Acute ischemic stroke (or ICH) within previous 48 h  
**Exclusion criteria:**  
- Impaired level of consciousness  
- Unable to swallow  
- Hypertensive emergency  
- BP >200/120 mm Hg  
- Premorbid disability  
- Intravenous alteplase  
**Comparator:** Stop previous antihypertensive medication/s (n=384) | **Intervention:** Continue previous antihypertensive medication/s (n=379) | **1° endpoint:** Death or major disability (mRS 3–6) at 14 d: RR: 0.86 (95% CI: 0.65–1.14; p=0.3)  
**Safety endpoint:** Adverse events, minor and serious: p>0.05 for all | **Relevant 2° endpoint**  
- 2-wk NIHSS: p=0.46 and 2-wk Barthel Index: p=0.30  
- 2-wk BP: significantly lower in the continue arm (mean difference of -13 mm Hg in SBP and -8 mm Hg in DBP) p<0.0001  
- 6-month mortality: p=0.98; 6-month disability p<0.05  
**Study limitations**  
- Trial was terminated early because of slow recruitment, and consequently it was underpowered  
- Treatment was not homogeneous (different drugs, no specific BP target)  
- No differences when analysis restricted to patients with ischemic stroke  
**Summary/conclusions**  
- Early reinitiation of antihypertensive medications was safe but ineffective to prevent death or dependency  
- Early reinitiation of antihypertensives was associated with better BP control at 2 wk |
| **CATIS** | **Aim:** Evaluate whether immediate blood pressure reduction in patients with acute ischemic stroke would reduce death and major disability at 14 d or hospital discharge.  
**Study type:** RCT  
**Size:** 4071  
**Inclusion criteria:**  
- Age >22 y  
- Acute ischemic stroke within previous 24 h  
**Exclusion criteria:**  
- Impaired level of consciousness  
- Hypertensive emergency  
- BP >220/120  
- Atrial fibrillation  
- Intravenous alteplase  
**Intervention:** Antihypertensive medication to maintain BP <140/90 for the first wk (n=2038)  
**Comparator:** No antihypertensive medication for the first wk (n=2033)  
**1° endpoint:** Death or major disability (mRS 3–6) at 14 d: OR: 1.0 (95% CI: 0.88–1.14; p=0.98)  
**Safety endpoint:**  
- Vascular disease events p=0.28  
- Recurrent stroke p=0.07  
**Relevant 2° endpoint:**  
- Death or major disability (mRS 3–5) at 90 d: OR: 0.99 (95% CI: 0.86–1.15; p=0.93)  
- Lower blood pressure at 14 d (mean difference of -8.6 mm Hg in SBP and -3.9 mm Hg in DBP; p<0.001) and at 90 d (mean difference of -2.9 mm Hg in SBP and -1.4 mm Hg in DBP; p<0.001) in the active arm  
**Study limitations:** Antihypertensive regimen was not standardized  
**Summary/conclusions:**  
- Early treatment of hypertension was safe but ineffective to prevent death or dependency  
- Early initiation of antihypertensives was associated with better BP control at 2 wk  |
| **Wang H, et al., 2014 (195)** | **Aim:** To assess the effects of early BP lowering on early and long-term outcomes after acute stroke.  
**Study type:** Systematic review and meta-analysis of RCTs.  
**Study size:** 17 trials (n=13,236 pts)  
**Inclusion criteria:** Prospective RCTs of pts ≥18 y with acute ischemic or hemorrhagic stroke; intervention compared with placebo was initiated within 7 d of stroke onset; intervention aimed to lower BP or intervention achieved BP reduction; 1 or more functional outcomes reported, such as death or dependency.  
**Key findings:**  
- Early BP lowering after acute stroke onset associated with more death within 30 d compared with placebo RR: 1.34; 95% CI: 1.02–1.74; p=0.03.  
- Early BP lowering after acute stroke onset not associated with early neurological deterioration, early death within 7 d, long-term death, early and long-term dependency, early and long-term combination of death or dependency, long-term stroke recurrence, long-term MI and long-term CVE.  
**Summary:** Results do not support early BP lowering after acute stroke. Early BP lowering may be associated with greater risk of death within 30 d after acute stroke. |
| **Zhao R, et al., 2015 (196) 26061309** | **Aim:** To determine whether lowering BP during the acute phase of an ischemic stroke improves short- and long-term outcomes.  
**Study type:** Systematic review and meta-analysis of RCTs.  
**Study size:** 22 RCTs | **Exclusion criteria:**  
Studies with the pts of subarachnoid hemorrhage, studies without available full-text or relevant data, studies about ongoing trials and those written in languages other than English.  
**Inclusion criteria:** Pts with acute stroke (ischemic or hemorrhagic) treated with an antihypertensive agent or placebo.  
**Groups:** Treatment groups were n=5,672 (range, 6–2,308), and in the control groups was 5,416 (range, 6–2033).  
**Follow-up:** Ranged from 5 d–12 mo | **1° outcomes:** Change in SBP and DBP after treatment and short- and long-term dependency and mortality rates.  
**Key findings:**  
● Treatment groups had a greater decrease in BP than control groups, and this effect was seen with different classes of antihypertensive drugs.  
● Short-term and long-term dependency rates were similar between treatment and control groups (short-term dependency: pooled OR: 1.041; 95% CI: 0.936–1.159; p=0.457; long-term dependency: pooled OR: 1.013; 95% CI: 0.915–1.120; p=0.806).  
● Short-term or long-term mortality was similar between the treatment and control groups (short-term mortality: pooled OR: 1.020 (95% CI: 0.749–1.388; p=0.902); long-term mortality: pooled OR: 1.039 (95% CI: 0.883–1.222; p=0.644). | **Summary:** Antihypertensive agents effectively reduce BP during the acute phase of an ischemic stroke, but seem to confer no benefit with regard to short- and long-term dependency and mortality. |

| **Ahmed N, et al., 2000 (197) 10835440** | **Aim:** To investigate outcome in INWEST subgroups with increasing levels of BP reduction.  
**Inclusion criteria:** Pts with a diagnosis of ischemic stroke in the carotid artery territory within 24 h.  
**Interventions:**  
● Nimodipine as IV infusion of 1 mg/h for 5 d followed by oral dose of 120 mg daily for a total treatment period of 21 d (n=101) | **Key findings:**  
● Nimodipine treatment resulted in a significant reduction in BP from baseline vs. placebo during the first few d. | **Summary:** DBP, but not SBP, reduction was associated with neurological worsening after the IV high-dose nimodipine after acute stroke.  
● For low-dose nimodipine, the results were inconclusive. |
<table>
<thead>
<tr>
<th>Study type: Post-hoc analysis of RCT</th>
<th>Study type: Meta-analysis of RCTs of interventions that aimed to alter BP vs. control in pts within 1 wk of acute ischemic or hemorrhagic stroke</th>
<th>Study type: Post-hoc analysis of RCT</th>
<th>Study type: Meta-analysis of RCTs of interventions that aimed to alter BP vs. control in pts within 1 wk of acute ischemic or hemorrhagic stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Size</strong>: 265</td>
<td><strong>Inclusion criteria</strong>: RCTs of interventions that aimed to alter BP compared with control in pts with 1 wk of acute ischemic or hemorrhagic stroke</td>
<td><strong>Comparator</strong>: Placebo (n=100)</td>
<td><strong>Comparator</strong>: Placebo (n=100)</td>
</tr>
<tr>
<td>● Nimodipine as IV infusion of 2 mg/h for 5 d followed by oral dose of 120 mg daily for a total treatment period of 21 d (n=94)</td>
<td>● BP lowering after acute stroke onset compared with placebo</td>
<td>● A significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49; p=0.048).</td>
<td>● A significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49; p=0.048).</td>
</tr>
<tr>
<td><strong>Aim</strong>: To assess the clinical effectiveness of altering BP in pts with acute stroke, and the effect of different vasoactive drugs on BP in acute stroke. Update of previously published Cochrane reviews (1997, 2001, and 2008).</td>
<td><strong>1° outcome</strong>: Functional outcome</td>
<td><strong>Key findings</strong>:</td>
<td><strong>Key findings</strong>:</td>
</tr>
<tr>
<td><strong>Summary</strong>:</td>
<td><strong>Summary</strong>:</td>
<td>● At 24 h after randomization #1: Oral ACEIs reduced SBP MD: -8 mm Hg (95% CI: -17–1) and DBP MD: -3 mm Hg (95% CI: -9–2), sublingual ACEIs reduced SBP MD: -12.00 mm Hg (95% CI: -26–2) and DBP MD: -2 (95% CI: -10–6).</td>
<td>● No current evidence showing that lowering BP during the acute phase of stroke improves functional outcome.</td>
</tr>
<tr>
<td>Bath PM, et al., 2014 (198) 25353321</td>
<td></td>
<td>● Oral angiotensin receptor antagonists reduced SBP MD: -1 mm Hg (95% CI: -3–2) and DBP MD: -1 mm Hg (95% CI: -3–1).</td>
<td>● It seems reasonable to withhold BP-lowering drugs until pts are medically and neurologically stable, after which drugs can then be reintroduced.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Oral BBs reduced SBP MD: -14 mm Hg (95% CI: -27–1) and DBP MD: -1 mm Hg (95% CI: -9–7), IV BBs reduced SBP MD: -5 mm Hg (95% CI: -18–8) and DBP MD: -5 mm Hg (95% CI: -13–3).</td>
<td>● CCBs, ACEI, angiotensin receptor antagonists, BBs and nitric oxide donors each lower BP in acute stroke while phenylephrine appears to increase BP.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Oral CCBs reduced SBP MD: -13 mm Hg (95% CI: -43–17) and DBP MD: -6 mm Hg (95% CI: -14–2). IV CCBs reduced SBP MD: -32 mm Hg (95% CI: -65–1) and DBP MD: -13 (95% CI: -31–6).</td>
<td></td>
</tr>
</tbody>
</table>
### Aim:
To determine the association of BP and antihypertensive therapy with clinical outcomes after thrombolysis for acute ischemic stroke

### Study type:
Retrospective analysis of prospectively maintained thrombolysis registry.

### Inclusion criteria:
- Pts with acute ischemic stroke treated with IV rtPA
- BP values were recorded at baseline, 2 h, and 24 h after thrombolysis.

### Categories:
By history of HTN and antihypertensive therapy within 7 d after thrombolysis:
- Group 1, HTN treated with antihypertensives (n=5,612)

### 1st outcomes:
Symptomatic (National Institutes of Health Stroke Scale score deterioration ≥4) ICH Type 2, mortality, and independence at (modified Rankin Score 0 to 2) 3 mo.

### Key findings:
- High SBP 2–24 h after thrombolysis as a continuous variable was associated with worse outcome (p<0.001) and as a categorical variable had a linear association with symptomatic hemorrhage and a U-shaped association with mortality and independence with SBP 141–150 mm Hg associated with most favorable outcomes.
- No difference in symptomatic hemorrhage OR: 1.09 (95% CI: 0.83–1.51; p=0.58) and independence OR: 1.03 (95% CI: 0.93–1.10; p=0.80) but lower mortality OR: 0.82 (95% CI: 0.79–0.85).

### Summary:
- Strong association of high SBP after thrombolysis with poor outcome.
- Higher BPs during the initial 24 h were associated with greater risk of ICH in a linear fashion.
- U-shaped relation found between BP during initial 24 h and death or dependency at 3 mo, with best outcomes associated with SBP of 141–150 mm Hg.
### ACCESS

**Schrader J, et al., 2003 (200)**  

**Aim:** To assess safety of modest BP reduction by candesartan in early treatment of stroke; and provide an estimate of the number of cases required to perform a larger phase III efficacy study.  

**Study type:** Prospective, double-blind, RCT; multicenter phase II study.  

**Size:** 342 pts  

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>Exclusion criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor deficit, a cerebral CT scan excluding ICH, and necessity to treat HTN per prevailing recommendation</td>
<td>&gt;85 y, disorders in consciousness preventing acquisition of consent, occlusion or &gt;70% stenosis of the internal carotid artery, malignant HTN, manifest cardiac failure, high-grade aortic or mitral stenosis, UA pectoris, or contraindications against candesartan.</td>
</tr>
</tbody>
</table>

**Design:** 4 mg candesartan daily or placebo on d 1. On d 2, dosage was increased to 8 or 16 mg candesartan or placebo if BP >60 mm Hg SPB or 100 mm Hg DBP. Treatment was targeted to a 10%–15% BP reduction within 24 h.  

**1° outcome:** Trial was stopped prematurely when 342 pts (339 valid) had been randomized because of an imbalance in endpoints.  

**Key findings:** Cumulative 12 mo mortality and the number of vascular events differed significantly in favor of the candesartan cilexetil group (OR: 0.475; 95% CI: 0.252–0.895).  

**Summary:** Early antihypertensive therapy with candesartan might be a safe therapeutic option in acute stroke, but study sample size very small.

### SCAST

**Sandset EC, et al., 2011 (201)**  

**Aim:** To examine whether careful BP-lowering treatment with the candesartan is  

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>Design:</th>
<th>1° effect variables:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pts &gt;18 y with acute stroke (ischemic or hemorrhagic) and SBP of ≥140 mm Hg were randomized to candesartan (n=1,017) or placebo (1,012) (1:1) for 7 d, with doses</td>
<td>Pts randomized to candesartan (n=1,017) or placebo (1,012) (1:1) for 7 d, with doses</td>
<td>Composite of vascular death, MI, or stroke during the first 6 mo; and functional outcome at 6 mo, as measured by the modified Rankin Scale.</td>
</tr>
</tbody>
</table>

**Relevant 2° endpoint:**  

- Similar effects for all prespecified 2° endpoints.  
- During follow-up, 9 (1%) pts on candesartan and 5 (<1%) on
beneficial in pts with acute stroke and raised BP.

**Study type:** Double-blind RCT

**Study size:** 2,029 pts

included within 30 h of symptom onset.

increasing from 4 mg on d 1–16 mg on d 3–7.

Data for status at 6 mo were available for 2,004 pts (99%; 1,000 candesartan, 1,004 placebo).

**Key findings:**
- BPs significantly lower in pts allocated candesartan vs. placebo (mean 147/82 mm Hg [SD 23/14] in the candesartan group on d 7 vs. 152/84 mm Hg [22/14] in the placebo group; p<0.0001).
- Risk of the composite vascular endpoint did not differ between treatment groups (candesartan, 120 events, vs. placebo, 111 events; adjusted HR: 1.09; 95% CI: 0.84–1.41; p=0.52.
- Analysis of functional outcome suggested a higher risk of poor outcome in the candesartan group (adjusted OR: 1.17; 95% CI: 1.00–1.38; p=0.048).

placebo had symptomatic hypotension, and renal failure was reported for 18 (2%) pts taking candesartan and 13 (1%) allocated placebo.

**Summary:** Careful BP-lowering treatment with candesartan was not beneficial in pts with acute stroke and raised BP. Indeed, there was the suggestion of a harmful effect.

---

**CATIS**

He J, et al., 2014 (202) 24240777

**Aim:** To evaluate whether immediate BP reduction in pts with acute ischemic stroke would reduce death and major disability at 14 d or hospital discharge.

**Study type:** Single-blind, blinded end-points RCT.

**Study size:** 4,071 pts

Pts with nonthrombolysed ischemic stroke within 48 h of onset and elevated SBP

**Inclusion criteria:** Pts (n=2,038) randomized to antihypertensive treatment (aimed at lowering SBP by 10% to 25% within first 24 h, achieving BP <140/90 mm Hg within 7 d, and maintaining this level during hospitalization) vs. to discontinue all antihypertensive medications (control) (n=2,033).

**Design:**

1° outcome: Combination of death and major disability (modified Rankin Scale score ≥3) at 14 d or hospital discharge.

**Key findings:**
- Mean SBP was reduced from 166.7 mm Hg to 144.7 mm Hg (-12.7%) within 24 h in the antihypertensive treatment group and from 165.6 mm Hg to 152.9 mm Hg (-7.2%) in the control group within 24 h after randomization (difference, -5.5% (95% CI: -4.9–-6.1%); absolute difference, -9.1 mm Hg (95% CI: -10.2–-8.1), p<0.001).
- 1° outcome did not differ between treatment groups (OR: 1.00; 95% CI: 0.88–1.14; p=0.98) at 14 d or hospital discharge.
- BP at 14 d and 90 d: significantly lower in the active arm (mean difference of -2.9 mm Hg in systolic BP and -1.4 mm Hg in diastolic BP)

Relevant 2° endpoint: Death and major disability at 3-mo posttreatment follow-up did not differ between treatment groups (500 events [antihypertensive treatment] vs. 502 events [control]; OR: 0.99; 95% CI: 0.86–1.15; p=0.93).

**Summary:** Among pts with acute ischemic stroke, BP reduction with antihypertensive medications, vs. absence of hypertensive medication, did not reduce the likelihood of death and major disability at 14 d or hospital discharge.

- Early initiation of antihypertensives was associated with better BP control at 2 wk
| **COSSACS** | **Aim:** To assess the efficacy and safety of continuing or stopping pre-existing antihypertensive drugs in pts who recently had a stroke. | **Inclusion criteria:** Pts >18 y taking antihypertensive drugs enrolled within 48 h of stroke and last dose of antihypertensive drug. | **Design:** Continue (n=379) or stop (n=384) pre-existing antihypertensive drugs for 2 wk. | **1° outcome:** Death or dependency at 2 wk. | **Key findings:**  
- 72 of 379 pts in the continue group and 82 of 384 pts in the stop group reached the 1° endpoint RR: 0.86; 95% CI: 0.65–1.14; p=0.3.  
- Difference in SBP at 2 wk between the continue group and the stop group was 13 mm Hg (95% CI: 10–17) and the difference in DBP was 8 mm Hg (6–10; difference between groups; p<0.0001).  
- No substantial differences were observed between groups in rates of serious adverse events, 6-mo mortality, or major CV events. | **Summary:**  
- Continuation of antihypertensive drugs did not reduce 2-wk death or dependency, CV event rate, or mortality at 6 mo  
- Early reinitiation of antihypertensives was associated with better BP control at 2 wk  
- Lower BP levels in those who continued antihypertensive treatment after acute mild stroke were not associated with an increase in adverse events.  
- Of note, COSSACS was likely underpowered due to early termination of the trial. |
| --- | --- | --- | --- | --- | --- |
| **CHHIPS** | **Aim:** To assess feasibility, safety, and effects of 2 regimens for lowering BP in pts who with acute stroke. | **Inclusion criteria:** Pts with cerebral infarction or cerebral hemorrhage who were hypertensive SBP >160 mm Hg | **Design:**  
- Within 36 h of symptom onset:  
  #1: Oral labetalol, lisinopril vs. placebo if they were nondysphagic;  
  #2: IV labetalol, sublingual lisinopril, or placebo if they had dysphagia.  
- Labetalol (n=58), lisinopril (n=58), or placebo (n=63).  
- Doses were titrated up if target BP was not reached. | **1° outcome:** Death or dependency at 2 wk. | **Key findings:**  
- 1° outcome occurred in 61% (69) of the active vs. 59% (35) of the placebo group (RR: 1.03; 95% CI: 0.80–1.33; p=0.82)  
- No evidence of early neurological deterioration with active treatment (RR: 1.22; 95% CI: 0.33–4.54; p=0.76) despite greater drop in SBP within the first 24 h in this group vs. placebo (21 [17–25] mm Hg vs. 11 [5–17] mm Hg; p=0.004).  
- No rise in serious adverse events with active treatment (RR: 0.91; 95% CI: 0.69–1.12; p=0.50) but 3-mo mortality was halved (9.7% vs. 20.3%; HR: 0.40; 95% CI: 0.2–1.0; p=0.05). | **Summary:**  
- Labetalol and lisinopril are effective antihypertensive drugs in acute stroke that do not raise risk of serious adverse events.  
- Early lowering of BP with lisinopril and labetalol after acute stroke may be a promising approach to lower mortality and disability.  
- However, pilot nature and very small sample size limit generalizability. |
| **Bath PM, et al., 2015 (205)** | **Aim:** To assess outcomes after stroke in pts given transdermal glyceryl trinitrate | **Inclusion criteria:** Pts admitted to hospital with an acute ischemic stroke | **Design:**  
- 7 d of transdermal glyceryl trinitrate (5 mg | **1° outcome:** Function, assessed with the modified Rankin Scale at 90 d | **Summary:**  
- In pts with acute stroke and high BP transdermal glyceryl trinitrate
drugs to lower their BP.

**Study type:**
Multicenter, randomized partial-factorial trial

**Study size:** 4,011 pts

<table>
<thead>
<tr>
<th><strong>Key findings:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>● Mean BP was 167 (SD: 19) mm Hg/90 (13) mm Hg at baseline (median 26 h (16–37) after stroke onset), and was significantly reduced on d 1 in 2,000 pts allocated to glyceryl trinitrate vs. 2,011 controls (difference: -7.0 (95% CI: -8.5–-5.6) mm Hg/3.5 [-4.4–-2.6] mm Hg; both p&lt;0.0001), and on d 7 in 1,053 pts allocated to continue antihypertensive drugs compared with 1,044 pts randomized to stop them (difference: -9·5 (95% CI: -11.8–-7.2) mm Hg/-5.0 [-6.4–-3.7] mm Hg; both p&lt;0.0001).</td>
</tr>
<tr>
<td>● D-90 functional outcome did not differ in either treatment comparison-glyceryl trinitrate vs. no glyceryl trinitrate (OR: 1.01; 95% CI 0.91–1.13; p=0.83), and with continue vs. stop antihypertensive drugs (OR: 1.05; 95% CI: 0.90–1.22; p=0.55).</td>
</tr>
</tbody>
</table>

lowered BP with acceptable safety but did not improve functional outcome.

Continuing prestroke antihypertensive drugs in acute stroke pts in the first few d did not confer benefit.

---

**ATACH-1**

**2010 (192)**

**Aim:** To determine the feasibility and acute (i.e., within 72 h) safety of 3 levels of SBP reduction in subjects with supratentorial ICH treated within 6 h after symptom onset.

**Study type:** Phase I, dose-escalation, multicenter prospective study.

**Study size:** 60

<table>
<thead>
<tr>
<th><strong>Inclusion criteria:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pts with ICH with elevated SBP ≥170 mm Hg who presented to the ED within 6 h of symptom onset.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Design:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>● IV nicardipine to reduce SBP to a target of:</td>
</tr>
<tr>
<td>#1: 170–200 mm Hg in the first cohort of pts</td>
</tr>
<tr>
<td>#2: 140–170 mm Hg in the 2nd cohort</td>
</tr>
<tr>
<td>#3: 110–140 mm Hg in the third cohort.</td>
</tr>
<tr>
<td>● Each subject was followed-up for 3 mo to preliminarily assess mortality and the clinical outcomes. A total of 18, 20, and 22 pts were enrolled in the respective 3 tiers of SBP treatment goals.</td>
</tr>
</tbody>
</table>

| **1° outcome:** Treatment feasibility (achieving and maintaining the SBP goals for 18–24 h) |
| **2° outcomes:** |
| #1: Neurologic deterioration within 24 h; |
| #2: Serious adverse events within 72 h. |

**Summary:**

Observed proportions of neurologic deterioration and serious adverse events were below the prespecified safety thresholds, and the 3-mo mortality rate was lower than expected in all SBP tiers.

Results formed the basis of an ongoing larger randomized trial (ATACH-2) addressing the efficacy of SBP reduction in pts with ICH.
### INTERACT-1
Anderson CS, et al., 2008 (193) 18396107

**Aim:** To assess the safety and efficiency of this treatment, as a run-in phase to a larger trial.

**Study type:** Randomized pilot trial

**Study size:** 404

**Inclusion criteria:** Pts with acute spontaneous ICH diagnosed by CT within 6 h of onset, elevated SBP (150–220 mm Hg), and no definite indication or contraindication to treatment

**Design:** Early intensive lowering of BP (target SBP 140 mm Hg; n=203) vs. standard guideline-based management of BP (target SBP 180 mm Hg; n=201).

**1° outcome:** Proportional change in hematoma volume at 24 h.

**2° outcomes:** Measurements of hematoma volume.

**Safety and clinical outcomes:** Assessed for up to 90 d.

**Key findings:**
- Mean hematoma volumes were smaller in the guideline group (12.7 mL, SD 11.6) than in the intensive group (14.2 mL, SD 14.5).
- From randomization to 1 h, mean SBP was 153 mm Hg in the intensive group and 167 mm Hg in the guideline group (difference 13.3 mm Hg (95% CI: 8.9–17.6) mm Hg; p<0.0001); from 1 h to 24 h, BP was 146 mm Hg in the intensive group and 157 mm Hg in the guideline group (10.8 mm Hg; 95% CI: 7.7–13.9 mm Hg; p<0.0001).
- Mean proportional hematoma growth was 36.3% in the guideline group and 13.7% in the intensive group (difference 22.6%; 95% CI: 0.6%–44.5%; p=0.04) at 24 h.
- After adjustment for initial hematoma volume and time from onset to CT, median hematoma growth differed between the groups with p=0.06; the absolute difference in volume between groups was 1.7 mL (95% CI: -0.5–3.9; p=0.13). RR of hematoma growth ≥33% or ≥12.5 mL was 36% lower (95% CI: 0%–59%; p=0.05) in the intensive group than in the guideline group. Adjusted RR: 8% (95% CI: -1.0%–17%; p=0.05).
- Intensive BP-lowering treatment did not alter the risks of adverse events or 2° clinical outcomes at 90 d.

**Summary:** Early intensive BP-lowering treatment is clinically feasible, well tolerated, and appears to reduce hematoma growth in ICH.

### Hack W, et al., 2008 (206)

**Aim:** To assess the efficacy and

**Inclusion criteria:** Pts 18–80 y, who had

**Design:**

**1° outcome:** Disability at 90 d, dichotomized as a favorable outcome (a score of 0 or 1 on

**Summary:** Compared with placebo, IV alteplase administered between 3
<table>
<thead>
<tr>
<th>Study type</th>
<th>Study size</th>
<th>Inclusion criteria</th>
<th>Design</th>
<th>Key findings</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCT</td>
<td>821 pts</td>
<td>received a clinical diagnosis of acute ischemic stroke, and were able to receive the study drug within 3–4 h after the onset of symptoms.</td>
<td>Eligible pts were randomly assigned 1:1 to receive 0.9 mg of alteplase per kg, administered IV (with an upper limit of 90 mg), or placebo.</td>
<td>● More pts had a favorable outcome with alteplase than with placebo (52.4% vs. 45.2%; OR: 1.34; 95% CI: 1.02–1.76; p=0.04.</td>
<td>Despite an increased incidence of symptomatic ICH, treatment with IV t-PA within 3 h of the onset of ischemic stroke improved clinical outcome at 3 mo</td>
</tr>
<tr>
<td>Double-blind RCT</td>
<td>Pts with an ischemic stroke with a clearly defined time of onset (&lt;3 h), a deficit measurable on the NIH stroke scale, and a base-line CT scan of the brain that showed no evidence of ICH.</td>
<td>RCT with acute ischemic stroke pts randomized to t-PA vs. placebo</td>
<td>1° outcome: Clinical outcome at 3 mo, according to scores on the Barthel index, modified Rankin scale, Glasgow outcome scale, and NIH stroke scale:</td>
<td>● As compared with pts given placebo, pts treated with t-PA were at least 30% more likely to have minimal or no disability at 3 mo on the assessment scales.</td>
<td></td>
</tr>
<tr>
<td>NINDS rt-PA Stroke Study Group, 1995 (207) 7477192</td>
<td>Pts with an ischemic stroke with a clearly defined time of onset (&lt;3 h), a deficit measurable on the NIH stroke scale, and a base-line CT scan of the brain that showed no evidence of ICH.</td>
<td>RCT with acute ischemic stroke pts randomized to t-PA vs. placebo</td>
<td>2° outcome: global outcome analysis of 4 neurologic and disability scores combined.</td>
<td>Safety outcomes: death, symptomatic intracranial hemorrhage, and other serious adverse events.</td>
<td></td>
</tr>
</tbody>
</table>

**Aim:** To assess the difference in clinical efficacy between IV t-PA and placebo among pts with an acute ischemic stroke

**Exclusion criteria:** SBP >185 mm Hg or DBP >110 mm Hg or aggressive treatment (IV medication) necessary to reduce BP to these limits

**Eligible pts were randomly assigned 1:1 to receive 0.9 mg of alteplase per kg, administered IV (with an upper limit of 90 mg), or placebo.**

**418 pts were assigned to receive alteplase and 403 pts were assigned to receive placebo.**

**Key findings:**

- More pts had a favorable outcome with alteplase than with placebo (52.4% vs. 45.2%; OR: 1.34; 95% CI: 1.02–1.76; p=0.04).
- Incidence of ICH was higher with alteplase than with placebo (for any ICH, 27.0% vs. 17.6%; p=0.001; for symptomatic intracranial hemorrhage, 2.4% vs. 0.2%; p=0.008).
- Mortality did not differ significantly between the alteplase and placebo groups (7.7% and 8.4%, respectively; p=0.68).
- No significant difference in the rate of other serious adverse events.

**Summary:** Despite an increased incidence of symptomatic ICH, treatment with IV t-PA within 3 h of the onset of ischemic stroke improved clinical outcome at 3 mo.
### Data Supplement 43. RCTs Comparing Secondary Stroke Prevention (Section 9.4.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Size</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-stroke Antihypertensive Treatment Study (PATS) 1995 (208) 8575241</td>
<td><strong>Aim:</strong> To assess whether lowering BP prevents the recurrence of stroke in Chinese pts with history of cerebrovascular disease</td>
<td><strong>Study type:</strong> Double-blind RCT</td>
<td><strong>Inclusion criteria:</strong> Pts with history of stroke or TIA</td>
<td><strong>Intervention:</strong> Indapamide 2.5 mg daily (n=2,840 pts)</td>
<td><strong>1° outcome:</strong> Recurrence of fatal or nonfatal stroke. <strong>Key findings:</strong> Average SBP/DBP at randomization was 153.8/92.8 mm Hg. At median follow-up (2 y), BP was 6.8/3.3 mm Hg lower in pts on active treatment. 143 pts on indapamide vs. 219 pts on placebo had recurrent strokes (HR: 0.69; 95% CI: 0.54–0.89; p&lt;0.001). <strong>2° outcome:</strong> Major fatal and nonfatal CV events In addition, 199 pts on indapamide and 258 pts on placebo had a CV event (HR: 0.75; 95% CI: 0.89–0.62; p=0.002). <strong>Summary:</strong> For pts with a history of stroke or TIA, BP reduction of 5/2 mm Hg with 2.5 mg of indapamide lowered the first incidence of fatal and nonfatal stroke by 29%, with 3-y absolute benefit of 29 events per 1,000 pts.</td>
</tr>
<tr>
<td>PROGRESS 2001 (209) 11589932</td>
<td><strong>Aim:</strong> To determine effects of a BP-lowering regimen in hypertensive and nonhypertensive pts with a history of stroke or TIA.</td>
<td><strong>Study type:</strong> Double-blind, placebo-controlled trial</td>
<td><strong>Inclusion criteria:</strong> Pts with history of stroke (evidence of an acute disturbance of focal neurological function with symptoms lasting more than 24 h and</td>
<td><strong>Intervention:</strong> Active treatment comprised a flexible regimen based on the ACEI perindopril (4 mg daily), with addition of diuretic indapamide at discretion of treating physicians (n=3,051)</td>
<td><strong>1° outcome:</strong> Total stroke (fatal or nonfatal) <strong>Key findings:</strong> Over 4 y of follow-up, active treatment reduced BP by 9/4 mm Hg. 307 (10%) pts assigned active treatment suffered a stroke, vs. 420 (14%) assigned placebo (RR reduction: 28% [95% CI: 17, 38], p&lt;0.0001). Combination therapy with perindopril plus indapamide reduced BP by 12/5 mm Hg and stroke risk by 43% (95% CI: 30–54%). Single-drug therapy reduced Relevant 2° endpoint: Active treatment also reduced the risk of total major vascular events (26% [16–34]). There were similar reductions in the risk of stroke in hypertensive and nonhypertensive subgroups (all p&lt;0.01). <strong>Summary:</strong> This BP-lowering regimen reduced the risk of stroke among both hypertensive and nonhypertensive pts with a history of stroke or TIA. Combination therapy with perindopril and indapamide produced larger BP</td>
</tr>
<tr>
<td><strong>MOSES</strong></td>
<td><strong>Aim:</strong> To assess among hypertensive stroke pts, whether for the same level of BP control, eprosartan would be more effective than nitrendipine in reducing cerebrovascular and CV morbidity and mortality.</td>
<td><strong>Inclusion criteria:</strong> High-risk hypertensives with cerebral event during the last 24 mo (proven by cerebral CT scan or nuclear magnetic resonance)</td>
<td><strong>1° endpoint:</strong> Composite of total mortality and all CV and cerebrovascular events, including all recurrent events.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schrader J, et al., 2005 (210)</td>
<td><strong>Exclusion criteria:</strong> Internal carotid artery occlusion or stenosis &gt;70%, manifest HF (NYHA grade III–IV), age &gt;85 y at the time of study.</td>
<td><strong>Comparator:</strong> Nitrendipine 10 mg (n=671)</td>
<td><strong>Key findings:</strong> BP reduced to comparable extent without significant differences between 2 groups during study period (150.7/84 mm Hg vs. 152.0/87.2 mm Hg with eprosartan and nitrendipine therapy to 137.5/80.8 mm Hg and 136.0/80.2 mm Hg, respectively). 75.5% reached values &lt;140/90 mm Hg with eprosartan regimen and 77.7% with nitrendipine. During follow-up, 461 1° events occurred: 206 eprosartan and 255 nitrendipine (IDR: 0.79; 95% CI: 0.66–0.96; p=0.014).</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study type:</strong> PROBE design</td>
<td><strong>Intervention:</strong> Eprosartan 600 mg (n=681)</td>
<td><strong>Relevant 2° endpoint:</strong> CV events were: 77 eprosartan and 101 nitrendipine (IDR: 0.75; 95% CI: 0.55–1.02; p=0.06); cerebrovascular events: 102 eprosartan and 134 nitrendipine (IDR: 0.75; 95% CI: 0.58–0.97; p=0.03).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1,405</td>
<td><strong>75.5% reached values &lt;140/90 mm Hg with eprosartan regimen and 77.7% with nitrendipine. During follow-up, 461 1° events occurred: 206 eprosartan and 255 nitrendipine (IDR: 0.79; 95% CI: 0.66–0.96; p=0.014).</strong></td>
<td><strong>Summary:</strong> ● The combined 1° endpoint was significantly lower in the eprosartan group. ● However, it was a reduction in TIAs that accounted for most of the benefit in cerebrovascular events, with no significant difference in ischemic strokes. ● Also a more traditional analysis of time to first cerebrovascular event did not show a benefit of eprosartan.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **PROFESS** | **Aim:** To evaluate the effects of therapy with an ARB, telmisartan, initiated early after a stroke  
**Study type:** Double-blind RCT  
**Size:** 20,332 pts |
| --- | --- |
| **Inclusion criteria:** Pts ≥55 y with an ischemic stroke <90 d before randomization  
**Exclusion criteria:** 1° hemorrhagic stroke, severe disability after the qualifying stroke  |
| **Intervention:** Telmisartan 80 mg daily (n=10,146)  
**Comparator:** Placebo (n=10,186) |
| **1° endpoint:** Recurrent stroke |
| **Key findings:** During mean follow-up of 2.5 y, mean BP was 3.8/2.0 mm Hg lower in telmisartan group vs. placebo group. 880 pts (8.7%) in telmisartan group vs. 934 pts (9.2%) in placebo group had a subsequent stroke (HR: 0.95; 95% CI: 0.86–1.04; p=0.23). |
| **Relevant 2° endpoint:** Major CV events (death from CV causes, recurrent stroke, MI, or new or worsening HF) occurred in 1,367 pts (13.5%) in telmisartan group vs. 1,463 pts (14.4%) in placebo group (HR: 0.94; 95% CI: 0.87–1.01; p=0.11). |
| **Summary:**  
- Therapy with telmisartan initiated soon after ischemic stroke and continued for 2.5 y did not significantly lower Rate of recurrent stroke, or major CV events.  
- Impact of treatment with telmisartan may have been affected by the high rate of discontinuation of treatment medication because of hypotensive symptoms, syncope, diarrhea, and nausea experienced in the telmisartan arm and the more aggressive treatment with other standard antihypertensive therapies in the placebo arm. Thus, adverse side effects from treatment medications may affect quality of life and thus medication adherence after stroke. |

| **SPS-3** | **Aim:** To investigate effects of different BP targets on rate of recurrent stroke in pts  
**Inclusion criteria:** Pts with recent, MRI-defined symptomatic |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention:</strong> SBP target of 130–149 mm Hg (n=1,519)</td>
<td></td>
</tr>
<tr>
<td><strong>1° outcome:</strong> All stroke (including ischemic strokes and intracranial hemorrhages).</td>
<td></td>
</tr>
<tr>
<td><strong>Key findings:</strong> 2° outcomes: No difference between target groups in disabling or fatal stroke 0.81, (95% CI: 0.53–1.23; p=0.32) or composite outcome of MI or vascular death 0.84 (95% CI: 0.68–1.04; p=0.32). However,</td>
<td></td>
</tr>
</tbody>
</table>
### Study Type/Design

**Randomized open-label trial**

**Size**: 3,020 pts

**Exclusion criteria**: Pts with cortical strokes, cardioembolic disease, or carotid stenosis were excluded.

**Comparator**: SBP target of <130 mm Hg (n=1,501)

- After 1 y, mean SBP was 138 mm Hg (95% CI: 137–139) in the higher-target group and 127 mm Hg (95% CI: 126–128) in the lower-target group.
- Recurrent stroke was observed in 152 pts assigned to higher-target group (2.8% per y) vs. 125 assigned to the lower-target group (2.3% per y; HR: 0.81; 95% CI: 0.64–1.03).
- Hemorrhagic stroke occurred in 16 pts assigned to the higher-target group (0.29% per y) vs. 6 assigned to the lower-target group (0.11% per y; HR: 0.37 (95% CI: 0.15–0.95)). Serious complications of hypotension were observed in 15 pts assigned to the higher-target group (0.26% per y) and 23 assigned to the lower-target group (0.40% per y; HR: 1.53; 95% CI: 0.80–2.93).

**Summary**: Use of a SBP target of less than 130 mm Hg was not significantly better than a target of 130–149 mm Hg for preventing any recurrent stroke. However, the lower target appeared to confer benefit for prevention of hemorrhagic stroke.

---

### Data Supplement 44. Nonrandomized Trials, Observational Studies, and/or Registries of Secondary Stroke Prevention (Section 9.4.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Rashid P, et al., 2003 (213) 14576382 | Study type: Meta-analysis of RCTs Size: 7 RCTs | Inclusion criteria: Pts with a history of ischemic stroke, TIA, or ICH | 1° outcome: Recurrent stroke  
**Key findings**: Antihypertensive drug therapy associated with a 24% reduction in recurrent stroke risk (RR: 0.76; 95% CI: 0.63–0.92)  
Recurrent stroke risk reduction seen in both hypertensive and normotensive (as defined by the respective trials) pts and linked to magnitude of reduction in SBP | 2° outcomes: Nonfatal stroke OR: 0.79 (95% CI: 0.65–0.95), MI OR: 0.79 (95% CI: 0.63, 0.98), and total vascular events OR: 0.79 (95% CI: 0.66–0.95). No effect seen on vascular or all-cause mortality. ACEIs and diuretics separately, and particularly together, reduced vascular events, while beta-receptor antagonists had no discernable effect.  
**Summary**: Use of antihypertensive agents to lower BP for the prevention of vascular events in pts with previous stroke or TIA is efficacious. |
| Lakhan SE, et al., 2009 (214) 19843330 | Aim: To examine the role of BP reduction using antihypertensive | Inclusion criteria: Pts with a history of ischemic stroke, TIA, or ICH | 1° outcome: Recurrent stroke  
BP-lowering agents reduced recurrent stroke OR: 0.71 (95% CI: 0.59–0.86; p=0.0004) and | 2° outcomes: BP-lowering agents did not affect the rate of MI or all-cause mortality. |
| Study type: Systematic review and meta-analysis | Size: 10 RCTs | Aim: To examine role of BP reduction using antihypertensive agents to prevent recurrent stroke. | Inclusion criteria: Pts with a history of ischemic stroke, TIA, or ICH Followed up 2 to 5 y. | Exclusion criteria: N/A | 1° outcome: Recurrent stroke | Key findings: Antihypertensive drugs associated with significant reduction in recurrent strokes (RR: 0.78; 95% CI: 0.68–0.90). Impact of antihypertensive treatment after ischemic stroke was similar in a restricted group of subjects with HTN and when all subjects, including those with and without HTN, were included. Pooled OR: 0.63 (95% CI: 0.54–0.73; p=0.0001) for trials involving diuretics as a component of therapy and 0.93 (95% CI: 0.87–1.01; p=0.086) for trials in which treatment included renin system inhibitors (p<0.0001 for heterogeneity). | 2° outcomes: Significant reduction in recurrent stroke seen with diuretics (alone or in combination with ACEIs) but not with renal artery stenosis inhibitors, BBs, or CCBs used alone; however, statistical power was limited, particularly for the assessment of BBs and CCBs. | Summary: In conclusion, BP lowering by indapamide treatment reduced the recurrence of stroke and the incidence of CV events in Chinese pts with cerebrovascular disease. Whether prevention of stroke recurrence depends on drug class, degree of BP lowering or both requires further investigation. |

| Lee M, et al., 2012 (216) 21796663 | Study size: 11 studies with 42,572 pts and 794 stroke events. | Aim: To compare impact of achieving tight vs. usual SBP control on stroke prevention | Inclusion criteria: (1) Achieved SBP<130 mm Hg in an active treatment group and SBP 130 to 39 mm Hg in a comparator group by trial; (2) trial duration at least 6 mo; (3) total pts and number of stroke events reported separately for active treatment and comparator groups. | Exclusion criteria: (1) Nonrandomized trials; (2) trials in which either the | 1° outcome: Association of future stroke risk and achieved level of different SBP (intensive vs. usual) | Key findings: • Final SBPs, weighted for trial size, were a mean of 126.5 mm Hg in the intensive treatment arms and 132.6 mm Hg in the conventional arms (mean SBP reduction, 6.1 mm Hg). • In subgroup analyses, those with established (symptomatic) CVD at entry did not experience stroke risk reduction with tight control (0.92; 95% CI: 0.83–1.03). | Summary: Achieving an SBP <130 mm Hg vs. 130–139 mm Hg appears to provide additional stroke protection only among pts with risk factors but no established CVD. |
| Lee M, et al., 2012 (217) 22052520 | **Aim:** To evaluate whether use of ACEIs or ARB reduces future vascular events in persons with prior stroke.  
**Size:** 8 RCTs with 29,667 pts | **Inclusion criteria:** (1) RCT design; (2) pts had a history of stroke or TIA; (3) active treatment consisted of ACEIs or ARBs; (4) follow-up duration at least 6 mo; (5) total pts and number of future major vascular events and/or recurrent stroke were reported separately for active treatment and comparator groups.  
**Exclusion criteria:** (1) mandatory ACEI or ARB use in control groups; (2) study purpose was to examine efficacy of ACEIs or ARBs in pts with acute stroke | **1° outcome:** Major vascular event (nonfatal stroke, nonfatal MI, or death from CV causes) or stroke (ischemic or hemorrhagic)  
**Key findings:** Use of ACEIs or ARBs in persons with prior stroke was associated with lower risks of future major vascular events RR: 0.91 (95% CI: 0.87–0.97; p=0.001); NNT=71 and recurrent stroke RR: 0.93 (95% CI: 0.86–0.99; p=0.03); NNT=143.  
**Summary:** Treatment with an ACEI or ARB has a clear but rather modest effect on reducing vascular risk in persons with prior stroke. |
| Arima H, et al., 2006 (218) 16685221 | **Aims:**  
#1: To investigate the effects of randomized treatment on recurrent stroke by baseline BP levels  
#2: To investigate association | **Inclusion criteria:** Pts with history of cerebrovascular event (stroke or TIA) within the previous 5 y  
**Groups:** Defined by baseline BP of <120, 120–139, 140–159, and 160 mm Hg or greater | **1° outcome:** Total stroke (fatal or nonfatal)  
**Key findings:**  
- Smaller BP differences between active vs. placebo groups (p<0.0001) and corresponding lesser risk reductions (p trend=0.05) with lower baseline BPs  
**Summary:** These analyses provide no evidence of a J-curve relationship between BP level and stroke risk among pts with cerebrovascular disease. However, ischemic stroke, TIA, and hemorrhagic pts were all enrolled and within 5 y of the index event suggesting that these pts were generally neurologically stable and not acknowledging the...
between achieved follow-up BP levels and recurrent stroke risk.

**Study type:** Post-hoc analysis of PROGRESS trial.

**Size:** 6,105 pts

Follow-up SBP level was strong and continuous with no evidence of a J-curve in the range of achieved follow-up SBP from 112–168 mm Hg (p trend <0.0001). RR of study treatment on the discontinuation of randomized treatment increased progressively across the subgroups with lower baseline SBP levels at entry (p trend=0.04), but there was no corresponding difference in effects of randomized treatment on the risks of death or hospital admission (both p trend >0.2) or hypotension, renal dysfunction, electrolyte disturbance, hip fracture, or depression between pts with different levels of baseline BP at baseline (all p trend >0.1).

- Minor side-effects were progressively more common at lower BP levels (p homogeneity=0.04).

White CL, et al., 2015 (219) 25850462

**Aim:** To determine safety and tolerability of lowering BP in older adults with lacunar stroke

**Study type:** Post-hoc analysis of randomized trial

**Study Size:** 494 pts

**Inclusion criteria:** Pts with lacunar stroke ≥75 y

| 1° outcome | Rates of side effects related to lowering SBP |
| 2° outcome | Stroke recurrence and death from vascular causes |

**Key findings:**
- Older pts achieved SBP levels similar to younger pts (mean SBP of 125 mm Hg in lower SBP target group and 137 mm Hg in higher target group)
- 3.5 y of follow-up
  - 21% reported dizziness and 15% reported lightheadedness when standing; only significant difference between younger and older groups was unsteadiness when standing (23% vs. 32%, p<0.001). No difference in recurrent stroke by target SBP level among the older subjects (HR: 1.01; 95% CI: 0.59–1.73), but the differences in pathophysiologic mechanism between stroke types.
- First analysis showed that the effectiveness of antihypertensive treatment for 2° stroke prevention diminished as baseline BP declined (relative RRs were 39%, 31%, 14%, and 0%, respectively, in the groups defined previously). This trend of decreasing effect was despite successful reduction of mean SBP in each active-treatment group compared with placebo (11.1, 9.2, 7.6, and 7.4 mm Hg reductions, respectively, in the groups defined previously). Also of note, 40% of pts with a baseline BP<140 mm Hg were taking antihypertensive therapy at baseline.

**Summary:** Pts ≥75 y with a recent lacunar stroke who achieved a lower SBP target (<130 mm Hg) were significantly more likely to report unsteadiness on standing than their younger counterparts. Lower SBP was not related to a decrease in recurrent stroke risk in elderly pts with lacunar stroke but there was a potential protective advantage from vascular death.
| Study Type | Aim: To assess the association of maintaining low-normal vs. high-normal SBP levels with risk of recurrent stroke. | Inclusion criteria: Pts 55 y or older with an ischemic stroke <90 d before randomization | 1° outcome: First recurrence of stroke of any type | Key findings: Recurrent stroke rates were 8.0% (95% CI: 6.8%–9.2%) for the very low-normal SBP level group, 7.2% (95% CI: 6.4%–8.0%) for the low-normal SBP group, 6.8% (95% CI: 6.1%–7.4%) for the high-normal SBP group, and 14.1% (95% CI: 13.0%–15.2%) for the very high SBP group. Compared with pts in the high-normal SBP group, the risk of 1° outcome was higher for pts in the very low-normal SBP group AHR: 1.29 (95% CI: 1.07–1.56), in the high SBP group AHR: 1.24 (95% CI: 1.11–1.39), and in the very high SBP group AHR: 1.94 (95% CI: 1.74–2.16). | Summary: Results support a possible pattern of increased risk of recurrent stroke in pts with low-normal SBP levels during follow-up in the very low-normal (<120 mm Hg), high (140–≤150 mm Hg), or very high (≥150 mm Hg) range were associated with increased risk of recurrent stroke. |
| --- | --- | --- | --- | --- |
| **Ovbiagle B, et al., 2011 (220)** [22089721] | **Aim**: To assess the association of maintaining low-normal vs. high-normal SBP levels with risk of recurrent stroke. | **Inclusion criteria**: Pts 55 y or older with an ischemic stroke <90 d before randomization | **1° outcome**: First recurrence of stroke of any type | **Key findings**: Recurrent stroke rates were 8.0% (95% CI: 6.8%–9.2%) for the very low-normal SBP level group, 7.2% (95% CI: 6.4%–8.0%) for the low-normal SBP group, 6.8% (95% CI: 6.1%–7.4%) for the high-normal SBP group, and 14.1% (95% CI: 13.0%–15.2%) for the very high SBP group. Compared with pts in the high-normal SBP group, the risk of 1° outcome was higher for pts in the very low-normal SBP group AHR: 1.29 (95% CI: 1.07–1.56), in the high SBP group AHR: 1.24 (95% CI: 1.11–1.39), and in the very high SBP group AHR: 1.94 (95% CI: 1.74–2.16). | **Summary**: Among pts with recent noncardioembolic ischemic stroke, SBP levels during follow-up in the very low-normal (<120 mm Hg), high (140–≤150 mm Hg), or very high (≥150 mm Hg) range were associated with increased risk of recurrent stroke. |
| **Ovbiagle B, et al., 2013 (221)** [22244715] | **Aim**: To assess association of maintaining low-normal vs. high-normal SBP levels with risk of recurrent stroke. | **Inclusion criteria**: Pts with an ischemic stroke <120 d before randomization | **1° outcome**: First recurrence of stroke of any type | **Key findings**: Rate of recurrent stroke was 9.1% in the low-normal group, 6.7% in the high-normal group, and 10% in the high group. Difference in recurrent stroke rate between low-normal and high-normal groups was more prominent within the first 6 mo (low-normal, 4.5%; high-normal, 2.5%; high, 3.4%) vs. after 6 mo (low-normal, 4.6%; high-normal, 4.2%; high, 6.6%). Over study period, compared with the high-normal group, risk of the 1° outcome trended higher in the low-normal group AHR: 1.47 (95% CI: 0.94–2.29; p=0.09) and was higher in the high group AHR: 1.39 (95% CI: 1.08–1.79; p=0.01). | **Summary**: Results support a possible pattern of increased risk of recurrent stroke in pts with low-normal SBP levels, especially within the first 6 mo after first stroke. However, this study likely was not sufficiently powered to detect more than a strong statistical trend underlying this relationship. |
| **Lin MP, et al., 2015 (222)** | **Aim:** To assess link between SBP and mortality after stroke.  
**Study type:** Analyses of nationally representative survey data (NHANES)  
**Study Size:** 455 pts | **Inclusion criteria:** Adults ≥20 y with self-reported stroke.  
**Categories:** Baseline SBP was as low to normal (<120 mm Hg), normal (120–140 mm Hg), and high (≥140 mm Hg).  
**1° outcomes:** All-cause and vascular mortality  
**Key findings:**  
2 y after assessment, the low to normal SBP group tended to have the highest cumulative all-cause mortality (11.5%), compared with mortality rates of 8.5% and 7.5% in the normal and high SBP groups, respectively. Similar patterns were seen with vascular mortality. After adjusting for covariates, compared with the high SBP group, the low to normal group had higher all-cause mortality AHR: 1.96 (95% CI: 1.13–3.39; p=0.017) and trended toward higher vascular mortality AHR: 2.08 (95% CI: 0.93–4.6; p=0.075). Compared with the normal BP group, the risk of all-cause and vascular mortality trended higher in low to normal BP group but did not achieve statistical significance.  
**Summary:** After stroke, compared with SBP in the high range, low to normal SBP may be associated with poorer mortality outcomes. Study limited by self-reported nature and retrospective design. |  |
| **Kim J, et al., 2014 (223)** | **Aim:** To investigate the association between BP and vascular events up to 10 y after stroke.  
**Study type:** Analysis of population based study (North East Melbourne Stroke Incidence Study (NEMESIS)  
**Study size:** 5-y survivors of stroke  
**Categories:** Stratification by quartiles of SBP  
**Follow-up:** Annually by telephone at 6, 8, and 9 y and face-to-face interview at 7 and 10 y after stroke.  
**1° outcomes:** Composite of all-cause death or nonfatal vascular event (stroke or AMI); and all-cause death alone.  
**Key findings:** In 5-y survivors of stroke, compared to a SBP of 131–141 mm Hg, SBP of 120 mm Hg or less was associated with a 61% greater risk of stroke, acute MI and death (HR: 1.61; 95% CI: 1.08–2.41; p=0.019). Compared to the reference category of SBP 131–141 mm Hg, there were no differences in outcome in the pts with SBP 121–130 mm Hg (p=0.491) or 142–210 mm Hg (p=0.313). Findings were not modified after adjusting for antihypertensive drug prescriptions.  
**Summary:** There appears to be a greater risk of poor outcome in long-term survivors of stroke with low SBP. This is further evidence that low SBP may result in poor prognosis. |  |
| **Wang WT, et al., 2016 (224)** | **Aim:** To investigate the relative effects of BP-lowering therapies [ACEI, ARB, BB, CCBs, diuretics, and  
**Inclusion criteria:** RCTs comparing the effects of any of the 6 most commonly used BP-lowering drug classes [ACEI, ARB, alpha-blocker, BB, diuretics, and CCB] vs. placebo  
**1° outcome:** Recurrent stroke  
**2° outcome:** CHD, and MACCE  
**Key findings:**  
Virtually all BP-lowering medication classes reduced vascular events including recurrent stroke.  
The higher the average BP reduction between the treatment vs. control groups the larger the risk reduction in recurrent stroke events and MACCE. |  |
<table>
<thead>
<tr>
<th><strong>Aim:</strong> To assess the association of BP reduction with recurrent stroke and CV events using available RCT data on 2º stroke prevention</th>
<th><strong>Study size:</strong> 14 studies with 42,736 pts</th>
<th><strong>Inclusion criteria:</strong> RCTs of antihypertensives for 2º stroke prevention pts that reported achieved BP values during the follow-up period.</th>
<th><strong>Summary:</strong> BP reduction is linearly associated with the magnitude of risk reduction in recurrent cerebrovascular and CV events, but optimal BP target not evaluated.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria:</strong> RCTs of antihypertensives for 2º stroke prevention pts that reported achieved BP values during the follow-up period.</td>
<td><strong>Exclusion criteria:</strong> Observational studies, case series, case reports, RCTs in non-IS/TIA population, and studies not reporting data on finally achieved BP values</td>
<td><strong>1º outcome:</strong> Recurrent stroke</td>
<td><strong>Key findings:</strong></td>
</tr>
<tr>
<td><strong>Study size:</strong> 15 RCTs composed of 39,329 participants previous stroke</td>
<td>or comparing 1 type of antihypertensive agent with another type on pts who have suffered from stroke or TIA s</td>
<td><strong>2º outcome:</strong> MI, death from any cause, and risk of CV death</td>
<td><strong>SBP reduction linearly associated with lower risk of recurrent stroke (regression slope, 0.02; 95% CI: 0.01–0.04; p=0.049), MI (regression slope, 0.022; 95% CI: 0.002–0.041; p=0.024), death from any cause (regression slope, 0.02; 95% CI: 0.01–0.03; p=0.001), and CV death (regression slope, 0.05; 95% CI: 0.03–0.07; p&lt;0.001).</strong></td>
</tr>
<tr>
<td><strong>Study size:</strong> 15 RCTs composed of 39,329 participants previous stroke</td>
<td><strong>Diuretic-based treatments lowered the risk of recurrent stroke more than treatments that did not include diuretics.</strong></td>
<td></td>
<td><strong>No relation was observed between the degree of SBP reduction and the risk of disabling or fatal stroke (regression slope, 0.001; 95% CI: −0.024–0.022; p=0.944).</strong></td>
</tr>
<tr>
<td>or comparing 1 type of antihypertensive agent with another type on pts who have suffered from stroke or TIA s</td>
<td>RCTs reporting outcomes of interest with a follow-up of more than a month.</td>
<td></td>
<td><strong>Relation of SBP reduction with ischemic or hemorrhagic stroke was not assessed due to the small number of studies with available data (&lt;10).</strong></td>
</tr>
<tr>
<td><strong>Key findings:</strong></td>
<td><strong>Diuretics-based treatments resulted in a significantly larger reduction in BP (12.0 mm Hg; 95% CI: 7.0–16.9),</strong></td>
<td></td>
<td><strong>No relation was observed between the degree of SBP reduction and the risk of disabling or fatal stroke (regression slope, 0.001; 95% CI: −0.024–0.022; p=0.944).</strong></td>
</tr>
<tr>
<td><strong>Diuretic-based treatments lowered the risk of recurrent stroke more than treatments that did not include diuretics.</strong></td>
<td><strong>ACEI plus diuretic had a higher probability of being at the best ranking position (31%).</strong> Compared with regimens not including diuretics, diuretics-based treatments resulted in a significantly larger reduction in BP (12.0 mm Hg; 95% CI: 7.0–16.9),</td>
<td></td>
<td><strong>No relation was observed between the degree of SBP reduction and the risk of disabling or fatal stroke (regression slope, 0.001; 95% CI: −0.024–0.022; p=0.944).</strong></td>
</tr>
<tr>
<td><strong>Compared with regimens not including diuretics, diuretics-based treatments resulted in a significantly larger reduction in BP (12.0 mm Hg; 95% CI: 7.0–16.9),</strong></td>
<td><strong>Treatment regimens including diuretics had a RR of 0.619 (95% CI: 0.515–0.743) for recurrent stroke, which was significantly lower than treatments that did not include diuretics (RR=0.882; 95% CI: 0.800–0.973) with a p value for interaction of 0.0008.</strong></td>
<td></td>
<td><strong>No relation was observed between the degree of SBP reduction and the risk of disabling or fatal stroke (regression slope, 0.001; 95% CI: −0.024–0.022; p=0.944).</strong></td>
</tr>
<tr>
<td><strong>None of the between-drug comparisons showed significant differences in effect on outcomes</strong></td>
<td><strong>Diuretics-based treatments lowered the risk of recurrent stroke more than treatments that did not include diuretics.</strong></td>
<td></td>
<td><strong>No relation was observed between the degree of SBP reduction and the risk of disabling or fatal stroke (regression slope, 0.001; 95% CI: −0.024–0.022; p=0.944).</strong></td>
</tr>
<tr>
<td></td>
<td><strong>There were no significant differences in effect on 2º stroke reduction between the various individual antihypertensive medication classes.</strong></td>
<td></td>
<td><strong>No relation was observed between the degree of SBP reduction and the risk of disabling or fatal stroke (regression slope, 0.001; 95% CI: −0.024–0.022; p=0.944).</strong></td>
</tr>
</tbody>
</table>

Katsanos AH, et al., 2017 (225) 27802419
### Data Supplement 45. RCTs and Meta-analysis Comparing PAD (Section 9.5)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| HOPE Östergren J, et al., 2004 (226) 14683738 | **Aim:** To assess the impact of ramipril compared to placebo on the prevention of major CV events in PAD pts in the HOPE study.  **Study type:** Multicenter, double-blind RCT  **Size:** 9,541 randomized in HOPE (1,725 randomized who had baseline PAD, defined by ABI with pulse detection by either Doppler or palpation)  **Inclusion criteria:**  • ≥55 y  • Existing CVD (CAD, stroke, PAD) or DM with an additional CVD risk factor (smoking, HTN, hypercholesterolemia, low HDL, microalbuminuria)  **Exclusion criteria:**  • Received ACEI or vitamin E or had uncontrolled HTN  • HF or LV dysfunction  • All eligible pts had 7- to 10-d run-in period, received 2.5 mg ramipril daily; those who tolerated were then assigned placebo for 10–14 d and then were randomized to 1 of intervention arms or control | **Intervention:** Ramipril (10 mg/d): 4,645 randomized  **Intervention:** Placebo: 4,652 randomized | **1° endpoint:**  • Combined CV death, nonfatal MI, nonfatal stroke  • In pts with history of symptomatic PAD, comparing ramipril to placebo: RR: 0.75; 95% CI: 0.61–0.92  • In pts with no history of symptomatic PAD, but severe subclinical disease defined as ABI <0.6, comparing ramipril to placebo: RR: 0.77; 95% CI: 0.55–1.09  • In pts with no history of symptomatic PAD, but moderate subclinical disease defined as ABI 0.6–0.9, comparing ramipril to placebo: RR: 0.72; 95% CI: 0.56–0.92  **1° Safety endpoint:** N/A | **Summary:** Ramipril prevented clinical events in pts with clinical evidence of PAD as well as in those without PAD. The relative benefit was similar in pts classified by levels of ABI, even though event rates were higher in pts with subclinical and clinical ABI.  **Relevant 2° endpoint:**  • Individual components of composite endpoint, all-cause mortality, hospitalizations for HF, DM complications  • In pts with history of symptomatic PAD, comparing ramipril to placebo: for MI, RR: 0.75 (95% CI: 0.58–0.98); for stroke, RR: 0.72 (95% CI: 0.50–1.05); for CVD mortality, RR: 0.75 (95% CI: 0.56–0.99); for total mortality, RR: 0.85 (95% CI: 0.68–1.07); for DM complications, RR: 0.87 (95% CI: 0.74–1.09); for HF, RR: 0.81 (95% CI: 0.53–1.24)  • In pts with no history of symptomatic PAD, but severe subclinical disease defined as ABI <0.6, comparing ramipril to placebo: for MI, RR: 0.73 (95% CI: 0.48–1.11); for stroke, RR: 0.99 (95% CI: 0.52–1.89); for CVD mortality, RR: 0.76 (95% CI: 0.46–1.25); for total mortality, RR: 0.81 (95% CI: 0.55–1.19); for DM, RR: 0.83 (95% CI: 0.50–1.39); for HF, RR: 0.66 (95% CI: 0.34–1.28)  • In pts with no history of symptomatic PAD, but moderate subclinical disease defined as ABI 0.6–0.9, comparing ramipril to placebo: for MI, RR: 0.81 (95% CI: 0.48–1.09); for stroke, RR: 0.99 (95% CI: 0.52–1.89); for CVD mortality, RR: 0.76 (95% CI: 0.46–1.25); for total mortality, RR: 0.81 (95% CI: 0.55–1.19); for DM, RR: 0.83 (95% CI: 0.50–1.39); for HF, RR: 0.66 (95% CI: 0.34–1.28); for diabetic complications, RR: 0.80 (95% CI: 0.53–1.21); for HF, RR: 0.69 (95% CI: 0.38–1.23)
### Study Limitations and Adverse Events:

ABI not measured by Doppler gold standard

### Relevant 2° Endpoint:
- Pain-free walking distance (m), maximal walking distance
- In pts with baseline PAD, there was no difference in change in pain-free walking distance (m) between perindopril (+11 m) vs. placebo (+11 m); p>0.05
- In pts with baseline PAD, there was no difference in change in maximal walking distance between perindopril (pre-trial: 318 m (SD: 45), post-trial: 333 m (SD: 43)) vs. placebo (pre-trial: 333 m (SD: 43), post-trial: 369 m (SD: 46)

### Study Limitations and Adverse Events:

Short follow-up, unable to assess hard clinical outcomes

### Relevant 2° Endpoint:
- Intima/media thickness was 1.2 mm (SD: 0.31) in verapamil vs. 1.9 mm (SD: 0.47), p<0.001
- Septal thickness was 10.2 mm (SD: 1.1) in verapamil vs. 11.9 mm (SD: 2.3), p<0.001
- Cruorobrachial ratio dorsalis pedis was 0.76 (SD: 0.10) in verapamil vs. placebo was 0.72 (SD: 0.08)
additional risk factor: DM, hyperlipoproteinemia, total or subtotal vascular occlusion of dilated segmented, eccentric stenosis, residual stenosis of at least 30%, or stenosis localized in the distal superficial femoral artery

**Exclusion criteria:**
- History of pelvic stenosis
- Previous adjuvant therapy with calcium antagonists or beta-adrenergic blocking agents
- Age >75 y
- Prior revascularization of same area
- 1st, 2nd, or 3rd AV block, sinoatrial block, diseases of supporting or connective tissues, moderate arterial HTN with SBP >170 mm Hg and DBP >95 mm Hg
- Pts requiring stent for large anatomic segments or elastic stenosis

placebo was 69.6 (SD: 12.2), p<0.01

**1° Safety endpoint:** N/A

**Summary:** In pts with PAD at increased risk for restenosis, the administration of high dose verapamil prevented recurrent stenosis for 6 mo after successful peripheral angioplasty and was well tolerated.

Crurobrachial ratio tibial artery was 0.76 (SD: 0.09) in verapamil vs. placebo was 0.70 (SD: 0.10)

Arterial pressure was 134/87 mm Hg (SD: 6.5/4.4) in verapamil vs. placebo was 165/97 mm Hg (6.5/4.4), p<0.001

Total vessel diameter was 8.3 mm (SD: 0.3) in verapamil vs. 7.5 mm (SD: 0.3), p<0.001

**Study limitations and adverse events:** Short follow-up, unable to assess hard clinical outcomes

---

**Aim:** Evaluate the effects of treatment with the endothelium-dependent vasodilating beta 1-selective blocker nebivolol, as compared with the nonvasodilating beta 1-selective blocker metoprolol, on clinical parameters of PAD and endothelial function, and to compare the

**Inclusion criteria:**
- Stable intermittent claudication for ≥6 mo and an ABI of <0.9
- Stage 1 arterial HTN (SBP: 140–159 mm Hg, DBP: 90–99 mm Hg untreated, or treated stage 1 arterial HTN)
- SBP at time of enrollment 100–160 mm Hg

**Intervention arms:**
- Nebivolol (5 mg/d): 65 randomized
- Metoprolol (95 mg/d): 63 randomized

**1° endpoint:**
- Change in ABI measured by Doppler
- In nebivolol: initial ABI 0.62 (SD: 0.16), post-treatment ABI 0.68 (SD: 0.20), p-value for change: 0.002
- In metoprolol: initial ABI 0.63 (SD: 0.17), post-treatment ABI 0.67 (SD: 0.16)

**Relevant 2° endpoint:**
- Change in absolute claudication distance were 32.7 m in nebivolol (p-value 0.03) vs. 39.7 m in metoprolol (p-value 0.01), but no difference between 2 groups (p-value 0.54)
- Changes in SBP were -5.2 mm Hg in nebivolol (p=0.001) and -3.9 mm Hg in metoprolol (p=0.01), no difference between groups
### Study type: Double-blinded RCT (48 wk)

**Size:** 128

**Inclusion criteria:**
- DBP at time of enrollment <100 mm Hg
- Premenopausal women
- Critical limb ischemia with rest pain, leg ulcer, gangrene, severe angina pectoris that limits exercise capacity, severe HF that limits exercise capacity, hyperthyroidism, poorly controlled DM (HbA1c>10%)
- Contraindications for BBs
- Acute MI within 6 mo before screening
- Previous treatment with nebivolol or carvedilol

*Concomitant treatment with calcium antagonists, ACEIs, angiotensin II type 1 receptor antagonists, aspirin, clopidogrel, statins, estrogens was permitted if no change in dosage had been made in the previous 3 mo before screening*

**Exclusion criteria:**
- Critical limb ischemia with rest pain, leg ulcer, gangrene, severe angina pectoris that limits exercise capacity, severe HF that limits exercise capacity, hyperthyroidism, poorly controlled DM (HbA1c>10%)  
- Contraindications for BBs
- Acute MI within 6 mo before screening
- Previous treatment with nebivolol or carvedilol

**Summary:** BB therapy was well tolerated in pts with intermittent claudication and HTN during a treatment period of 1 y. In the direct comparison, there was no significant difference between nebivolol and metoprolol.

**Study limitations and adverse events:**
- Absence of placebo group
- 21 total adverse events, 10 in nebivolol, 11 in metoprolol (adverse events: bradycardia, tachycardia, blurred vision, worsening HTN, edema, worsening claudication, blurred vision, erectile dysfunction, edema, vertigo, temporary dysesthesia of the hands, dyspnea, skin irritation, headache, moderate diarrhea)

---

### 19996066

**Aim:** To examine the effect of average treated BP on adverse outcomes in PAD pts with CAD and to compare 2 antihypertensive medications

**Study type:** Post hoc analysis of international

**Inclusion criteria:**
- ≥50 y
- HTN, clinically stable CAD
- Pt reported PAD

**Exclusion criteria:**
- Contraindications to the treatment groups

**Interventions:**
- Calcium antagonist-based strategy: verapamil with or without trandolapril
- BB-based strategy: atenolol with or without hydrochlorothiazide

*2º medications only given to achieve BP of 0.21, p-value for change: 0.04
• Comparing ABI change in nebivolol to metoprolol: 0.02 (p=0.69).

**1º safety endpoint:** N/A

**Summary:**
- No change in flow-mediated dilatation in either group (p=0.16)
- This trial also notes the J-shaped relationship between BP achieved and clinical outcomes
- Risk of 1º outcome was reduced most when SBP was treated to 130–140 mm Hg and DBP 60–90, as opposed to <130/80 as 2005 guidelines suggest in PAD pts

**Study limitations and adverse events:**
- Absence of placebo group
- 21 total adverse events, 10 in nebivolol, 11 in metoprolol (adverse events: bradycardia, tachycardia, blurred vision, worsening HTN, edema, worsening claudication, blurred vision, erectile dysfunction, edema, vertigo, temporary dysesthesia of the hands, dyspnea, skin irritation, headache, moderate diarrhea)
**Aim:** To examine the effect of valsartan vs. amlodipine on cardiac morbidity and mortality in hypertensive pts at high CV risk

**Study type:** Prespecified additional analyses of international randomized, double-blind, parallel-group trial

**Size:** 15,245 in total trial (2,114 with PAD)

**Inclusion criteria:**
- ≥50 y
- HTN (untreated: 160–210/<115 mm Hg, treated: <210/<115 mm Hg)
- High risk for cardiac events (male sex, verified DM, current smoking, high cholesterol, LV hypertrophy by ECG, proteinuria on dipstick, serum creatinine 150–265 micromol/L, coronary disease diagnosis, cerebrovascular disease diagnosis, or PAD diagnosis)

**Exclusion criteria:**
- Renal artery stenosis
- Pregnancy
- AMI, coronary angioplasty or CABG in last 3 mo
- Severe hepatic disease
- Severe chronic renal failure

**Interventions:**
- Valsartan: 7,649 total
- Amlodipine: 7,596 total

*No PAD-specific numbers available

**1° endpoint:**
- Composite of sudden cardiac death, fatal MI, death during/after percutaneous coronary intervention or CABG, HF requiring hospitalization, nonfatal MI, or emergency procedure to prevent MI
- There was no significant difference in the 1° outcome by treatment group among all pts and by PAD status. Among pts with PAD, the 1° outcome occurred in 13.4% of valsartan vs. 13.6% of amlodipine pts. Among pts without PAD, the corresponding % were 10.1% and 9.9%.

**1st safety endpoint:** ---

**Summary:** The effects of treatments on occurrence of the 1° outcome did not differ by PAD status.

**Relevant 2° endpoint:** N/A

**Study limitations and adverse events:**
- Limited subgroup analyses, only 1° outcome reported
- High-risk population limits generalizability
• Congestive HF requiring ACEI therapy
• Pts on monotherapy with 3 blockers for both CAD and HTN

Piller LB, et al., 2014 (232)

Aim: To compare, by randomized treatment groups (amlodipine, lisinopril, chlorthalidone) hospitalized or revascularized PAD rates and subsequent morbidity and mortality.

Study type: Post-hoc analysis of prospective, randomized, double-blinded active-control trial (ALLHAT study—amlodipine, lisinopril compared to chlorthalidone control arm)

Size: 33,357 pts

Inclusion criteria:
• BP of 140–180/90–110 for untreated, 160/100 for treated pts
• Age ≥55 y
• Have at least1 CV risk factor (risk factors: old myocardial injury or stroke, history of coronary revascularization procedure, other documented atherosclerotic CVD PAD, history of intermittent claudication, peripheral artery revascularization or peripheral artery angioplasty, DM-2, current cigarette smoking, HDL <0.90 mmol/L, LVH, major ST depression, T-wave inversion)

Exclusion criteria:
• Canadian pts for whom outcome measures could not be assessed (n=533)

Intervention arms:
• Amlodipine: 8,898 randomized
• Lisinopril: 8,904 randomized
• Comparator: Chlorthalidone: 15,002 randomized

*Goal BP was <140/90 in each randomized group (achieved using study drug but adding open-label agents at physician discretion when necessary)

1° endpoint:
• PAD requiring hospitalization or outpatient revascularization procedure
• 830 cases of PAD over 8.8 y follow-up; no significant difference between treatment groups after adjustment
• HR comparing amlodipine to chlorthalidone: 0.86 (95% CI: 0.72, 1.03) after full adjustment, p-value: 0.099
• HR comparing lisinopril to chlorthalidone: 0.98 (95% CI: 0.83, 1.17) after full adjustment, p-value: 0.847
• Kaplan Meier: Y-to-PAD was longer amlodipine vs. chlorthalidone (no difference between lisinopril and chlorthalidone)

1° Safety endpoint: N/A

Relevant 2° endpoint:
• Post-PAD morbidity and mortality
• Comparing amlodipine to chlorthalidone, no difference in post-PAD morbidity or mortality: MI, HR: 0.82 (95% CI: 0.48, 1.40); Stroke, HR: 0.86 (95% CI: 0.41, 1.79); Cardiac Revascularization, HR: 1.39 (95% CI: 0.81, 2.39); HF, HR 1.32 (95% CI: 0.79, 2.18); Total Mortality, HR: 0.92 (95% CI: 0.74, 1.15)
• Comparing lisinopril to chlorthalidone, no difference in post-PAD morbidity or mortality: MI, HR: 0.74 (95% CI: 0.44, 1.25); Stroke, HR: 0.94 (95% CI: 0.48, 1.86); Cardiac Revascularization, HR: 1.25 (95% CI: 0.73, 2.13); HF, HR: 1.08 (95% CI: 0.65, 1.80); Total Mortality, HR: 0.95 (95% CI: 0.77, 1.18)

Thompson AM, et al., 2011 (113)

Aim: To evaluate the effect of antihypertensive treatment on 2° prevention of CVD events and all-cause mortality among pts

Inclusion criteria: RCTs of antihypertensive treatment among pts with BP <140/90 mm Hg for the prevention of CVD events.

Interventions: Any antihypertensive agent compared with placebo or no treatment.

Results: Compared with controls, pts receiving antihypertensive medications had a pooled RR of 0.77 (95% CI: 0.61, 0.77) for stroke: 0.80 (95% CI: 0.69, 0.94) for MI: 0.76 (95% CI: 0.65, 0.89) for total mortality

Study limitations and adverse events:
• PAD not specifically collected at baseline, thus cannot detect actual incidence (however, randomization presumably resulted in equal number of baseline PAD cases in each group)
• Asymptomatic PAD likely missed (definition used in this study based on hospitalization, likely only capturing very severe cases)

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
without clinically defined HTN.

**Study type:** Meta-analysis including 25 RCTs

**Size:** 64,162 pts without HTN.

**Exclusion criteria:** CVD events were not reported by HTN status that included participants with and without HTN; study population did not include persons with BP in the normal or prehypertensive ranges; study population did not include persons with preexisting CVD or CVD equivalents, such as DM; antihypertensive medication was not a part of the intervention; treatment allocation was not random; measure of variance not reported; participants were <18 y; there were differences between intervention and control groups other than antihypertensive treatment. Preexisting CVD included PAD.

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>0.93 (95% CI: 0.65, 0.77) for CHF: 0.71 (95% CI: 0.65, 0.77) for CVD mortality and 0.87 (95% CI: 0.80, 0.95) for all-cause mortality from random effect models. Results did not differ according to trial characteristics or subgroups defined by clinical history, although no specific PAD subgroup was defined.</td>
</tr>
</tbody>
</table>

**Summary:** Among pts with clinical history of CVD, including PAD, but without HTN, antihypertensive treatment was associated with reduced risk of stroke, CHF, composite CVD events and all-cause mortality.

---

### Data Supplement 46. RCTs and Meta-analyses Comparing BP Targets in DM (Section 9.6)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# pts) / Study Comparator (# pts)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADVANCE Kaplan NM, et al., 2007 (233) 17765962</td>
<td><strong>Aim:</strong> To assess the effects of an ACEI perindopril and a diuretic indapamide combination on serious vascular events in pts with DM-2 pts 30–55 y. <strong>Inclusion criteria:</strong> At least 1 of the following: history of major CVD, (stroke, MI, admission for TIA, UA, coronary</td>
<td>DM-2 pts 30–55 y. <strong>Inclusion criteria:</strong> At least 1 of the following: history of major CVD, (stroke, MI, admission for TIA, UA, coronary</td>
<td>Fixed combination of perindopril and indapamide compared with placebo.</td>
<td>1° endpoints: Composite of CV death, nonfatal MI, nonfatal stroke, new or worsening nephropathy, or retinopathy. <strong>Results:</strong> After 4.3 y follow-up, pts assigned to active therapy had a reduction of SBP of 5.6 mm Hg. RR of major macro- or micro-</td>
<td><strong>Summary:</strong> • This large RCT provides evidence that routine administration of fixed combination ACEI and thiazide-type diuretic therapy reduces risk of major CV events in those with at least 1 risk factor.</td>
</tr>
<tr>
<td>DM irrespective of initial BP levels or the use of other BP-lowering drugs.</td>
<td>revascularization, or amputation for PVD or at least 1 other risk factor (history of microvascular disease, microalbuminuria, proliferative diabetic retinopathy, retinal photocoagulation therapy, macular edema, blindness, cigarette smoking, high cholesterol, low HDL cholesterol, diagnosis of DM at least 10 y before enrollment or ≥65 y at entry</td>
<td>vascular events decreased by 9% (HR: 0.91; (95% CI: 0.83, 1.00), p&lt;0.04). Death from CVD decreased by 18%; RR: 0.82 (95% CI: 0.68, 0.98) and death from any cause decreased by 14%; RR: 0.86 (95% CI: 0.75, 0.98). The effects of study treatment did not differ by initial BP or concomitant use of other treatments at baseline. The pts had at least 1 CV risk factor.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>----</td>
<td>----</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study type</strong>: RCT</td>
<td><strong>Study type</strong>: RCT</td>
<td><strong>Study type</strong>: RCT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Size</strong>: 11,140 pts, 4.3 y follow-up</td>
<td><strong>Size</strong>: 11,140 pts, 4.3 y follow-up</td>
<td><strong>Size</strong>: 11,140 pts, 4.3 y follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The ADVANCE trial included DM pts both with and without HTN. In this RCT, pts were randomized to active treatment or placebo rather than to a different BP goal, so that it is impossible to determine whether the benefit was due to the treatment of HTN per se.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Aim**: To assess whether therapy targeting normal SBP (<120 mm Hg) reduces major CV events in DM-2 at high risk for CV events. | **Inclusion criteria**: DM-2 with HgbA1c ≥7.5%; ≥40 y with CVD or ≥55 y with anatomical evidence of atherosclerosis, albuminuria, LVH, or ≥2 additional risk factors for CVD. | **1° outcomes**: Nonfatal MI, nonfatal stroke, or CV death. |
| ACCORD Cushman WC, et al., 2010 (234) | **Exclusion criteria**: HbA1c target ≤6.5% or indication for insulin. | **Results**: Mean SBP in the intensive therapy group was 119.3 mm Hg and in the standard therapy group was 133.5 mm Hg. The annual 1° outcome 1.87% in the intensive therapy group and 2.09% in the standard therapy group (HR: 0.88; 95% CI: 0.073–1.06; p=0.20. The annual rates of death from any cause were 1.28% and 1.19% in the 2 groups, respectively (HR: 0.59; 95% CI: 0.39–0.89; p=0.01). Serious adverse events attributed to antihypertensive treatment occurred in 3.3% of the intensive therapy group and 1.3% of the standard therapy group (p<0.001). |
| **Study type**: RCT | **Study type**: RCT | **Study type**: RCT |
| **Size**: 4,733 pts, 4.7 y follow-up | **Study type**: RCT | **Study type**: RCT |
| **Exclusion criteria**: BMI ≥45, serum creatinine >1.5, and other serious illness. | | **Limitations**: This trial had an open label design. The rate of adverse events in the standard therapy group was less than expected. Pts younger than 40 y or older than 79 y were not included. |
| | | **Summary**: In pts with DM-2 and high risk for CV events, targeting SBP of <120 as compared with <140 mm Hg did not reduce the rate of composite outcome of fatal and nonfatal major CV events and was associated with greater risk for adverse events. |
| **Margolis KL et al., 2014 (235)** | **Aim:** To compare effects of combinations of standard and intensive treatment of glycemia and BP in the ACCORD trial.  
**Study type:** RCT  
**Size:** 4,733 pts, 4.7 y follow-up | **Inclusion criteria:** Type 2 DM with HgbA1c ≥7.5%; ≥40 y with CVD or ≥55 y with anatomical evidence of atherosclerosis, albuminuria, LVH, or at least 2 additional risk factors for CVD.  
**Exclusion criteria:** BMI ≥45, serum creatinine >1.5, and other serious illness.  
• Pts were randomly assigned to intensive therapy SBP<120 mm Hg or standard therapy SBP<140 mm Hg. | **1° outcomes:** Nonfatal MI, nonfatal stroke, or CV death.  
**Results:** In the BP trial, risk of the 1° outcome was lower in the groups intensively treated for glycemia HR: 0.67 (95% CI: 0.50, 0.91), BP HR: 0.74 (95% CI: 0.55, 1.00), or both HR: 0.71 (95% CI: 0.52, 0.96) compared with combined standard BP and glycemia treatment. For 2° outcomes, MI was significantly reduced by intensive glycemia treatment and stroke by intensive BP treatment; most other HRs were neutral or favored intensive treatment groups.  
**Limitations:** 2° analysis; results analyzed across individual cells of a factorial design with shorter follow-up than originally intended reducing power to detect meaningful differences and interactions; results may not apply to younger, healthier diabetics.  
**Conclusions:** Either intensive BP or glycemia control reduced major CVD compared with combined standard treatment, but the combination was no better than the individual intensive interventions. |

| **Soliman EZ et al., 2015 (236)** | **Aim:** To compare effects of combinations of standard and intensive control of BP on the risk of LVH in the ACCORD trial.  
**Study type:** RCT  
**Size:** 4,331 pts, 4.7 y follow-up | **Inclusion criteria:** DM-2 with HgbA1c ≥7.5%; ≥40 y with CVD or ≥55 y with anatomical evidence of atherosclerosis, albuminuria, LVH, or at least 2 additional risk factors for CVD.  
**Exclusion criteria:** BMI ≥45, serum creatinine >1.5, and other serious illness.  
• Pts were randomly assigned to intensive therapy SBP<120 mm Hg or standard therapy SBP<140 mm Hg. | **1° outcomes:** Nonfatal MI, nonfatal stroke, or CV death.  
**Results:** The outcome measures were electrocardiographic LVH defined by Cornell voltage (binary variable) and mean Cornell index (continuous variable). The baseline prevalence of LVH (5.3% vs. 5.4%; p=0.91) and the mean Cornell index (1,456 vs. 1,470 µV; p=0.45) were similar in the intensive (n=2,154) and standard (n=2,177) BP-lowering arms, respectively. However, after median follow-up of 4.4 y, intensive, compared with standard, BP lowering was associated with a 39% lower risk of LVH (OR: 0.61; 95% CI: 0.43–0.88; p=0.008) and a significantly lower adjusted mean Cornell index (1,352 vs. 1,447 µV; p<0.001). The lower risk of LVH associated with intensive BP lowering during follow-up was because of more regression of baseline LVH and lower rate of developing new LVH, compared with standard BP lowering. No interactions by age, sex, or race were observed.  
**Limitations:** 2° analysis; open-label design; LVH defined by EKG and not by echo or cardiac MRI; results may not apply to younger, healthier diabetics.  
**Conclusions:** Targeting a SBP of <120 mm Hg when compared with <140 mm Hg in pts with HTN and DM produces a greater reduction in LVH |
### Aim
To assess the efficacy and safety of intensive BP lowering strategies.

### Study type
Systematic review and meta-analysis

### Size
19 trials with 44,989 pts; 3.8 y of follow-up.

### Inclusion criteria
RCTs with different BP targets or different BP changes between more vs. less intense therapy with at least 6 mo follow-up.

### Exclusion criteria
Trials that did not assess a different target or relevant outcome.

### 1st outcomes
- 5 RCTs (6,960 pts) enrolled only pts with DM and 6 trials (2,809 pts) specifically recruited pts with CKD.
- Major CV events, defined as MI, stroke, HF or CV death, separately and combined; nonvascular and all-cause mortality; ESKD; and adverse events; new onset microalbuminuria/macroalbuminuria or change from micro- to macroalbuminuria and retinopathy in pts with DM.

### Results
Pts in the more intensive BP-lowering treatment group had mean BP 133/76 mm Hg compared with 140/81 mm Hg in the less intensive group. Intensive BP-lowering treatment achieved RR reductions for major CV events: 14% (95% CI: 4–22), MI: 13% (95% CI: 0–24), stroke: 22% (95% CI: 10–32), albuminuria: 10% (95% CI: 3–16), and retinopathy progression: 19% (95% CI: 0–34). However, more intensive treatment had no clear effects on HF: RR: 15% (95% CI: -11–34), CV death: 9% (-11–26), total mortality: 9% (95% CI: -3–19), or ESKD: 10% (95% CI: -6–23). The reduction in major CV events was consistent across pt groups, and additional BP lowering had a clear benefit even in pts with SBP <140 mm Hg. The absolute benefits were greatest in trials in which all enrolled pts had vascular disease, renal disease or DM. Serious adverse events associated with BP lowering were only reported by 6 trials and had an event rate of 1%–2% per y in intensive BP lowering group pts, compared with 0.9% in the less intensive treatment group (RR: 1.35; 95% CI: 0.93–1.97). Severe hypotension was more frequent in the more intensive treatment regimen (RR: 2.68; 95% CI: 1.21–5.89; p=0.015), but the absolute excess was small (0.3% vs. 0.1% per pt-y for the duration of follow-up).

### Study limitations
Only 6,960 pts with DM were included in the total study size of 44,989 pts.

### Conclusions
The absolute CV benefits were greatest in trials in which all enrolled pts had vascular disease, renal disease or DM. However, only 6,960 of the 44,989 pts had DM and no sub-analysis for DM was provided; however, the outcome benefits were qualitatively most striking for pts with DM, CKD and/or vascular disease.
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>1° outcomes</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCOMPLISH</td>
<td>To determine which combination therapy in pts with HTN and DM most effectively decreases CV events.</td>
<td>HTN and DM with high risk for CV events.</td>
<td>BMI &gt;45; serum Cr &gt;1.5; other serious illness</td>
<td>Composite of death from CV causes, nonfatal MI, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.</td>
<td>In pts with DM and HTN, combining an ACEI with a CCB, compared with hydrochlorothiazide, was superior in reducing CV events.</td>
</tr>
<tr>
<td>ASCOT</td>
<td>To compare the effects of an amlodipine-based regimen vs. and atenolol-based regimen on CV outcomes in pts with DM</td>
<td>Pts 40–65 y with HTN (&gt;160/100 mm Hg) or treated HTN and DM plus 2 additional CV risk factors: PAD, previous stroke or TIA, male sex, ≥55 y, microalbuminuria, smoking, total cholesterol to HDL ratio ≥6, or family history of CHD.</td>
<td>Pts were randomly assigned to an amlodipine-based regimen with addition of perindopril as required or an atenolol-based regimen with addition of a thiazide as required and therapy titrated as required to achieve target BP of 130/80 mm Hg.</td>
<td>Fatal CHD and nonfatal MI.</td>
<td>In the large DM subgroup of the BP-lowering arm of ASCOT, the benefits of an amlodipine-based treatment compared with an atenolol-based treatment on the incidence of total CV events and procedures was significant.</td>
</tr>
<tr>
<td>SHEP</td>
<td>To assess the long-term mortality rate of pts with DM pts in the SHEP trial randomly assigned to stepped care with chlorthalidone or placebo.</td>
<td>Isolated systolic HTN (SBP 160–219 mm Hg) with DBP &lt;90 mm Hg.</td>
<td>Pts with insulin–dependent DM and those who were randomly assigned to chlorthalidone or placebo.</td>
<td>CV mortality rate</td>
<td>Chlorthalidone-based treatment improved long-term outcomes in pts with DM.</td>
</tr>
<tr>
<td>Study type:</td>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size:</td>
<td>4,732 pts; follow-up 14.3 y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>required diuretic therapy.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1° outcome:</td>
<td>0.848 and total mortality rate: 0.805 (95% CI: 0.680, 0.952).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ROADMAP

**Menne J, et al., 2012 (240) 22418908**

**Aim:** To assess whether olmesartan compared to placebo delays the onset of albuminuria in pts with DM and HTN.

**Study type:** RCT

**Size:** 4,020 pts; follow-up 3.2 y

**Inclusion criteria:** Pts with HTN defined as BP ≥130/80 mm Hg and at least 1 CV risk factor.

- Pts were randomly assigned to olmesartan or placebo. Additional antihypertensive therapy except for ACEs and ARBs to lower BP.

**1° outcome:** Time to onset of microalbuminuria.

**Results:** Average BP was 126.3/74.7 and 129.5/76.6, respectively (significant not stated). Olmesartan delayed the onset of microalbuminuria by 25% (0.75; 95% CI: 0.61–0.92; p=0.007). CV events were comparable in the 2 groups.

**Summary:** Pts with better BP reduction are less likely to develop microalbuminuria. Treatment with an ARB delayed the onset of microalbuminuria independently of baseline BP and degree of BP reduction.

### ABCD

**Estacio RO, et al., 1998 (241) 9486993**

**Aim:** To compare the effects of “intensive” compared with “moderate” BP treatment on 24-h creatinine clearance (GFR) in pts with DM and HTN.

**Study type:** RCT – open label

**Size:** 472 pts; follow-up 5 y

**Inclusion criteria:** Pts with HTN defined as DBP ≥90 mm Hg and DM-2

- Pts were randomly assigned to “intensive” treatment (DBP<75 mm Hg and “moderate” treatment (DBP 80–89 mm Hg) with a combination of nisoldipine and enalapril as the initial antihypertensive medication.

**1° outcome:** Change in 24-h creatinine clearance.

**Results:**
- The mean BP achieved was 132/78 in the intensive group and 138/86 in the moderate control group. During the 5-y follow-up period, there was no difference in GFR between the groups. After the first y of antihypertensive treatment, GFR stabilized in both the intensive and moderate groups with normal albumin excretion or microalbuminuria. In contrast, pts with overt albuminuria demonstrated steady decline in GFR whether on intensive or moderate therapy. Neither was there a significant difference in the progression from normal to micro- or micro-to overt albuminuria.
- Intensive therapy demonstrated a lower overall incidence of deaths, 5.5% vs. 10.7%; p=0.037 (2° endpoint).

**Limitations:** Open-label design; the definition of DM was 2 fasting blood glucose measurements >140 mg/dL as opposed to >126 today; serious side effects were not reported. Risk of bias due to a greater proportion of pts with established CVD at baseline assigned to the standard BP target.

**Summary:** BP control of 138/86 or 132/78 with either nisoldipine or enalapril as the initial antihypertensive agent appeared to stabilize renal function in HTN pts with type 2 DM without overt albuminuria over a 5-y period. For the ABCD trials, only ABDC (H) included strictly pts with HTN and DM. The quality of evidence is low due to imprecision and risk of bias.

### Hypertension Optimal Treatment (HOT trial)

**Aim:** To assess the optimum target DBP

**Inclusion criteria:** Pts with HTN defined as

- Pts were randomly assigned to 1 of 3 DBP target

**1° outcomes:** Major CV events, MI, stroke, CV mortality and total mortality.

**Limitations:** Open-label design; the definition of DM-2 fasting blood glucose measurements >140 mg/dL
### Hansson L, et al., 1998 (242) 9635947

- **Aim:** To determine whether tight control of BP prevents macrovascular and microvascular complications in pts with DM-2.
- **Study type:** RCT
- **Size:** 1,501 pts in the DM subgroup; follow-up 3.8 y
- **DBP** 100–115 mm Hg and DM.
- **Groups:** ≤90, ≤85, or ≤80 mm Hg.

#### Results
- In the group randomized to ≤80 mm Hg, the risk of major CV events was halved in comparison to the target ≤90. CV mortality was lower in the ≤80 group compared to the other groups.

#### Limitations
- As opposed to >126 today; serious side effects were not reported; potential bias due to subgroup analysis.

#### Summary
- Intensive lowering of BP was associated with a low rate of CV events. The quality of evidence is low to very low due to imprecision and risk of bias.

### UKPDS 1998 (243) 9732337

- **Aim:** To determine whether tight control of BP prevents macrovascular and microvascular complications in pts with HTN.
- **Study type:** RCT
- **Size:** 1,148 hypertensive pts with type 2 DM
- **Follow-up:** 8.4 y
- **Inclusion criteria:**
  - Fasting plasma glucose concentration >6 mmol/l in 2 mornings.
  - Ketonuria >3 mmol/l; history of MI in the previous y; current angina or HF; >1 major vascular episode; serum creatinine concentration >175 µmol/l; retinopathy requiring laser treatment; malignant HTN; an uncorrected endocrine abnormality; an occupation that would preclude insulin treatment; a severe concurrent illness; inadequate understanding or unwillingness to enter the study.

#### Outcomes
- **1st outcomes:**
  1. First clinical endpoint related to DM (sudden death, death from hyperglycemia or hypoglycemia, fatal or nonfatal MI, angina, HF, stroke, renal failure, amputation, vitreous hemorrhage, retinal photocoagulation, blindness in 1 eye or cataract extraction).
  2. Death related to DM.
  3. Death from all causes.

#### Results
- BP in the tight BP control group was 144/82 compared with the group assigned less tight control (154/87), p<0.0001. Reductions in risk in the group assigned tight BP control compared with those of the less tight control group were 24% (95% CI: 8%–38%; p=0.0046) in DM related endpoints; 32% in deaths related to DM (95% CI: 6%–51%; p<0.019; 44% in strokes (95% CI: 11%–65%; p<0.013; and 37% (95% CI: 11%–36%; p<0.0092 in microvascular endpoints, predominantly due to risk of retinal photocoagulation.

#### Limitations
- DBP targets were high (85 mm Hg in the tight control group and 105 mm Hg in the less tight control group) and similar to the cutoffs for the no treatment groups in trials comparing treatment with no treatment. UKPDS evaluated lowering both SBP and DBP so it is impossible to separate the outcomes effects of DBP. Therefore, the evidence is of low quality.

#### Summary
- Tight BP control in pts with HTN and DM-2 achieved a clinically important reduction in the risk of death related to DM, complications related to DM, progression of DM retinopathy and deterioration of visual acuity, but the quality of evidence is low.

### Arguedas JA, et al., 2013 (244) 24170669

- **Aim:** To determine if “lower” BP targets (any target <130/85)
- **Inclusion criteria:**
  - RCTs in which individuals were

#### Outcomes
- **Total mortality, total serious adverse events, MI, stroke, CHF, and ESRD.

#### Conclusions
- Evidence from RCTs does not support BP targets lower
mm Hg) are associated with reduction in mortality and morbidity compared to “standard” BP targets (<140–160/90–100 mm Hg) in pts with DM.

**Study type:** Meta-analysis of RCTs.

**Size:** 5 RCTs recruiting a total of 7,314 ps.

**Mean follow-up:** 4.5 y

randomized to a “lower” compared with a “standard” BP target.

**Exclusion criteria:** Studies that did not meet the inclusion criteria. Excluded studies were UKPDS 1998, HTN in Diabetes Study IV 1996, SANDS 2008, Lewis 1999 and the Steno-2 study.

**Results:** Only 1 trial (ACCORD) compared outcomes associated with ‘lower’ (<120 mm Hg) or ‘standard’ (<140 mm Hg) SBP targets in 4734 pts. Despite achieving a significantly lower BP (119.3/64.4 mm Hg vs. 133.5/70.5 mm Hg, p<0.0001), and using more antihypertensive medications, the only significant benefit in the group assigned to ‘lower’ SBP was a reduction in the incidence of stroke: RR: 0.58; (95% CI: 0.39–0.88; p=0.009), absolute risk reduction 1.1%. The effect of SBP targets on mortality was compatible with both a reduction and increase in risk: RR: 1.05 (95% CI: 0.84, 1.30), low quality evidence. Trying to achieve the ‘lower’ SBP target was associated with a significant increase in the number of other serious adverse events: RR: 2.58, (95% CI: 1.70–3.91; p<0.00001, absolute risk increase 2.0%. 4 trials (ABCD-H, ABCD-N, ABCD-2V, and a subgroup of HTN Optimal Treatment) specifically compared clinical outcomes associated with ‘lower’ vs. ‘standard’ targets for DBP in pts with DM. The total number of pts included in the DBP target analysis was 2580. Pts assigned to ‘lower’ DBP had a significantly lower achieved BP: 128/76 mm Hg vs. 135/83 mm Hg; p<0.0001. There was a trend towards reduction in total mortality in the group assigned to the ‘lower’ DBP target: RR: 0.73 (95% CI: 0.53–1.01), mainly due to a trend to lower non-CV mortality. There was no difference in stroke: RR: 0.67, (95% CI: 0.42–1.05), in MI: RR: 0.95 (95% CI: 0.64–1.40) or in CHF: RR: 1.06 (95% CI: 0.58–1.92), low-quality evidence. End-stage renal failure and total serious adverse events were not reported in any of the trials. A sensitivity analysis of trials comparing DBP targets <80 mm Hg (as suggested in clinical guidelines) than standard targets in pts with HTN and DM.
Palmer SC, et al., 2015 (245)  
**Aim:** To investigate the benefits and harms of BP-lowering drugs in adults with DM  
**Study type:** Network meta-analysis of RCTs.  
**Size:** 157 studies in 43,256 pts mostly with DM and CKD.  
**Mean follow-up:** 4.5 y  
**Inclusion criteria:** Pts ≥18 y with DM and CKD and were treated in clinical trials that compared any orally administered antihypertensive agent alone or in combination with a 2nd antihypertensive agent or combination, placebo, or control.  
**Exclusion criteria:** Pts who underwent kidney transplantation or dialysis.  
**1° outcomes:** All-cause mortality and ESKD (need for dialysis or transplantation).  
**Results:** No drug regimen was more effective than placebo for reducing all-cause mortality. However, compared with placebo, ESRD was significantly less likely after dual treatment with an ARB and an ACEI: OR: 0.62 (95% CI: 0.43–0.90) and after ARB monotherapy: OR: 0.77 (95% CI: 0.65–0.92). No regimen significantly increased hyperkalemia or acute kidney injury, although combined ACEI and ARB treatment had the lowest rank among all interventions because of borderline increases in estimated risks of these harms; OR: 2.69 (95% CI: 0.97–7.47) for hyperkalemia; OR: 2.69 (95% CI: 0.98–7.38) for acute kidney injury.  
**Limitations:** Effects of BP treatment on CV events and related mortality were uncertain. Data for the outcome of ESKD were restricted largely to pts with macroalbuminuria. Acute kidney injury was poorly defined with low quality of evidence.  
**Conclusions:** No BP-lowering strategy prolonged survival in adults with DM and CKD. ACEIs and ARBs, alone or in combination, were the most effective strategies against ESKD. Any benefits of combined ACEI and ARB treatment need to be balanced against potential harms of hyperkalemia and acute kidney injury.

Turnbull F, et al., 2005 (246)  
**Aim:** To determine the benefits associated with different treatment regimens in pts with and without DM and whether there are important differences in the effects of different BP-lowering regimens in these 2 pt groups.  
**Study type:** Meta-analysis of RCTs.  
**Inclusion criteria:** Randomization of pts between a BP-lowering agent and a control (placebo or less intensive BP-lowering regimen) or randomization of pts between regimens based on different classes of BP-lowering drugs.  
**Exclusion criteria:** Studies not meeting the above criteria.  
**1° outcomes:** Nonfatal stroke or death from cerebrovascular disease; nonfatal MI or death from CAD; HF causing death or requiring hospitalization; total CV events; total CV deaths; and total mortality.  
**Results:** Total major CV events were reduced to a comparable extent in individuals with and without DM by regimens based on ACEIs, calcium antagonists, ARBs and diuretics/BBs (p<0.19 for all). There was limited evidence that lower BP goals produced larger reductions in total major CV events in pts with vs. without DM (p<0.03).  
**Limitations:** No analysis of renal outcomes, risk of new DM or progression of existing DM; combined comparison of persons taking diuretics and BBs; some studies selected pts on the basis of the presence or absence of DM.  
**Summary:** Effects of BP-lowering agents on major CV events were broadly comparable for pts with and without DM.
**Size:** 27 RCTs including 158,709 pts (33,395 with DM and 125,314 without DM).

**Follow-up:** Minimum 1,000 pt-y

---

**ALLHAT**

*Whelton PK, et al., 2005 (247) 15983290*

**Aim:** To determine the optimal first step antihypertensive drug therapy in DM-2 or impaired fasting blood glucose levels and specifically whether treatment with a CCB or ACEI decreases clinical complications compared to treatment with a thiazide type diuretic.

**Study type:** RCT

**Size:** 31,512 pts stratified into type 2 DM (13,101), IFG (1,399) and normoglycemia (17,012)

**Inclusion criteria:** Pts ≥55 y with HTN and at least 1 other risk factor for CHD.

**Exclusion criteria:** No history of DM or no fasting glucose measurement or nonfasting glucose level ≥110 mg/dL.

• Pts were randomly assigned to double-blind first-step treatment with chlorthalidone 12.525 mg/d, amlodipine 2.5–10 mg/d or Lisinopril 10–40 mg/d.

**1° outcomes:** Fatal CHD and nonfatal MI

**Results:** There was no significant difference in RR (RR) for the 1° outcome in DM or NG pts assigned to amlodipine or lisinopril vs. chlorthalidone or in IFG pts assigned to lisinopril vs. chlorthalidone RR: 1.73 (95% CI: 1.10, 2.72). A significantly higher RR was noted for the 1° outcome in IFG pts assigned to amlodipine vs. chlorthalidone. Stroke was more common in NG pts assigned to lisinopril vs. chlorthalidone RR: 1.31 (95% CI: 1.10, 1.57). HF was more common in DM and NG pts assigned to amlodipine RR: 1.39 (95% CI: 1.22, 1.59) and 1.30 (95% CI: 1.12, 1.51), respectively or lisinopril: 1.15 (95% CI: 1.00–1.32) and 1.19 (95% CI: 1.02, 1.39), respectively vs. chlorthalidone.

**Limitations:** Microalbuminuria was not measured.

**Summary:** Our results provide no evidence of superiority for treatment with CCBs or ACEIs compared with a thiazide-type diuretic during first-step antihypertensive therapy in DM, IFG, or NG.

---

**Data Supplement 47. Nonrandomized Trials, Observational Studies, and/or Registries in DM (Section 9.6)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
### ADVANCE

**Hata J, et al., 2013 (248) 23926207**

**Aim:** To assess the effects of visit-to-visit SBP variability and maximum SBP on the risks of macrovascular or microvascular outcomes by using data from the ADVANCE trial.

**Study type:** Observational analysis

**Size:** 8,811 pts

**Inclusion criteria:** Pts had not experienced major macro- or microvascular events during first 2 y of the ADVANCE trial

**Exclusion criteria:** None

**1st endpoint:** Composite of CV death, nonfatal MI, nonfatal stroke, new or worsening nephropathy, or retinopathy.

**Results:** Major macro- and micro-vascular events were associated with SBP variability even after adjustment for mean SBP and other confounding factors. For the highest 10% variability, HR: 1.54 (95% CI: 0.99, 2.39) for macrovascular events; for microvascular events, HR: 1.84 (95% CI: 1.19, 2.84).

**Summary:** Visit-to-visit SBP variability and maximum SBP are independent risk factors for macro- and micro-vascular events.

### ADVANCE-ON

**Zoungas S, et al., 2014 (249) 25234206**

**Aim:** To determine whether the mortality benefit that had been observed among pts originally assigned to BP-lowering therapy were still evident at the end of 6-y follow-up

**Study type:** Observational analysis

**Size:** 8,494 pts

**Inclusion criteria:** Pts with DM who participated in post-trial follow-up for 6 y

**Exclusion criteria:** See above

**1st endpoint:** Death from any cause and major macrovascular complications (a composite of nonfatal MI, nonfatal stroke, or death from any CV cause.

**Results:** The reductions in the risk of death from any cause and of death from CV causes that had been observed in the group receiving active BP-lowering treatment during the ADVANCE trial were attenuated but significant at the end of the post-trial follow-up. HRs were 0.95 (95% CI: 0.84–0.99; p=0.03) and 0.88 (95% CI: 0.77–0.99; p=0.04), respectively.

**Summary:** Benefits were attenuated but still present at the end of 6 y.

### ROADMAP

**Mene J, et al., 2014 (250) 24772521**

**Aim:** To determine whether the ROADMAP olmesartan medoxomil treatment resulted in a potential long-term micro- and macro-vascular benefit.

**Study type:** Observational analysis

**Size:** 1,758 pts; 3.3 y follow-up

**Inclusion criteria:** See above

**Exclusion criteria:** See above

**1st endpoint:** See above

**Results:** The original ROADMAP study showed a 23% reduction in microalbuminuria despite good and comparable BP control in both groups. Pts who developed microalbuminuria had a higher incidence of cardio- and cerebrovascular events. OR: 1.77 (95% CI: 1.03–3.03; p=0.039) compared to those in whom this was not the case. DM retinopathy and HF requiring hospitalization also were reduced.

**Summary:** renal artery stenosis blockade might cause a sustained reduction in micro- and macro-vascular events.

### Edmin C, et al., 2015 (251)

**Aim:** Determine associations between BP-lowering

**Inclusion criteria:** All RCTs of BP-lowering treatment in

- BP-lowering drug vs. placebo: 26 RCTs

**Limitations:** Reliability of this meta-analysis is limited by the scarcity of large trials with
<table>
<thead>
<tr>
<th>Study type: Large meta-analysis of 40 high quality RCTs (1/1966–10/2014) judged low risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Size:</strong> 100,354 pts with DM; all trials &gt;1,000 pt-y of follow-up BP-lowering drug vs. placebo: 26 RCTs</td>
</tr>
<tr>
<td>• More intensive vs. less intensive BP lowering: 7 RCTs</td>
</tr>
<tr>
<td>• BP-lowering vs. another drug: 17 RCTs</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong> Trials conducted predominantly in pts with type 1 DM were excluded.</td>
</tr>
</tbody>
</table>

which entire trial population had DM-2 or in which the results of a DM subgroup were obtained. Studies were included regardless of the presence or absence of defined HTN.

**Results:** Baseline BP: A 10-mm Hg SBP reduction was associated with a significantly lower risk of all-cause mortality RR: 0.87 (95% CI: 0.78–0.96), CVD events RR: 0.89 (95% CI: 0.80–0.98), and stroke events RR: 0.73 (95% CI: 0.64–0.83). The associations for HF and renal failure were not significant. For microvascular events, a 10-mm reduction in SBP was associated with a lower risk of retinopathy RR: 0.87 (95% CI: 0.76–0.99) and albuminuria RR: 0.83 (95% CI: 0.79–0.87).

**Stratified by initial SBP:**
Trials stratified by SBP >140 to <140 mm Hg showed significant interactions for all-cause mortality RR: 0.73 (95% CI: 0.64–0.84) vs. 1.07 (95% CI: 0.92–1.26), CVD RR: 0.74 (95% CI: 0.65–0.85) vs. RR: 0.96 (95% CI: 0.88–1.05), CHD RR: 0.73 (95% CI: 0.61–0.87) vs. RR: 0.97 (95% CI: 0.86–1.10), HF RR: 0.75 (95% CI: 0.59–0.94) vs. RR: 0.97 (95% CI: 0.79–1.19) and albuminuria RR: 0.71 (95% CI: 0.63–0.79) vs. RR: 0.86 (95% CI: 0.81–0.99).

**Stratified by achieved SBP:**
Trials stratified by SBP achieved in the treatment group ≥130 or <130 mm Hg and the associations of a 10-mm Hg SBP reduction compared between the strata showed significant interactions for all-cause mortality RR: 0.75 (95% CI: 0.65–0.86) vs. RR: 1.06 (95% CI: 0.90–1.265), CVD RR: 0.74 (95% CI: 0.64–0.85) vs. RR: 0.96 (95% CI: 0.88–1.05), CHD RR: 0.70 (95% CI: 0.58–0.83) vs. RR: 0.97 (95% CI: 0.85–1.10), HF achieved SBP levels in the 120–130 mm Hg range. The relatively short follow-up of included trials may have prevented associations of BP-lowering treatment with vascular outcomes from being observed, particularly for outcomes such as HF and renal failure, which are often a consequence of MI or albuminuria, respectively.

**Summary:**
• This large meta-analysis of 40 RCTs provides evidence that BP lowering is associated with lower risks of outcomes in pts with initial mean SBP ≥140 mm Hg compared with those <140 mm Hg with the exception of stroke, albuminuria and retinopathy. When trials were stratified by achieved SBP treatment was associated with lower risks only in the <130 mm Hg stratum for stroke and albuminuria.
• This meta-analysis shows that although BP lowering was not associated with a lower risk of CVD or CHD events at a baseline SBP <140 mm Hg, it does observe lower risks of stroke, retinopathy and progression of albuminuria.
• This study provides evidence that for individuals at high risk for these outcomes (history of cerebrovascular disease or mild nonproliferative retinopathy), commencement of therapy below an initial SBP of 140 mm Hg and treatment to SBP <130 may be indicated.
### Table: Hypertension Guideline Data Supplements

<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheng J, et al., 2014 (252)</td>
<td>To separately evaluate the effects of ACEIs and ARBs on all-cause mortality, CV deaths, and major CV events in pts with DM</td>
<td>RCTs including post hoc analyses and subgroups for DM with median follow-up of at least 12 mo. Comparisons with placebo, no treatment or other antihypertensive drugs, including ACEIs and ARBs.</td>
<td>• ACEIs significantly reduced the risk of all-cause mortality by 13% (RR: 0.87; 95% CI: 0.78–0.98), CV deaths by 17% (RR: 0.83; 95% CI: 0.70–0.99), and major CV events by 14% (RR: 0.86; 95% CI: 0.77–0.95), including MI by 21% (RR: 0.79; 95% CI: 0.65–0.95) and HF by 19% (RR: 0.81; 95% CI: 0.71–0.93). Treatment with ARBs did not significantly affect all-cause mortality (RR: 0.94; 95% CI: 0.82–1.08), CV death rate (RR: 1.21 (95% CI: 0.81–1.80) and major CV events (RR: 0.94; 95% CI: 0.85–1.01) with the exception of HF (RR: 0.70; 95% CI: 0.59–0.82).</td>
<td>Evidence from RCTs does not support BP targets lower than standard targets in pts with HTN and DM.</td>
</tr>
<tr>
<td>Arguedas JA, et al., 2013 (244)</td>
<td>To determine if “lower” BP targets (any target &lt;130/85 mm Hg) are associated with reduction in mortality and morbidity compared to “standard” BP targets (&lt;140–160/90–100 mm Hg) in pts with DM.</td>
<td>RCTs in which individuals were randomized to a “lower” compared with a “standard” BP target.</td>
<td>Only 1 trial (ACCORD) compared outcomes associated with “lower” (&lt;120 mm Hg) or ‘standard’ (&lt;140 mm Hg) SBP targets in 4734 pts. Despite achieving a significantly lower BP (119.3/64.4 mm Hg vs. 133.5/70.5 mm Hg, p&lt;0.0001), and using more antihypertensive medications, the only significant benefit in the group assigned to ‘lower’ SBP was a reduction in the incidence of serious adverse events, MI, stroke, CHF, and ESRD.</td>
<td>Evidence from RCTs does not support BP targets lower than standard targets in pts with HTN and DM.</td>
</tr>
<tr>
<td><strong>Size</strong>:</td>
<td>5 RCTs recruiting a total of 7,314 pts.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mean follow-up</strong>:</td>
<td>4.5 y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996, SANDS 2008, Lewis 1999 and the Steno-2 study.</td>
<td>of stroke: RR: 0.58 (95% CI: 0.39–0.88; p=0.009), absolute risk reduction 1.1%. The effect of SBP targets on mortality was compatible with both a reduction and increase in risk: RR: 1.05 (95% CI: 0.84–1.30), low-quality evidence. Trying to achieve the ‘lower’ SBP target was associated with a significant increase in the number of other serious adverse events: RR: 2.58 (95% CI: 1.70–3.91; p&lt;0.00001), absolute risk increase 2.0%. 4 trials (ABCD-H, ABCD-N, ABCD-2V, and a subgroup of HOT) specifically compared clinical outcomes associated with ‘lower’ vs. ‘standard’ targets for DBP in pts with DM. The total number of pts included in the DBP target analysis was 2580. Pts assigned to ‘lower’ DBP had a significantly lower achieved BP: 128/76 mm Hg vs. 135/83 mm Hg, p&lt;0.0001. There was a trend towards reduction in total mortality in the group assigned to the ‘lower’ DBP target: RR: 0.73 (95% CI: 0.53–1.01), mainly due to a trend to lower non-CV mortality. There was no difference in stroke: RR: 0.67 (95% CI: 0.42–1.05), in MI: RR: 0.95 (95% CI: 0.64–1.40) or in CHF: RR: 1.06 (95% CI: 0.58–1.92), low quality evidence. End-stage renal failure and total serious adverse events were not reported in any of the trials. A sensitivity analysis of trials comparing DBP targets &lt;80 mm Hg (as suggested in clinical guidelines) vs. &lt;90 mm Hg showed similar results. There was a high risk of selection bias for every outcome analyzed in favor of the ‘lower’ target in the trials included for the analysis of DBP targets.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Aim:** To assess whether therapy targeting normal SBP (<120 mm Hg) reduces major outcomes: 1.1%. The effect of SBP targets on mortality was compatible with both a reduction and increase in risk: RR: 1.05 (95% CI: 0.84–1.30), low-quality evidence. Trying to achieve the ‘lower’ SBP target was associated with a significant increase in the number of other serious adverse events: RR: 2.58 (95% CI: 1.70–3.91; p<0.00001), absolute risk increase 2.0%. 4 trials (ABCD-H, ABCD-N, ABCD-2V, and a subgroup of HOT) specifically compared clinical outcomes associated with ‘lower’ vs. ‘standard’ targets for DBP in pts with DM. The total number of pts included in the DBP target analysis was 2580. Pts assigned to ‘lower’ DBP had a significantly lower achieved BP: 128/76 mm Hg vs. 135/83 mm Hg, p<0.0001. There was a trend towards reduction in total mortality in the group assigned to the ‘lower’ DBP target: RR: 0.73 (95% CI: 0.53–1.01), mainly due to a trend to lower non-CV mortality. There was no difference in stroke: RR: 0.67 (95% CI: 0.42–1.05), in MI: RR: 0.95 (95% CI: 0.64–1.40) or in CHF: RR: 1.06 (95% CI: 0.58–1.92), low quality evidence. End-stage renal failure and total serious adverse events were not reported in any of the trials. A sensitivity analysis of trials comparing DBP targets <80 mm Hg (as suggested in clinical guidelines) vs. <90 mm Hg showed similar results. There was a high risk of selection bias for every outcome analyzed in favor of the ‘lower’ target in the trials included for the analysis of DBP targets. |

Inclusion criteria: Type 2 DM with HgbA1c ≥7.5%; ≥40 y with CVD or ≥55 y with anatomical evidence of Pts were randomly assigned to intensive therapy SBP<120 mm Hg or standard therapy SBP<140 mm Hg. |

Limitations: This trial had an open label design. The rate of adverse events in the standard therapy group was less than...
### Hartley L, et al., 2014 (253) 25436436

**Study type:** Literature review of RCTs  
**Inclusion criteria:**  
≥3 mo duration, healthy adults or adults at high risk of CVD, comparison of no or minimal intervention.  
**Exclusion criteria:** Multi-factorial interventions  
**1° outcomes:** Clinical CVD events and major CVD risk factors  
**Results:** No conclusions of the effectiveness of transcendental meditation for the 1° prevention of CVD  
**Summary:** No conclusions as to the effectiveness of transcendental meditation for the 1° prevention of CVD. There was considerable heterogeneity between trials and the included studies were small, short-term, and at overall serious risk of bias.  

### Schmieder RE, et al., 2007 (254) 17416265

**Study type:** Topic review  
**Inclusion criteria:** N/A  
**Exclusion criteria:** N/A  
**1° outcomes:** N/A  
**Results:** N/A  
**Summary:** N/A  

### Lv, et al., 2013 (127) 23798459

**Study type:** Systematic review  
**Size:** 9,287 pts with CKD and 1,264 kidney failure events  
**Inclusion criteria:**  
- Randomized trials of pts with CKD assigned to different target BP that reported kidney failure and CV events.  
- 11 trials on 9,287 pts with CKD and 1,264 kidney failure events (doubling of serum creatinine, 50% decline in GFR or ESKD)  
- Included AASK, REIN-2,  
**Results:** Compared with standard regimens, more intensive BP lowering reduced risk of composite endpoint HR: 0.82 (95% CI: 0.68–0.98) and ESKD HR: 0.79 (95% CI: 0.67–0.93). Effect was modified by proteinuria (p=0.006) and markers of trial quality. Intensive BP lowering reduced the risk of kidney failure HR: 0.73 (95% CI: 0.62–0.86) but not in pts without proteinuria at baseline HR: 1.12 (95% CI: 0.67–1.87). No clear effect on CV events or death.  
**Limitations:** All trials used open label, in 2 pts were blinded, substantial variability in design quality. There was substantial variability in BP targets by MAP, SBP and DBP or only DBP. Most trials did not include pts with diabetic kidney disease  
**Summary:** Renal outcomes: 7 trials (N=5308) recorded a total of 1,264 kidney failure events. A -7.7 mm Hg difference in SBP and a -4.9 mm Hg
| MDRD, Wuhl (children), Toto, Schrier plus 5 trials with CKD subgroups, also included the late nonrandomized follow-up studies for AASK and MDRD | • BP targets varied substantially between trials. 2 trials targeted mean BP <92 mm Hg for the intensive treatment arm, and 107 mm Hg in the standard treatment arm. 1 trial aimed for BP <130/80 mm Hg vs. a DBP of 90 mm Hg, 1 study targeted <120/80 mm Hg vs. 135–140/85–90 mm Hg, and 4 studies had DBP <75–80 mm Hg vs. from 80–90 mm Hg. A trial involving pediatric pts targeted a 24-h mean BP <the 50th percentile, compared with the 50th to 95th percentiles in the control group. 2 trials had more liberal targets for intensive treatment (<140–150 mm Hg SBP, 85 mm Hg DBP) | difference in DBP seen between treatment arms. Overall, a more intensive regimen reduced risk of composite kidney failure events by 17% (HR: 0.82; 95% CI: 0.68, 0.98), reduced the risk of ESKD alone by 18% (pooled HR for composite outcomes: 0.79; 95% CI: 0.67, 0.93).
• Intensive BP lowering had no effect on kidney failure in pts who did not have proteinuria (3 trials involving 1,218 pts (HR: 1.12; 95% CI: 0.67–1.87), but it did reduce the risk of progressive kidney failure by 27% (5 trials involving 1,703 pts (HR: 0.73; 95% CI: 0.62–0.86) in pts who did have proteinuria at baseline.
• CV outcomes: major CV events reported in 5 trials (472 CV events in 5,308 pts with CKD). Intensive BP lowering did not reduce risk of CV events in pts with CKD, but the CIs remained wide (RR: 1.09 (95% CI: 0.83, 1.42). 6 trials reported stroke outcomes (197 events in 5,411 pts), 5 trials reported MI (138 events in 4,317 pts), and 5 trials reported HF (118 events in 5,308 pts). They saw no clear effect of intensive treatment on any of these vascular outcomes.
• Death: 10 trials involving 6,788 pts reported 846 deaths. There was no clear effect of intensive BP lowering on risk of all-cause death (RR: 0.94 (95% CI: 0.84, 1.05) or CV death (RR: 1.20 (95% CI: 0.82, 1.75). |
## Data Supplement 48. Atrial Fibrillation (Section 9.8)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study</th>
<th>Study Type</th>
<th>Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoints</th>
<th>P Value; OR, HR, or RR; &amp; 95% CI</th>
<th>Study Limitations &amp; Adverse Events</th>
</tr>
</thead>
</table>
| Jibrini, et al., 2008 (255) 18223352 | **Aim:** To assess the effectiveness of ACEIs and ARBs in the prevention of AF, and to identify those clinical entities in which RAAS inhibition would most likely benefit the pts.  
**Study type:** Meta-analysis  
- 11 published studies; 55,989 pts (26,973 pts in intervention, 29,016 pts in comparator)  
**Inclusion criteria:** Studies of RAAS blockade in CHF, MI, electrical cardioversion, and HTN with incidence of AF noted during follow-up.  
**Exclusion criteria:** Studies without the measurement of AF or use of RAAS blockade.  
**Intervention:** RAAS blockade  
**Intervention:** Placebo, amlodipine, BB or thiazide diuretic | **1° endpoint (efficacy and results):** AF occurrence or reoccurrence. | Treatment with RAAS blockers reduced RR of AF in pts with HTN by 23% (p<0.001), by 11% in pts after MI (p<0.05), by 51% after electrical cardioversion (p<0.001), by 32% in pts with HF (p<0.001) and by 19% overall (p<0.001). | Not a comprehensive analysis of all antihypertensive. Adverse events not catalogued in meta-analysis. |
| Zhao et al., 2015 (256) 26668582 | **Aim:** To investigate the effectiveness and safety of ACEIs or angiotensin II receptor blockers (ARBs) on preventing AF in essential hypertensive pts.  
**Study type:** Meta-analysis  
- RAAS blockade, n=20,491  
- Comparator: BB/calcium antagonist, n=22,401 | **Inclusion criteria:** RCTs on the effects of ACEI/ARBs on essential hypertensive pts.  
**Exclusion criteria:** Non-RCTs, subjects who were not treated with ACEI or ARB, and trials not | **1° endpoint:** AF occurrence or reoccurrence. | ACEI/ARBs reduced the incidence of AF recurrence compared to calcium antagonists (RR: 0.48; 95% CI: 0.40–0.58; p<0.00001) or β-blockers (RR: 0.39; 95% CI: 0.20–0.74; p=0.005). ACEI/ARBs may reduce the incidence of AF recurrence and CHF, with fewer serious adverse effects, but did not prevent new onset of AF. | Doxazosin was associated with a higher incidence (2%) of AF/AFL prior to having the drug discontinued by the trial. Excluding doxazosin, there was no relationship between treatment drug and AF/AFL incidence. | 2° analysis of RCT. |
### Data Supplement 49. Valvular Heart Disease (Section 9.9)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Patient Population</th>
<th>Endpoints</th>
<th>P Value; OR, HR, or RR; &amp; 95% CI</th>
<th>Study Limitations &amp; Adverse Events</th>
</tr>
</thead>
</table>
| Healey et al., 2005 (257)            | **Aim**: Systematic review of all RCT evaluating the benefit of trials of ACEI and ARBs in prevention of AF  
**Study type**: Meta-analysis  
**Size**: 11 studies included with 56,308 pts | **Intervention**: n=27,089 RAAS blockade  
**Comparators**: n=29,220 placebo or active control antihypertensive | **Inclusion criteria**: Studies of RAAS blockade in CHF, MI, electrical cardioversion, and HTN with incidence of AF noted during follow-up  
**Exclusion criteria**: Studies without the measurement of AF or use of RAAS blockade. | **1° endpoint**: AF occurrence or reoccurrence | - ACEIs and ARBs reduced RR of AF by 28% (p=0.0002), greatest in pts with HF (RR reduction: 44%; p=0.007). No significant reduction in AF in pts with HTN (RR reduction: 12%; p=0.4), but 1 trial found a significant 29% reduction in pts with LVH. Following cardioversion there was a large effect (48% RR reduction; 95% CI: 21%–65%). | - ACEIs and ARBs appear to be effective in prevention of AF probably limited to pts with systolic LV dysfunction or HTN LVH |
| Jibrini et al., 2008 (255)           | **Aim**: To assess the effectiveness of ACEIs and ARBs in the prevention of AF, and to identify those clinical entities in which RAAS inhibition would most likely benefit the pts.  
**Study type**: Meta-analysis | **Intervention**: n=26,973 RAAS blockade  
**Comparators**: n=29,016 placebo, amlodipine, BB or thiazide diuretic | **Inclusion criteria**: Studies of RAAS blockade in CHF, MI, electrical cardioversion, and HTN with incidence of AF noted during follow-up  
**Exclusion criteria**: Studies without the measurement of AF or use of RAAS blockade. | **1° endpoint**: AF occurrence or reoccurrence | - Treatment with RAAS blockers reduced RR of AF in pts with HTN by 23% (p<0.001), by 11% in pts after MI (p<0.05), by 51% after electrical cardioversion (p<0.001), by 32% in pts with HF (p<0.001) and by 19% overall (p<0.001). | N/A |
| **Size:** 11 studies, 55,989 pts | **Intervention:** RAAS blockade, n=20,491 | **Inclusion criteria:** RCTs on the effects of ACEI/ARBs on essential hypertensive pts. | **1° endpoint:** AF occurrence or reoccurrence. | • ACEI/ARBs reduced the incidence of AF recurrence compared to calcium antagonists (RR: 0.48; 95% CI: 0.40–0.58; p<0.00001) or b-blockers (RR: 0.39; 95% CI: 0.20–0.74; p=0.005). ACEI/ARBs may reduce the incidence of AF recurrence and CHF, with fewer serious adverse effects, but did not prevent new onset of AF. |

| **Zhao et al., 2015 (256)** | **Comparator:** BB/calcium antagonist, n=22,401 | **Exclusion criteria:** Non-RCTs, subjects who were not treated with ACEI or ARB, and trials not mentioning of AF prevention. |  | N/A |

| **Size:** 10 studies, n=42,892 | **Intervention:** Captopril, n=5,592 | **Inclusion criteria:** Pts aged 25–66 y with a measured DBP of ≥100 mm Hg on 2 occasions were included. | **1° endpoint:** Fatal and nonfatal MI and stroke, and other CV deaths. | • Captopril and conventional treatment did not differ in rates of all cardiac events—fatal and nonfatal MI, other CV deaths and sudden deaths, IHD, CHF, or AF (0.94; p=0.30). |

| **Hansson et al., 1999 (258)** | **Comparator:** 5,493 pts were allocated to diuretics or BBs | **Exclusion criteria:** 2° HTN, serum creatinine concentration of more than 150 micromol/L, and disorders that required treatment with BB. | **2° endpoint:** New or deteriorated IHD and CHF, AF, DM, TIA s, and death from all causes. | N/A |

| **Size:** 10,985 | **Intervention:** n=2205 pts treated with ACEI | **Inclusion criteria:** HTN with BP ≥ 180 mm Hg systolic, aged 70–84 y | **1° endpoint:** CV death | • Old and new antihypertensive drugs were similar in prevention of CV mortality or major events. Decrease in BP was of major importance for the prevention of CV events. No difference in AF frequency was found (5.3% with ACEI, 4.1% with CCB and 5.2% with older drugs). |

| **Hansson et al., 1999 (259)** | **Comparator:** n=2,213 pts treated with BB or diuretic combination or n=2,196 pts treated with CCB | **Exclusion criteria:** Outside of the age range (n=14) | **2° endpoint:** CV events, DM and AF | N/A |

| **Size:** 10,985 | **Intervention:** Captopril, n=5,592 | **Inclusion criteria:** Pts aged 25–66 y with a measured DBP of ≥100 mm Hg on 2 occasions were included. | **1° endpoint:** Fatal and nonfatal MI and stroke, and other CV deaths. | • Captopril and conventional treatment did not differ in rates of all cardiac events—fatal and nonfatal MI, other CV deaths and sudden deaths, IHD, CHF, or AF (0.94; p=0.30). |

| **Hansson et al., 1999 (258)** | **Comparator:** 5,493 pts were allocated to diuretics or BBs | **Exclusion criteria:** 2° HTN, serum creatinine concentration of more than 150 micromol/L, and disorders that required treatment with BB. | **2° endpoint:** New or deteriorated IHD and CHF, AF, DM, TIA s, and death from all causes. | N/A |

| **Size:** 10,985 | **Intervention:** n=2205 pts treated with ACEI | **Inclusion criteria:** HTN with BP ≥ 180 mm Hg systolic, aged 70–84 y | **1° endpoint:** CV death | • Old and new antihypertensive drugs were similar in prevention of CV mortality or major events. Decrease in BP was of major importance for the prevention of CV events. No difference in AF frequency was found (5.3% with ACEI, 4.1% with CCB and 5.2% with older drugs). |

<p>| <strong>Hansson et al., 1999 (259)</strong> | <strong>Comparator:</strong> n=2,213 pts treated with BB or diuretic combination or n=2,196 pts treated with CCB | <strong>Exclusion criteria:</strong> Outside of the age range (n=14) | <strong>2° endpoint:</strong> CV events, DM and AF | N/A |</p>
<table>
<thead>
<tr>
<th>Study type</th>
<th>Size</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>1° endpoint</th>
<th>2° endpoint</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIFE trial</td>
<td>6,614</td>
<td>n=4,298 treated with losartan</td>
<td>Hypertensive pts with LVH by echo</td>
<td>New-onset AF</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Wachtell et al., 2005 (260)</td>
<td></td>
<td>n=4,182 treated with atenolol</td>
<td>Prior AF history in 342 pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIFE trial</td>
<td>9,193</td>
<td>n=4,298 treated with losartan</td>
<td>Hypertensive pts with LVH by echo</td>
<td>New-onset AF</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Haywood et al., 2009 (261)</td>
<td></td>
<td>n=4,182 treated with atenolol</td>
<td>Prior AF history in 342 pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALLHAT</td>
<td>81,474</td>
<td>n=42,418 on diuretics</td>
<td>Essential HTN with BP &gt;140/90 without medications, &gt;180 systolic if on medications</td>
<td>AF/AFL occurred in 641 pts on follow-up</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Julius et al., 2004 (610)</td>
<td>81,474</td>
<td>n=39,056</td>
<td>Not meeting inclusion criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial</td>
<td></td>
<td></td>
<td>Essential HTN with BP &gt;140/90 without medications, &gt;180 systolic if on medications</td>
<td>AF/AFL occurred in 641 pts on follow-up</td>
<td>None</td>
<td>N/A</td>
</tr>
<tr>
<td>Julius et al., 2004 (610)</td>
<td>7,649</td>
<td>n=7,596 on valsartan</td>
<td>Hypertensive pts, ≥50 y with DM, current smoking, high total cholesterol, LVH by ECG, proteinuria on dipstick and CKD (not end-stage)</td>
<td>Cardiac mortality, morbidity, HF, stroke, all-cause death, new onset DM</td>
<td>AF</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>7,596 on valsartan</td>
<td>Hypertensive pts at high CV risk</td>
<td>Hypertensive pts at high CV risk</td>
<td>Safety endpoint: Hypotension, syncope</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7,596 on valsartan</td>
<td>Hypertensive pts at high CV risk</td>
<td>Hypertensive pts at high CV risk</td>
<td>Safety endpoint: Hypotension, syncope</td>
<td>AF</td>
<td></td>
</tr>
</tbody>
</table>
### Data Supplement 50. RCTs and Meta-analysis Comparing Valvular Heart Disease (Section 9.9)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Study Intervention (# patients)/Study Comparator (# patients)</th>
<th>Patient Population</th>
<th>Endpoints</th>
<th>P Value; OR, HR, or RR; &amp; 95% CI</th>
<th>Study Limitations &amp; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCOPE-AS Chockalingam A, et al., 2004 (262) 15077102</td>
<td>Aim: To determine the clinical tolerance and efficacy of the ACEI enalapril in the setting of symptomatic severe AS. <strong>Study type:</strong> RCT <strong>Size:</strong> 56 pts</td>
<td><strong>Intervention:</strong> Enalapril 2.5 mg BID increasing to 10 mg BID (37 pts) <strong>Comparator:</strong> Placebo (19 pts)</td>
<td><strong>Inclusion criteria:</strong> Severe aortic stenosis (aortic valve area &lt;0.75 cm², mean aortic gradient &gt;50 mm Hg, or aortic valve Doppler jet &gt;4.5 m/s) and symptomatic NYHA class III or IV dyspnea or angina <strong>Exclusion criteria:</strong> Persistent hypotension (SBP &lt;90 or mean BP &lt;60), severe mitral stenosis (mitral valve orifice &lt;1.0 cm²), known intolerance for ACEI, and renal dysfunction (serum creatinine &gt;2.5 mg/dL).</td>
<td><strong>1º endpoint:</strong> Improvements in Borg dyspnea index and 6-min walk distance at 1 mo <strong>Safety endpoint:</strong> Development of hypotension</td>
<td>• Pts who tolerated enalapril (n=34) had significant improvement in NYHA class, Borg index (5.4 ± 1.2 vs. 5.6 ± 1.7; p=0.03), and 6-min walk distance (402 ± 150 vs. 376 ± 174; p=0.003) compared with control pts.</td>
<td>• Treatment with enalapril resulted in hypotension in 3 of 5 pts with LV dysfunction and congestive HF had hypotension.</td>
</tr>
</tbody>
</table>
| **SEAS**
Riick ÅE
Hypertension, 2012 (263) 22647889 |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To determine the impact of HTN on LV structure and outcome during progression of aortic valve stenosis</td>
</tr>
<tr>
<td><strong>Study type:</strong> RCT observational substudy of SEAS trial</td>
</tr>
<tr>
<td><strong>Size:</strong> 1616 pts</td>
</tr>
<tr>
<td><strong>Intervention:</strong> 1,340 pts with HTN</td>
</tr>
<tr>
<td><strong>Comparator:</strong> 276 pts without HTN</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> Pts 45-85 y who had asymptomatic, mild-to-moderate aortic valve stenosis, as assessed on echo, with a peak aortic-jet velocity of 2.5–4 m per second, were eligible for the study.</td>
</tr>
<tr>
<td><strong>1° endpoint:</strong> Echo LV mass; MACE; mortality</td>
</tr>
<tr>
<td>• HTN predicted 51% higher incidence of abnormal LV geometry at final study visit independent of other confounders (p&lt;0.01).</td>
</tr>
<tr>
<td>• HTN was associated with a 56% higher rate of ischemic CV events and a 2-fold increased mortality (both p&lt;0.01).</td>
</tr>
<tr>
<td>• No specific randomized intervention for HTN.</td>
</tr>
<tr>
<td>Eleid MF, et al., 2013 (264) 23956211</td>
</tr>
<tr>
<td><strong>Aim:</strong> To evaluate the hemodynamic effects of vasodilator therapy in pts with LGSAS</td>
</tr>
<tr>
<td><strong>Study type:</strong> Nitroprusside infusion</td>
</tr>
<tr>
<td><strong>Size:</strong> 24</td>
</tr>
<tr>
<td><strong>Intervention:</strong> Infusion of IV sodium nitroprusside to reduce BP and arterial afterload (18 pts with hypertensive LGSAS)</td>
</tr>
<tr>
<td><strong>Comparator:</strong> Baseline hemodynamics (6 pts with low EF LGSAS)</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> Symptomatic pts with HTN (aortic SBP &gt;140 mm Hg) and low-gradient (mean gradient &lt;40 mm Hg) severe aortic stenosis (aortic valve area &lt;1 cm² (2)) with preserved EF (EF &gt;50%).</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong> Moderate or severe concomitant valvular heart disease (e.g., aortic, mitral or tricuspid regurgitation), reduced left ventricular EF (&gt;50%), age &lt;18 y, and complex CHD.</td>
</tr>
<tr>
<td><strong>1° endpoint:</strong> Nitroprusside reduced mean PA pressure (25±10 mm Hg) and LV end-DBP (11±5 mm Hg; p&lt;0.001 for both compared with baseline).</td>
</tr>
<tr>
<td><strong>2° endpoint:</strong> Aortic valve area (0.86±0.11 to 1.02±0.16 cm² (2); p=0.001) and mean gradient (27±5 to 29±6 mm Hg; p=0.02) increased with nitroprusside.</td>
</tr>
<tr>
<td>• Treatment of HTN with vasodilator therapy results in a lowering of the total LV afterload, with a decrease in LV filling pressures and PA pressures.</td>
</tr>
<tr>
<td>• No translation to clinical or ambulatory vasodilator use.</td>
</tr>
</tbody>
</table>
| **RIAS Trial**
Bull S, et al., 2015 (265) 25796267 |
| **Aim:** To determine if ACEIs improve outcomes in AS. |
| **Study type:** RCT |
| **Size:** 100 |
| **Intervention:** Ramipril ramped up from 2.5 to 5 to 10 mg for 1 y (50 pts) |
| **Comparator:** Placebo (50 pts) |
| **Inclusion criteria:** Pts >18 y with moderate or severe aortic stenosis (valve area <1.5 cm², or peak velocity >3.0 m/s [peak valve gradient >36 mm Hg]), 2 who were asymptomatic as judged by pt-reported symptoms, |
| **1° endpoint:** Adverse events; laboratory abnormalities; change in LVM from baseline to 12 mo measured by CMR. |
| **2° endpoint:** Change in LV EF and function by CMR and echo, change in preserved tissue Doppler systolic velocity compared with placebo (+0.0 vs. -0.5 cm/s; |
| • Reduction in LVM in the ramipril group vs. placebo group (mean change -3.9 vs. +4.5 g, respectively; p=0.0057); preserved tissue Doppler systolic velocity compared with placebo (+0.0 vs. -0.5 cm/s; |
| • A larger clinical outcome trial to confirm these findings and explore their clinical relevance is required. |
### Scognamiglio R, et al., 1994 (266) 8058074

**Aim:** To assess whether vasodilator therapy reduces or delays the need for valve replacement

**Study type:** RCT

**Size:** 143

**Intervention:** Nifedipine 20 mg Q12 H (69 pts)

**Comparator:** Digoxin 0.25 mg daily (74 pts)

**Inclusion criteria:**
- Asymptomatic pts with isolated, chronic, severe aortic regurgitation and normal LV systolic function

**Exclusion criteria:**
- Worsening aortic regurgitation within 6 mo, DBP above 90 mm Hg, CAD, aortic valve gradient ≥ 20 mm Hg, other valvular or CHD, poor quality echo or an LV EF <50%.

**1° endpoint:**
- Frequency of valve replacement

- At 6 y, a 34% of the digoxin group had undergone valve replacement, but only 15% of the nifedipine group (p<0.001)

- No placebo group, and digoxin is a poor comparator due to toxicity which is now recognized.

### Evangelista A, et al., 2005 (267) 16192479

**Aim:** To identify the possible beneficial effects of vasodilator therapy on LV function and the need for aortic-valve replacement.

**Study type:** RCT

**Size:** 95 pts

**Intervention:**
- Nifedipine 20 mg Q12 H or enalapril 20 mg daily (32 pts nifedipine, 32 pts enalapril)

**Comparator:** Placebo (31 pts)

**Inclusion criteria:**
- Consecutive pts with asymptomatic, chronic, severe aortic regurgitation and normal LV function

**Exclusion criteria:**
- LVEF <50%, AF, CAD or other nonaortic VHD

**1° endpoint:**
- Frequency of valve replacement

- Rate of aortic-valve replacement was similar among the groups: 39% in the control group, 50% in the enalapril group, and 41% in the nifedipine group (p=0.62).
### Scognamiglio R, et al., 1994 (266) 8058074

**Aim:** To assess whether vasodilator therapy delays need for valve replacement in pts with asymptomatic severe AR.

**Study type:** RCT

**Size:** 143 pts

**Intervention:** 69 pts received nifedipine

**Comparator:** 74 pts received digoxin

**Inclusion criteria:** Severe aortic regurgitation without symptoms

**Exclusion criteria:** DBP >90, recent worsening of aortic regurgitation, mixed aortic stenosis / aortic regurgitation or any additional valve disease, LVEF <50.

**1° endpoint:** Worsening symptoms, LVEF decline to <50% or both, requiring valve replacement surgery

- 15% met criteria for valve replacement with nifedipine, but 34% did with digoxin (p<0.001)
- No placebo control.

### Evangelista A, et al., 2005 (14) 16192479

**Aim:** To assess whether vasodilator therapy delays need for valve replacement in pts with asymptomatic severe AR.

**Study type:** RCT

**Size:** 95 pts

**Intervention:** 32 pts received enalapril; 32 pts received nifedipine

**Comparator:** 31 pts received placebo

**Inclusion criteria:** Severe aortic regurgitation without symptoms

**Exclusion criteria:** Not listed.

**1° endpoint:** Worsening symptoms, LVEF decline to <50% or both, requiring valve replacement surgery

- 41% met criteria for valve replacement with nifedipine, 50% did with enalapril, and 39% in the control group (p=0.62)
- BP of 145/75 average between the 3 groups, indicate lack of severity. Post-Rx BP is not reported.

### Data Supplement 51. RCTs Comparing Race/Ethnicity (Section 10.1)

<table>
<thead>
<tr>
<th>Study Acronym; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (± study comparator)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| Leenen F, et al., 2006 (268) 16864749 | **Study type:** RCT comparison of an alpha blocker, ACEI, or CCB, each compared to a thiazide-type diuretic. This is post hoc comparison between | • >50 y  
• Lisinopril (n=9,054); Amlodipine (9,048)  
• African American 15,085 (35.5%)  
• White 11,580 (47.0%)  | • Amlodipine vs. Lisinopril | • No significant difference in 1° outcome (nonfatal MI and fatal CHD) or other prespecified outcomes:  
• CHD, 1° outcome plus revascularization and hospitalized  | • In African Americans, Lisinopril less effective than amlodipine for BP reduction (mean follow-up BP 2.7/1.6 mm Hg higher with Lisinopril) and in reducing strokes (RR:1.51; 95% CI: 1.22–1.86) and |
### CCB vs. ACEI incl in race subgroup.

**Size:** 42,418

- **Study type:** Race subgroup comparison of RCT comparison of an ACEI or CCB compared to a thiazide-type diuretic on nonfatal or fatal CHD in pts with metabolic syndrome

- >50 y
- African American n=12,818
- Non-African American n=24,473

- Chlorothalidone vs. Amlodipine, or Lisinopril

- No difference in 1° outcome (nonfatal MI and fatal CHD). Other prespecified outcomes:
  - CHD, 1° outcome plus revascularization and hospitalized angina, composite CVD, stroke, HF, ESRD

- In African Americans with metabolic/cardiovascular syndrome: Amlodipine similar for chlorthalidone for all outcomes but inferior for HF (HR: 1.50; 95% CI: 1.18–1.90) and combined CVD (HR: 1.14; 95% CI: 1.00–1.29). Lisinopril less effective for SBP reduction by 4 mm Hg; combined CHD (HR: 1.19 (95% CI: 1.01, 1.40); combined CVD (HR: 1.24; 95% CI: 1.09–1.40); stroke (HR: 1.37; 95% CI: 1.07–1.76); HF (HR: 1.49; 95% CI: 1.17–1.90); and ESRD (HR: 1.70; 95% CI: 1.13–2.55)

### Wright JT et al. 2008 (269) 18227370

**Study type:** Race subgroup comparison of RCT comparison of an ACEI or CCB compared to a thiazide-type diuretic

**Size:** 9,061

- >50 y
- (35.5% African American)

- Chlorthalidone vs. Doxazosin

- No difference in 1° outcome (nonfatal MI and fatal CHD). Other prespecified outcomes:
  - CHD, 1° outcome plus revascularization and hospitalized angina, composite CVD, stroke, HF, ESRD

- In African Americans: combined CVD (HR: 1.28; 95% CI: 1.16–1.42); HF (HR: 1.84; 95% CI: 1.51–2.24); stroke HR (CI): 1.10–1.73

### SPRINT

**Aim:** To test the effectiveness of a goal SBP<120 mm Hg vs. a goal SBP<140 mm Hg for the prevention of CVD in pts with SBP≥130 mm Hg at baseline.

**Study type:** RCT

**Inclusion criteria:**
- SBP≥130 mm Hg, with upper limit varying as number of pre-trial BP-lowering meds increased. age ≥50 y
- Presence of at least 1 of the following:
  - Clinical or subclinical CVD
  - CKD stage 3 or greater
  - Age≥75 y

**Intervention:** Intensive BP-lowering treatment to goal SBP<120 mm Hg

**Comparison:**
- Standard BP-lowering treatment to goal SBP<140 mm Hg

**1° endpoint:** CVD (MI, ACS, stroke, HF, CVD death) HR: 0.75 (0.64–0.89)

**Other endpoints:**
- Total deaths: 0.73 (0.60–0.90)
- 1° or death: 0.78 (0.67–0.90)
- Components of 1° composite mostly consistent in direction other than ACS – no difference.

**CKD outcomes:**

**Summary:**
- More intensive SBP lowering to a goal of <120 mm Hg with achieved mean of ~121 mm Hg resulted in less CVD and lower total mortality over 3.26 y in comparison with a goal SBP<140 mm Hg and achieved SBP of ~135 mm Hg.
- There were small increases in some expected SAEs. Perhaps unexpected, a sizable
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Study Type</th>
<th>Size</th>
<th>Exclusion Criteria</th>
<th>Adverse Events</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>VA Coop 1967 (262) 4862069</td>
<td>Study type: RCT to examine effect of treatment of severe HTN</td>
<td>143</td>
<td>Framingham General CVD risk ≥15% in 10 y</td>
<td>Major ones included DM, history of stroke, ESRD (eGFR &lt;20)</td>
<td></td>
</tr>
<tr>
<td>Size: 9361 participants followed median of 3.26 y</td>
<td>During the trial, mean SBP was 121.5 vs. 134.6.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Framingham General CVD risk ≥15% in 10 y</td>
<td>• Framingham General CVD risk ≥15% in 10 y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclusion criteria: Major ones included DM, history of stroke, ESRD (eGFR &lt;20)</td>
<td>• During the trial, mean SBP was 121.5 vs. 134.6.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• During the trial, mean SBP was 121.5 vs. 134.6.</td>
<td>• 1° in CKD pts: reduction in GFR of ≥50% or ESRD 0.89 (0.42–1.87)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Incident albuminuria: 0.72 (0.48–1.07)</td>
<td>• Incident albuminuria: 0.81 (0.63–1.04)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• In pts without CKD: reduction in GFR ≥30% and to &lt;60</td>
<td>• During the trial, mean SBP was 121.5 vs. 134.6.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 3.49 (2.44–5.10)</td>
<td>• Increase in reduced eGFR in the non-CKD group and AKI/ARF overall was observed in the intensive group. While of uncertain etiology and significance, there is speculation this could be an acute hemodynamic effect, especially given the findings regarding albuminuria.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Incident albuminuria: 0.72 (0.48–1.07)</td>
<td>• 1.7% fewer pts had orthostatic hypotension in intensive group; p=0.01.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events:</td>
<td>SAEs: 1.04; p=0.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Significant absolute increases seen in intensive group for hypotension (1%), syncope (0.6%), electrolyte abnormality (0.8%), acute kidney injury/acute renal failure (1.6%) over the study period.</td>
<td>Significant absolute increases seen in intensive group for hypotension (1%), syncope (0.6%), electrolyte abnormality (0.8%), acute kidney injury/acute renal failure (1.6%) over the study period.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.7% fewer pts had orthostatic hypotension in intensive group; p=0.01.</td>
<td>1.7% fewer pts had orthostatic hypotension in intensive group; p=0.01.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VA Coop 1970 (271) 4914579</td>
<td>Study type: RCT to examine effect of treatment of mild to moderately severe HTN</td>
<td>380</td>
<td>54% African American</td>
<td>CVD or stroke events, Grade 3 or 4 retinopathy, doubling of creatinine or BUN. Study terminated early for 27 events vs. 2 events (placebo vs. active)</td>
<td>Few participants were untreated at baseline ~9%, so SPRINT provides little if any insight at present regarding BP-lowering medication initiation for untreated people with SBP 130–139.</td>
</tr>
<tr>
<td>Size: 143</td>
<td>DBP 115–129 mm Hg</td>
<td>HCTZ, Reserpine, Hydralazine vs. placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VA Coop 1970 (271) 4914579</td>
<td>Study type: RCT to examine effect of treatment of mild to moderately severe HTN</td>
<td>380</td>
<td>42% African American</td>
<td>CVD or stroke events, Grade 3 or 4 retinopathy, doubling of creatinine or BUN</td>
<td></td>
</tr>
<tr>
<td>Size: 380</td>
<td>DBP 90–115 mm Hg</td>
<td>HCTZ, Reserpine, Hydralazine vs. placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VA Coop 1970 (271) 4914579</td>
<td>Study type: RCT to examine effect of treatment of mild to moderately severe HTN</td>
<td>380</td>
<td>42% African American</td>
<td>CVD or stroke events, Grade 3 or 4 retinopathy, doubling of creatinine or BUN</td>
<td></td>
</tr>
<tr>
<td>Size: 380</td>
<td>DBP 90–115 mm Hg</td>
<td>HCTZ, Reserpine, Hydralazine vs. placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Description</th>
<th>Results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN Detection and Follow-up Program (HDFP)</td>
<td>Study type: RCT; comparison of stepped care at academic centers vs. usual care provided by community</td>
<td>44% African American · 30–69 y</td>
<td>Chlorthalidone, Reserpine, Hydralazine, Guanethidine vs. referral to community care · 23% decrease in mortality in African Americans on Stepped Care</td>
</tr>
<tr>
<td>LIFE</td>
<td>Study type: RCT; comparison of an ARB compared to a BB on CVD</td>
<td>55–80 y (mean 66.9 y) · African American 533 (6) · White 8,503 (92) · Asian 43 (0.5) · Hispanic 100 (1) · Other 14 (0.2)</td>
<td>Losartan vs. Atenolol · Interaction of race and treatment on CVD events (p=0.005) CVD increased 55% in African Americans in the Losartan group</td>
</tr>
<tr>
<td>VALUE</td>
<td>Study type: RCT; comparison of an ARB vs. a CCB on CVD</td>
<td>&gt;50 y (mean 67.3 y) · African American 658 (4.3) · White 13,643 (89.1) · Asian 535 (3.5) · Other 474 (3.1)</td>
<td>Valsartan vs. Amlodipine · CVD increased ~20% (NS) in African Americans in Valsartan group</td>
</tr>
<tr>
<td>AASK</td>
<td>Study type: RCT; comparison of 2 BP targets and 3 drug regimens on renal outcomes</td>
<td>18–70 y; African Americans; · eGFR: 25–65 mL/min/1.73 m²</td>
<td>MAP of &lt;92 mm Hg compared to MAP 102–107 mm Hg and an ACEI or CCB each compared to a BB · No difference between BP targets. ACEI &gt; BB &gt; CCB</td>
</tr>
<tr>
<td>ALLHAT</td>
<td>Study type: RCT; comparison of an alpha blocker, ACEI, or CCB, each compared to a thiazide-type diuretic</td>
<td>&gt;50 y · African American 15,085 (35.5) · White 19,977 (47.0) · Hispanics 5,299 (12.5)</td>
<td>Chlorthalidone vs. Doxazosin, Amlodipine, or Lisinopril · No difference in 1° outcome (nonfatal MI and fatal CHD) · Chlorthalidone (and amlodipine was superior in reducing BP by 4/1 mm Hg and CVD events (stroke and CVD) vs. lisinopril in African Americans</td>
</tr>
<tr>
<td>INVEST</td>
<td>Study type: RCT; comparison of CCB plus an ACEI</td>
<td>≥ 50 y with HTN and CHD · 36% Hispanic</td>
<td>Verapamil/trandolapril vs. Atenolol/ HCTZ · No difference in 1° outcome (nonfatal MI, nonfatal stroke, all-cause mortality). Mean SBP</td>
</tr>
</tbody>
</table>
### Data Supplement 52. RCTs Comparing Women With Hypertension (Section 10.2.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
</table>
| Turnbull F, et al., 2008 (277) 18852183 | **Aim:** Assess sex differences in response to BP treatment  
**Study type:** Meta-analysis of 31 RCTs  
**Size:** 103,268 men, 87,349 women | **Mean ages:**  
- Women: 63.0 y  
- Men: 61.7 y | **Intervention:** N/A  
**Comparator:** N/A | **1° endpoint:** Nonfatal stroke or death from cerebrovascular disease (ICD 430–438); (ii) nonfatal MI or deaths from CHD, excluding SCD (ICD 410–414); (iii) HF causing death or requiring hospitalization (ICD 428); (iv) total major CV events (stroke, CHD events, HF, other CV death); (v) total CV deaths (ICD 396–459); and (vi) total mortality  
**Safety endpoint:** N/A | **Summary:** Achieved BP reductions were comparable for men and women in every comparison made. For the 1° outcome of total major CV events there was no evidence that men and women obtained different levels of protection from BP-lowering or that regimens based on ACEIs, calcium antagonists, ARBs, or diuretics/BBs were more effective in1 sex than the other (all p-homogeneity >0.08). |
| Wing L, et al., 2003 (278) 12584366 | **Aim:** Comparison of ACE vs. Diuretic on incident CVD  
**Inclusion criteria:** Pts 65–84 y | **Intervention:** ACE  
**Comparator:** Diuretic | **Endpoint:** All CV events or death from any cause  
**Safety endpoint:** N/A | **Summary:** Among male subjects, HR: 0.83 (95% CI: 0.71–0.97; p=0.02); among female subjects, HR: 1.00 (95% CI: 0.83–1.21; p=0.98); the p value for
<table>
<thead>
<tr>
<th>Study type:</th>
<th>Practice-based RCT open label treatment, blinded event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size:</td>
<td>6,083 pts</td>
</tr>
</tbody>
</table>

**Exclusion criteria:** Life-threatening illness, contraindication to an ACEI or diuretic, a plasma creatinine concentration of more than 2.5 mg per deciliter (221 micromol per liter), malignant hypertension, or dementia. 

Note: Clinicians chose which ACE or diuretic the interaction between sex and treatment-group assignment was 0.15.

Fletcher A, et al., 1988 (279) 2907053

**Aim:** Monitoring event rates in pts assigned to treatment by clinicians

**Study type:** Observational

**Size:** 2,607

**Inclusion criteria:** Age >18 y

**Exclusion criteria:** N/A

**Intervention:** N/A

**1° endpoint:** Total mortality incident “IHD”

**Safety endpoint:** N/A

Summary: BBs reduced mortality in men but not women (p<0.01)

Forette F, et al., 2002 (280) 12374512

**Aim:** Legacy follow-up for dementia prevention

**Study type:** RCT with legacy follow-up

**Size:** 2,902 in the legacy follow-up

**Inclusion criteria:** Age ≥60 y

**Exclusion criteria:** HTN 2° to a disorder that needed specific medical or surgical treatment; congestive HF; dissecting aortic aneurysm; serum creatinine concentration at presentation of 180 micromol/l or more; stroke or MI in the y before the study; dementia; substance abuse; any disorder prohibiting a sitting or standing position; any severe concomitant or non-CVD

**Intervention:** Nitrendipine + HCTZ

**Comparator:** Placebo

**1° endpoint:** Incidence of dementia

**2° endpoint:** Cognitive decline measured by MMSE

**Safety endpoint:** N/A

- Cases Active: 21
- Cases Placebo; 43
- Rate 3.3 vs. 7.4 cases/1,000 pt y 0.38 (95% CI: 0.23–0.64; p<0.001)
- MMSE: No impact

Summary dementia:
- Study discontinued early for CVD benefit so a legacy follow-up with both groups (off protocol) yielded a follow-up of 3.7 y SBP was 149 mm Hg in treatment vs. 156 mm Hg in control arm

Summary dementia:
- Compared with the controls, long-term antihypertensive therapy reduced the risk of dementia by 55%, from 7.4–3.3 cases per 1,000 pt-y (43 vs. 21 cases; p<0.001). After adjustment for sex, age, education, and entry BP, the relative HR associated with the use of nitrendipine was 0.38 (95% CI: 0.23, 0.64), p<0.001.
- Lack of impact on MMSE not surprising given low sensitivity to change and large sample size
### Data Supplement 53. RCTs Comparing Pregnancy (Section 10.2.2)

<table>
<thead>
<tr>
<th>Study Acronym (if applicable) Author Year</th>
<th>Study Type/Design*; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Pucci M, et al., 2015 (281)              | **Study type:** Review of published reports of fetotoxicity of ACE/ARB antihypertensives in the first trimester of pregnancy. Usually case/control design. **Size:** N/A | **Inclusion criteria:** Pregnant women receiving ACE/ARB in the 1st trimester of pregnancy only and comparable controls **Exclusion criteria:** Use of ACE/ARB later in pregnancy | 1° **endpoint:** Adverse outcomes of pregnancy  
**Results:** Adverse events are higher in pregnancies of women who receive ACE/ARB in the first trimester of pregnancy but results are not independent of known confounders  
• Fetotoxicity in the first trimester of pregnancy cannot be definitely attributed to ACE/ARB treatment; data are inconclusive.  
• Other known causes of fetotoxicity may be responsible for increased risk in the first trimester (HTN, obesity, undiagnosed DM, other anti-hypertensives) | - |
| Moretti ME, et al., 2012 (282)           | **Study type:** Case control comparing pts exposed to ACE/ARB in the first trimester to healthy controls and those on other anti-hypertensives **Size:** 388 total pts (equally divided) | **Inclusion criteria:** Mothers calling into the Mother Risk Program re: medication toxicity during pregnancy **Exclusion criteria:** Non-English speaking | 1° **endpoint:** Malformations and adverse fetal outcomes  
**Results:** No difference among groups but study under-powered | • Supportive of above review |
| Ferrer RL, et al., 2000 (283)            | **Study type:** Meta-analysis **Size:** 46 observational studies and randomized control trials | **Inclusion criteria:** Prespecified quality entrance criteria **Exclusion criteria:** N/A | 1° **endpoint:** Adverse pregnancy outcomes  
**Results:**  
• Maternal HTN increases risk for 1) perinatal mortality (OR: 3.4:1) and 2) placental abruption (2.1:1)  
• ACEIs are associated with fetopathy (fetal renal failure) | • HTN by itself is associated with adverse perinatal outcomes  
• ACEIs independently are responsible for some outcomes |

*Quality assessment analysis may need to be applied on a case-by-case basis for controversial studies (by ERC chairs).*
### Data Supplement 54. RCT for Older Persons (Section 10.3.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPRINT Senior Williamson JD, et al., 2016 (190) 27195814</td>
<td>Aim: Intensive SBP goal &lt;120 mm Hg) vs. standard (SBP goal &lt;140)</td>
<td>Inclusion criteria: Men and women age 75+; mean age 79.8 y; 38% women; 17% black, 74% Caucasian Exclusion criteria: Nursing home residents; prevalent DM, stroke, Class III/IV HF, dementia Mean follow-up: 3.1 y</td>
<td>Intervention: Medications and dietary advice to achieve SBP of &lt;120 mm Hg Comparator: Medications and dietary advice to achieve SBP of &lt;140 mm Hg • Achieved SBP: Intensive=123.4 mm Hg Standard=134.8 mm Hg</td>
<td>1° endpoint: Composite CVD outcome (AMI, non-MI ACS, stroke, HF, CVD death. Results: • 102 events in the intensive treatment group vs. 148 events in the standard treatment group; HR: 0.66; 95% CI: 0.51–0.85 and all-cause mortality (73 deaths vs. 107 deaths, respectively; HR: 0.67; 95% CI: 0.49–0.91. No difference in falls, orthostatic hypotension, or overall SAEs. • NNT for 1° outcome=27 and NNT for all-cause mortality=41</td>
<td>Limitations: Does not apply to nursing home pts or those with dementia or advance Conclusions: Intensive SBP is safe and effective for lowering CVD events and total mortality in adults ≥75 y</td>
</tr>
</tbody>
</table>

### Data Supplement 55. RCTs Comparing Hypertensive Crises and Emergencies (Section 11.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLUE Peacock WF, et al., 2011 (284) 21707983</td>
<td>Aim: Compare safety and efficacy of IV nicardipine vs. labetalol in the management of acute HTN.</td>
<td>Inclusion criteria: SBP ≥180 mm Hg on 2 consecutive occasions 10 min apart in the ED. • 110 pts randomized to nicardipine; 116 to labetalol. End-organ damage preceded randomization in 63% with no difference between the groups. The target BP range (TR; at the discretion of the</td>
<td>Within 39 min, nicardipine pts reached TR than labetalol pts (91.7 vs. 82.5%; p=0.039). Of 6 BP measurements taken 5 min apart, nicardipine pts had a higher rate of 5 and 6 SBP measures in the TR than labetalol pts (47.3 vs. 32.8%);</td>
<td>Limitations: Study unblinded; large number of pts without end-organ damage (which usually defines a hypertensive emergency); physicians ordered fewer dose titrations of labetalol than nicardipine; thus, lack of BP decline might have been due to insufficient dosing by physicians hesitant to administer successively increasing doses of labetalol as recommended by the FDA.</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Size</td>
<td>Aim</td>
<td>Inclusion criteria</td>
<td>Results</td>
<td>Limitations</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-----</td>
<td>--------------------</td>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Liu-DeRyke X, et al., 2013 (285) 23760911</strong></td>
<td>226 pts</td>
<td>Compare ability of IV nicardipine and labetalol to lower BP in acute hemorrhagic or ischemic stroke.</td>
<td>Pts with acute hemorrhagic or ischemic stroke who were at or exceeded AHA guidelines BP recommendations.</td>
<td>Nicardipine pts were more likely in the TR than labetalol pts (OR: 2.73; 95% CI: 1.1–6.7; p=0.028). Less rescue medication had to be given to the nicardipine than the labetalol group (p&lt;0.001).</td>
<td>Very small; pseudo-randomization.</td>
</tr>
<tr>
<td><strong>CATIS</strong> He J, et al., 2014 (202) 24240777</td>
<td>4,071 pts</td>
<td>Evaluate whether immediate BP reduction in pts with acute ischemic stroke would reduce death and major disability in 14 d or hospital discharge.</td>
<td>Pts had nonthrombolysed ischemic stroke within 48 h of onset and elevated SBP. Baseline SBP was 166.7 mm Hg in the antihypertensive treatment group and 165.6 mm Hg in the control group.</td>
<td>In the antihypertensive treatment group, SBP was reduced from 166.7 to 144.7 mm Hg (-12.7%) within 24 h and in the control group from 165.6 to 152.9 mm Hg (-7.2%) (absolute difference -9.1 mm Hg; 95% CI: -10.2– -8.1; p&lt;0.001). Mean SBP was 137.3 mm Hg in the antihypertensive treatment.</td>
<td>Study excluded pts with BP ≥220/120 mm Hg, so the results do not apply to such pts. Pts treated acutely with thrombolytic therapy were excluded. Trial performed exclusively in Chinese pts.</td>
</tr>
</tbody>
</table>
reduction strategy rather than the efficacy of specific antihypertensive drugs. Pts in the control group discontinued their home BP medications.  

1° outcome: Combination of death and major disability at 14 d or hospital discharge.  

The 1° outcome did not differ between treatment groups (OR: 1.00; 95% CI: 0.88–1.14) at 14 d or hospital discharge. The 2° outcome of death and major disability at 3 mo post-treatment follow-up did not differ between the groups.

<table>
<thead>
<tr>
<th>INTERAC-2</th>
<th>Anderson CS, et al., 2013 (191)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type:</td>
<td>RCT</td>
</tr>
<tr>
<td>Size:</td>
<td>2,839 pts</td>
</tr>
</tbody>
</table>

To compare the management strategy of targeting SBP<140 mm Hg within 1 h with the current guideline strategy of targeting SBP to <180 mm Hg with the use of agents of the physicians' choosing.  

This was an international, multicenter, prospective randomized open-treatment, blinded endpoint trial. The pts had onset of spontaneous ICH within 6 h of enrollment.  

1° outcome: Death or major disability, defined as a score of 3-6 on the modified Rankin scale, at 90 d.

Results: 719 of 1,382 pts receiving intensive treatment as compared to 785 of 1,412 pts receiving guideline-recommended treatment had a 1° outcome event [OR with intensive treatment: 0.87; 95% CI: 0.75–1.01; p=0.06). Ordinal analysis showed significantly lower modified Rankin scores with intensive treatment (OR for greater disability: 0.87; 95% CI: 0.77–1.00; p=0.04). Mortality was 11.9% in the group receiving intensive treatment and 12.0% in the group receiving guideline-recommended treatment. Nonfatal serious events were not significantly different between the groups.

Limitations: No major limitations.

Conclusions: In pts with ICH, intensive lowering of BP resulted in a borderline significant reduction in the rate of death or severe disability at 90 d. An ordinal analysis of modified Rankin scores indicated improved functional outcomes with intensive lowering of BP. Intensive BP reduction was shown to be safe and to result in significantly better health-related quality of life.
PRONTO
Peacock WF, et al., 2014 (286) 24655702

**Study type:** RCT

**Size:** 104 pts

- To determine the efficacy and safety of clevidipine vs. standard-of-care (SOC) iv antihypertensive therapy in hypertensive acute HF.

- This was a randomized, open-label, active control study of clevidipine vs. standard-of-care in ED pts with acute HF with SBP ≥160 mm Hg.

**1° outcome:** Co-1° endpoints were median time to and % attaining a SBP within a prespecified TR at 30 min.

**Results:** More clevidipine pts reached target BP reduction (71%) than did those receiving standard-of-care (37%) and clevidipine was faster to target (p=0.0006). Serious adverse events were similar between clevidipine and standard-of-care.

**Limitations:** Small study, open-label design.

**Conclusions:** In hypertensive acute HF, clevidipine safely and rapidly reduced BP and improved dyspnea more effectively that standard-of-care.

Farias S, et al., 2014 13849948 (287)

**Aim:** To determine if achievement of target BP is less likely in pts with higher initial BP using a post hoc analysis in a pt subset from CLUE

**Study type:** RCT Post-hoc Analysis

**Size:** 223 pts

**Inclusion criteria:** SBP ≥180 mm Hg on 2 consecutive occasions 10 min apart in the ED.

**Exclusion criteria:** Contraindication to giving either a BB or CCB or clinical scenarios in which a compelling agent was indicated.

- This was a post hoc analysis of CLUE, an RCT, in which pts were dichotomized using the median presenting SBP as the partition point. Individuals above and below the median were evaluated as to the proportion achieving the 1° outcome.

**1° outcome:** Achievement of target SBP range within 30 min.

**Results:** Early achievement of target SBP was independent of presenting SBP.

**Limitations:** 2° analysis of the 1° CLUE study; SBP control only evaluated for the first 30 min posttreatment; no inclusion of critically ill pts; 80% of enrolled subjects were African-American.

**Conclusions:** Presenting SBP does not appear to affect the ultimate ability to reduce BP for pts with marked, acute HTN in the ED when treated with either IV nicardipine or IV labetalol.

---

Data Supplement 56. RCTs Assessing Impact of Hypertension Therapy on Dementia Incidence (Section 11.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHEP Applegate WB, et al., 1994 (288) 7944835</td>
<td><strong>Aim:</strong> Compare loss of instrumental activities of daily living by SBP</td>
<td><strong>Inclusion criteria:</strong> 60–80 y (mean 71.6 y)</td>
<td><strong>Intervention:</strong> Chlorthalidone + Atenolol or reserpine</td>
<td><strong>1° endpoint:</strong> Loss of dementia-related functions (instrumental activities of daily living)</td>
<td><strong>Relevant 2° endpoint:</strong> Incidence of surrogate markers for dementia</td>
</tr>
</tbody>
</table>
### Treatment vs. Placebo

**Study type:** RCT  
**Size:** 4,736  
**Duration:** 5 y  

**Exclusion criteria:** History and/or signs of major CVDs (e.g., previous MI, coronary artery surgery, major arrhythmias, conduction defect, recent stroke, carotid artery disease, ≥2 TIA and signs or symptoms in a single neurological distribution); other major diseases (e.g., cancer, alcoholic liver disease, established renal dysfunction) with competing risk factors for the 1° endpoint; stroke; presence of medical management problems (e.g., insulin dependent DM, history of dementia, evidence of alcohol abuse); bradycardia; people maintained on BBs, diuretics, other antihypertensive drugs, anticoagulants.

**Comparator:** Placebo  
**SBP Treatment/Placebo difference:** -12 mm Hg  
**Achieved mean SBP:** 143 mm Hg in treatment group vs. 155 mm Hg in placebo group

**Cases:**  
- Active: 37  
- Placebo: 44  
- p=0.84 (0.54,1.31)  
- No cognitive function instrument included in trial

**Summary:** Nonsignificant 16% lower incidence of incident instrumental activity of daily living disability. However, assignment to the placebo group and the resulting occurrence of CV events independently predicted missed assessments. However, when 20%–30% and 40%–80% of the subjects who missed the assessment were assumed to be cognitively/functionally impaired, assignment to active treatment reduced the risk of these outcomes. Thus, in the SHEP study, the cognitive and functional evaluations were biased toward the null effect by differential dropout. This might have obscured the appraisal of a protective effect of treatment on the cognitive and functional decline of older hypertensive adults.

### Syst-Eur

**Aim:** Incident dementia  
**Study type:** RCT  
**Size:** 2,418 pts  
**Duration:** 2 y  

**Inclusion criteria:** ≥60 y

**Exclusion criteria:** HTN 2° to a disorder that needed specific medical or surgical treatment; congestive HF; dissecting aortic aneurism; serum creatinine concentration at presentation of 180 micromoles/l or more; stroke or MI in the y before the study; dementia; substance abuse; any disorder prohibiting a sitting or standing position; any severe concomitant or non-CVD

**Intervention:** Nitrendipine ± enalapril ± HCTZ

**Comparator:** Placebo  
**SBP treatment/placebo difference:** -8.3 mm Hg  
**Achieved SBP:** 152 mm Hg in treatment arm; 160 mm Hg placebo arm

**Endpoint:** Dementia (defined by MMSE)

**Cases:**  
- Active: 11  
- Placebo: 21  
- (3.8 vs. 7.7 per 1,000 pt-y)  
- p=0.05

**Summary:** Trial stopped early for positive effect on CVD outcomes.
### Syst-Eur (legacy follow-up)
Forette F, et al., 2002 (280)  

| **Aim:** Legacy follow-up for dementia prevention | **Inclusion criteria:** ≥60 y  
**Exclusion criteria:** HTN 2ndary to a disorder that needed specific medical or surgical treatment; congestive HF; dissecting aortic aneurysm; serum creatinine concentration at presentation of 180 micromoles/l or more; stroke or MI in the y before the study; dementia; substance abuse; any disorder prohibiting a sitting or standing position; any severe concomitant or non-CVD | **Intervention:** Open label follow-up of Syst-Eur pts originally assigned to Nitrendipine ± enalapril ± HCTZ vs. placebo  
**SBP Treatment/Placebo difference:** -7.0 mm Hg  
Achieved SBP in 149 mm Hg treatment arm 156 mm Hg placebo arm | **1st endpoint:** Incidence of dementia  
**Endpoint 2:** Cognitive decline measured by MMSE  
**SBP Treatment/Placebo difference:** -7.0 mm Hg  
Achieved SBP in 149 mm Hg treatment arm 156 mm Hg placebo arm  
**Safety endpoint:** N/A  
**Dementia Cases:**  
Active: 21  
Placebo: 43  
**p=1.08 (0.75–1.56)**  
**Cognitive decline slower in treatment group**  
**Summary:**  
Mean follow-up 3.7 y. Treatment group SBP=144 mm Hg and placebo 147 mm Hg; thus, relatively minimal differences in achieved SBP between arms  
There were no significant differences between the treatment groups in either dementia or cognitive decline.  

### SCOPE
Lithell H, et al., 2003 (290)  

| **Aim:** Incident dementia (cognitive decline as 2nd outcome) | **Inclusion criteria:** 70–89 y (mean 76 y)  
**Exclusion criteria:** Prevalent dementia; 2nd HTN, SBP >180 mm Hg, orthostatic hypotension, need for antihypertensive treatment other than hydrochlorothiazide during run-in; stroke or MI within 6 mo; decompensated HF; serum creatinine>180 micromole/l (men) or>140 micromole/l (women) | **Intervention:** Candesartan ± HCTZ  
**Comparator:** Placebo ± Rx for community based SPB standard  
**SBP Treatment/Placebo difference:** -3.2 mm Hg | **Endpoint:**  
• Incident dementia  
• Also decline in MMSE  
**Dementia Cases:**  
• Active: 62  
• Placebo: 57  
• p=1.08 (0.75–1.56)  
• Cognitive decline slower in treatment group | **Summary:**  
Mean follow-up 3.7 y. Treatment group SBP=144 mm Hg and placebo 147 mm Hg; thus, relatively minimal differences in achieved SBP between arms  
There were no significant differences between the treatment groups in either dementia or cognitive decline.  

### PROGRESS
Tzourio C, et al., 2003 (291)  

| **Aim:** Dementia with or without recurrent stroke | **Inclusion criteria:** Prior stroke or TIA, any adult age | **Intervention:** Perindopril ± indapamide  
**Comparator:** Placebo | **Endpoint:** Dementia alone or with recurrent stroke  
**Dementia cases:** Only stroke-related dementia reduction of 34% (95% CI: 3–55), p=0.03.  
**Summary:** Dementia alone was not affected in this trial. Only dementia associated with incident cerebrovascular accident |
### Hypertension in the Very Elderly Trial (HYVET-Cog)

<table>
<thead>
<tr>
<th>Aim</th>
<th>Incidence dementia 2º aim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type</td>
<td>RCT</td>
</tr>
<tr>
<td>Size</td>
<td>3,336</td>
</tr>
<tr>
<td>Duration</td>
<td>2.2 y</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>≥80 y</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong></td>
<td>Prevalent dementia</td>
</tr>
<tr>
<td><strong>Intervention:</strong></td>
<td>Indapamide ± Perindopril</td>
</tr>
<tr>
<td><strong>Comparator:</strong></td>
<td>Placebo</td>
</tr>
<tr>
<td><strong>SBP treatment/placebo difference:</strong></td>
<td>-15 mm Hg</td>
</tr>
</tbody>
</table>
- Target SBP 150 mm Hg
- Achieved SPB in treatment arm = 146 mm Hg

**1º endpoint:** Incident dementia

**Events:**
- Treatment = 126
- Placebo = 137
- 14% reduction not significant

**HR:** 0.86 (95% CI: 0.67–1.09)

**Summary:** Stopped early due to benefit in 1º outcome.

### Data Supplement 57. RCTs for Patients Undergoing Surgical Procedures (Section 11.5)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2º Endpoint (if any); Study Limitations; Adverse Events; Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POISE</strong> Study Group, et al., 2008 (293) [16875901]</td>
<td><strong>Aim:</strong></td>
<td>Definitively establish the effects of BB therapy in pts undergoing noncardiac surgery</td>
<td><strong>Inclusion criteria:</strong> Pts undergoing noncardiac surgery with, or at risk for ASVD</td>
<td><strong>Intervention:</strong> extended release metoprolol succinate</td>
<td><strong>1º endpoint:</strong> Composite of CV death, NFMI, NF cardiac arrest</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Comparator:</strong></td>
<td>Placebo</td>
<td><strong>Results:</strong> Fewer pts taking metoprolol than placebo reached the 1º endpoint, HR: 0.84; 95% CI 0.70–0.99; p=0.0399.</td>
<td><strong>Limitations:</strong> No data for pts &lt;45 y, no data for pts undergoing cardiac surgery</td>
<td><strong>Conclusions:</strong> This study highlights combined benefits and</td>
<td></td>
</tr>
</tbody>
</table>
### Summary

**Study type:** RCT  
**Size:** 8,351  

However more in metoprolol group had death HR: 1.33; 1.03–1.74; p=0.0317 and more had stroke HR: 2.17; 1.26–3.74; p=0.0053.  

Risk of BB regimen in noncardiac surgery and importance of pt physician discussion in deciding upon its use.

---

**Data Supplement 58. Observational and Nonrandomized Studies for Patients Undergoing Surgical Procedures (Section 11.5)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Howell SJ, et al., 2004 (294) 15013960 | **Study type:** A systematic review and meta-analysis  
**Size:** 30 observational studies | **Inclusion criteria:** Available crude OR for association between HTN and periop CV complications along with variance  
**Exclusion criteria:** N/A. Studies defining HTN solely on admission BP | **1st endpoint:** Periop CV complications  
**Results:** Pts with SBP >180 or DBP >110 mm Hg more prone to periop ischemia, arrhythmias, and CV lability OR: 1.35 (1.17–1.56). | - Pts with SBP >180 or DBP >110 mm Hg more prone to periop ischemia, arrhythmias, and CV lability OR: 1.35 (1.17–1.56).  
- There was no evidence that deferring surgery in such pts reduces periop risk  
- Conclude that planned surgery should not be deferred on basis of single admission BP. History of target organ damage more important than preop BP in predicting complications |
| Hart GR and Anderson RJ, 1981 (295) 6114720 | **Study type:** Literature review  
**Size:** 72 pts BB s, 148 pts Clonidine | **Inclusion criteria:** Symptoms on cessation of BBs or clonidine  
**Exclusion criteria:** CP Bypass, carotid endarterectomy | **1st endpoint:** CV symptoms or events after abrupt cessation of BBs or clonidine  
**Results:** Symptoms of anxiety, chest pain with tachycardia, HTN, myocardial ischemia; less frequently MI may occur on abrupt withdrawal of BB or Clonidine | - Summary of case reports. CV events such as tachycardia, HTN, angina, myocardial ischemia or infarction can occur after abrupt withdrawal of BB or Clonidine. No information on incidence. |
| Shammash JB, et al., 2001 (296) 11136500 | **Study type:** Prospective observational study  
**Size:** 140 pts | **Inclusion criteria:** Review of 140 pts undergoing vascular surgery at university hospitals  
**Exclusion criteria:** N/A | **1st endpoint:** In-hospital mortality  
**Results:** 50% mortality in 8 pts with BB discontinued vs. 1.5% mortality in pts with BB continued. OR: 65.0; p=0.001 | - Discontinuing BB immediately after vascular surgery may increase the risk of postoperative CV morbidity and mortality |
<table>
<thead>
<tr>
<th>Study type: Retrospective cohort</th>
<th>Inclusion criteria: Age &gt;18 y, major noncardiac surgery</th>
<th>1° endpoint: In-hospital mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 122,338 pts</td>
<td>Exclusion criteria: contraindication to BB therapy</td>
<td>Results: On BB therapy, mortality in low risk (RCRI =0) OR: 1.43 (1.29–1.58) to high risk (RCRI) OR 4 or higher OR 0.57 (0.42–0.76)</td>
</tr>
</tbody>
</table>

• Periop BB therapy is associated with a reduced risk of in-hospital death among high-risk, but not low-risk pts undergoing major noncardiac surgery.

<table>
<thead>
<tr>
<th>Study type: Retrospective cohort study</th>
<th>Inclusion criteria: All surgical pts at SF VAMC</th>
<th>1° endpoint: 30-d and 1-y mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 38,779 operations</td>
<td>Exclusion criteria: N/A</td>
<td>Results: Addition of BB therapy associated with reduction in 30-d OR: 0.52 (0.33–0.83; p=0.006) and 1-y OR: 0.64 (0.51–0.79; p&lt;0.0001) mortality</td>
</tr>
</tbody>
</table>

• Periop BB therapy based upon periop Cardiac Risk Reduction protocol is associated with a reduction in 30-d and 1-y mortality. Periop withdrawal of BB is associated with increased mortality.

<table>
<thead>
<tr>
<th>Study type: Retrospective cohort study</th>
<th>Inclusion criteria: Pts with IHD undergoing noncardiac surgery</th>
<th>1° endpoint: 30-d risk of MACE and all-cause mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 28,263 pts</td>
<td>Exclusion criteria: N/A</td>
<td>Results: Among pts with HF BB Rx HR: 0.78 (0.67–0.90) for MACE and all-cause mortality 0.80 (0.70-0.92) all-cause mortality; and with recent Hx MI HR: 0.60 (0.42–0.86) MACE, 0.80 (0.53–1.21) all-cause mortality</td>
</tr>
</tbody>
</table>

• Among pts with IHD undergoing noncardiac surgery, use of BB associated with lower risk of 30-d MACE and mortality only among those with HF or recent MI

<table>
<thead>
<tr>
<th>Study type: Prospective survey</th>
<th>Inclusion criteria: Pts 18 y and older undergoing peripheral vascular surgery</th>
<th>1° endpoint: 1-y mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 771 pts</td>
<td>Exclusion criteria: N/A</td>
<td>Results: 1 y BB use had lower mortality c/w non-BB users (HR: 0.4; 95% Cl: 0.2–0.7); BB withdrawal had increased mortality c/w nonusers (HR: 2.7; 95% Cl: 1.2–5.9)</td>
</tr>
</tbody>
</table>

• Periop BB use was independently associated with lower risk of 1-y mortality while periop withdrawal was associated with higher risk of 1-y mortality

<table>
<thead>
<tr>
<th>Study type: Retrospective cohort study</th>
<th>Inclusion criteria: Pts undergoing vascular surgery</th>
<th>1° endpoint: Long-term mortality, median follow-up 2.7 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 3,062 pts</td>
<td>Exclusion criteria: N/A</td>
<td>Results: Use of BB over study period c/w no BB reduced mortality (HR: 0.84; 95% Cl: 0.73–0.96; p=0.0106)</td>
</tr>
</tbody>
</table>

• The use of propensity-adjusted BB c/w use reduced long-term mortality by 16%

<table>
<thead>
<tr>
<th>Study type: Retrospective cohort analysis</th>
<th>Inclusion criteria: Pts undergoing major noncardiac surgery</th>
<th>1° endpoint: All-cause 30-d mortality and cardiac morbidity (cardiac arrest, or non-Q wave MI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 136,745 pts</td>
<td>Exclusion criteria: N/A</td>
<td>Results: BB therapy was associated with lower rates of 30-d all-cause mortality in pts with ≥2 Revised Cardiac Index Factors</td>
</tr>
</tbody>
</table>
### 2017 Hypertension Guideline Data Supplements

#### Exclusion criteria

**N/A**

#### Results

**BB exposure lower 30-d mortality in pts with 2 or more RCIF (RR: 0.63; 95% CI: 0.50–0.80; p<.001)**

#### Study type: Matched observational study

**Size:** 79,228 pts

#### Inclusion criteria

Pts with noncardiac surgery

#### Exclusion criteria

**N/A**

**1° endpoint:** Intraoperative and postoperative upper airway complications, in-hospital complications, and 30-d mortality

**Results:** ACEI usage was not associated with either 30-d mortality (OR: 0.93; 95% CI: 0.73–1.19; p=0.22)

- No association found between use of ACEIs and intraoperative or postoperative upper airway complications, in-hospital complications, or 30-d mortality

---

#### Study type: Review of observational and randomized studies

**Size:** 434 pts

#### Inclusion criteria

Adult pts, most >18 y, nonemergent surgery, using ACEI or ARA chronically

#### Exclusion criteria

**N/A**

**1° endpoint:** Hypotension requiring vasopressors at or shortly after induction of anesthesia

**Results:** Pts receiving preoperative ACEI or ARA more likely to develop hypotension requiring vasopressors. RR: 1.51; 95% CI: 1.14–2.01

- Pts receiving immediate preoperative ACEI or ARA were more likely to develop hypotension requiring vasopressors at or shortly after induction of anesthesia. Sufficient data were not present to assess other outcomes.

---

#### Study type: International prospective cohort

**Size:** 14,687 pts

#### Inclusion criteria

Pts at least 44 y undergoing noncardiac surgery requiring overnight hospital admission

#### Exclusion criteria

**N/A**

**1° endpoint:** 30-d all-cause death, stroke, or myocardial injury

**Results:** ACEI/ARB users who withheld ACEI/ARB in the 24 H before surgery were less likely to suffer death, MI or stroke 0.82; 95% CI: 0.70–0.96; p=0.01

- Withholding ACEI/ARB before major noncardiac surgery was associated with a lower risk of death and postoperative vascular events.

---

### Data Supplement 59. RCTs of Adherence and Compliance with Fixed Dose Combinations Regimens (Section 12.1.1)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**COMFORT**
Matsumura K, et al., 2012 (306) 22447014

**Aim:** Evaluate whether a combination pill of antihypertensive drugs improves medication adherence in hypertensive pts vs. use of single agents.

**Study type:** Multicenter, open, RCT at 29 sites in Japan. Adherence assessed by pill count.

**Size:** 207 pts

**Inclusion criteria:**
- ≥20 y agent with HTN
- Could be treated with an ARB and diuretic

**Exclusion criteria:**
- Extremely high BP (≥200 mm Hg SBP or ≥120 mm Hg DBP)
- Serious renal or liver dysfunction
- Taking >4 tablets, excluding study drugs

**Intervention:** Combination tablet of (Losartan 50 mg/HCTZ 12.5 mg; n=103)

**Comparator:** ARB and a thiazide diuretic as separate agents (n=104)

**1st endpoint:** Adherence rates as assessed by pill count 98% in both groups (p=0.89) over entire study period (0–6 mo).

**Safety endpoint:** No differences in serious adverse events (1% vs. 1%; p=0.99) or mild adverse events (6% vs. 10%; p=0.31)

**2nd endpoint:** No significant difference in mean SBP and DBP (0.3 and 0.1 mm Hg respectively; p=0.84/0.96).

**Study limitations:**
- Adherence rate very high for both groups and likely does not represent real-world rates.
- Short duration (6 mo) and thus does not provide much information on medication persistence (continuation of drug therapy long-term)
- Possible selection bias with 2 run-in phases
- Different healthcare system (Japan) with medications provided through public medical insurance

---

**Data Supplement 60. Nonrandomized Trials, Observational Studies, and/or Registries of Antihypertensive Medication Adherence Strategies (Section 12.1.1)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Schroeder K, et al., 2004 (307) 15078641 | **Study type:** Systematic review of RCTs. **Size:** 38 studies testing 58 different interventions containing data on 15,519 pts; 9 studies assessed simplification of dosing regimen | **Inclusion criteria:**
  - Database search for all RCTs, all languages, in Cochrane Controlled Trials Register, MEDLINE, EMBASE, and CINAHL (all y through 2002)
  - Population of interest were pts with essential HTN in primary care, outpatient, or community setting
  - Interventions aimed to increase adherence to BP-lowering medication
  - Reported outcome was adherence | **1st endpoints:** Adherence as assessed by pill counts, self-report, or electronic monitoring system
  **Results:**
  - 9 studies assessed simplification of dosing regimen, 7 of which compared adherence associated with frequency of administration (twice daily vs. once daily [n=6] or 3 times daily vs. twice daily [n=1]).
  - All studies examining effect of dosing frequency demonstrated improved adherence (range: 8%, 19.6% improvement; p<0.01 for all). | • Adherence to antihypertensive medication was significantly improved with once daily vs. multiple daily dosing regimens. Most studies used an electronic monitoring system. Limitations in the systematic review include heterogeneity in pts, interventions, and outcomes, and the majority of studies were of low quality. In addition, different definitions of adherence in the RCTs make it difficult to examine the precise relationship of adherence to BP control. |
| Iskedjian M, et al., 2002 (308) | **Study type:** Meta-analysis  
**Size:** 8 studies involving a total of 11,485 observations (1,830 for once daily dosing, 4,405 for twice daily dosing, 4,147 for >twice daily dosing, 9,655 for maximum daily dose). | **Inclusion criteria:**  
- 1° studies that compared adherence rates between different dosing regimens  
- Prospective trials (e.g., RCTs, cohort studies), retrospective studies, database analyses  
- Any published study using an instrument to measure adherence, but must have used some measurement tool in each comparison group.  
- Adherence rates to solid, oral dosage form for treatment of HTN of at least 10 wk duration | **1° endpoints:** Medication adherence rates compared between once daily and maximum daily dose, once daily and twice daily, twice daily and >twice daily  
**Results:**  
- Average adherence rates with once daily dosing were greater compared to maximum daily dose regimens (91.4% [SD=2.2%] vs. 83.2% [SD=3.5%]; z=4.46; p<0.001.)  
- Average adherence rates with once daily dosing were greater compared to twice daily dosing regimens (92.7% [SD=2.3%] vs. 87.1% [SD=2.9%]; z=2.22; p=0.026.)  
- There was no difference in adherence rates between regimens dosed twice daily or greater than twice daily (90.8% [SD=4.7%] vs. 86.3% [SD=6.7%]; z=1.82; p=0.069). | **Antihypertensive regimens dosed once daily were associated with significantly improved adherence compared to twice daily or maximum daily dose regimens.** |
| Claxton AJ, et al., 2001 (309) | **Study type:** Systematic review  
**Size:** 76 studies | **Inclusion criteria:**  
- Database search of MEDLINE, Psychinfo, HealthStar, Health & Psychological Instruments, and Cochrane library 1986–2000  
- Compliance rates assessed using electronic monitoring device  
- Data pooled to calculate mean compliance with once daily, twice daily, 3 times daily, and 4 times daily dosing regimens | **1° endpoints:** Mean compliance rates by prescribed dose regimen  
**Results:**  
- 26 studies evaluated CVD; 17 HTN only.  
- For all studies, mean dose-taking compliance defined as number of appropriate doses taken during each d was 79% for once daily, 69% for twice daily, 65% for 3 times daily and 51% for 4 times daily dosing (p≤0.001 for once daily vs. 3 times daily, once daily vs. 4 times daily, and twice daily vs. 4 times daily; no statistically significant between once daily vs. twice daily or twice daily vs. 3 times daily dosing). | **Medication compliance as measured by electronic monitoring devices were improved with less frequent dosing. Once-daily dosing was associated with the greatest rate of compliance. Limitations of this analysis include heterogeneity of studies and disease states studied.** |
| Sherrill B, et al., 2011 (310) 22142349 | **Study type:** Meta-analysis to compare health resource use cost, adherence, and persistence between groups of pts taking antihypertensives as SPCs vs. free-equivalent components.  
**Size:** 15 retrospective database studies in HTN | **Inclusion criteria:**  
- Database search of PubMed, EMBASE, The Cochrane Library, and EconLit (no limit on publication dates)  
- English-language publications  
- Clinical trial or observational study (e.g., database or registry) that compared SPC with free-equivalent components  
- Data on compliance, adherence, persistence, and/or health care costs and/or resource use (unadjusted cost analyses)  
**1° endpoints:** Health care costs, adherence, persistence  
**Results:**  
- All-cause total costs were estimated to be lower with SPC vs. free-equivalent components free-equivalent components by $2,039 (95% CI: $1030, $3047) in 2009 dollars and HTN/CV-related costs were lower by $709 (95% CI: $117, $1,032), 2009 dollars.  
- Adherence as measured by MPR was greater for SPC vs. free-equivalent components (total inverse variance 13.31; 95% CI: 8.26–18.35).  
- Persistence to therapy was greater with SPC than free-equivalent components (risk ratio: 2.13; 95% CI: 1.11–4.09)  
- Medication adherence and persistence was significantly greater with SPC than free-equivalent components. Costs were also significantly lower with SPC than with free-equivalent components. However, cost data should be interpreted with caution considering unadjusted costs were used in this meta-analysis. In addition, heterogeneity was present in analyses of each outcome. This meta-analysis did not include the observational study by Yang et al. as that study used an adjusted analysis methodology.  
**Yang W, et al., 2010 (311) 20629600** | **Study type:** Observational analysis using multivariate regression-adjusted analysis to compare compliance/persistence, health care resources, and cost associated with SPC or FC antihypertensives over 6 mo study period both nationally and at the state level.  
**Size:** 579,581 pts (382,476 SPC and 197,375 FC) identified in MarketScan Database (2006–2008) | **Inclusion criteria:**  
- Pts in MarketScan Database  
- Diagnosis of HTN based on ICD-9 codes 401.xx and 405.xx  
- Pts initiated on any of the following SPC treatments or the same FC: ARB + CCB, ARB + HCTZ, ACEI + HCTZ  
- For SPC cohort, at least 1 prescription filled in observational window  
- For FC cohort, pts filled individual components separately within 15 d of each other and with 15 d overlap of supply  
- ≥18 y  
**Endpoints:**  
- 1° outcome: Compliance and persistence with the index therapy (SPC or FC) measured by MPR within 6 mo of index date  
- 2° outcomes: Healthcare resource utilization (number of all-cause hospitalizations, number ER visits, number CV hospitalizations, and CV-related ER visits) and health care costs (all cause medical costs, all-prescription drug costs, CV-related medical service costs, and HTN prescription-related drug costs)  
**Results:**  
- Compliance nationally as assessed by MPR was improved in pts taking SPC vs. FC antihypertensives (difference=11.6%; 95% CI: 11.4%–11.7%).  
- This large observational study found that medication compliance/persistence to antihypertensives was improved with SPC compared to FC using an adjusted multivariate regression model. All-cause medical costs were also decreased with the use of SPC antihypertensives, although prescription costs were greater. |
<table>
<thead>
<tr>
<th>Gupta, et al., 2010 (312) 20026768</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study type:</strong> Meta-analysis to assess compliance, adherence, persistence, BP control, and safety with FDC antihypertensives compared to their free components</td>
</tr>
<tr>
<td><strong>Size:</strong> 15 studies (n=32,331) with ≥1 evaluated outcome; 3 cohort studies and 2 trials of compliance (n=17,999); 3 cohort studies on persistence (n=12,653); 5 trials of adverse drug effects of FDCs (n=1.775); 9 trials of BP change (n=1,671)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Inclusion criteria:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Database search of PubMed (1966–February 2008), Web of Science (1970 to April 2008), and the Cochrane Controlled Trial (1800–April 2008).</td>
</tr>
<tr>
<td>Clinical trials or cohort studies included if published in English and compared an FDC of hypertensive agents with free-drug combination of its components.</td>
</tr>
<tr>
<td>Extractable data reported including compliance (or adherence), persistence, BP-lowering effects, adverse effects</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>1st endpoint:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Compliance (or adherence) and persistence to therapy</td>
</tr>
<tr>
<td>BP-lowering efficacy</td>
</tr>
<tr>
<td>Adverse effects</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Results:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of FDC therapy was associated with a 21% increase in compliance, both in the cohort studies (n=5) and clinical trials (OR: 1.21; 95% CI: 1.00–1.47) and (OR: 1.21; 95% CI: 1.03–1.43). There was a 50% increase in persistence with therapy, but this was not statistically significant (OR: 1.54; 95% CI: 0.95–2.49). Analysis of all 6 retrospective cohort studies indicated that FDC therapy was associated with a 29% increase in compliance and persistence to therapy (OR: 1.29; 95% CI: 1.11–1.50). No sign of heterogeneity of publication bias.</td>
</tr>
<tr>
<td>FDC therapy was associated with a nonsignificant reduction in SBP (-4.1 mm Hg; 95% CI: -9.8–1.5 mm Hg; p=0.15) and DBP (-3.1 mm Hg; 95% CI: -7.1–0.9 mm Hg; p=0.13) compared to free-drug combinations. Strong evidence of heterogeneity but no evidence of publication bias.</td>
</tr>
<tr>
<td>FDC therapy was associated with a 20% nonsignificant decrease in adverse effects (OR:</td>
</tr>
</tbody>
</table>

| **• Continuous eligibility in database for 6 mo after index date** |
| **• Valid 3-digit zip code in database** |

| **• Treatment discontinuation rates were lower with SPC vs. FC antihypertensives (40.7% vs. 59.3%; 95% CI: 0.46–0.48).** |
| **• There were fewer all-cause hospitalizations and ER visits in SPC vs. FC pts IRR: 0.77 (95% CI: 0.75–0.79) and IRR: 0.87 (95% CI: 0.86, 0.89), respectively.** |
| **• All-cause medical costs were reduced with SPC vs. FC (-$208; 95% CI: -$302– -$114), but antihypertensive prescription costs were greater ($53; 95% CI: $51–$55).** |

© 2017 American College of Cardiology Foundation and American Heart Association, Inc. 217
<table>
<thead>
<tr>
<th>Study, Year, and Country</th>
<th>Study type</th>
<th>Inclusion criteria</th>
<th>I^o endpoint</th>
<th>Results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangalore S, et al., 2007 (313) 17679131</td>
<td>Meta-analysis to assess if compliance is improved with FDC therapy compared to free-drug regimens in chronic diseases including HTN, HIV, tuberculosis, and DM</td>
<td>Database search of MEDLINE (1966–2005)</td>
<td>Compliance, considered as either adherence or persistence to medication therapy</td>
<td>Use of FDC therapy was associated with a 26% decreased risk of noncompliance vs. free-drug combinations (pooled RR: 0.74 (95% CI: 0.69, 0.80), p&lt;0.0001) in all diseases states. There was no evidence of heterogeneity.</td>
<td>Marked heterogeneity in how compliance was measured among studies</td>
</tr>
<tr>
<td>Kumagai N, et al., 2013 (314) 23072348</td>
<td>Prospective, multicenter, observational study of pts converted from free-drug combinations of an ARB and amlopidine to the same product as a FDC.</td>
<td>Outpatients with essential HTN, Self-measured home BP, Prescribed FDC of an ARB (8 mg candesartan, 80 mg valsartan, or 40 mg telmisartan) and 5 mg) and 5 mg amlopidine. Pts divided into 2 groups: Group 1 received an ARB and amlopidine in the morning as free drug combinations and Group 2 took ARB in the morning and amlopidine in the evening. After 1 mo, both groups converted to once daily FDC product.</td>
<td>Adherence to antihypertensive therapy as measured by self-reporting, Self-monitored BP measurements and clinical BP measurements before and after switch to FDC antihypertensive therapy.</td>
<td>Use of FDC with an ARB and amlopidine was associated with improved adherence, lower BP, and decreased health care costs compared to free-drug combination therapy. Limitations to this study include the observational design, low numbers of pts, use of self-reported adherence, short follow-up period, non-U.S. country with a different health care system (Japan), and very high baseline rate of adherence (~95%) as well post-switch to FDC (~99%), which is not what is seen in usual practice.</td>
<td>• Use of FDC combination therapy in hypertensive pts was associated with a 24% decreased risk of noncompliance compared to use of free-drug regimens.</td>
</tr>
</tbody>
</table>
compared to the group without improved drug adherence (~4 mm Hg; p<0.05).

- Healthcare costs were decreased by 31% per pt from 17,075 yen ($216.93 USD; Aug. 2012) to 11,815 yen ($150.10 USD; Aug. 2012) over the 3 mo period.

### Mazzaglia G, et al., 2009 (315) 19805653

<table>
<thead>
<tr>
<th>Study type: Retrospective cohort</th>
<th>Inclusion criteria: Newly diagnosed and treated hypertensive pts ≥35 y initially free of CVD identified from Italian general pt registry.</th>
<th>1° endpoint: Describe adherence to antihypertensive therapy and its associate with concurrent drug use, comorbidities, and CV risk factors. Adherence was estimated by calculating the proportion of days which pt had pills available during the follow-up.</th>
<th>• High adherence was associated with a 38% decreased risk of CV events compared with low adherence. Combination therapy associated with 29% improved adherence compared to monotherapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 18,046 pts</td>
<td>Exclusion criteria: CHD, cerebrovascular disorders, congestive HF who had been hospitalized for CABG or coronary angioplasty, those recovered in a cardiology ward before index diagnosis, incident CV event in the 180 d after index diagnosis, pts receiving nitrates</td>
<td>Results: At baseline (6 mo after index diagnosis), adherence rates were high (≥80% proportion of days covered) in 8.1% of pts, intermediate (40-79% proportion of d covered) in 4.5%, and low (≤40% proportion of d covered) in 51%. Multiple drug treatment (1.62; 95% CI: 1.43–1.83), dyslipidemia (1.52; 95% CI: 1.24–1.87), DM (1.40; 95% CI: 1.15–1.71), obesity (1.50; 95% CI: 1.26–1.78) and antihypertensive combination therapy (1.29; 95% CI: 1.15–1.45) were associated with high adherence to treatment (p&lt;0.001).</td>
<td></td>
</tr>
</tbody>
</table>

### Jackson KC, et al., 2008 (316) 18803997

<table>
<thead>
<tr>
<th>Study type: Retrospective cohort study</th>
<th>Inclusion criteria: ≥18 y and diagnosis of HTN ● Benefit-eligible for pharmacy claims ● Antihypertensive naive (no prescription fill for antihypertensive drug ≥110 d prior to index date) ● Received 1 of 3 regimens: 1.) 2 pill regimen with valsartan + amlodipine, 2.) 2-pill regimen with valsartan/HCTZ in FDC + amlodipine, 3.) 3-pill regimen with valsartan + HCTZ + amlodipine as free-drug components</th>
<th>1° endpoint: Adherence as measured by MPR</th>
<th>• An inverse relationship existed between the number of pills and adjusted MPR, with lower adherence noted in 3-pill regimens vs. 2-pill regimens.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size: 908 pts</td>
<td>Results: 224 pts received valsartan + amlodipine, 619 received valsartan/HCTZ + amlodipine, and 65 received valsartan + HCTZ + amlodipine. MPR ratios were 75.4% with valsartan + amlodipine, 73.1% with valsartan/HCTZ + amlodipine, and 60.5% with valsartan + HCTZ + amlodipine (p=0.005). Older age was associated with improved MPR (75.2% for those ≥64 y. vs. 69.6% for 18 to &lt;36 y; p=0.023).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Exclusion criteria
Pts who received <2 prescription fills, did not continuously have prescriptions refilled for each medication, or switched from 1 medication to another without a time overlap.

### Study type: Retrospective cohort study

### Size: 5,704 pts

### Inclusion criteria:
- 65–100 y on index date
- Received at least 2 prescriptions for study drugs (amlodipine/benazepril FDC n=2336) or DHP-CCB and ACEI as separate agents [n=3368] between 1997–2001
- Continuously eligible for Medicaid for 12 mo following index date

### Exclusion criteria:
- >180 d of hospitalization
- <30 d of study drug supply
- Any nursing home claims during the 12 mo follow-up period

### 1st endpoint: Determine rates of compliance (MPR) and total costs of care (defined as sum of payments for Medicaid claims for ambulatory care, hospital claims, prescription drug claims, and Medicare ross claims) in pts treated with FDC amldipine/benazepril vs. a DHP-CCB and ACEI prescribed as free-combination agents.

### Results:
MPR was significantly higher for pts receiving FDC compared with free-combination therapy (63.5% vs. 49%; p<0.05). Average total cost of care (2002 value) was $3,179 with FDC compared to $5,236 with free-combination agents (p<0.0001). Multivariate regression analysis indicated an increase of 0.5% for each 1-unit increase in MPR, and for each comorbidity there was a 10.4% increase. Total cost of care for FDC group was 12.5% lower than free-combination group (p<0.003).

- FDC combination therapy with amldipine/benazepril was associated with better compliance than a DHP-CCB and ACEI as free-combination agents. FDC was also associated with lower total costs of care.

### Data Supplement 61. RCTs and Meta-analysis on Strategies to Promote Lifestyle Modification (Section 12.1.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2nd Endpoint; Study Limitations; Adverse Events Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artinian NT, et al., 2010 (318) 20625115</td>
<td>Aim: To provide evidence-based recommendations on implementing PA and dietary interventions among adults,</td>
<td>Inclusion criteria: Included studies were limited to adult pts ≥18 y; English language; randomized controlled or quasi-experimental designs</td>
<td>Cognitive-behavioral strategies for promoting behavior change including Goal Setting, Self-Monitoring, Frequent and Prolonged Contact, Feedback and Reinforcement, Self-Efficacy Enhancement, Incentives, Modeling, Problem Solving, Relapse Prevention, Motivational</td>
<td>Variable, too numerous to summarize here.</td>
<td>Variable, too numerous to summarize here.</td>
</tr>
</tbody>
</table>
including adults of racial/ethnic minority and/or socioeconomically disadvantaged populations.

**Study type:** Literature review, evidence synthesis and recommendations using ACC/AHA evidence grading.

**Size:** 70 studies, including 65 RCTs published from 1997–2007.

or meta-analyses; focused on the effects of diet or PA interventions on weight, BP, PA level, aerobic and resistance exercise, fitness, or consumption of calories, fruits, vegetables, fiber, total fat, saturated fat, cholesterol or salt

**Exclusion criteria:** Feeding trials, observational studies of specific nutrients, and observational studies of aerobic capacity were excluded. Given the varying goals and outcomes of the different identified intervention studies, when possible we used a common measure of effect size to quantify and compare the success of each intervention.

**Comparator:** Usual care or other comparison group

---

### Data Supplement 62. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Structured, Team-based Care Interventions for Hypertension Control (Section 12.2)

<table>
<thead>
<tr>
<th>Document</th>
<th>Inclusion criteria</th>
<th>Comparator</th>
<th>Endpoint Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eckel RH, et al., 2013 (319) 24239922</td>
<td>N/A</td>
<td>Usual care or other comparison group</td>
<td>N/A</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
| Brownstein JN, et al., 2007 (320) 17478270 | **Aim:** Examine the effectiveness of community health workers in supporting the care of pts with HTN |
| **Study type:** Systematic review |
| **Size:** 14 studies, including 8 RCTs |
| **Inclusion criteria:** Studies examining the effects of an intervention involving community health workers on the care of pts with HTN |
| **Exclusion criteria:** Studies that focused exclusively on outcomes among community health workers and those involving peers who merely led support groups |
| **Intervention:** Community health workers as HTN care team members. Community health workers were broadly defined as health workers who were trained as part of an intervention, had no formal paraprofessional designation, and had relationship with the community being served. The community health workers, predominantly women, were recruited from the community, and resembled the pts in race/ethnicity and socioeconomic background. Roles included: (1) providing health education and information to pts and families; (2) ensuring that pts received services necessary for BP control; (3) providing direct services, including measuring and monitoring BP; (4) providing social support to the pts and their family members; and (5) serving as mediators between pts and the healthcare and social service systems. |
| **Comparator:** Usual care or other comparison group |
| **1° endpoint:** Differences between groups in BP control groups favored community health worker groups over control and ranged from 4%–46% over 6–24 mo, across 7 RCTs; though 1 RCT showed no difference between groups. |
| **Safety endpoint:** N/A |
| **2° endpoints:** |
| • Appointment keeping: significant improvements ranging from 19%–39% (relative changes) over 12–24 mo in community health worker intervention |
| • Adherence to medications: Range of findings included significant improvement in community health worker intervention group compared with control, between-group differences ranged from 8%–14%; 26% greater compliance among pts receiving intense community health worker interventions; and 17% significant improvement in adherence to medication with counseling by community health workers. |
| **Limitations:** High level of heterogeneity of the populations, settings, interventions, and outcomes |
| **Summary:** Including community health workers as part of the HTN care team resulted in significant improvements BP control, appointment keeping, and adherence to antihypertensive medications, primarily among low income, urban African Americans. |
| Carter BL, et al., 2009 (321) 19858431 | **Aim:** Determine potency of interventions for BP involving nurses and pharmacists  
**Study type:** Meta-analysis  
**Size:** 37 RCTs of team-based HTN care involving nurse or pharmacist intervention | **Inclusion criteria:** RCT of team-based HTN care involving nurse or pharmacist intervention  
**Exclusion criteria:** Absence of above | **Intervention:** Team-based HTN care involving nurse or pharmacist intervention in nearly all studies involving nurses or pharmacists in clinics, consistent and dedicated case management activities were provided that were distinct from traditional nursing or pharmacist duties. However, pharmacists in community pharmacies usually had to incorporate the intervention with traditional medication dispensing functions.  
**Comparator:** Usual care | **1° endpoint:** OR (95% CI) for controlled BP were nurses: 1.69 (1.48, 1.93); pharmacists within primary care clinics: 2.17 (1.75, 2.68); and community pharmacists: 2.89 (1.83, 4.55). Mean (SD) reductions in SBP were: nurse intervention, 5.84 (8.05) mm Hg; pharmacists in clinics, 7.76 (7.81) mm Hg; and community pharmacists, 9.31 (5.00) mm Hg. There were no significant differences between nurse and pharmacist effects (p ≥0.19).  
**1° Safety endpoint:** N/A  
**Summary:** Interventions involving pharmacists or nurses were associated with significantly improved BP control. |
| --- | --- | --- | --- | --- |
| Clark CE, et al., 2010 (322) 20732968 | **Aim:** Review trials of nurse led interventions for HTN in primary care to clarify the evidence base, establish whether nurse prescribing is an important intervention | **Inclusion criteria:** RCT of nursing intervention for HTN  
**Exclusion criteria:** Absence of above | **Intervention:** Interventions were categorized as nurse support delivered by either telephone, community monitoring or nurse led clinics. These were held in either primary care or 2° care. 1 study used alternate  
**1° endpoint:** Compared with usual care, interventions that included a stepped treatment algorithm showed greater reductions in SBP (weighted MD -8.2 mm Hg (95% CI: -11.5—-4.9));  
**Summary:** Nurse led interventions that included a stepped treatment algorithm or nurse led prescribing showed significantly greater reductions of SBP and DBP than usual care. Telephone monitoring was associated with higher achievement of study targets for BP. Community monitoring showed lower |
<table>
<thead>
<tr>
<th>Study type: Meta-analysis</th>
<th><strong>Size:</strong> 32 RCTs of nursing intervention for HTN</th>
<th><strong>Study type:</strong> Systematic review</th>
<th><strong>Size:</strong> 52 studies of team-based primary care for pts with 1° HTN</th>
</tr>
</thead>
</table>

**Aim:** Examine current evidence on the effectiveness of team-based care in improving BP outcomes (update of prior systematic review)

**Inclusion criteria:**
- Study of team-based care; conducted in a high-income economy; reported at least 1 BP outcome of interest; included a comparison group or had an interrupted time-series design with at least 2 measurements before and after the intervention; targeted populations with 1° HTN or populations with comorbid conditions such as DM as long as the 1° focus of the intervention was BP control; and did not have interrupted time-series design or include more than 1° intervention.

**Intervention:** Team-based care was defined as adding new staff or changing the roles of existing staff to work with a PCP for HTN care. Team members who collaborated with pts and PCPs were predominantly nurses (28 studies); pharmacists (15 studies); both nurses and pharmacists (5 studies); or community health workers, integrated care managers, or behavioral interventionists (4 studies). Key roles included HTN medication management, active pt follow-up, and adherence and self-management support. Interventions were usually 1° endpoint:
- Proportion with controlled BP: Absolute percentage point (pct pt) change in pts with controlled BP from 33 studies comparing team-based care to usual care: median effect estimate was 12 pct pts (IQI=3.2–20.8 pct pts). Most individual effect estimates in the favorable direction were significant (p<0.05).
- Reduction in SBP (44 studies): The median reduction in SBP was 5.4 mm Hg (IQI=2.0–7.2 mm Hg). Most individual effect estimates were significant (p<0.05).
- Reduction in DBP: The overall median reduction in outcome SBP, greater reductions in SBP and DBP, and although pooling of data was not possible, greater achievement of study BP targets.

**Comparator:** Usual care

- Nurse prescribing showed greater reductions SBP, −8.9 mm Hg, (95% CI: −12.5– -5.3), and DBP, −4.0 mm Hg, (95% CI: −5.3– -2.7);
- Telephone monitoring showed higher achievement of BP targets (RR: 1.24; 95% CI: 1.08–1.43);
- Community monitoring showed greater reductions in (weighted MD) SBP, −4.8 mm Hg, (95% CI: -7.0– -2.7), and DBP, −3.5 mm Hg, (95% CI: −4.5– -2.5).

**Safety endpoint:** N/A
| **Exclusion criteria:** | Inclusion of populations with 2° HTN (e.g., pregnancy) or with a history of CVD (e.g., MI) | implemented across multiple settings in the healthcare system and in the community, where they were implemented in pharmacies and through home outreach visits. | DBP was 1.8 mm Hg (IQR=0.7–3.2 mm Hg) from 38 studies. | Number of team members added: Adding ≥2 members demonstrated larger improvements in the proportion of pts with controlled BP and reduction in DBP compared to adding only 1; median reductions in SBP were similar regardless of team size. | • Improvement in the proportion of pts with controlled BP was similar for studies from both healthcare and community settings. |
| **Safety endpoint:** | No harm to pts was identified from team-based care interventions in the included studies or the broader literature. | Comparator: Usual care Comparator: Usual care | Comparator: Usual care | | • Limitations: Included studies reported significant differences in pt demographics between intervention and comparison groups at baseline, possible contamination within intervention and comparison groups, and issues related to inadequate description of populations and implemented interventions. |

**Aim:** Assess effect of pharmacists interventions on BP and determine potential determinants of heterogeneity

**Study type:** Meta-analysis

**Size:** 39 RCTs were included with 14,224 pts

**Inclusion criteria:** RCT of pharmacist intervention delivered by a pharmacist alone or in collaboration with other healthcare professionals

| **Intervention:** | Pharmacist intervention delivered by a pharmacist alone or in collaboration with other healthcare professionals. Pharmacist interventions mainly included pt education, feedback to physician, and medication management. |
| **1° endpoint:** | Pharmacist interventions were associated with a large reduction in systolic and DBP of -7.6 mm Hg (95% CI: -9.0–-6.3 mm Hg) and -3.9 mm Hg (95% CI: -5.5–-2.8 mm Hg), respectively |

| **Safety endpoint:** | N/A |

**Summary:** There is strong evidence that team-based care is effective in improving BP outcomes, especially when pharmacists and nurses are part of the team.

**Summary:** Pharmacist interventions, alone or in collaboration with other healthcare professionals, improved BP management.

**Santschi V, et al., 2014 (324) 24721801**
<table>
<thead>
<tr>
<th>Study</th>
</tr>
</thead>
</table>
| **Aim:** Determine whether nurse-managed protocols are effective for outpatient management of pts with DM, HTN, and hyperlipidemia (HTN RCT outcomes only included here)  
**Study type:** Meta-analysis  
**Size:** 12 RCTs, with 10,362 pts, of nurse-managed protocols for outpatient management of HTN  
**Inclusion criteria:** RCT of nurse-managed protocols for outpatient management of HTN  
**Exclusion criteria:** Absence of above  
**Intervention:** Involvement of a registered nurse or a licensed practical nurse functioning beyond the usual scope of practice, such as adjusting medications and conducting interventions based on a written protocol. All studies used a nurse who titrated medications by following a protocol.  
**Comparator:** Usual care  
**1° endpoint:**  
- SBP and DBP decreased by 3.68 mm Hg (95% CI: 1.05–6.31 mm Hg) and 1.56 mm Hg (95% CI: 0.36–2.76 mm Hg), respectively, with high variability (I²>70%)  
- Nurse-managed protocols were more likely to achieve target BP than control protocols (OR: 1.41; 95% CI: 0.98–2.02), though difference was not significant and treatment effects were highly variable (Q 35.20; I²=74%).  
**Safety endpoint:** N/A  

**Summary:** Nurse-managed protocols for HTN care were associated with a mean decrease in SBP and DBP but not increase in HTN control.

<table>
<thead>
<tr>
<th>Study</th>
</tr>
</thead>
</table>
| **Aim:** Evaluate if a physician/pharmacist collaborative model would be implemented as determined by improved BP control and whether long-term BP control could be sustained  
**Study type:** Cluster RCT  
**Size:** 32 primary care offices from 15 states enrolled 625 pts with uncontrolled HTN; 54% from racial/ethnic minority groups and 50% with DM or CKD  
**Inclusion criteria:** Offices were required to have an onsite clinical pharmacist must have practiced in the office. Pts were eligible if they were English or Spanish speaking, ≥18 y with uncontrolled BP as measured by the SC on the baseline visit.  
**Exclusion criteria:** Absence of above  
**Intervention:** Pharmacist conducted medical record review and a structured interview with the subject, including 1) a medication history; 2) an assessment of knowledge of BP medications, dosages and timing, and potential side effects; and 3) other barriers to BP control (e.g., side effects and nonadherence). The model recommended a telephone call at 2 wk, structured face-to-face visits at baseline, 1, 2, 4, 6, and 8 mo and additional visits if BP remained uncontrolled. The pharmacist created a care plan with recommendations for the physician to adjust  
**Comparator:** Usual care  
**1° endpoint:** BP control at 9 mo was 43% in intervention offices compared with 34% in control group (adjusted OR: 1.57 (95% CI: 0.99, 2.50), p=0.059).  
**2° endpoints:**  
- The adjusted difference in mean SBP/DBP between the intervention and control groups for all pts at 9 mo was −6.1/−2.9 mm Hg (p=0.002 / p=0.005, respectively), and it was −6.4/−2.9 mm Hg (p=0.009 / p=0.044, respectively) in pts from racial or ethnic minorities.  
- BP control and mean BP were significantly improved in pts from racial minorities in intervention offices at 18 and 24 mo (p=0.048 and p<0.001) compared with the control group.  
**Summary:** Although the results of the 1° outcome (BP control) were negative, the key 2° endpoint (mean BP) was significantly improved in the intervention group. Thus, the findings for 2° endpoints suggest that team-based care using clinical pharmacists significantly...
therapy based on the JNC-7, and the BP goals were <140/90 mm Hg for uncomplicated HTN or <130/80 mm Hg for pts with DM or CKD. The pharmacists did not follow algorithms or protocols other than JNC-7. Physicians were free to accept or to reject any recommendation or to modify the plan. Recommendations to pts focused on medication education, improving adherence, and strategies to implement lifestyle modifications.

Comparator: Pharmacists in control offices were instructed to avoid intervention for study pts with HTN, but they could provide usual care curbside consultations if physicians specifically asked questions.

Study Acronym | Author | Year Published | Aim of Study; Study Type; Study Size (N) | Patient Population | Study Intervention (# patients) / Study Comparator (# patients) | Endpoint Results (Absolute Event Rates, P value; OR or RR; & 95% CI) | Relevant 2* Endpoint (if any); Study Limitations; Adverse Events Summary
--- | --- | --- | --- | --- | --- | --- | ---
Bardach NS, et al., 2013 (327) 24026600 | **Aim:** To assess the effect of P4P incentives on quality in EHR-enabled small practices in the • Participating clinics (n=42 for each group) had similar baseline characteristics, with | • A city program provided all participating clinics with the same EHR software with decision support | • Intervention clinics had greater adjusted absolute improvement in rates of appropriate antithrombotic prescription (12.0% vs. 9.2%, p < 0.01) | • Although the effect of the intervention was lower than the 10% improvement that we estimated a priori, the absolute risk reduction for BP control among pts with DM was 7.8% (NNT, 13). This
**Study type and size:** A cluster-randomized trial of small (<10 clinicians) primary care clinics in New York City from April 2009 through March 2010.

A mean of 4,592 (median, 2,500) pts at the intervention group clinics and 3,042 (median, 2,000) at the control group clinics. • Incentivized clinics were paid for each pt whose care met the performance criteria, but they received higher payments for pts with comorbidities, who had Medicaid insurance, or who were uninsured (maximum payments: $200/pt; $100,000/clinic). Quality reports were given quarterly to both the intervention and control groups.

<table>
<thead>
<tr>
<th>Study type</th>
<th>Sample size</th>
<th>Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-y, cross-sectional sample using pt EHRs.</td>
<td>251,590 pts ≥18 y.</td>
<td>Underlying HTN was defined as 2 or more abnormal BP readings ≥140/90 mm Hg and/or pharmaceutical treatment. Appropriate HTN diagnosis was defined by the reporting of ICD-9 codes (401.0–) and pt registry functionalities and QI specialists offering technical assistance. To identify prevalent and incident HTN cases in a large outpatient healthcare system, examine the diagnosis rates of prevalent and incident HTN, and identify clinical and demographic factors.</td>
<td>The prevalence of HTN was 28.7%, and the diagnosis rate was 62.9%. The incidence of HTN was 13.3%, with a diagnosis rate of 19.9%. Predictors of diagnosis for prevalent HTN included older age, Asian, African American, higher BMI, and increased number. Outpatient EHR diagnosis rates are suboptimal, yet EHR diagnosis of HTN is strongly associated with treatment. Targeted efforts to improve diagnosis should be a priority.</td>
</tr>
</tbody>
</table>

Banerjee D, et al., 2012 (328) 22031453

Limitations: Some clinics exited the program after randomization, with more control clinics leaving than intervention clinics. Additionally, this intervention occurred in the setting of a voluntary QI program. This may reflect a high level of intrinsic motivation to improve among practices in the study, as demonstrated by engagement with the QI specialists.
Factors associated with HTN diagnosis were assessed through multivariate analyses of pt clinical and demographic characteristics.

Factors associated with appropriate HTN diagnosis.

ABP readings. Predictors for incident HTN diagnosis were similar. In pts with 2 or more abnormal BP readings, HTN diagnosis was associated with significantly higher medication treatment rates (92.6% vs. 15.8%; p<0.0001).

### Aim:
Study the effect of a multipronged, system-based, QI approach on HTN control.

### Study type:
Observational

### Size:
All pts with HTN in the KPNC system were included

#### Inclusion criteria:
350,000 pts in the KPNC system with HTN in 2001, increasing to 650,000 in 2009

#### Eligibility:
- ≥2 HTN diagnoses coded in primary care visits in the prior 2 y
- ≥1 primary care HTN diagnoses and 1 or more hospitalizations with a 1° or 2° HTN diagnosis in the prior 2 y
- ≥1 primary care HTN diagnoses and 1 or more filled prescriptions for HTN medication within the prior 6 mo, or
- ≥1 primary care HTN diagnoses and 1 or more stroke-related hospitalizations or a history of coronary disease, HF, or DM

#### Intervention:
KPNC HTN Program includes:
- HTN registry
- HTN control monitoring and feedback system
- Evidence-based practice guidelines
- Medical assistant BP recheck program
- Promotion of single polypill formulation (lisinopril-hydrochlorothiazide)

#### Comparator:
Insured pts in California from 2006–2009 who were included in the HEDIS commercial measurement by California health insurance plans participating in the NCQA quality measure reporting process. A 2° comparison group was included to obtain the reported national mean NCQA HEDIS commercial rates of HTN control.

#### 1° endpoint:
- HTN control rates in KPNC pts with HTN improved from 43.6% (95% CI: 39.4%, 48.6%) in 2001 to 80.4% (95% CI: 75.6%, 84.4%) by the end of the study period (p<0.001 for trend).
- By comparison, national mean NCQA HEDIS commercial measurement HTN control increased from 55.4%–64.1%.
- California mean NCQA HEDIS commercial rates of HTN control were similar to those reported nationally from 2006–2009 (63.4%–69.4%).

#### 1° Safety endpoint:
N/A

A system-based approach to HTN control that includes performance measurement and QI strategies led to a significant improvement in HTN control (80%, compared to 44% baseline control) in a large population of pts in a managed care health plan.

---

© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
Rakotz MK, et al., 2014 (330) 25024244

| Aim: The goal of this study was to develop a technology-based strategy to identify pts with undiagnosed HTN in 23 primary care practices and integrate this innovation into a continuous QI initiative in a large, integrated health system. | Of the 139,666 active adult primary care pts in these 23 practices, 47,822 already had a diagnosis of HTN, white-coat HTN, pre-HTN, or elevated BP. The 3 screening algorithms for undiagnosed HTN were applied to the remaining pts' EHRs. There were 1,586 pts who met the criteria of 1 or more of the algorithms and were therefore considered at risk for undiagnosed HTN. | In phase 1, we reviewed EHRs using algorithms designed to identify pts at risk for undiagnosed HTN. We then invited each at-risk pt to complete an automated office BP protocol. In phase 2, we instituted a QI process that included regular physician feedback and office-based computer alerts to evaluate at-risk pts not screened in phase 1. Study pts were observed for 24 additional mo to determine rates of diagnostic resolution. After phase 1, we established a continuous QI initiative to further evaluate pts who remained at risk for undiagnosed HTN. In this 24-mo follow-up phase (phase 2), all primary care physicians received monthly lists of their pts who continued to be at risk for undiagnosed HTN. | Of the 1,033 at-risk pts who remained active during phase 2, 740 (72%) were classified by the end of the follow-up period: 361 had HTN diagnosed, 290 had either white coat HTN, pre-HTN, or elevated BP diagnosed, and 89 had normal BP. By the end of the follow-up period, 293 pts (28%) had not been classified and remained at risk for undiagnosed HTN. | Although we used multiple algorithms to identify pts with elevated BP readings, it is unlikely that we identified all pts with undiagnosed HTN. |
These pts were contacted by staff via telephone or letter to arrange a follow-up appointment. These pts remained on the physicians’ lists until an automated office BP evaluation was completed or an ICD-9 diagnosis was entered into the chart that indicated the pt's at-risk status had been resolved. In addition, when an at-risk pt arrived for an office visit for any reason, a best practice advisory was prominently displayed on that pt's EHR screen to notify the medical assistant and physician that an automated office BP measurement was needed.

| Borden WB, et al., 2014 (331) 25447261 |
| A**im**: The purpose of this study was to examine the effect of the 2014 expert panel BP management recommendations on pts managed in U.S. ambulatory CV practices. |
| • Using the National CV Data Registry PINNACLE Registry, we assessed the proportion of 1,185,253 pts who met the 2003 and 2014 panel recommendations, highlighting the populations of pts for whom the BP goals changed. |
| N/A |
| • Of 1,185,253 pts in the study cohort, 706,859 (59.6%) achieved the 2003 JNC-7 goals. Using the 2014 recommendations, 880,378 (74.3%) pts were at goal. Among the 173,519 (14.6%) for whom goal achievement changed, 40,323 (23.2%) had a prior stroke or TIA, and 112,174 (64.6%) had CAD. In addition, the average Framingham risk score in... |
| • Among U.S. ambulatory cardiology pts with HTN, nearly 1 in 7 who did not meet JNC-7 recommendations would now meet the 2014 treatment goals. |
this group was 8.5 ± 3.2%, and the 10-y atherosclerotic CVD risk score was 28.0 ± 19.5%.

---

### Data Supplement 64. RCTs, Meta-analyses, and Systematic Reviews on the Effect of Telehealth Interventions to Improve Hypertension Control (Section 12.3.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2°Endpoint (if any); Study Limitations; Adverse Events</th>
<th>Summary</th>
</tr>
</thead>
</table>
| Burke LE, et al., 2015 (332) 26271892 | **Aim**: Review of the Scientific Literature on mHealth Tools Related to CVD Prevention  
**Study type**: Systematic review  
**Size**: 69 studies of the use of mobile technologies to reduce CVD risk behaviors | **Inclusion criteria**  
Studies of electronic and mobile technology tools in CV prevention; published from 2004–2014 in English language; enrolling adults except for smoking cessation, for which adolescents were also included; conducted in the U.S. and in developed countries.  
**Exclusion criteria**: Absence of above. | **Intervention**: Mobile technologies to reduce CVD risk behaviors—varied across studies  
**Comparator**: Varied across studies. | **1° endpoint**: Varied across studies.  
**1° Safety endpoint**: N/A | mHealth or mobile technologies have the potential to transform the delivery of health-related messages and ongoing interventions targeting behavior change. Moreover, the use of monitoring devices (e.g., Bluetooth-enabled BP monitors and blood glucose monitors) permits the sharing of important pt self-management parameters with healthcare providers in real time and the delivery of feedback and guidance to pts when they need it. Furthermore, using mHealth tools for monitoring provides the clinician data that far exceed what can be measured in the brief clinical encounter and reflect the status of physiological or behavioral measures in the person’s natural setting. |
| Liu S, et al., 2013 (333) 23618507 | **Aim**: Assess the efficacy of e-counselling in reducing BP  
**Inclusion criteria**: 1) Trials that investigated the effect of Internet-based lifestyle interventions on SBP and DBP; 2) trials that included | | **Intervention**: Internet-based intervention as preventive e-counselling or advice using Web sites or e-mails to modify exercise or diet as a | **1° endpoint**: MD in BP reduction (Internet-based – usual care); SBP: -3.8 mm Hg (95% CI: -5.63– -2.06), I²=61 | • Behavior change techniques that were used in more than 50% of the successful Internet-based interventions included the following: providing information on consequences of behavior in general |
**Study type:** Systematic review, meta-analysis  
**Size:** 13 RCTs or case-control studies  

supplemental components such as mobile text messages, telephone, or in-person support, 3) intervention duration of at least 8 wk, and 4) SBP and DBP reported as 1° or 2° outcome, measured at a clinic or office.

**Exclusion criteria:** Absence of above.

means of improving BP control. These Internet-based interventions were primarily self-guided, and access was gained via desktop computer, laptop, tablet, or smart phone. The duration of each intervention had to be at least 8 wk in order to achieve clinically meaningful outcomes, including the pt's ability to learn and adhere to complex new behaviors, and to allow for sufficient time to demonstrate a stable reduction in BP. The majority (9/13) of interventions had supplemental components that were not internet-based, such as text messages, in-person visits, and live support and 10/13 targeted both exercise and diet behaviors.

**Comparator:** Usual care with no internet-based strategy.

**Influence of intervention attributes:**

- **Intervention duration:**  
  - Long-term (≥6 mo) intervention: SBP -5.8 mm Hg (95% CI: -4.3--4.1)  
  - DBP mean reduction: results not reported, not statistically significant.

- **# of behavior change techniques:**  
  - ≥5 behavior change techniques: SBP -5.92 mm Hg (95% CI: -7.43--4.42) / DBP -2.45 mm Hg (95% CI: -3.50--1.41)  
  - <5 behavior change techniques: SBP -2.69 mm Hg (95% CI: -4.61--0.78) / DBP -0.02 mm Hg (95% CI: 1.20--1.17)

**1° Safety endpoint:** N/A

**Omboni S, et al., 2013 (334)**  

**Aim:** Review data from RCTs on the effectiveness of HBPT vs. usual care with respect to improvement of BP control, healthcare resources utilization and costs,  

**Inclusion criteria:**  
- English language  
- Published up to Feb. 2012  
- RCT testing HBPT vs. usual care.

**Intervention:** HBPT had to be based on the use of an electronic automated BP monitor storing values obtained at the pt's home and transferring them to a remote computer.

**1° endpoint:** Compared to usual care, HBPT improved:  
- Office SBP by 4.71 mm Hg (95% CI: 6.18--3.24; p<0.001; I²=52.2%; p=0.003  
- Office DBP by 2.45 mm Hg (95% CI: 3.33--1.57; p<0.001; I²=40.4%; p=0.048

**Limitations:**  
- HBPT intervention features (telemonitoring systems and self-monitoring programs) as well as inclusion criteria and demographic and clinical characteristics of the comparative groups varied across
pt's quality of life and adverse events.

**Study type:** Meta-analysis

**Size:** 23 unique RCTs with 7037 pts (though not all studies reported on all outcomes of interest)

**Exclusion criteria:** Absence of above through a telephone line (wired or wireless), a modem or an Internet connection. At least 1 self BP measurement had to be available for each pt in the intervention group.

**Comparator:** Usual care

- Office BP Control (<140/90 mm Hg nondiabetic pts and <130/80 mm Hg diabetic pts): RR: 1.16 (95% CI: 1.04–1.29; p<0.001); I²=69%; p<0.001

**2° endpoint:** Compared to usual care, HBPT improved:
- Greater prescription of antihypertensive medications: weighted MD 0.40 (95% CI: 0.17–0.62; p<0.001); I²=84.2%; p<0.001
- Lower number of office visits: weighted MD -0.18 (95% CI: -0.37–0.00); I²=32.7%; p=0.146
- Quality of life physical component of SF-12 or SF-36 questionnaire: weighted MD 2.78 (95% CI: 1.15–4.41); I²=0.0%; p=0.853
- There was no difference between HBPT and usual care in:
  - Therapeutic adherence [92% HBPT vs. 90% usual care; between-group difference +1.30% (95% CI: 2.31–4.90; p=0.481), I²=0.00%; p=0.888]
  - Quality of life mental component of SF-12 or SF-36 questionnaire: weighted MD -0.11 (95% CI: -1.65–1.43); I²=0.0%; p=0.984

**Cost:**
- Healthcare costs were significantly higher in the studies and contributed to the high heterogeneity of the studies
- Most studies were powered to test differences in BP lowering, not 2° outcomes

**Summary:** HBPT yielded greater SBP and DBP reductions and a larger proportion of pts achieving BP control than usual care. HBPT vs. usual care resulted in greater prescription of antihypertensive medications and fewer office visits but no difference in therapeutic adherence. Healthcare costs were higher with HBPT than usual care, but when HBPT-related costs were excluded, medical costs were similar between groups. Use of HBPT vs. usual care improved quality of life physical component but not mental. Authors note that the amount of office BP reduction attributable to HBPT was in line with that observed in RCTs of antihypertensive drugs compared with placebo. The estimate was also larger than that usually related to HBP self-monitoring, which speaks in favor of a possible added value of the teletransmission approach.
| Verberk W, et al., 2011 (335) 21527847 | **Aim:** Examine the usefulness of telecare for HTN management  
**Study type:** Meta-analysis  
**Size:** 9 RCTs with 2,501 pts | **Inclusion criteria:** 1) Published in the English language, 2) pts were diagnosed as hypertensive and performed BP self-measurement at home, 3) RCTs that compared telecare of BP with usual care, 4) data were transmitted to healthcare providers by telephone, modem, Internet, or mail, and 5) either change in BP or the number of pts that reached their target BP was an outcome and was provided in the study. Date restrictions not reported.  
**Exclusion criteria:** Absence of above | **Intervention:** Telecare for HTN management (treatment and/or coaching). Telecare involved a data transmission process to collect data on a pt’s health status to allow remote HTN management. Procedures varied in length and frequency of contact and method of delivery (i.e., often telephone or cell phone with or without internet/computer; with or without behavioral counseling by nurse or pharmacist), often as an adjunct to “usual care” clinical visits.  
**Comparator:** Usual care | **HBPT group vs. usual care:** weighted MD 662.92 (95% CI: 540.81–785.04) euros per pt; I²=99.6%; p<0.001; but costs were similar when only medical costs (excluding HBPT-related costs) were considered (-12.4; 95% CI: -930.52–906.23) euros; p=0.767.  
**Safety endpoint:** No difference was observed in the risk of adverse events (RR: 1.22; 95% CI: 0.86–1.71; p=0.111)  
**1° endpoint:** Difference in BP Reduction (Telecare-Usual care):  
- SBP 5.2 ± 1.5 mm Hg (95% CI: 2.31–8.07)  
- DBP 2.1 ± 0.8 mm Hg (95% CI: 0.52–3.69)  
**Safety endpoint:** N/A  
**Limitations:** Telecare intervention methods varied greatly across studies  
**Summary:** Telecare led to a greater decrease in SBP and DBP compared with usual care. Telecare seems a valuable tool to support HTN management.
Aim: Quantify both the magnitude and mechanisms of benefit (including effect on therapeutic inertia) of home BP monitoring on BP reduction. Therapeutic inertia was defined as no change in medications combined with uncontrolled BP.

Study type:
Systematic review and meta-analysis

Size: 37 RCTs with 9,446 pts. Trial settings included community (n=5), dialysis unit (n=2), general practices (n=18), hospitals and general practice (n=1), and hospital-based outpatient units (n=11).

Inclusion criteria:
Studies that randomized pts to control or home BP monitoring group

Exclusion criteria:
Absence of above

Intervention: Home BP monitoring as an adjunct to usual care for HTN

Comparator: Usual care with BP monitoring in clinic

1° endpoint: Compared with usual care alone, home-based BP monitoring:
- Reduced SBP: -2.63 mm Hg (95% CI: -4.24 – -1.02) and
- Reduced DBP: -1.68 mm Hg (95% CI: -2.58– -0.79)

- Greater reduction in SBP by HBPM interventions was seen with added telemonitoring (effect size -3.20; 95% CI: -4.66– -1.73) vs. home BP monitoring (effect size -1.26; 95% CI: -2.20– -0.31; p=0.029). This finding is relevant to telemonitoring

2° endpoints:
- More frequent reductions in antihypertensive medication (presumably due to identification of white coat HTN): RR: 2.02 (95% CI: 1.32–3.11)
- Lowered therapeutic inertia (i.e., unchanged medication despite elevated BP: RR for unchanged medication 0.82 (95% CI: 0.68–0.99)

Limitations: Different inclusion and exclusion criteria, different BP measurement techniques, drug titration protocols, pt populations, and duration of follow-up across studies likely introduced significant heterogeneity in effect size.

Summary: Home BP monitoring leads to a small but significant reduction in SBP and DBP. Greater reduction in SBP is seen when HBPM is accompanied by specific programs to titrate antihypertensive drugs. 1 such strategy is telemonitoring, in which BP readings obtained at home are relayed to the provider who can then take appropriate action, thus reducing therapeutic inertia.
### Study 1: Svetkey LP, et al., 2009 (336) 19920081

**Aim:** Study the effect of physician intervention and/or pt intervention vs. usual care, to assess the impact of education, monitoring, and feedback protocol to help improve HTN control

**Study type:** Nested 2x2 RCT

**Size:** 8 primary care practices, 32 physicians, 574 pts

**Inclusion criteria:** Practices: matched pairs (intervention vs. usual care) by specialty (internal medicine vs. family physician) and by pt socioeconomic mix. All physicians were invited to participate.

**Pt eligibility:** ≥25 y, hypertensive by billing code.

**Pt exclusion:** Self-reported CKD, CVD event within past 6 mo, pregnant, breastfeeding, or planning a pregnancy.

**Physician Intervention:** 18 mo of online training, self-monitoring, quarterly feedback reports.

**Pt Intervention:** 20 weekly group sessions for 6 mo, followed by 12 monthly telephone counseling contacts, focused on weight loss, DASH dietary pattern, exercise, and reduce sodium intake.

**Comparator:** Usual care

**1° endpoint:** Pt intervention + physician intervention group had greatest BP lowering at 6 mo (-9.7 mm Hg ± 12.7), but at 18 mo there was no significant difference between groups.

**1° Safety endpoint:** N/A

- This trial suggests that pt level monitoring and feedback, in combination with physician level monitoring and feedback, provides additional 6 mo BP control above and beyond usual care. The impact of the intervention diminished after the weekly pt group sessions ended and monthly telephone calls began instead.

### Study 2: Jaffe MG, et al., 2013 (329) 23989679

**Aim:** Study the effect of a multipronged, system-based, QI approach on HTN control.

**Study type:** Observational

**Size:** All pts with HTN in the KPNC system were included

**Inclusion criteria:** 350,000 pts in the KPNC system with HTN in 2001, increasing to 650,000 in 2009

**Eligibility:**
- ≥2 HTN diagnoses coded in primary care visits in the prior 2 y
- ≥1 primary care HTN diagnoses and 1 or more hospitalizations with a 1° or 2° HTN diagnosis in the prior 2 y
- ≥1 primary care HTN diagnoses and 1 or more filled prescriptions for HTN medication within the prior 6 mo, or

**Intervention:** KPNC HTN Program includes: HTN registry, HTN control monitoring and feedback system, evidence-based practice guidelines, medical assistant BP recheck program, and promotion of single polypill formulation (lisinopril-hydrochlorothiazide)

**Comparator:** Insured pts in California from 2006–2009 who were included in the HEDIS commercial measurement by California health insurance plans participating in the NCQA quality measure reporting process. A 2° comparison group was included to obtain the reported national mean NCQA HEDIS commercial rates of HTN control from 2001–2009.

**1° endpoint:** HTN control rates in KPNC pts with HTN improved from 43.6% (95% CI: 39.4%–48.6%) in 2001 to 80.4% (95% CI: 75.6%–84.4%) by the end of the study period (p<0.001 for trend).

- By comparison, national mean NCQA HEDIS commercial rates of HTN control were similar to those reported nationally from 2006–2009 (63.4%–69.4%).

- A system-based approach to HTN control that includes performance measurement and QI strategies led to a significant improvement in HTN control (80%, compared to 44% baseline control) in a large population of pts in a managed care health plan.
### Data Supplement 66. RCTs, Meta-analyses, and Systematic Reviews on Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events Summary</th>
</tr>
</thead>
</table>
| Walsh JM, et al., 2006 (338) 16793359 | **Aim:** Assess the effectiveness of QI strategies in lowering BP | **Inclusion criteria:** Trials, controlled before–after studies, and interrupted time series evaluating QI interventions targeting HTN control and reporting BP outcomes. | **Intervention:** QI interventions targeting some component of provider behavior or organizational change to improve HTN control | **Comparator:** Contemporaneous | • The majority of articles described interventions consisting of more than 1 strategy with the median number of QI strategies per comparison =3. Results are organized below by type of QI strategy. 
• Variety of strategies used | **Limitations:** Studies varied by design, population, sample size, setting, and methodological quality. Definition of each QI strategy varied across studies. Few studies assessed a single QI strategy; because most studies included more than 1 QI strategy, it could not be discerned which individual QI strategies had the... |
**Size:** 44 articles reporting 57 comparisons

**Exclusion criteria:** Articles focusing only on 2º HTN or specialized subpopulations (e.g., HTN in pts with alcoholism)

- Inclusion criteria: observation of cohorts differing primarily with respect to exposure to the QI intervention

<table>
<thead>
<tr>
<th>QI Intervention</th>
<th>SBP/DBP, median reduction:</th>
<th>SBP/DBP control:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider reminders</td>
<td>SBP/DBP, median reduction: 4.5 mm Hg (IQR: 1.5–11.0)/ 2.1 mm Hg (IQR: -0.2–5.0)</td>
<td>16% (IQR: 10.3–32.2)/ 6% (IQR: 1.5–17.5)</td>
</tr>
<tr>
<td>Facilitated relay of clinical data</td>
<td>1.2 mm Hg (IQR: 1.0–1.9)/ 0.3 mm Hg (IQR: -0.2–1.7)</td>
<td>5% (IQR: 2.0–7.0)</td>
</tr>
<tr>
<td>Audit and feedback</td>
<td>8.0 mm Hg (IQR: 2.5–12.3)/ 1.8 mm Hg (IQR: -0.1–4.5)</td>
<td>25% (IQR: 17.0–34.2)/ 2% (IQR: 1.6–5.0)</td>
</tr>
<tr>
<td>Provider education</td>
<td>1.5 mm Hg (IQR: 1.2–1.7)/ 0.6 mm Hg (IQR: 0.4–1.0)</td>
<td>-3.5% (IQR: -5.7–1.4)/ 2.0% (IQR: 1.7–4.3)</td>
</tr>
<tr>
<td>Pt education</td>
<td>3.3 mm Hg (IQR: 1.2–5.4)/ 0.6 mm Hg (IQR: -0.7v3.4)</td>
<td>11% (IQR: 1.4–13.1)/ 4% (IQR: 1.7–11.3)</td>
</tr>
<tr>
<td>Promotion of self–management</td>
<td>8.1 mm Hg (IQR: 3.3–11.8)/ 3.8 mm Hg (IQR: 0.6–6.7)</td>
<td>19% (IQR: 11.4–32.2)/ 17% (IQR: 11.4–24.5)</td>
</tr>
</tbody>
</table>

SBP/DBP, median reduction: 1.2 mm Hg (IQR: 1.0–1.9)/ 0.3 mm Hg (IQR: -0.2–1.7) DBP control: 5% (IQR: 2.0–7.0)

- **Summary:** QI strategies are associated with improved HTN control. QI strategies improved SBP and the proportion of pts achieving SBP control and had a more modest effect on DBP and the proportion of pts achieving DBP control. Team change (i.e., a focus on HTN by someone in addition to the pt’s physician) had the largest effect on both SBP and DBP. All of the strategies assessed may be beneficial in terms of clinically meaningful reductions in BP under some circumstances and in varying combinations.
| Carter BL, et al., 2009 (321) 19858431 | **Aim:** Determine potency of interventions for BP involving nurses and pharmacists  
**Study type:** Meta-analysis  
**Size:** 37 RCTs of team-based HTN care involving nurse or pharmacist intervention  
**Inclusion criteria:** RCT of team-based HTN care involving nurse or pharmacist intervention  
**Exclusion criteria:** Absence of above  
**Intervention:** Team-based HTN care involving nurse or pharmacist intervention  
In nearly all studies involving nurses or pharmacists in clinics, consistent and dedicated case management activities were provided that were distinct from traditional nursing or  
**1° endpoint:**  
- OR (95% CI) for controlled BP were: nurses: 1.69 (1.48, 1.93); pharmacists within primary care clinics: 2.17 (1.75, 2.68); and community pharmacists: 2.89 (1.83, 4.55).  
- Mean (SD) reductions in SBP were: nurse intervention: 5.84 (8.05) mm Hg; pharmacists in clinics: 7.76(7.81) mm Hg; and  
**Safety endpoint:** N/A | SBP/DBP, median reduction: 3.3 mm Hg (IQR: 2.6–10.1)/2.8 mm Hg (IQR: 0.4–6.7)  
SBP/DBP control: 13%/9% (IQR: 5.3–11.4)  
- Pt reminders  
SBP/DBP, median reduction: 3.3 mm Hg (IQR: 2.3–4.5)/0.4 mm Hg (IQR: -2.4–5.0)  
DBP control: 2% (IQR: 1.1–9.4)  
- Team change  
SBP/DBP, median reduction: 9.7 mm Hg (IQR: 4.2–14.0) (p<0.05)/4.2 mm Hg (IQR: 0.2–6.8) (p<0.05)  
SBP/DBP control: 22% (IQR: 9.0–33.8)/17% (IQR: 5.7–24.5)  
- Financial incentives  
SBP/DBP, median reduction: -13.3 mm Hg/0.0 mm Hg (IQR: -2.0–2.5)  
DBP control: 4% (IQR: -1.1–9.4)  
**Stepwise regression** was used to compare studies that included a given intervention strategy with studies that did not. Several individual components of the interventions were associated with significant reductions in mean SBP including pharmacist recommended medication to physician (-27.21 mm Hg; p=0.002), counseling about lifestyle modification (-12.63 mm Hg; p=0.03), pharmacist performed the intervention (-11.70 mm Hg; p=0.03), use of a treatment
<table>
<thead>
<tr>
<th>Pharmacist Intervention</th>
<th>Community Pharmacists: 9.31 (5.00) mm Hg.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• There were no significant differences between nurse and pharmacist effects (p≥0.19).</td>
</tr>
<tr>
<td>Comparator: Usual care</td>
<td>Safety endpoint: N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator: Home BP monitoring as an adjunct to usual care for HTN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety endpoint: N/A</td>
</tr>
</tbody>
</table>

**Aim:** Quantify both the magnitude and mechanisms of benefit (including effect on therapeutic inertia) of home BP monitoring on BP reduction. Therapeutic inertia was defined as no change in medications combined with uncontrolled BP.

**Study type:** Systematic Review and Meta-analysis

**Inclusion criteria:** Studies that randomized pts to control or home BP monitoring group

**Exclusion criteria:** Absence of above

**Intervention:** Home BP monitoring as an adjunct to usual care for HTN

**Comparator:** Usual care with BP monitoring in clinic

**1° endpoint:** Compared with usual care alone, home-based BP monitoring:

- Reduced SBP: -2.63 mm Hg (95% CI: -4.24--1.02) and
- Reduced DBP: -1.68 mm Hg (95% CI: -2.58--0.79)

**2° endpoints:**

- More frequent reductions in antihypertensive medication (presumably due to identification of white coat HTN): RR: 2.02; 95% CI: 1.32–3.11
- Lowered therapeutic inertia (i.e., unchanged medication despite elevated BP: RR for unchanged medication 0.82 (95% CI: 0.68–0.99)

**Limitations:** Different inclusion and exclusion criteria, different BP measurement techniques, drug titration protocols, pt populations, and duration of follow-up across studies likely introduced significant heterogeneity in effect size.
### Anchala R, et al., 2012 (339) 23071713

| **Aim:** Evaluate the role of decision support systems in prevention of CVD among pts |
| **Study type:** Systematic review and meta-analysis |
| **Size:** 10 studies with 5 studies reporting effect on BP (BP results only reported here) |

**Inclusion criteria:**
1. Cross-sectional, case control, cohort, and RCTs, 2. Studies conducted among adult pts ≥18, 3. Studies on prevention of CV disorders (MI, stroke, CHD, peripheral vascular disorders and HF) and management of HTN, 4. Studies on interventions including: decision support systems, clinical decision supports systems, computerized decision support systems, clinical decision making tools and medical decision making

**Exclusion criteria:**
Absence of above

**Intervention:** Decision support systems, clinical decision supports systems, computerized decision support systems, clinical decision making tools and medical decision making in the management of HTN

**Comparator:** Usual care

**1° endpoint:**
- Reduction in SBP (5 studies): 2.32 mm Hg (95% CI: -3.96–-0.69)
- Reduction in DBP (2 studies): 0.42 mm Hg (95% CI: -2.30–1.47)

**Safety endpoint:** N/A

**Summary:**
- Clinical decision support resulted in modest reduction of SBP and no significant reduction of DBP.

**Limitations:**
- Small number of studies of varied quality.
- Interventions varied across studies.

### Proia KK, et al., 2014 (323) 24933494

| **Aim:** Examine current evidence on the effectiveness of team-based care in improving BP outcomes (update of Proia KK, et al., 2012 (339)) |
| **Study of team-based care; conducted in a high-income economy; reported at least 1 BP outcome of interest; included a comparison group or had | **Intervention:** Team-based care was defined as adding new staff or changing the roles of existing staff to work with a PCP for HTN care. Team members who |

**Inclusion criteria:**
1. Proportion with controlled BP: Absolute percentage point (pct pt) change in pts with controlled BP from 33 studies comparing team-based care to usual care: median effect

**2° endpoints:**
- Compared with pts in usual care, the proportion of pts receiving team-based care with "high" medication adherence (defined as taking medications as prescribed >80% of the time) increased by a median of 16.3 pct pts (9 studies).

**Summary:**
- Home BP monitoring leads to small but significant reduction in SBP and DBP. Greater reduction in SBP is seen accompanied by specific programs to titrate antihypertensive drugs. One such strategy is telemonitoring, in which BP readings obtained at home are relayed to the provider who can then take appropriate action.
prior systematic review

**Study type:** Systematic review

**Size:** 52 studies of team-based primary care for pts with 1<sup>st</sup> HTN

**Exclusion criteria:**
- Inclusion of populations with 2<sup>nd</sup> HTN (e.g., pregnancy) or with a history of CVD (e.g., MI)
- Exclusion of populations with 2<sup>nd</sup> HTN or populations with comorbid conditions such as DM as long as the primary focus of the intervention was BP control; and did not

**Comparator:** Usual care

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Systematic review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size:</td>
<td>52 studies of team-based primary care for pts with 1&lt;sup&gt;st&lt;/sup&gt; HTN</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>Inclusion of populations with 2&lt;sup&gt;nd&lt;/sup&gt; HTN (e.g., pregnancy) or with a history of CVD (e.g., MI)</td>
</tr>
<tr>
<td>Comparator:</td>
<td>Usual care</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator:</th>
<th>Usual care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimate:</td>
<td>12 pct pts (IQI=3.2–20.8 pct pts). Most individual effect estimates in the favorable direction were significant (p&lt;0.05).</td>
</tr>
<tr>
<td>Reduction in SBP:</td>
<td>The median reduction in SBP was 5.4 mm Hg (IQI=2.0–7.2 mm Hg). Most individual effect estimates were significant (p&lt;0.05).</td>
</tr>
<tr>
<td>Reduction in DBP:</td>
<td>The overall median reduction in DBP was 1.8 mm Hg (IQI=0.7–3.2 mm Hg) from 38 studies.</td>
</tr>
</tbody>
</table>

**Safety endpoint:** No harm to pts was identified from team-based care interventions in the included studies or the broader literature.

**Limitations:** Included studies reported significant differences in pt demographics between intervention and comparison groups at baseline, possible contamination within intervention and comparison groups, and issues related to inadequate description of populations and implemented interventions.

**Summary:** There is strong evidence that team-based care is effective in...

**Stratified analyses for BP outcomes:**
- **Team member role in medication management:** Larger improvements in BP outcomes than overall estimates were demonstrated when team members could make changes to medications independent of the PCP or team members could provide medication recommendations and make changes with the PCP’s approval as compared to team members providing only adherence support and information on medication and HTN.
- **Number of team members added:** Adding ≥2 members demonstrated larger improvements in the proportion of pts with controlled BP and reduction in DBP compared to adding only 1; median reductions in SBP were similar regardless of team size.
- **Improvement in the proportion of pts with controlled BP was similar for studies from both healthcare and community settings.**
**Improving BP outcomes, especially when pharmacists and nurses are part of the team.**

Data Supplement 67. Nonrandomized Trials, Observational Studies, and/or Registries of Effect of Quality Improvement Strategies on Hypertension Treatment Outcomes (Section 12.4.2)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Study Type/Design; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (include P value; OR or RR; &amp; 95% CI)</th>
<th>Summary/Conclusion Comment(s)</th>
</tr>
</thead>
</table>
| Thomas KL, et al., 2014 (340) 25351480 | **Study type:** Community-based HTN QI program (multifaceted BP control program using a web-based health portal (Heart360), community health coaches, and PA guidance) to improve HTN control in a diverse community setting  
**Design:** Pre-post study without a concurrent control  
**Size:** 1756 pts with HTN from 8 clinics:  
- Median age, 60 y  
- Female, 65.6%  
- African American, 76.1% | **Inclusion criteria:** Individuals from pt sites >18 y with a previous billing diagnosis of HTN (ICD-9 code 401.X) or a previous clinical diagnosis of HTN in the medical record.  
**Exclusion criteria:** Did not reside in Durham County or had a neurocognitive disorder that prevented enrollment | **1° endpoint:** 1) Difference in SBP and DBP from enrollment (BP obtained in the clinic at enrollment) to the last BP as measured in clinic within 6 mo after enrollment, 2) proportion of pts that achieved BP <140/90 mm Hg by last clinic visit within 6 mo, and 3) proportion of pts with BP <140/90 mm Hg or drop in SBP ≥10 mm Hg by last visit relative to their enrollment BP.  
**Results:**  
- Mean change in BP: -4.7 mm Hg (SD ± 21.4) / -2.8 mm Hg (SD ± 11.8) after 6 mo  
- BP control (<140/90 mm Hg) rate: Increased from 51% at baseline to 63% at 6 mo  
- Proportion with BP<140/90 or ≥10 mm Hg decrease in SBP at 6 mo was 69%  
- Among those who were in tiers 1 (BP=140/60–159/99 mm Hg) and 2 (BP≥159/99 mm Hg) at enrollment (n=889), BP change was -8.8 mm Hg (SD ± 15.8) / -5.0 mm Hg (SD ± 10.0) and -23.7 mm Hg (SD ± 26.5) / -10.1 mm Hg (SD ± 14.1), respectively. | Summary: A multicomponent-tiered HTN program that included team-based care with PAs and community health coaches was associated with improved BP control in a diverse community-based population. Though the web-based approach presented technical challenges for some pts, there was a direct association between higher use of Heart360 and larger recorded BP declines as entered into Heart360. This provides some indirect evidence that those pts who were more engaged with their BP self-monitoring achieved better BP control. |
| Jaffe MG, et al., 2013 (329) 23989679 | **Study type:** Quasi-experimental evaluation of multi-faceted QI program that included 1) Health system-wide HTN registry, 2) HTN control rates (with provider audit and feedback), 3) | **Inclusion criteria:** Pts identified with HTN within an integrated health care delivery system (KPNC) from 2001–2009 | **1° endpoint:** BP control using NCQA HEDIS measures  
**Results:** BP control increased from 44%–80% from 2001–2009 with the KPNC QI program compared to 55.4% to 64.1% for the national mean and 63.4% to | Summary: Implementation of a large-scale HTN program was associated with a significant increase in HTN control compared with state and national control rates. |
### Data Supplement 68. RCTs Comparing Financial Incentives (Section 12.5)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P value; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events Summary</th>
</tr>
</thead>
</table>
| Peterson LA, et al., 2013 (341) 24026599 | **Aim:** To test the effect of explicit financial incentives to reward guideline recommended HTN care.  
**Study type:** Cluster randomized trial of 12 VA Outpatient clinics with 5 performance periods and a 12-mo washout  
**Size:** 83 PCPs and 42 nonphysician | • Study population was providers, not pts: a minimum of 5 fulltime PCPs from 12 hospital-based primary care clinics in 5 A Networks. Then, the clinics were randomized to 1 of 4 study groups, 1) physician level (individual) incentives, 2) practice-level incentives, 3) physician-level plus practice-level (combined) incentives, and 4) no incentives (control). | **Interventions:** Education, Financial Incentives, Audit and Feedback; Intervention group pts received up to 5 incentive payments in their paychecks –every 4 mo and were notified each time a payment was posted.  
**Comparator:** 4 different groups, 1 paid incentives at the practice level, 1 paid incentives at the physician level, 1 paid incentives at both levels, and 1 no incentives | **1° endpoint:** In unadjusted analyses, the percentage of pts either with controlled HTN or receiving an appropriate response increased for each incentive group between baseline and final performance period, 75% to 84% in the individual group, 80% to 85% in the practice group, and 79% to 88% in the combined group.  
Performance did not change in control group, 86%. The adjusted estimated absolute change over the study of the pts meeting the combined BP or Summary:  
• Mean (SD) total payments over the study were $4,270 ($459), $2672 ($153), and $1,648 ($248) for the combined, individual, and practice-level interventions, respectively. Change in BP control or appropriate response to uncontrolled BP compared with the control group was significantly greater only in the individual incentives group. Change in guideline-recommended medication use was not significant compared with the control group. The effect of the incentive was not sustained after a washout. |
Main Outcomes and Measures: Among a random sample, number of pts achieving guideline-recommended BP thresholds or receiving an appropriate response to uncontrolled BP, number of pts prescribed guideline-recommended medications, and number who developed hypotension.

Financial incentives may constitute an insufficiently strong intervention to influence goal commitment when providers attribute performance to external forces beyond their control.

Summary: Population BP control has improved since the introduction of P4P renal indicators, and this improvement has been sustained. This was associated with a significant increase in the use of antihypertensive medication, resulting in increased prescription cost. Longer-term follow-up will establish whether or not this translates to improved outcomes in terms of progression of CKD, CVD and pt mortality.

| Study type: | Prospective cohort study using a large primary care database. |
| Inclusion criteria: | A total of 10,040 pts had confirmed stage 3–5 CKD in the 2 y pre-QOF and formed the study cohort. |
| Intervention: | The implementation of national estimated GFR reporting and the inclusion of renal-specific indicators in a primary care P4P system since April 2006 has promoted identification and better management of risk factors related to CKD. In the UK, the P4P framework is known as the QOF. |
| Comparator: | N/A |
| Aim: | The aim of this study was to evaluate the effectiveness of renal indicators outlined in P4P on the management of HTN in primary care. To estimate the cost implications of the resulting changes in prescribing patterns of antihypertensive medication following introduction of such indicators. |
| Exclusion criteria: | None |
| Safety endpoint: | N/A |

Mean age of the cohort at the start of the study period was 64.8 y, 55% were female. In those pts with stage 3–5 CKD 83.9% were hypertensive, defined by a pre-P4P BP of >140/85 or currently taking antihypertensive medication. The proportion of pts with CKD 3–5 attaining the BP target of 145/80 increased from 41.5% in the pre-QOF period to 50.0% in the post-QOF period. This increase was even more marked for those with HTN in the pre-QOF period (28.8%–45.1%). In the hypertensive pts, mean BP fell from 146/79 mm Hg to 140/76 in the first 2 y post-P4P (p<0.01, analysis of variance).
This cohort was taken from a database collated as part of a clinical decision support system used to assist the management of CKD in primary care. **Size:** 90,250 pts on general practitioner registers with a valid serum creatinine estimation in the 6-y study period. A total of 10 040 pts had confirmed stage 3–5 CKD in the 2 y pre-QOF and formed the study cohort.

Serumaga B, et al., 2011 (344) 21266440

**Aim:** The aim of this study was to evaluate the effectiveness of renal indicators outlined in P4P on the management of HTN in primary care. To estimate the cost implications of the resulting changes in prescribing patterns of antihypertensive medication following introduction of such indicators.

**Study type:** Interrupted time series study

**Inclusion criteria:** Pts with HTN diagnosed between Jan. 2000–Aug. 2007.

**Exclusion criteria:** None

**Intervention:** The UK P4P incentive (the Quality and Outcomes Framework), which was implemented in April 2004 and included specific targets for general practitioners to show high quality care for pts with HTN (and other diseases).

**Comparator:** None

- After accounting for secular trends, no changes in BP monitoring: level change: 0.85 (95% CI: −3.04–4.74), p=0.669 and trend change: −0.01, (95% CI: −0.24–0.21), p=0.615, control: −1.19 (95% CI: −2.06–1.09), p=0.109 and −0.01 (95% CI: −0.06–0.03), p=0.569, or treatment intensity; 0.67: (95% CI: −1.27–2.81), p=0.412 and 0.02 (95% CI: −0.23–0.19, p=0.706 were attributable to P4P. P4P had no effect on the cumulative incidence of stroke, MI, renal failure, HF, or all-cause mortality in both treatments experienced and newly treated subgroups.

**Summary:** Good quality of care for HTN was stable or improving before P4P was introduced. P4P had no discernible effects on processes of care or on HTN related clinical outcomes. Generous financial incentives, as designed in the UK P4P policy, may not be sufficient to improve quality of care and outcomes for HTN and other common chronic conditions.
Bardach NS, et al., 2013 (327) 24026600

**Size:** 470,725 pts with HTN diagnosed between Jan 2000–Aug 2007.

**Aim:** To assess the effect of P4P incentives on quality in EHR-enabled small practices in the context of an established QI initiative.

**Study Type & Size:** A cluster-randomized trial of small (<10 clinicians) primary care clinics in New York City from April 2009–March 2010.

- Participating clinics (n=42 for each group) had similar baseline characteristics, with a mean of 4,592 (median, 2,500) pts at the intervention group clinics and 3,042 (median, 2,000) at the control group clinics.

- A city program provided all participating clinics with the same EHR software with decision support and pt registry functionalities and QI specialists offering technical assistance.

- Incentivized clinics were paid for each pt whose care met the performance criteria, but they received higher payments for pts with comorbidities, who had Medicaid insurance, or who were uninsured (maximum payments: $200/pt; 100,000/clinic). Quality reports were given quarterly to both the intervention and control groups.

- Intervention clinics had greater adjusted absolute improvement in rates of appropriate antithrombotic prescription: 12.0% vs. 6.1%, difference: 6.0% (95% CI: 2.2%–9.7%; p=0.001 for interaction term), BP control (no comorbidities): 9.7% vs. 4.3%, difference: 5.5% (95% CI: 1.6%–9.3%; p=0.01 for interaction term); with DM: 9.0% vs. 1.2%, difference: 7.8% (95% CI: 3.2%–12.4%; p=0.007 for interaction term); with DM or ischemic vascular disease: 9.5% vs. 1.7%, difference: 7.8% (95% CI: 3.0%–2.6%; p=0.01 for interaction term), and in smoking cessation interventions (12.4% vs. 7.7%, difference: 4.7% (95% CI: −0.3%–9.6%; p=0.02 for interaction term).

- Intervention clinics performed better on all measures for Medicaid and uninsured pts except cholesterol control, but no differences were statistically significant.

**Summary:** In our study, although the effect of the intervention was lower than the 10% improvement that we estimated a priori, the absolute risk reduction for BP control among pts with DM was 7.8% (NNT, 13). This suggests that, for every 13 pts seeing incentivized clinicians, 1 more pt would achieve BP control. The 7.8% absolute change in BP control for pts with DM represents a 46% relative increase in BP control among intervention pts compared with the baseline of 16.8%. Further research is needed to determine whether this effect of the P4P intervention on BP control increases or decreases over time. However, this NNT to achieve BP control through incentives, taken together with the large relative increase in percentage of pts with BP control and the potential effect of BP control on risk of ischemic vascular events, suggests a reasonable opportunity to reduce morbidity and mortality through P4P as structured in this study.

**Limitations:** Some clinics exited the program after randomization, with more control clinics leaving than intervention clinics. Additionally, this intervention occurred in the setting of a voluntary QI program. This may reflect a high level of intrinsic...
Maimaris W, et al., 2013 (345) 23935461

**Aim:** To assess strategies for influencing HTN care including procurement of essential medications, the existence of simple national guidelines for HTN management, introduction of financial incentives for health care practitioners to diagnose or treat HTN, and enhanced health insurance coverage.

**Study type:** Systematic review examining the effect of national or regional health system arrangements on HTN care and control

<table>
<thead>
<tr>
<th>Study selection criteria based on:</th>
<th>• The screening process is described using an adapted PRISMA flowchart. 5,514 articles were screened by title and abstract for inclusion. The full text of 122 of the 5,514 articles was obtained and assessed for eligibility. 53 studies met eligibility criteria for this review. 51 of the included studies were quantitative and 2 were qualitative. Of the 51 quantitative studies, 1 was an RCT; 12 were cohort studies, 2 of which were retrospective; 3 were case-control studies; 32 were cross-sectional studies; and 3 were ecological studies. 42 of the 53 studies (79%) were carried out in countries classified by the World Bank as high-income countries, 36 of which were in the U.S. 6 studies were carried out in upper middle-income countries, 3 in lower middle-income countries.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) HTN awareness. Defined as pts with clinically measured hypertensives who have been diagnosed by a health care professional as hypertensive. 2) HTN treatment. Defined as the use of at least 1 antihypertensive medication in a pt with known HTN. 3) Antihypertensive medication adherence. Defined as consistently taking the antihypertensive medication regimen as prescribed by the health care provider. 4) HTN control: defined as the achievement of BP&lt;140/90 mm Hg (or other explicitly defined threshold) in individuals being treated for HTN, or, alternatively, measured by the mean BP amongst individuals with HTN.</td>
<td>• Health insurance status: 15 cross-sectional studies reported comparisons of HTN outcomes in insured and uninsured pts. 8 of these 15 studies reported that insurance was associated with improved HTN treatment, control or medication adherence. The 7 other cross-sectional studies that compared HTN outcomes in insured pts and uninsured pts, reported no significant negative or positive associations between insurance status and HTN outcome.</td>
</tr>
<tr>
<td>• Although lacking longitudinal studies, we found a large positive association between having a routine physician or place of care for HTN management and treatment, awareness, control, and adherence to antihypertensive treatment, again in the U.S. publication and reporting bias noted by authors.</td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation and American Heart Association, Inc. 249
| countries, and 1 in a low-income country. | studies reported associations between increased medication costs or co-payments and reductions in HTN control or reduced adherence to antihypertensive medication, although for 1 of these 7 cohort studies, the association between increased copayments and reduced medication adherence was only found for low medication co-payments, and at high co-payment levels medication adherence was actually found to increase (OR for medication adherence vs. baseline of 1 for $0 co-payments was 0.72 for $1–$9 co-payments (p=0.05), 1.02 for $10–$29 co-payments (p=0.05), and 1.32 for co-payments > $30 (p=0.05). |
| • Physician remuneration models: 2 studies evaluated the association of physician remuneration models with HTN control or treatment adherence, 1 an ecological study set in Canada, and 1 a U.S. cross-sectional study. Neither study had a low risk of bias. The U.S. study reported improved rates of HTN control amongst pts treated under a capitation model compared to fee-for-service pts (adjusted OR for HTN control: 1.82 (95% CI: 1.02–3.27) for capitation vs. fee-for-service pts). The Canadian study reported highest rates of HTN |
treatment and control among practices using a capitation model, compared to fee-for-service and salary model. HTN awareness levels were highest in practices with a fixed salary remuneration model.
Additional Data Supplement Tables and Figures

Data Supplement A. Treatment of HFrEF Stages C and D

Colors correspond to COR in Table 1. For all medical therapies dosing should be optimized and serial assessment exercised.

*See text for important treatment directions.

†Hydral-Nitrates Green Box- The combination of ISDN/HYD with ARNI has not been robustly tested. BP response should be carefully followed.

‡See 2013 HF guideline.

§Participation in investigational studies is also appropriate for stage C, NYHA class II and III HF.

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BP, blood pressure; bpm, beats per minute; C/I, contraindication; CRT-D, cardiac resynchronization therapy-device; COR, class of recommendation; Dx, diagnosis; GDMT, guideline-directed management and therapy; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; ISDN/HYD, isosorbide dinitrate hydral-nitrates; LBBB, left bundle-branch block; LVEF, left ventricular ejection fraction.
Data Supplement B. Medication Adherence Assessment Scales

**Hill-Bone Compliance Scale (346)**

How often do you:

1. Forget to take your high BP medicine?
2. Decide NOT to take your high BP medicine?
3. Eat salty foods
4. Shake salt on your food before you eat it?
5. Eat fast food?
6. Make the next appointment before you leave the doctor’s office?
7. Miss scheduled appointments?
8. Forget to get prescriptions filled?
9. Run out of high BP pills?
10. Skip your high BP medicine before you go to the doctor?
11. Miss taking your high BP pills when you feel better?
12. Miss taking your high BP pills when you feel sick?
13. Take someone else’s high BP pills?
14. Miss taking your high BP pills when you are careless?

Response:

1. All of the Time
2. Most of the Time
3. Some of the Time
4. None of the Time

Medication taking subscale: Items 1,2, 8,9,10,11,12,13,14.
Reducing sodium intake subscale: Items 3,4,5.
Appointment keeping subscale: Items 6,7.

BP indicates blood pressure.

Data Supplement C. Categories Defining Normal BP, Elevated BP, and Stages 1, 2, and 3 Hypertension

<table>
<thead>
<tr>
<th>SBP (mm Hg)</th>
<th>&lt;120</th>
<th>120–129</th>
<th>130–139</th>
<th>140–159</th>
<th>160+</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;80</td>
<td>Normal</td>
<td>Elevated</td>
<td>Stage 1</td>
<td>Stage 2</td>
<td>Stage 2</td>
</tr>
<tr>
<td>80–89</td>
<td>Stage 1</td>
<td>Stage 1</td>
<td>Stage 1</td>
<td>Stage 2</td>
<td>Stage 2</td>
</tr>
<tr>
<td>90–99</td>
<td>Stage 2</td>
<td>Stage 2</td>
<td>Stage 2</td>
<td>Stage 2</td>
<td>Stage 2</td>
</tr>
<tr>
<td>100+</td>
<td>Stage 2</td>
<td>Stage 2</td>
<td>Stage 2</td>
<td>Stage 2</td>
<td>Stage 2</td>
</tr>
</tbody>
</table>
Stages 1, 2, and 3 refer to the stage of hypertension.

BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
# Data Supplement D. Fixed-Dose Combination Antihypertensive Drugs

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Dosage Strengths (mg/mg)</th>
<th>Daily Frequency*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2-drug combinations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACE Inhibitors + Thiazide</td>
<td>Benazepril/Hydrochlorothiazide</td>
<td>10/12.5, 20/12.5, 20/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Captopril/Hydrochlorothiazide</td>
<td>25/15, 50/15, 25/25, 50/25</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Enalapril/Hydrochlorothiazide</td>
<td>5/12.5, 10/25</td>
<td>1 or 2</td>
</tr>
<tr>
<td></td>
<td>Fosinopril/Hydrochlorothiazide</td>
<td>10/12.5, 20/12.5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Lisinopril/Hydrochlorothiazide</td>
<td>10/12.5, 20/12.5, 20/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Moexipril/Hydrochlorothiazide</td>
<td>7.5/12.5, 15/12.5, 15/25</td>
<td>1 or 2</td>
</tr>
<tr>
<td></td>
<td>Quinapril/Hydrochlorothiazide</td>
<td>10/12.5, 20/12.5, 20/25</td>
<td>1 or 2</td>
</tr>
<tr>
<td>ARBs + Thiazide</td>
<td>Azilsartan/Chlorthalidone</td>
<td>40/12.5, 40/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Candesartan/Hydrochlorothiazide</td>
<td>16/12.5, 32/12.5, 32/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Eprosartan/Hydrochlorothiazide</td>
<td>60/12.5, 600/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Irbesartan/Hydrochlorothiazide</td>
<td>50/12.5, 100/12.5, 100/25</td>
<td>1 or 2</td>
</tr>
<tr>
<td></td>
<td>Losartan/Hydrochlorothiazide</td>
<td>20/12.5, 40/12.5, 40/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Telmisartan/Hydrochlorothiazide</td>
<td>40/12.5, 80/12.5, 80/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Valsartan/Hydrochlorothiazide</td>
<td>80/12.5, 160/12.5, 320/12.5, 160/25, 320/25</td>
<td>1</td>
</tr>
<tr>
<td>CCB – dihydropyridine + ACEIs</td>
<td>Amlodipine/Benazepril</td>
<td>2.5/10, 5/10, 5/20, 10/20, 5/40, 10/40</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Enalapril/Felodipine</td>
<td>5/5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Perindopril/Amlodipine</td>
<td>3.5/2.5, 7.5/5, 14/10</td>
<td>1</td>
</tr>
<tr>
<td>CCB – dihydropyridine + ARB</td>
<td>Amlodipine/Olmesartan</td>
<td>5/20, 10/20, 4/40</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Amlodipine/Valsartan</td>
<td>5/160, 10/160, 5/320, 10/320</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Telmisartan/Amlodipine</td>
<td>40/5, 80/5, 40/10, 80/10</td>
<td>1</td>
</tr>
<tr>
<td>CCB – nondihydropyridine + ACEIs</td>
<td>Trandolapril/Verapamil</td>
<td>2/180, 1/250, 2/240, 4/240</td>
<td>1</td>
</tr>
<tr>
<td>Beta blocker + Thiazide</td>
<td>Atenolol/Chlorthalidone</td>
<td>50/25, 100/25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Bisoprolol/Hydrochlorothiazide</td>
<td>2.5/6.25, 5/6.25, 10/6.25</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Metoprolol succinate/Hydrochlorothiazide</td>
<td>25/12.5, 50/12.5, 100/12.5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Metoprolol tartrate/Hydrochlorothiazide</td>
<td>50/25, 100/25, 100/50</td>
<td>1 or 2</td>
</tr>
<tr>
<td></td>
<td>Nadolol/Bendroflumethiazide</td>
<td>40/5, 80/5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Propranolol/Hydrochlorothiazide</td>
<td>40/25, 80/25</td>
<td>1 or 2</td>
</tr>
<tr>
<td>Direct renin inhibitor + CCB – dihydropyridine</td>
<td>Aliskiren/amlopidine</td>
<td>150/5, 150/10, 300/5, 300/10</td>
<td>1</td>
</tr>
<tr>
<td>Direct renin inhibitor + Thiazide</td>
<td>Aliskiren/Hydrochlorothiazide</td>
<td>150/12.5, 150/25, 300/12.5, 300/25</td>
<td>1</td>
</tr>
<tr>
<td>Direct renin inhibitor + CCB – dihydropyridine</td>
<td>Aliskiren/Amlodipine</td>
<td>150/5, 150/10, 300/5, 300/10</td>
<td>1</td>
</tr>
<tr>
<td>Direct renin inhibitor + Thiazide</td>
<td>Aliskiren/Hydrochlorothiazide</td>
<td>150/12.5, 150/25, 300/12.5, 300/25</td>
<td>1</td>
</tr>
<tr>
<td>Central acting agent + Thiazide</td>
<td>Clonidine/Chlorthalidone</td>
<td>0.1/15, 0.2/15, 0.3/15</td>
<td>1 or 2</td>
</tr>
<tr>
<td></td>
<td>Metyldopa/Hydrochlorothiazide</td>
<td>250/15, 250/25</td>
<td>2</td>
</tr>
<tr>
<td>Diuretic - potassium sparing + Thiazide</td>
<td>Amlorilide/Hydrochlorothiazide</td>
<td>5/50</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Triamterene/Hydrochlorothiazide</td>
<td>37.5/25, 75/50</td>
<td>1</td>
</tr>
<tr>
<td>Diuretic - aldosterone antagonist + Thiazide</td>
<td>Spironolactone/Hydrochlorothiazide</td>
<td>25/25</td>
<td>1 or 2</td>
</tr>
</tbody>
</table>

**3-drug combinations**

| | Olmesartan/Amlodipine/Hydrochlorothiazide | 20/5/12.5, 40/5/25, 10/5/12.5, 40/10/25, 30/10/25 | 1 |
| Direct renin inhibitor + CCB – dihydropyridine + Thiazide | Aliskiren/Amlodipine/Hydrochlorothiazide | 150/5/12.5, 300/5/12.5, 300/5/25, 300/10/12.5, 300/10/25 | 1 |

ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; and CCB, calcium channel blocker.

From Chobanian et al. JNC 7. (347)

Data Supplement E. Examples of Hypertension Quality Improvement Strategies

<table>
<thead>
<tr>
<th>Quality Improvement Strategy</th>
<th>Examples</th>
</tr>
</thead>
</table>
| Audit and feedback on performance                   | • Feedback of performance to individual providers  
• Benchmarking – provision of outcomes data from top performers for comparison with provider’s own data  
• Performance measures, quality indicators and reports  
• Use of registries to track BP control status at system and provider levels |
| Provider education                                   | • In person, online, or other education to improve BP measurement and management skills  
• Training to improve communication, cultural competency, and ability to inspire and support lifestyle modification |
| Patient education                                    | • Intensive education strategies promoting hypertension self-management  
• Cultural and linguistic tailoring of materials to increase acceptability |
| Promotion of self-management                        | • Reduce barriers for patients to receive and adhere to medications and to implement lifestyle modification |
| Patient reminder systems (for follow-up appointments, BP checks, and self-management) | • Postcards, calls, texts, or emails to patients  
• Telehealth-delivered reminders |
| System change                                        | • Standardization of BP measurement using an automated device and standardized protocol  
• Screening to identify all patients eligible for hypertension management  
• Systematic follow-up of patients for the initiation and intensification of antihypertensive therapy  
• Decision support to providers to guide protocol-based treatment decisions  
• Physician or other clinical champion designated to lead hypertension care improvement initiatives  
• Hypertension specialist available for consult  
• Partner with community resources to support BP management |

BP indicates blood pressure.

Adapted with permission from Walsh et al. (348).
# Data Supplement F. Barriers and Improvement Strategies in Antihypertensive Medication Adherence (349-353)

<table>
<thead>
<tr>
<th>Barriers</th>
<th>Improvement Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient Level</strong></td>
<td><strong>Provider and Health System Levels</strong></td>
</tr>
<tr>
<td>· Multiple comorbid conditions requiring complex medication regimens</td>
<td>· Assess for nonadherence and explore barriers to medication adherence</td>
</tr>
<tr>
<td>· Convenience factors (e.g., dosing frequency)</td>
<td>· Use a multifactorial approach to optimize adherence</td>
</tr>
<tr>
<td>· Health beliefs</td>
<td>· Participate in training to enhance communication skills and increase cultural competence</td>
</tr>
<tr>
<td>· Behavioral factors</td>
<td>· Use a multifactorial approach to optimize adherence</td>
</tr>
<tr>
<td>· Lack of involvement in the treatment decision-making process</td>
<td>· Reduce complexity of medication regimen</td>
</tr>
<tr>
<td>· Issues with treatment of asymptomatic diseases (e.g., treatment side effects)</td>
<td>· Utilize agents that are dosed once daily over those which require multiple daily doses</td>
</tr>
<tr>
<td>· Resource constraints</td>
<td>· Utilize fixed-dose combination agents when available and simplify drug regimens</td>
</tr>
<tr>
<td>· Suboptimal health literacy</td>
<td>· Consider overall side effect profile and preferentially use agents that are well tolerated</td>
</tr>
</tbody>
</table>

- Educate patients about hypertension, consequences of hypertension, and possible adverse effects of medications
- Collaborate with patient to establish goals of therapy and plan of care
- Maintain contact with patients; consider telehealth approaches (Section 12.3.2).
- Integrate pill-taking into daily routine activities of daily living with adherence support tools such as reminders, pillboxes, packaging, or other aids
- Use motivation interventions to support medication adherence and lifestyle modification efforts
- Use medication adherence scales to facilitate identification of barriers and facilitators to and behaviors associated with adequate adherence
- Address health literacy
  - Teach-back method
  - Empower patients to ask questions
  - Use visual, interactive education
  - Health literacy universal precautions tool kit
  - Provide medication list/pictorial medication schedule

- Prescription of complex drug regimens
- Inadequate communication with patient about regimen, adverse effects, treatment goals
- Inadequate communication among multiple providers
- Office visit time limitations
- Limited access to care, pharmacies, prescription refills

- Use low-cost and generic antihypertensives from drug classes where RCTs have demonstrated a reduction in cardiovascular events when appropriate (354)
- Use team-based care approaches (Section 12.2)
- Use health information technology-based approaches (Section 12.3)

**RCTs** indicate randomized controlled trials.
### Data Supplement G. Examples of Strategies to Promote Lifestyle Modification Interventions in Patients With Hypertension (318, 319, 355-361)

<table>
<thead>
<tr>
<th>Lifestyle Modification Intervention</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tobacco Cessation</strong></td>
<td>(361, 362)</td>
</tr>
<tr>
<td>• Ask all adults about tobacco use</td>
<td></td>
</tr>
<tr>
<td>• Advise them to stop using tobacco</td>
<td></td>
</tr>
<tr>
<td>• Provide behavioral interventions</td>
<td></td>
</tr>
<tr>
<td>• Consider pharmacotherapy for tobacco cessation</td>
<td></td>
</tr>
<tr>
<td><strong>Weight Loss</strong></td>
<td>(355, 356)</td>
</tr>
<tr>
<td>• Offer or refer obese adults to intensive cognitive and behavioral interventions aimed at to improve weight status and other risk factors for important health outcomes.</td>
<td></td>
</tr>
<tr>
<td><strong>Sodium Reduction</strong></td>
<td></td>
</tr>
<tr>
<td>• Offer or refer to behavioral counselling aimed at reduced intake of dietary sodium</td>
<td></td>
</tr>
<tr>
<td>• Encourage use of food labels to choose lower sodium products</td>
<td></td>
</tr>
<tr>
<td><strong>Alcohol</strong></td>
<td>(357, 358)</td>
</tr>
<tr>
<td>• Screen adults ≥18 y of age for alcohol misuse and provide persons engaged in risky or hazardous drinking with behavioral counseling interventions to reduce alcohol misuse.</td>
<td></td>
</tr>
<tr>
<td><strong>Physical Activity and Diet</strong></td>
<td>(359, 360)</td>
</tr>
<tr>
<td>• Use medium- to high-intensity behavioral counseling interventions to improve intermediate health outcomes; addressing barriers, such as lack of access to affordable healthier foods, transportation barriers and poor local safety.</td>
<td></td>
</tr>
</tbody>
</table>
Data Supplement H. Responsibilities and Roles of the Hypertension Team

<table>
<thead>
<tr>
<th>Hypertension Team Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Communication and care coordination among various team members, the patient and family members or other support persons.</td>
</tr>
<tr>
<td>• Effective use of evidence-based diagnosis and management guidelines</td>
</tr>
<tr>
<td>• Regular, structured follow-up mechanisms and reminder systems to monitor patient progress</td>
</tr>
<tr>
<td>• Engage patients in their care by shared decision making</td>
</tr>
<tr>
<td>• Medication adherence support and appropriate education about hypertension medication</td>
</tr>
<tr>
<td>• Medication addition and titration using evidence-based treatment algorithms</td>
</tr>
<tr>
<td>• Use of evidence-based tools and resources designed to maximize self-management (including health behavior change, lifestyle modification, etc.)</td>
</tr>
<tr>
<td>• Follow a single, personalized plan of care based upon patient characteristics and needs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Individual Hypertension Team Members</th>
<th>Roles (examples)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Care Physician, Physician Assistant, Advanced Practice Nurse</td>
<td>Routine and complex hypertension care, managing primary care issues.</td>
</tr>
<tr>
<td>Cardiologist</td>
<td>Routine and complex hypertension care, especially for patient with cardiac disease or high risk for major cardiovascular events.</td>
</tr>
<tr>
<td>Nephrologist, Endocrinologist, Hypertension Specialist</td>
<td>Management of complex hypertension care, especially due to secondary causes, and/or resistant hypertension.</td>
</tr>
<tr>
<td>Nurse (including in-office, home care, internal and external population health personnel)</td>
<td>Accurate assessment of BP, medication reconciliation, patient education, self-management, lifestyle modification and adherence.</td>
</tr>
<tr>
<td>Clinical Pharmacist</td>
<td>Comprehensive medication management, which involves identification and documentation of medication-related problems, initiating, modifying, and discontinuing medication to address identified problems, and educating patients on their medication regimen.</td>
</tr>
<tr>
<td>Dietician</td>
<td>Ongoing patient-centered counseling to assess dietary habits and preferences, set and monitor goals for healthy lifestyle</td>
</tr>
<tr>
<td>Social Worker</td>
<td>Assess for psychosocial, cultural and financial barriers, find solutions to overcome these barriers.</td>
</tr>
<tr>
<td>Community Health Providers</td>
<td>Assess for psychosocial, cultural and financial barriers, identify and promote acceptable community-based resources to overcome these barriers.</td>
</tr>
</tbody>
</table>

BP indicates blood pressure.
Data Supplement I. Examples of Telehealth Strategies and Technologies to Promote Effective Hypertension Management

<table>
<thead>
<tr>
<th>Telehealth strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Automated BP data capture and transmission of the patient’s self-measured BP</td>
</tr>
<tr>
<td>• Self-management support including education, reminders, and feedback that is automated or delivered by a healthcare professional</td>
</tr>
<tr>
<td>• Medication titration and follow-up monitoring protocols/algorithm</td>
</tr>
<tr>
<td>• Prescription refill reminders</td>
</tr>
<tr>
<td>• Medication adherence assessments</td>
</tr>
<tr>
<td>• Self-monitoring of lifestyle behaviors</td>
</tr>
<tr>
<td>• Integration of behavior change techniques, including in person or e-counseling</td>
</tr>
<tr>
<td>• Case/care/population health management</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Commonly used telehealth technologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Wired “land line” telephone</td>
</tr>
<tr>
<td>• Wireless smart phone applications</td>
</tr>
<tr>
<td>• Internet-based website via computers and handheld devices</td>
</tr>
<tr>
<td>• Text messaging</td>
</tr>
<tr>
<td>• E-mail messaging</td>
</tr>
<tr>
<td>• Social networking and social media websites/applications</td>
</tr>
<tr>
<td>• Wireless BP measurement devices</td>
</tr>
<tr>
<td>• Electronic pill dispensers/counters</td>
</tr>
</tbody>
</table>

BP indicates blood pressure.
## Data Supplement J. Publicly Available Performance Measures Used to Assess Hypertension Care Quality Services (363-367)

<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>Source</th>
<th>Description</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlling High BP PQRS Measure #236; NQF #0018</td>
<td>NCQA</td>
<td>Percentage of patients 18–85 y of age who had a diagnosis of hypertension and whose BP was adequately controlled (&lt;140/90 mm Hg during the measurement period)</td>
<td>Used in the CMS, PQRS, MSSP, Medicare Advantage “Stars” ratings; component of Commercial Health Plan HEDIS quality measure set</td>
</tr>
</tbody>
</table>
| Comprehensive Diabetes Care: BP Control (<140/90 mm Hg) NQF #0061               | NCQA   | The percentage of patients 18–75 y of age with DM (type 1 and type 2) whose most recent BP level taken during the measurement y is <140/90 mm Hg                                                                 | Used for:  
  - Accreditation  
  - Decision-making by businesses about health plan purchasing  
  - Decision-making by consumers about health plan/provider choice  
  - External oversight/Medicaid  
  - External oversight/Medicare  
  - External oversight/State government program  
  - Internal quality improvement  
  - Public reporting                                                                 |
| Adult Kidney Disease: BP Management PQRS #122                                   | PCPI, RPA | Percentage of patient visits for those patients ≥18 y of age with a diagnosis of CKD (stage 3, 4, or 5, not receiving renal replacement therapy) with a BP<140/90 mm Hg OR ≥140/90 mm Hg with a documented plan of care | Used in PQRS                                                                                               |
| Percentage of patients ≥18 y of age with BP documented in the medical record (every 2 y if <120/80 mm Hg, every y if 120–139/80–89 mm Hg) | ICSI   | This measure is used to assess the percentage of patients age 18 y of age and older with BP documented in the medical record (every 2 y if <120/80 mm Hg, every y if 120–139/80–89 mm Hg) | Used for internal quality improvement                                                                  |
| Controlling High BP for People with Serious Mental Illness NQF #2602            | NCQA   | The percentage of patients 18–85 y of age with serious mental illness who had a diagnosis of hypertension and whose BP was adequately controlled during the measurement | Current Use:  
  - Accreditation  
  - Decision-making by businesses about health plan purchasing  
  - Decision-making by consumers about health plan/provider choice  
  - External oversight/Medicaid  
  - External oversight/state government program \internal quality improvement |
| Diabetes Care for People with Serious Mental Illness: BP Control (<140/90 mm Hg) NQF #2606 | NCQA   | The percentage of patients 18–75 y of age with a serious mental illness and DM (type 1 and type 2) whose most recent BP reading during the measurement year is <140/90 mm Hg | Current Use:  
  - Accreditation  
  - Decision-making by businesses about health plan purchasing  
  - Decision-making by consumers about health plan/provider choice  
  - External oversight/Medicaid |
<table>
<thead>
<tr>
<th>Quality Measure</th>
<th>Source</th>
<th>Description</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension diagnosis and treatment: percentage of adult patients ≥ 18 y of age diagnosed with hypertension who are not at goal for hypertension and have received counseling on diet and physical activity in the past 12 mo</td>
<td>ICSI</td>
<td>Used to assess the percentage adult patients ≥ 18 y of age diagnosed with hypertension who are not at goal for hypertension and have received counseling on diet and physical activity in the past 12 mo</td>
<td>Used for Internal Quality Improvement</td>
</tr>
<tr>
<td>Ambulatory care sensitive conditions: age-standardized acute care hospitalization rate for conditions where appropriate ambulatory care prevents or reduces the need for admission to the hospital per 100,000 population &lt; 75 y of age</td>
<td>CIHI</td>
<td>Used to assess the age-standardized acute care hospitalization rate for conditions where appropriate ambulatory care prevents or reduces the need for admission to the hospital per 100,000 population &lt; 75 y of age</td>
<td>Used for: Monitoring health state(s) National health policymaking National reporting State/Provincial health policymaking</td>
</tr>
<tr>
<td>Hypertension: the relative resource use by members with hypertension during the measurement y</td>
<td>NCQA</td>
<td>Used to assess the relative resource use by members with hypertension by reporting total standard cost and service frequency for all services for which the organization has paid or expects to pay during the measurement y</td>
<td>Used for: Accreditation External oversight/Medicaid External oversight/Medicare External oversight/State government program Monitoring and planning Public reporting</td>
</tr>
</tbody>
</table>

BP indicates blood pressure; CIHI, Canadian Institute for Health Information; CKD, chronic kidney disease; CMS, Centers for Medicare and Medicaid Services; DM, diabetes mellitus; HEDIS, healthcare Effectiveness Data and Information Set; ICSI, Institute for Clinical Systems Improvement; MSSP, Medicare Shared Savings Program; NCQA, National Committee for Quality Assurance; NQF, National Quality Forum; OR, odds ratio; PCPI, Physician Consortium for Performance Improvement; and PQRS, Physician Quality Reporting System; and RPA, Renal Physicians Association.
Data Supplement K. Online Quality Improvement Resources for Treatment and Control of Hypertension

American College of Cardiology/American Heart Association/Centers for Disease Control Science Advisory for the Effective Approach to High Blood Pressure Control

http://content.onlinejacc.org/article.aspx?articleid=1778408

American Medical Association Measure, Act and Partner (M.A.P.) to help patients control blood pressure and ultimately prevent heart disease


United States Health and Human Services (HHS)/Centers for Disease Control (CDC) Million Hearts Campaign Evidence-based Treatment Protocols for Improving Blood Pressure Control

http://millionhearts.hhs.gov/resources/protocols.html

Department of Defense/Veterans’ Affairs

http://www.healthquality.va.gov/guidelines/CD/htn/

Kaiser Permanente Hypertension Management programs to improve blood pressure control

http://kpcmi.org/how-we-work/hypertension-control/

Institute for Clinical Systems Improvement (ICSI) Hypertension Diagnosis and Treatment Guidelines

https://www.icsi.org/guidelines_more/catalog_guidelines_and_more/catalog_guidelines/catalog_cardiovascular_guidelines/hypertension/

New York Health and Hospitals Corporation (HHC) Hypertension Collaborative Care Pathway

References


© 2017 American College of Cardiology Foundation and American Heart Association, Inc.


271. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970; 213:1143-52.


© 2017 American College of Cardiology Foundation and American Heart Association, Inc.


© 2017 American College of Cardiology Foundation and American Heart Association, Inc.
361. Tobacco smoking cessation in adults, including pregnant women: behavioral and pharmacotherapy interventions. 2015.
### Author Relationships With Industry and Other Entities (Comprehensive)—2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (October 2017)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul K. Whelton (Chair)</td>
<td>Tulane University School of Hygiene and Tropical Medicine—Show Chwan Professor of Global Public Health</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• NIH–SPRINT trial* (PI)</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert M. Carey (Vice Chair)</td>
<td>University of Virginia School of Medicine—Dean Emeritus, and Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• NIH*</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Wilbert S. Aronow</td>
<td>Westchester Medical Center and New York Medical College—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Donald E. Casey, Jr</td>
<td>Thomas Jefferson College of Population Health—Adjunct Faculty; Alvarez &amp; Marsal Ipo4health—Principal and Founder</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Karen J. Collins</td>
<td>Collins Collaboration—President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• North Carolina A&amp;T State University Alumni Association†</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

© 2018 by the American College of Cardiology Foundation and the American Heart Association, Inc.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Position</th>
<th>Medical Societies/Foundations/Pharmaceutical Companies</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cheryl Dennison Himmelfarb</td>
<td>John Hopkins University—Professor of Nursing and Medicine, Institute for Clinical and Translational Research</td>
<td>• MedThink Communications</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Helene Fuld Health Trust*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• NIH*</td>
<td>Preventive Cardiovascular Nurses Association†</td>
</tr>
<tr>
<td>Sondra M. DePalma</td>
<td>PinnacleHealth CardioVascular Institute—Physician Assistant; American Academy of PAs—Director, Regulatory and Professional Practice</td>
<td>• American Society of Hypertension</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Accreditation Council for Clinical Lipidology†</td>
<td>None</td>
</tr>
<tr>
<td>Samuel Gidding</td>
<td>Alfred I. Dupont Hospital for Children—Chief, Division of Pediatric Cardiology, Nemours Cardiac Center</td>
<td>• Familial Hypercholesterolemia Foundation†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Familial Hypercholesterolemia Foundation†</td>
<td>• NIH*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• American Society of Hypertension</td>
<td>Cardiology Division Head†</td>
</tr>
<tr>
<td>David C. Goff, Jr‡</td>
<td>Colorado School of Public Health—Professor and Dean, Department of Epidemiology</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kenneth A. Jamerson</td>
<td>University of Michigan Health System—Professor of Internal Medicine and Frederick G.L. Huetwell Collegiate Professor of Cardiovascular Medicine</td>
<td>• American Society of Hypertension</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• NIH/NIDDK/NHL BI*</td>
<td>American Society of Hypertension†</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>International Society of Hypertension In Blacks†</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bayer Healthcare Pharmaceuticals</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Leadership</td>
<td>Research Funding</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Daniel W. Jones</td>
<td>University of Mississippi Medical Center—Professor of Medicine and Physiology; Metabolic Diseases and Nutrition—University Sanderson Chair in Obesity Mississippi Center for Obesity Research—Director, Clinical and Population Science</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eric J. MacLaughlin</td>
<td>Texas Tech University Health Sciences Center—Professor and Chair, Department of Pharmacy Practice, School of Pharmacy</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paul Muntner</td>
<td>University of Alabama at Birmingham—Professor, Department of Epidemiology</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bruce Ovbiagele</td>
<td>Medical University of South Carolina—Pihl Professor and Chairman of Neurology</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Sidney C. Smith, Jr</td>
<td>University of North Carolina at Chapel Hill—Professor of Medicine; Center for Cardiovascular Science and Medicine—Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crystal C. Spencer</td>
<td>Spencer Law, PA—Attorney at Law</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randall S. Stafford</td>
<td>Stanford Prevention Research Center—Professor of Medicine; Program on Prevention Outcomes—Director</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandra J. Taler</td>
<td>Mayo Clinic—Professor of Medicine, College of Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randal J. Thomas</td>
<td>Mayo Clinic—Medical Director, Cardiac Rehabilitation Program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Industry</td>
<td>Clinical</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Kim A. Williams, Sr</td>
<td>Rush University Medical Center—James B. Herrick Professor; Division of Cardiology—Chief</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeff D. Williamson</td>
<td>Wake Forest Baptist Medical Center—Professor of Internal Medicine; Section on Gerontology and Geriatric Medicine—Chief</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jackson T. Wright, Jr</td>
<td>Case Western Reserve University—Professor of Medicine; William T. Dahms MD Clinical Research Unit—Program Director; University Hospitals Case Medical Center—Director, Clinical Hypertension Program</td>
<td>None</td>
<td>Amgen*</td>
</tr>
</tbody>
</table>

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to [http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy](http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy) for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.
†No financial benefit.
‡Dr. David C. Goff resigned from the writing committee in December 2016 due to a change in employment before the recommendations were balloted. The writing committee thanks him for his contributions, which were extremely beneficial to the development of the draft.

© 2018 by the American College of Cardiology Foundation and the American Heart Association, Inc.